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Abstract	
Bardet-Biedl	Syndrome	(BBS)	is	a	rare	pleiotropic	disorder,	characterised	by	loss	of	vision,	obesity,	
renal	dysfunction,	learning	difficulties,	and	hypogonadism.	This	multisystem	phenotype	is	caused	
by	defects	in	genes	that	localize	to	the	basal	body	of	the	primary	cilia,	where	over	20	genes	have	
now	 been	 attributed	 to	 cause	 BBS.	 However,	 ~32%	 of	 patients	 are	 affected	 by	 a	 recurrent	
missense	variant,	namely	BBS1	p.M390R,	which	contributes	greatly	to	the	overall	burden	of	BBS.	
Despite	 recent	 advances	 in	 understanding	 the	 syndrome’s	 genetic	 aetiology,	 much	 of	 the	
pathobiology	of	BBS1	p.M390R	remains	elusive.	This	thesis	aimed	to	use	an	innovative	multi-omic	
strategy,	 implementing	 genomic,	 transcriptomic,	 and	 proteomic	 technologies,	 to	 uncover	 the	
molecular	pathology	of	a	cohort	of	15	BBS	patients,	each	carrying	the	common	BBS1	p.M390R	
variant.	
	
Phenotypic	variability	is	a	hallmark	feature	of	BBS,	where	clinical	heterogeneity	exists	within	the	
BBS1	 genotype,	 even	 if	 patients	 have	 the	 same	 underlying	 pathogenic	mutation.	 It	 has	 been	
suggested	that	differences	in	disease	expressivity	are	linked	to	secondary	mutations	that	modify	
the	 manifestation	 of	 the	 primary	 locus.	 Here,	 the	 objective	 was	 to	 identify	 putative	 genetic	
modifying	alleles	from	whole	genome	sequencing	data	generated	from	BBS1	p.M390R	patients	
expressing	 discordant	 disease	 presentation.	 A	 novel	 4-tier	 variant	 categorisation	 system	 was	
developed	where	37	candidate	modifiers	were	detected	in	13	patients.	This	 included	a	known	
modifying	variant	previously	shown	to	have	a	high	penetrance	with	ciliopathies,	TTC21B	p.L1002V	
found	in	2	patients.	Furthermore,	it	was	investigated	whether	the	presence	of	these	modifying	
variants	 contributed	 to	 the	 overall	 mutational	 burden	 of	 BBS.	 Mutational	 burden	 analysis	
determined	 that	 there	was	no	 significant	enrichment	of	 variants	 in	primary	 cilia	 genes	 in	BBS	
patients	compared	to	control	individuals.	
	
There	is	a	definitive	lack	of	molecular	biomarkers	for	rare	diseases,	such	as	BBS.	Untargeted	and	
targeted	proteomic	profiling	assays	were	applied	to	plasma	and	urine,	which	aimed	to	uncover	
novel	biomarkers	specific	to	BBS.	8	significantly	differentially	expressed	proteins	were	identified	
from	urine,	including	PEDF,	a	secreted	factor	that	is	linked	to	fatty	acid	metabolism	and	insulin	
resistance	 in	obesity	 (Log2FC:	2.56,	p	=	0.015).	 Similarly,	plasma	proteomic	analysis	 identified	
putative	 biomarkers	 that	 are	 linked	 to	 secondary	metabolic	 features	 of	 BBS,	 such	 as	 LEP	 and	
ApoM.	Markers,	such	as	these,	will	become	subsequent	targets	for	 further	validation	 in	 larger	
cohorts.	
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BBS	 patient-derived	 fibroblasts	 were	 profiled	 by	 transcriptomic	 and	 proteomic	 technologies,	
which	aimed	to	identify	dysregulated	pathways	at	a	cellular	level	compared	to	control	cultures.	
Pathway	 analysis	 uncovered	 discordant	 expression	 of	 centrosomal	 genes	 between	 BBS	 and	
control	cells,	as	well	as	a	significant	enrichment	of	genes	associated	with	adipogenesis,	which	
may	provide	 insight	 into	obesity	manifested	by	BBS	patients.	Analysis	of	protein	profiling	data	
revealed	 dysregulation	 of	 processes	 not	 detected	 by	 RNA-seq,	 including	 actin	 cytoskeleton	
remodelling	and	hedgehog	signalling.	Finally,	pathways	were	integrated	to	increase	the	power	of	
analysis,	identifying	17	pathways	that	were	found	to	be	impaired	at	both	transcript	and	protein	
levels.	
	
The	phenotype	of	retinal	dystrophy	is	one	of	the	most	detrimental	effects	on	patient	welfare,	and	
affects	over	90%	of	BBS	patients.	As	retinal	degeneration	of	BBS	patients	cannot	be	investigated	
in	vivo,	this	project	utilised	BBS	patient-derived	induced	pluripotent	stem	cells	with	the	aim	of	
developing	a	model	for	the	study	of	retinal	degeneration	in	vitro.	For	the	first	time,	it	was	shown	
that	BBS	patient	cells	can	differentiate	into	three-dimensional	optic	cups,	which	recapitulated	the	
temporal	expression	of	key	retinal	markers	of	in	vivo	mammalian	eye	development.	Furthermore,	
immunohistochemistry	and	electron	microscopy	assays	determined	that	BBS-derived	optic	cups	
could	successfully	undergo	ciliogenesis,	which	was	demonstrated	by	 the	 formation	of	nascent	
photoreceptor	outer	segments.	
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SHH	 Sonic	hedgehog	
SIFT	 Sorting	intolerant	from	tolerant	
siRNA	 Small	interfering	RNA	
SLS	 Senior-Løken	Syndrome	
Smo	 Smoothened	
snRNA	 Small	nuclear	RNA	
SNV	 Single	nucleotide	variant	
SOP	 Standard	operating	protocol	
SRS	 Silver	Russell	Syndrome	
TBE	 Tris/Borate/EDTA	
TEM	 Transmission	electron	microscope	
TFA	 Trifluoroacetic	acid	
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ToF	 Time	of	flight	
TPR	 Tetratricopeptide	repeat	
TRiC	 TCP-1	Ring	Complex	
tRNA	 Transfer	RNA	
TZ	 Transition	zone	
UCSC	 University	of	California,	Santa	Cruz	
UDG	 Uracil-DNA	glycosylase	
UPLC	 Ultra	performance	liquid	chromatography	
UPR	 Unfolded	protein	response	
USH	 Usher	Syndrome	
UTI	 Urinary	tract	infection	
UV	 Ultraviolet	
VPA	 Valproic	acid	
VEO-IBD	 Very	Early	Onset-Inflammatory	Bowel	Disease	
WES	 Whole	exome	sequencing	
WGS	 Whole	genome	sequencing	
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1.1	Eukaryotic	cilia	
Cilia	 are	 evolutionarily	 conserved	 microtubule-based	 organelles	 present	 on	 eukaryotic	 cells.	
These	microtubules	stretch	from	the	cell	body	and	can	act	as	cellular	signalling	antennae,	beat	in	
waves	to	encourage	movement	of	fluids,	or	have	critical	transport	roles	in	highly	specialised	cells.	
The	microtubule	structures	are	robust	and	stable	due	to	acetylation	of	tubulin	monomers.	There	
are	3	types	of	cilia	characterised	by	different	microtubule	arrangements,	which	determine	their	
function	(Figure	1.1B).	
	
Motile	cilia	are	organised	in	a	9	+	2	arrangement,	with	a	central	microtubule	pair	surrounded	by	
9	outer	microtubule	doublets.	Dynein	 arms	and	 radial	 spokes	protrude	 from	 regular	 intervals	
along	the	microtubule	doublets.	Hydrolysis	of	ATP	allows	the	dynein	arms	to	drive	a	sliding	motion	
between	the	microtubule	doublet	relative	to	the	central	pair,	causing	the	motile	cilia	to	beat	(King	
2016).	Motile	 cilia	 are	 found	 in	 large	 numbers	 on	 the	 apical	 surface	 of	 specialised	 cells	 and	
function	in	coordinated	rolling	waves.	For	example,	they	beat	away	secretions	in	the	respiratory	
epithelium	and	middle	ear,	cerebrospinal	fluid	in	the	brain,	or	encourage	movement	of	sperm	in	
the	fallopian	tubes	(Mitchison	and	Valente	2017).	
	
A	second	form	of	cilia	are	located	at	the	embryonic	node,	thus	are	known	as	nodal	cilia.	In	contrast	
to	motile	cilia,	they	lack	a	central	microtubule	pair,	demonstrating	a	9	+	0	arrangement.	With	one	
cilium	per	 cell,	 they	 use	 the	 retention	 between	 dynein	 arms	 and	microtubules	 to	 generate	 a	
rotatory	motion	(Szymanska	and	Johnson	2012).	This	mediates	a	leftward	flow	of	morphogens	
during	 development	 to	 establish	 left-right	 patterning	 (Wagner	 and	 Yost	 2000;	 Praetorius	 and	
Spring	2005).	
	
The	final	form	are	primary	cilia,	also	known	as	sensory	cilia	(figure	1.1A).	Previously	considered	a	
vestigial	accessory	to	the	cell	(Webber	and	Lee	1975),	primary	cilia	are	now	known	to	be	a	crucial	
cellular	 signalling	 hub	 in	 postmitotic	 cells.	 They	 display	 a	 9	 +	 0	 arrangement,	 but	 lack	 dynein	
machinery	 rendering	 them	stationary.	 They	are	present	 in	 the	 single	 form	on	all	 non-dividing	
eukaryotic	cells,	with	the	exception	of	bone	marrow	derived	cells	(Praetorius	and	Spring	2005).	
They	 are	 thought	 to	 have	 many	 tissue	 specific	 roles,	 including	 protein	 trafficking,	
mechanosensation	for	external	chemical	stimuli,	and	acting	as	an	interface	for	 ligand-receptor	
interactions	(Wolfrum	and	Schmitt	2000;	Lee	et	al.	2015;	Berbari	et	al.	2008).	For	the	purpose	of	
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this	thesis,	the	anatomy	and	molecular	function	of	the	primary	cilium	shall	be	explored	in	more	
detail.	
	
1.2	The	core	of	the	primary	cilium	
The	 centrosome	 is	 an	 organelle	 comprised	 of	 barrel-shaped	mother	 and	 daughter	 centrioles,	
which	are	surrounded	by	an	unstructured	protein	mass,	called	pericentriolar	material	(PCM).	The	
centrioles	act	as	a	microtubule	organising	centre	(MTOC)	throughout	the	cell	cycle.	During	the	
early	 G1	 phase,	 the	 centrioles	 migrate	 to	 the	 apical	 plasma	 membrane	 where	 the	 mother	
subsequently	forms	the	basal	body	of	the	primary	cilium.	The	basal	body	displays	a	“pin-wheel”	
9	x	3	+	0	microtubular	structure	anchored	by	transition	fibres	to	the	plasma	membrane	and	is	the	
nucleation	point	of	the	9	microtubule	doublets,	known	collectively	as	the	axoneme	(figure	1.1)	
(Reiter	et	al.	2012).	The	transition	fibres	have	a	dual	function,	as	they	also	serve	as	docking	sites	
for	transport	particles	(Wei	et	al.	2015).	At	the	proximal	end	of	the	basal	body,	the	transition	zone	
forms	in	the	early	stages	of	ciliogenesis.	The	transition	zone	is	characterised	by	Y-linking	proteins	
that	 attach	 the	 axoneme	 to	 the	 ciliary	 membrane	 and	 act	 as	 a	 membrane	 diffusion	 barrier,	
referred	 to	 as	 the	 ciliary	 gate	 (Reiter	 et	 al.	 2012;	 Garcia-Gonzalo	 et	 al.	 2011).	 This	
compartmentalisation	allows	regulated	entry	and	exit	between	the	cytoplasm	and	the	cilium,	and	
instigates	 an	 exclusive	 signalling	 environment.	 The	 axoneme	extends	 from	 the	basal	 body	 via	
ciliogenesis.	 The	 primary	 cilium	 is	 topologically	 continuous	with	 the	 cell	membrane,	 allowing	
movement	of	membrane	associated	proteins	from	the	cell	body	to	the	ciliary	tip.	
	
1.3	Intraflagellar	transport	
The	ciliary	axoneme	extends	perpendicular	from	the	cell	body	and	can	vary	in	length,	from	1µm	
up	to	9µm	(Dummer	et	al.	2016).	The	extension	of	the	axoneme	requires	transportation	of	~600-
1000	distinct	proteins	from	the	endoplasmic	reticulum	(ER)	and	Golgi	apparatus	to	the	nascent	
ciliary	tip	(Lechtreck	2015).	The	polarised	nature	of	tubulin	heterodimers	allows	motor	proteins,	
namely	kinesin	and	dynein,	 to	deliver	proteins	up	and	down	 the	organelle	 in	a	process	called	
intraflagellar	transport	(IFT).	 IFT	 is	a	highly	conserved	bi-directional	movement	of	cargo	within	
the	ciliary	membrane.	As	the	cilium	is	devoid	of	protein	synthesis	apparatus,	robust	anterograde	
and	 retrograde	 transport	 (away	 and	 towards	 the	 cell	 body,	 respectively)	 of	 proteins	 by	 IFT	
machinery	is	required	for	ciliogenesis,	cilium	maintenance,	and	transfer	of	signalling	cargo	to	the	
ciliary	tip.	
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Figure	1.1	–	Cross	sections	of	cilia.	A)	The	primary	cilium	is	an	extension	of	the	plasma	membrane	that	
projects	from	the	cell	body.	9	microtubule	doublets	nucleate	from	the	basal	body,	acting	as	the	scaffold	for	
intraflagellar	transport.	B)	Horizontal	cross	section	of	different	microtubule	patterns	in	cilia	and	the	basal	
body.	
	
Proteins	 KIF3A,	 KIF3B,	 and	 KAP3	 form	 the	 kinesin-2	motor	 complex,	which	 specifically	 travels	
towards	the	plus-ended	ciliary	tip.	The	kinesin	motor	associates	with	IFT	machinery,	made	up	of	
IFT-A	and	IFT-B	complexes	(table	1.1),	and	an	inactive	cytoplasmic	dynein	motor	(Pedersen	et	al.	
2008).	 Anterograde	 protein	 cargo	 is	 thought	 to	 specifically	 bind	 to	 a	 loading	 site	 on	 IFT-B	
(Lechtreck	 2015).	 At	 the	 ciliary	 tip,	 the	 cargo	 is	 released	 for	 use	 in	 ciliogenesis	 or	 signal	
transduction,	and	IFT	machinery	is	turned	over	for	transport	back	to	the	cell	body.	The	retrograde	
specific	IFT-A	particle	functions	to	recycle	cargo	and	anterograde	machinery	to	the	base	of	the	
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cilium.	Retrograde	 transport	 is	 also	 crucial	 for	 the	 conserved	Sonic	hedgehog	 (SHH)	 signalling	
pathway	(Huangfu	and	Anderson	2005).	IFT	machinery	turnover	activates	dynein-2,	consisting	of	
DYNC2H1	and	DYNC2LI1,	which	specifically	returns	along	the	minus	direction	of	the	microtubules	
(Pazour	et	al.	1998).	
	
It	is	thought	that	cargo	entry	into	the	cilium	is	mediated	by	the	BBSome,	a	complex	derived	from	
8	 evolutionarily	 conserved	 proteins	 (BBS1,	 BBS2,	 BBS4,	 BBS5,	 BBS7,	 TTC8/BBS8,	 BBS9,	
BBIP10/BBS18)	(Nachury	et	al.	2007;	Loktev	et	al.	2008;	Jin	et	al.	2010).	All	BBSome	proteins	have	
separately	been	implicated	in	causing	Bardet-Biedl	Syndrome.	It	was	proposed	that	the	BBSome	
was	implicated	in	IFT	after	it	was	found	to	move	at	the	same	rate	as	the	IFT	machinery	through	
the	cilium	(Blacque	et	al.	2004).	Since	then,	it	was	shown	to	have	a	crucial	role	in	IFT	turnover,	as	
inactivity	of	the	BBSome	resulted	in	accumulation	of	IFT-B	complex	at	the	ciliary	tip	(Wei	et	al.	
2012).	 It	 has	 been	 proposed	 that	 BBSome	 proteins,	 BBS7	 and	 BBS8,	 act	 as	 a	 cohesive	 factor	
required	for	IFT	machinery	assembly	(Ou	et	al.	2005)	and	are	required	for	proficient	IFT	function	
within	the	cilium	(Wei	et	al.	2012).	The	BBSome	also	has	a	role	in	recruitment	of	ciliogenesis	or	
signalling	cargo	to	the	base	of	the	cilium	for	trafficking.	Via	interaction	with	small	GTPases,	such	
as	 RAB,	 ARF,	 and	 ARL	 families,	 the	 BBSome	 is	 recruited	 to	 the	 ciliary	 membrane.	 Here,	 the	
BBSome	 was	 shown	 to	 interact	 with	 RAB8GTP	 and	 RABIN8,	 which	 was	 proposed	 to	 promote	
docking	and	fusion	of	vesicles	carrying	cargo	from	the	Golgi	to	the	cilium	base	(Nachury	et	al.	
2007;	Loktev	et	al.	2008).	
	
IFT-A	 IFT-B	 Kinesin-2	 Dynein-2	 BBSome	
IFT43	 IFT20	 KIF3A	 DYNC2H1	 BBS1	
IFT122A	 IFT27	 KIF3B	 DYNC2LI1	 BBS2	
IFT122B	 IFT46	 KAP3	 	 BBS4	
IFT139	 IFT52	 	 	 BBS5	
IFT140	 IFT57	 	 	 BBS7	
IFT144	 IFT72	 	 	 TTC8/BBS8	
	 IFT74	 	 	 BBS9	
	 IFT80	 	 	 BBIP10/BBS18	
	 IFT81	 	 	 	
	 IFT88	 	 	 	
	 IFT172	 	 	 	
Table	1.1	–	Proteins	found	in	different	key	complexes	required	for	IFT	
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1.4	Key	processes	enabled	by	primary	cilia	
The	primary	cilium	is	responsible	for	coordinating	a	plethora	of	core	cellular	processes.	Cilia	can	
have	various	tissue	specific	functions	on	different	specialised	cells.	In	essence,	they	act	as	cellular	
signalling	antennae.	 Through	 IFT,	 as	many	as	1000	proteins	are	 trafficked	 to	 the	apical	 ciliary	
membrane	 (Liu	 et	 al.	 2007;	Gherman	 et	 al.	 2006)	 and	 translation	 of	 stimuli	 is	 facilitated	 into	
downstream	 intracellular	signalling	cascades.	Due	to	 the	compartmentalisation	of	 the	primary	
cilium,	it	can	be	ensured	that	signalling	is	well	orchestrated,	regulated	and	highly	sensitive.	Their	
responsibility	is	broad,	regulating	cellular	events	including	polarity,	migration,	differentiation	and	
tissue	morphology	(Basten	and	Giles	2013;	Singla	and	Reiter	2006;	Ishikawa	and	Marshall	2011).	
	
1.4.1	G-Protein	Coupled	Receptors	
The	 cilium	 creates	 an	 efficient	 appendage	 for	 G-protein	 coupled	 receptor	 (GPCR)	 localisation	
(figure	 1.2A).	 GPCRs	 are	 well	 characterised	 transmembrane	 receptors,	 constructed	 from	 a	
tertiary	structure	of	7	transmembrane	spanning	alpha	helices.	Briefly,	signal	transduction	occurs	
by	detection	of	a	sensory	 input	by	the	GPCR	N-terminal	extracellular	domain.	This	 initiates	an	
activation	of	the	cytosolic	G-protein	by	exchange	of	binding	from	GDP	to	GTP.	The	activation	by	
GTP	 dissociates	 a	 subunit	 from	 the	 G-protein	 trimer,	 which	 prompts	 downstream	 signalling	
through	cAMP	transduction	(Schou	et	al.	2015).	
	
There	 are	 approximately	 800	 different	 GPCRs	 in	 humans,	 each	 activated	 by	 a	 vast	 range	 of	
agonists,	 including	 peptides,	 lipids,	 nucleotides,	 ions,	 odorants	 and	 photons	 (Milligan	 and	
Kostenis	2006;	Schou	et	al.	2015).	At	least	25	GPCRs	are	known	to	localise	to	the	primary	cilium	
to	date	(Hilgendorf	et	al.	2016),	the	utilities	of	which	span	many	cellular	processes.	These	include	
phototransduction	by	opsins	(Sun	et	al.	2012;	Masyuk	et	al.	2008),	olfactory	function	(Lowe	and	
Gold	1991),	energy	homeostasis	and	control	of	food	consumption	(Händel	et	al.	1999;	Loktev	and	
Jackson	2013),	neuronal	processes	(Omori	et	al.	2015),	and	reproductive	function	(Koemeter-Cox	
et	al.	2014).	 It	 is	 thought	that	the	BBSome	directly	 interacts	with	components	of	some	GPCRs	
(Berbari	et	al.	2008;	Domire	et	al.	2011;	Jin	et	al.	2010).	Knockout	studies	in	mice	have	displayed	
aberrant	 localisation	 and	 signalling	 of	 the	 somatostatin	 receptor,	 Sstr3	 (Händel	 et	 al.	 1999),	
melanin-concentrating	 hormone	 receptor,	 Mchr1	 (Berbari	 et	 al.	 2008)	 and	 a	 neuropeptide	
receptor,	 Npy2R	 (Loktev	 and	 Jackson	 2013).	 Also,	 BBSome	 knockdown	 in	 murine	 neuronal	
primary	cilia	has	demonstrated	increased	dopamine	accumulation,	though	the	localisation	of	the	
dopamine	receptor	was	not	affected	(Domire	et	al.	2011).	
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1.4.2	Hedgehog	signalling	
Efficient	IFT	within	the	primary	cilium	is	vital	for	key	signal	transduction	pathways,	including	the	
hedgehog	(HH)	pathways.	HH	is	required	for	successful	mammalian	embryonic	development	for	
organogenesis	and	development	of	the	body	axis,	as	well	as	regulation	of	adult	stem	cells	in	tissue	
maintenance	and	regeneration	(Petrova	and	Joyner	2014).	There	are	3	known	HH	ligands,	namely	
Sonic	hedgehog	(SHH),	Indian	hedgehog	(IHH),	or	Desert	hedgehog	(DHH),	where	SHH	is	the	best	
characterised	and	thus	is	more	commonly	studied	with	respect	to	the	primary	cilium.	The	first	
connection	 between	 the	 primary	 cilium	 and	HH	 signalling	was	 acquired	 through	mutagenesis	
screens	in	mouse	embryos.	Disruption	of	two	components	of	the	IFT-B	complex,	Ift172	and	Ift88,	
resulted	in	a	marked	decrease	in	downstream	Shh	mediators,	as	well	as	aberrant	Shh-dependent	
development	 of	 the	 neural	 tube	 (Huangfu	 et	 al.	 2003).	 Further	 investigations	 disrupted	 both	
retrograde	and	anterograde	complexes	and	determined	 that	although	Shh	 ligand	binding	was	
unaffected,	downstream	mediators	were	aberrantly	expressed,	including	the	HH	receptor	Ptch1	
and	pathway	effectors	Gli	 transcription	 factors	 (Liu	et	al.	2005;	Huangfu	and	Anderson	2005).	
These	experiments	suggested	that	the	primary	cilium	is	a	structural	requirement	for	robust	HH	
signalling	(figure	1.2B).	
	
1.4.3	Mechanosensation	
Despite	 their	 rigidity	 enforced	 by	 a	 strong	microtubule	 backbone,	 the	 primary	 cilium	 detects	
physical	 stimuli	 by	movement	under	 fluid	 flow	or	pressure,	 called	mechanosensation.	 Studies	
have	focussed	on	the	link	between	mechanosensation	and	cilia	that	protrude	from	epithelial	cells	
of	the	renal	tubular	lumen	(Nauli	and	Zhou	2004;	Nauli	et	al.	2003).	In	this	tissue	specific	role,	
bending	of	cilia	by	fluid	flow	regulates	proliferation	and	differentiation	of	renal	cells	by	activating	
an	intracellular	Ca2+	signalling	cascade	(Praetorius	and	Spring	2001).	
	
The	polycystin	proteins,	PC1	and	PC2,	are	encoded	by	the	PKD1	and	PKD2	genes	respectively,	
which	 are	 mutated	 in	 autosomal	 dominant	 polycystic	 kidney	 disease	 (ADPKD)	 (Boucher	 and	
Sandford	2004).	Together,	these	proteins	heterodimerise	to	form	a	receptor	channel	complex,	
located	at	the	ciliary	membrane	of	renal	epithelial	cells	(Nauli	et	al.	2003).	It	was	determined	that	
shear	stress	by	fluid	flow	triggers	a	PC1/PC2	dependent	influx	of	Ca2+	into	the	primary	cilium.	This	
increase	in	intracellular	Ca2+	concentration	can	lead	to	a	variety	of	consequences,	including	cell	
morphology,	differentiation,	growth,	and	apoptosis.	Furthermore,	 it	 is	 thought	that	Ca2+	 influx	
switches	on	non-canonical	Wnt	signalling	(Happé	et	al.	2011)	(figure	1.2C).	
	
		
Figure	1.2	–	Examples	of	key	processes	enabled	by	primary	cilia	(legend	on	next	page)	
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Figure	1.2	(on	previous	page)	–	A)	Cilia	specific	GPCR	trafficking:	(1)	The	BBSome	recruits	the	cilia	associated	
GPCR,	such	as	SSTR3,	to	the	ciliary	membrane	via	interaction	with	ARL6	(BBS3).	(2)	The	receptor	is	trafficked	
to	the	ciliary	tip	by	interaction	with	the	anterograde	IFT-B	complex.	(3)	The	ligand,	such	as	somatostatin,	
induces	a	conformational	change	upon	binding,	converting	GDP	to	GTP	and	dissociating	the	G	protein.	(4)	
Release	 of	 G	 proteins	 activates	 downstream	 pathways,	 for	 example,	 through	 the	 cAMP-dependent	
signalling.	
B)	 Hedgehog	 signalling:	 (1)	 Localisation	 of	 PTCH1	 at	 the	 plasma	 membrane	 sequestered	 SMO	 in	 the	
cytoplasm,	allowing	the	repressed	GLI	form	(GLI-R)	to	be	processed.	(2)	HH	binds	to	PTCH1,	quenching	its	
suppression	 on	 SMO.	 (3)	 SMO	 is	 free	 to	 be	 trafficked	 to	 the	 ciliary	 tip,	 where	 it	 inhibits	 SUFU.	 (4)	
Suppression	of	SUFU	allows	accumulation	of	GLI	at	the	ciliary	tip,	which	is	processed	to	the	active	form	
(GLI-A).	(5)	GLI-A	translocates	to	the	nucleus	where	it	activates	HH	pathways.	
C)	Mechanosensation:	(1)	Detection	of	extracellular	fluid	flow	induces	influx	of	calcium	through	PC1/PC2	
receptor	 channel	 complex.	 (2)	 Calcium	 translocates	 and	 accumulates	 in	 the	 cytosol,	 which	 activates	
subcellular	pathways	to	prevent	pro-proliferative	signalling.	(3)	Canonical	Wnt	signalling	is	prevented	as	β-
catenin	is	sequestered	in	the	cytosol	where	it	is	ubiquitinated	for	proteasomal	degradation.	
	
1.4.4	Wnt	signalling	and	planar	cell	polarity	
Similar	 to	 HH	 signalling,	 Wnt	 signalling	 is	 an	 evolutionarily	 conserved	 pathway	 and	 in	 some	
circumstances,	may	be	mediated	or	organised	by	the	primary	cilium.	Canonical	Wnt	signalling,	
non-canonical	 planar	 cell	 polarity	 (PCP)	 and	 non-canonical	 Wnt/Ca2+	 pathways	 have	 been	
characterised.	The	canonical	pathway	is	pro-proliferative,	whereas	non-canonical	pathways	are	
responsible	for	differentiation,	homeostasis,	and	polarisation	of	tissues	(Wallingford	and	Mitchell	
2011).	Canonical	Wnt	signalling	is	β-catenin	dependent,	while	non-canonical	signalling	occurs	in	
the	 absence	 of	 β-catenin.	 Although	 the	 primary	 cilium	 is	 not	 essential	 for	 Wnt	 signalling	
(Eggenschwiler	 and	 Anderson	 2007),	 it	 has	 been	 suggested	 that	 the	 cilium	 plays	 a	 role	 in	
restricting	the	canonical	pathway	(Gerdes	et	al.	2007),	and	orchestrates	a	cellular	switch	towards	
non-canonical	Wnt	pathways	(Basten	and	Giles	2013;	Simons	et	al.	2005;	Ross	et	al.	2005).	
	
The	downstream	effect	of	canonical	Wnt	signalling	accumulates	β-catenin	in	the	cytosol,	which	
subsequently	translocates	to	the	nucleus	and	activates	pro-proliferation	transcription	factors.	In	
the	absence	of	Wnt	ligand,	β-catenin	is	sequestered	in	the	cytosol	and	targeted	for	degradation.	
As	a	result,	a	cellular	switch	drives	cellular	differentiation	and	PCP.	The	primary	cilium	is	thought	
to	act	as	a	closed	system	for	non-canonical	Wnt	signalling,	where	interacting	proteins	are	isolated	
to	prevent	the	accumulation	of	β-catenin	(Gerdes	et	al.	2007;	Simons	et	al.	2005).	
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1.5	The	nonmotile	ciliopathies	
Due	 to	 its	 pivotal	 role	 in	 development,	 cellular	 function	 and	 orchestration	 of	 key	 signalling	
pathways,	 defective	primary	 cilia	 can	 lead	 to	 a	number	of	disabling	 rare	diseases,	 collectively	
termed	ciliopathies.	At	least	73	genes	have	been	uncovered	so	far,	which	are	implicated	in	over	
20	different	ciliopathies	of	primary	cilia	(Rachel,	Li,	et	al.	2012;	Waters	and	Beales	2011).	These	
numbers	are	likely	to	expand,	as	new	genes	are	being	diagnosed	and	ciliopathies	proposed.	For	
example,	 it	has	been	suggested	that	amyotrophic	lateral	sclerosis	(ALS)	(Ma	et	al.	2011),	Lowe	
syndrome	 (Coon	 et	 al.	 2012),	 3M	 syndrome,	 and	 Hermansky-Pudlak	 syndrome	 may	 be	 new	
ciliopathies	 (Boldt	 et	 al.	 2016).	 The	 well-defined	 ciliopathies	 are	 Alström	 syndrome	 (ALMS),	
Bardet-Biedl	 Syndrome	 (BBS),	 Ellis	 van	 Creveld	 syndrome	 (EVC),	 Jeune’s	 asphyxiating	 thoracic	
dystrophy	 (JATD),	 Joubert	 Syndrome	 (JBTS),	 Oro-Facial-Digital	 syndrome	 (OFD),	 McKusick-
Kaufman	Syndrome	(MKKS),	Meckel-Gruber	Syndrome	(MKS),	Nephronophthisis	(NPHP),	Leber	
Congenital	 Amaurosis	 (LCA),	 Senior-Løken	 Syndrome	 (SLS),	 and	 Usher	 syndrome	 (USH).	
Nonmotile	 ciliopathies	 can	 be	 generally	 classified	 into	 three	 groups:	 syndromic	 nonskeletal,	
syndromic	skeletal,	and	nonsyndromic	ciliopathies	(table	1.2).	
	
1.5.1	Syndromic	nonskeletal	ciliopathies	
Alström	syndrome	(ALMS)	is	an	autosomal	recessive	disease,	characterised	by	retinal	dystrophy,	
childhood	obesity	and	neurosensory	hearing	 loss.	Due	 to	a	 strong	phenotypic	overlap	 to	BBS,	
including	secondary	features	of	renal	disease,	hypogonadism	in	males	and	type	II	diabetes,	it	can	
often	be	misdiagnosed	(Tobin	and	Beales	2009).	However,	it	is	genetically	distinct	from	BBS	as	a	
single	gene,	ALMS1,	accounts	for	all	diagnoses	(Collin	et	al.	2002).		
	
Bardet-Biedl	 Syndrome	 (BBS)	 is	 an	 autosomal	 recessive	 disorder,	 characterised	 by	 retinal	
dystrophy,	obesity,	renal	dysfunction,	polydactyly,	genital	abnormalities,	and	learning	difficulties.	
Currently	21	genes	are	thought	to	cause	the	syndrome,	making	 it	one	of	 the	most	genetically	
heterogeneous	 ciliopathies.	As	 the	 subject	of	 this	 thesis,	BBS	 is	 comprehensively	described	 in	
section	1.8.	
	
McKusick-Kaufman	 Syndrome	 (MKKS)	 is	 an	 autosomal	 recessive	 disorder	 resulting	 in	 genital	
abnormalities,	 particularly	 hydrometrocolpos	 in	 females,	 polydactyly,	 and	 rarely,	 features	 of	
cardiac	defects.	As	with	ALMS,	there	can	often	be	diagnostic	overlap	with	BBS	in	early	childhood.	
The	key	distinguishing	feature	is	lack	of	retinal	dystrophy,	learning	problems,	renal	dysfunction,	
or	 obesity	 (Elise	 Schaefer	 et	 al.	 2011).	 The	MKKS	 gene	 accounts	 for	 all	 known	 cases	 of	 the	
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syndrome.	 Shortly	 after	 determining	 its	 causative	 role	 in	 MKKS	 (Stone	 et	 al.	 2000),	 it	 was	
identified	as	the	6th	locus	to	be	mutated	in	BBS	(BBS6)	(Katsanis	et	al.	2000).	
	
Phenotype	
Syndromic	nonskeletal	ciliopathies	
Syndromic	skeletal	
ciliopathies	
Nonsyndromic	
ciliopathies	
ALMS	 BBS	 MKKS	 MKS	 JBTS	 SLS	 USH	 EVC	 JATD	 OFD	 NPHP	 LCA	
Retinal	
dystrophy	
1	 1	 	 	 2	 1	 1	 	 2	 2	 	 1	
Renal	
dysfunction	
2	 1	 	 1	 2	 1	 	 	 2	 2	 1	 	
Polydactyly	 	 1	 1	 1	 2	 	 	 1	 1	 1	 	 	
Learning	
difficulties	
	 1	 	 	 1	 	 	 	 	 2	 	 	
Structural	CNS	
abnormalities	
	 	 	 1	 1	 	 	 	 2	 2	 	 	
Severe	skeletal	
abnormalities	
	 	 	 	 	 	 	 1	 1	 1	 	 	
Genital	
abnormalities	
2	 1	 1	 2	 	 	 	 	 	 	 	 	
Obesity	 1	 1	 	 	 	 	 	 	 	 	 	 	
Hearing	loss	 1	 2	 	 	 	 	 1	 	 	 	 	 	
Table	1.2	–	The	clinical	features	of	the	different	nonmotile	ciliopathies,	demonstrating	the	large	phenotypic	
overlap	between	disorders.	Primary	diagnostic	features	are	marked	with	1,	whereas	2	denotes	secondary	
or	 less	commonly	associated	phenotypes.	Data	adapted	from	Mockel	et	al.	2011	and	Online	Mendelian	
Inheritance	in	Man	(OMIM).	
	
Joubert	Syndrome	(JBTS)	is	an	autosomal	recessive	disorder	characterised	by	a	hallmark	“molar	
tooth	sign”	from	cranial	magnetic	resonance	imaging	(MRI)	indicative	of	brain	stem	and	cerebellar	
malformations.	 Additional	 neurological	 symptoms	 include	 ataxia,	 hypoplasia	 of	 the	 cerebellar	
vermis,	 developmental	 delay,	 irregular	 breathing,	 and	 oculomotor	 apraxia	 (Tobin	 and	 Beales	
2009).	Secondary	features	have	some	overlap	with	other	ciliopathies,	such	as	retinal	dystrophy,	
renal	dysfunction	and	polydactyly	(table	1.2).	JBTS	is	highly	heterogeneous	with	at	least	17	genes	
accounting	 for	 diagnoses	 (table	 1.3).	 ~50%	 of	 all	 cases	 arise	 from	 loss	 of	 function	mutations	
(nonsense,	splice-site	disrupting	or	frameshift	variants)	in	CEP290	(Brancati	et	al.	2007),	a	gene	
mutated	in	6	other	ciliopathies.	
	
Meckel-Gruber	 Syndrome	 (MKS)	 is	 a	 severe	 autosomal	 recessive	 disorder,	 which	 commonly	
results	in	embryonic	or	neonatal	lethality	due	to	cilia	dysfunction	during	development.	Cases	are	
characterised	 by	 severe	 renal	 failure,	 encephalocoele	 or	 other	 structural	 CNS	malformations,	
hepatic	 abnormalities	 and	 polydactyly.	 Some	 cases	 report	 a	 characteristic	 sloping	 forehead,	
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bowing	 of	 the	 limbs,	 and	 underdeveloped	 genitalia	 (Salonen	 1984).	 With	 both	 syndromes	
displaying	severe	CNS	defects,	there	is	clinical	and	genetic	overlap	between	MKS	and	JBTS;	8	out	
of	 11	MKS	 genes	 are	 shared	with	 JBTS	 (table	 1.3).	 The	 first	 identified	MKS	 gene,	MKS1,	 was	
implicated	as	the	13th	identified	BBS	gene	(BBS13)	(Leitch	et	al.	2008).	
	
Senior-Løken	Syndrome	(SLS)	is	an	autosomal	recessive	disease	characterised	by	the	combinatory	
features	of	 two	distinct	ciliopathies,	cystic	kidneys	of	NPHP	and	retinal	dystrophy	of	LCA.	As	a	
result,	SLS	has	notable	genetic	overlap	with	NPHP	and	LCA	(Omran	et	al.	2002)	(table	1.3).	
	
Usher	 syndrome	 (USH)	 is	 an	 autosomal	 recessive	 condition	 resulting	 in	 early	 onset	 retinal	
dystrophy	and	congenital	 sensorineural	hearing	defects.	 In	Usher	 syndrome	 type	 I,	 caused	by	
mutations	 in	MYO7A,	USH1C,	CDH23,	PCDH15,	 or	USH1G,	 unintelligible	 speech	 and	 constant	
vestibular	 dysfunction	 are	 also	 observed.	 It	 is	 a	 relatively	 recent	 addition	 to	 the	 ciliopathy	
spectrum	 (Sorusch	et	al.	2014).	Usher	proteins	are	 thought	 to	have	 tissue	specific	 roles,	both	
mediating	trafficking	in	the	connecting	cilium	of	photoreceptors,	and	acting	as	structural	supports	
in	stereocilia	of	cochlear	hair	cells	(Cosgrove	and	Zallocchi	2014).	
	
1.5.2	Skeletal	ciliopathies	
Jeune’s	 asphyxiating	 thoracic	 dystrophy	 (JATD)	 is	 a	 severe	 autosomal	 recessive	 ciliopathy,	
characterised	 by	 short	 ribs,	 narrowed	 thoracic	 cage,	 and	 shortening	 of	 bones.	 Polydactyly	 is	
commonly	an	additional	feature,	as	well	as	secondary	phenotypes	including	renal,	liver,	or	retinal	
dysfunction.	Mortality	commonly	occurs	within	the	first	 few	years	of	 life,	owing	to	respiratory	
constriction	 from	 pulmonary	 hypoplasia	 (Tobin	 and	 Beales	 2009).	 JATD	 is	 a	 genetically	
heterogeneous	disorder,	where	genes	mutated	are	involved	in	intraflagellar	transport	(table	1.3).	
The	skeletal	abnormalities	indicative	of	JATD	are	thought	to	arise	from	aberrant	SHH	signalling	
caused	by	defective	IFT	(Haycraft	et	al.	2007).	
	
Ellis	 van	 Creveld	 syndrome	 (EVC)	 is	 an	 autosomal	 recessive	 skeletal	 dysplasia,	 displaying	
phenotypic	 overlap	 with	 JATD.	 Features	 include	 short	 limbs,	 polydactyly,	 short	 ribs,	 and	
developmental	delay,	while	ectodermal	and	cardiac	defects	distinguish	the	syndrome	from	JATD	
(Waters	 and	 Beales	 2011).	 Two	 genes,	 EVC	 and	 EVC2,	 have	 been	 uncovered	 to	 cause	 the	
syndrome,	which	both	localise	to	the	primary	cilium.	The	molecular	distinction	between	EVC	and	
JATD	may	be	attributed	to	defects	 in	 Indian	hedgehog	signalling,	rather	than	SHH	disrupted	in	
JATD	(Ruiz-Perez	et	al.	2007).	
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Oro-Facial-Digital	 syndrome	 (OFD)	 is	 an	 X-linked	 dominant	 disorder,	 characterised	 by	
developmental	malformations	of	the	oral	cavity,	face,	and	digits.	Commonly	these	features	are	
accompanied	 by	 polycystic	 kidneys,	 structural	 CNS	 abnormalities,	 and	 learning	 difficulties	
(Waters	 and	 Beales	 2011).	 A	 single	 gene,	OFD1,	 has	 been	 associated	with	 the	 disorder,	 also	
mutated	in	an	X-linked	recessive	form	of	JBTS	(Coene	et	al.	2009).	
	
1.5.3	Nonsyndromic	ciliopathies	
Leber	Congenital	Amaurosis	(LCA)	is	an	autosomal	recessive	retinopathy,	characterised	by	severe	
retinal	 degeneration,	 pigmentation	 (retinitis	 pigmentosa	 (RP)),	 and	 nystagmus.	 Degeneration	
usually	presents	within	the	first	year	of	life,	but	patients	have	been	reported	to	have	profound	
retinal	 dysfunction	 from	 birth	 (Chung	 and	 Traboulsi	 2009).	 LCA	 is	 genetically	 heterogeneous,	
affecting	proteins	localising	only	to	the	basal	body	or	transition	zone	(table	1.3).	There	is	some	
genetic	overlap	with	BBS,	NPHP,	and	SLS,	which	may	be	explained	by	mutations	affecting	LCA	
protein	function	in	a	photoreceptor	specific	manner	(Parfitt	et	al.	2016).	
	
Nephronophthisis	(NPHP)	is	an	autosomal	recessive	nephropathy,	characterised	by	early	onset	
renal	 cysts	 and	 tubulointerstitial	 fibrosis.	 Additional	 renal	 features	 may	 include	 polyuria,	
polydipsia,	secondary	enuresis,	and	anaemia.	In	~10%	of	cases,	extrarenal	symptoms	have	been	
described,	but	these	are	associated	with	diagnostic	features	of	other	ciliopathies	such	as	retinal	
dystrophy	(SLS),	skeletal	dysplasia	(JATD),	or	hypoplasia	of	the	cerebellar	vermis	(JBTS)	(Parisi	et	
al.	 2004;	 Tory	 et	 al.	 2007;	 Hoefele	 et	 al.	 2005;	 E	 Schaefer	 et	 al.	 2011).	 NPHP	 is	 genetically	
heterogeneous,	with	8	out	of	13	proteins	localising	the	transition	zone	of	the	primary	cilium	and	
a	distinct	 lack	of	causative	basal	body	proteins	(table	1.3).	There	 is	genetic	overlap	with	other	
ciliopathies	with	nephropathy	features,	such	as	BBS,	SLS,	MKS	and	JBTS.	
	
1.6	A	spectrum	of	overlapping	heterogeneous	disorders	
The	ciliopathies	are	often	described	as	a	spectrum	of	disorders,	as	disruption	of	a	single	organelle	
exhibits	 a	 range	 of	 severities	 and	 phenotypes.	 Ciliopathies	 span	 from	 severe	 multisystem	
disorders	 resulting	 in	 embryonic	 lethality	 (MKKS)	 to	 nonsyndromic	 retinal	 degeneration	 that	
occurs	late	in	life	(LCA)	(Azari	et	al.	2006;	Estrada-Cuzcano	et	al.	2012).	To	complicate	the	model	
further,	there	 is	profound	clinical	heterogeneity	within	each	disorder,	which	may	be	driven	by	
secondary	modifying	mutations	(Ramsbottom	et	al.	2015;	Kousi	and	Katsanis	2015;	Badano	et	al.	
2006).	The	confines	of	each	disease	can	be	challenging	to	diagnose,	as	often	intellectual	disability,	
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retinal	 defects,	 digit	 malformations,	 and	 renal	 or	 hepatic	 dysfunction	 can	 present	 in	 all	
ciliopathies	(Gerdes	et	al.	2009).	
Genes	 BBS	 JATD	 JBTS	 MKKS	 MKS	 NPHP	 LCA	 SLS	 OFD	 Location	
BBS1	 	 	 	 	 	 	 	 	 	
BB	
BBS2	 	 	 	 	 	 	 	 	 	
ARL6	(BBS3)	 	 	 	 	 	 	 	 	 	
BBS4	 	 	 	 	 	 	 	 	 	
BBS5	 	 	 	 	 	 	 	 	 	
MKKS	(BBS6)	 	 	 	 	 	 	 	 	 	
BBS7	 	 	 	 	 	 	 	 	 	
TTC8	(BBS8)	 	 	 	 	 	 	 	 	 	
BBS9	 	 	 	 	 	 	 	 	 	
BBS10	 	 	 	 	 	 	 	 	 	
BBS12	 	 	 	 	 	 	 	 	 	
MKS1	(BBS13)	 	 	 	 	 	 	 	 	 	
LZTFL1	(BBS17)	 	 	 	 	 	 	 	 	 	
BBIP10	(BBS18)	 	 	 	 	 	 	 	 	 	
C8ORF37	(BBS21)	 	 	 	 	 	 	 	 	 	
LCA5	 	 	 	 	 	 	 	 	 	
RP2	 	 	 	 	 	 	 	 	 	
OFD1	 	 	 	 	 	 	 	 	 	
TMEM216	 	 	 	 	 	 	 	 	 	
ARL13B	 	 	 	 	 	 	 	 	 	
AHI1	 	 	 	 	 	 	 	 	 	
TRIM32	(BBS11)	 	 	 	 	 	 	 	 	 	 IF	
CEP290	(BBS14)	 	 	 	 	 	 	 	 	 	
TZ	
WDPCP	(BBS15)	 	 	 	 	 	 	 	 	 	
SDCCAG8	(BBS16)	 	 	 	 	 	 	 	 	 	
IQCB1	 	 	 	 	 	 	 	 	 	
RPGRIP1L	 	 	 	 	 	 	 	 	 	
RPGR	 	 	 	 	 	 	 	 	 	
RP1	 	 	 	 	 	 	 	 	 	
RPGRIP1	 	 	 	 	 	 	 	 	 	
NPHP4	 	 	 	 	 	 	 	 	 	
NEK8	 	 	 	 	 	 	 	 	 	
NPHP3	 	 	 	 	 	 	 	 	 	
B9D2	 	 	 	 	 	 	 	 	 	
NPHP1	 	 	 	 	 	 	 	 	 	
CC2D2A	 	 	 	 	 	 	 	 	 	
B9D1	 	 	 	 	 	 	 	 	 	
TCTN2	 	 	 	 	 	 	 	 	 	
TCTN3	 	 	 	 	 	 	 	 	 	
TCTN1	 	 	 	 	 	 	 	 	 	
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TMEM67	 	 	 	 	 	 	 	 	 	
Ax	INPP5E	 	 	 	 	 	 	 	 	 	
INVS	 	 	 	 	 	 	 	 	 	
IFT27	(BBS19)	 	 	 	 	 	 	 	 	 	
IFT	
IFT172	(BBS20)	 	 	 	 	 	 	 	 	 	
TTC21B	 	  	 	 	  	 	 	
WDR19	 	 	 	 	 	 	 	 	 	
WDR35	 	  	 	 	 	 	 	 	
DYNC2H1	 	  	 	 	 	 	 	 	
IFT80	 	 	 	 	 	 	 	 	 	
KIF7	 	 	 	 	 	 	 	 	 	
CT	
GLIS2	 	 	 	 	 	 	 	 	 	
Table	1.3	–	The	genetic	heterogeneity	of	nonmotile	ciliopathies,	both	within	a	single	disorder	and	across	
different	ciliopathies.	Genes	are	listed	by	localisation	within	primary	cilium,	where	BB	=	basal	body,	IF	=	
intermediate	filaments,	TZ	=	transition	zone,	Ax=Axoneme,	 IFT=	 intraflagellar	transport	machinery,	CT	=	
ciliary	tip.	Table	adapted	from	Rachel	et	al.	2012	and	localisation	taken	from	SYSCILIA	gold	standard	version	
1	(SCGSV1)	database.	
	
The	 spectrum	 also	 exists	 at	 a	 molecular	 level.	 ALMS	 and	 MKKS	 are	 molecularly	 defined	 by	
mutations	 in	 a	 single	 gene,	ALMS1	 and	MKKS	 (BBS6),	 respectively.	On	 the	other	hand,	BBS	 is	
caused	by	pathogenic	variants	across	at	least	21	genes	(table	1.3).	A	single	gene	is	also	capable	
of	manifesting	multiple	 syndromes,	 for	example,	CEP290	 (BBS,	 JBTS,	MKS,	NPHP,	 LCA	or	 SLS),	
RPGRIP1L	(JBTS,	MKS,	NPHP	or	LCA)	and	TTC21B	(JATD,	JBTS	or	NPHP).	In	these	cases,	the	way	
the	genetic	variant	affects	the	protein	function	plays	a	role	in	determining	the	phenotypic	effect.	
For	example,	null	mutations	in	MKS1	resulting	in	nonsense	mediated	decay	(NMD)	cause	MKS,	
whereas	missense	variants	in	MKS1	exhibit	BBS	(Leitch	et	al.	2008).	Furthermore,	LCA	commonly	
results	 from	 a	 deep	 intronic	 variant	 in	CEP290,	 which	 produces	 a	 cryptic	 exon	 as	 a	 result	 of	
aberrant	 splicing.	 This	 variant	 is	 thought	 to	 specifically	 affect	 the	 retina	 due	 to	 a	 residual	
unaffected	CEP290	transcript	rescuing	other	cell	types	(Drivas	et	al.	2015;	Parfitt	et	al.	2016).	
	
Although	 primary	 cilia	 are	 ubiquitously	 expressed,	 each	 ciliopathy	 affects	 a	 combination	 of	
varying	 tissues,	 suggesting	 tissue	specific	 roles	 for	genes	mutated	 in	 respective	disorders.	The	
mechanism	that	separates	the	molecular	differences	between	disorders	is	not	fully	understood.	
There	is	a	general	trend	that	certain	ciliopathies	are	attributed	to	mutation	of	proteins	localising	
to	the	same	ciliary	compartment	(Shaheen	et	al.	2016).	For	example,	JATD	is	caused	by	defects	in	
IFT	proteins,	whereas	JBTS	and	MKS	proteins	primarily	localise	to	the	transition	zone	or	axoneme.	
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Furthermore,	unlike	BBS	proteins,	NPHP	and	SLS	proteins	do	not	localise	to	the	basal	body	(table	
1.3).	
	
1.7	The	Ciliome	
The	cilium	is	a	compartmentalised	organelle	that	is	temporally	and	spatially	distinct	from	other	
cellular	interactions.	As	a	result,	the	proteins	involved	in	cilia	assembly,	function,	maintenance,	
and	disassembly	are	thought	to	work	in	an	intricate	and	relatively	closed	network.	The	interacting	
compendium	of	proteins	has	been	named	the	ciliome	(Inglis	et	al.	2006).	A	curated	database	of	
cilia	and	basal	body	associated	proteins	was	first	assembled	in	2006,	derived	from	comparative	
genomic,	 proteomic,	 microarray	 and	 promoter	 studies	 from	 a	 variety	 of	 model	 organisms	
(Gherman	et	al.	2006).	The	first	edition	of	the	ciliome	consisted	of	over	1000	proteins,	however	
estimates	have	been	considered	at	1200	to	2500	ciliary-related	genes	(van	Dam	et	al.	2017;	Inglis	
et	al.	2006;	Lai	et	al.	2011).	
	
A	number	of	silencing	experiments	using	RNA	interference	(RNAi)	in	ciliated	cells	has	identified	
novel	 ciliary	 genes,	 complexes,	 functions	 and	 interactions	 (J.	 Kim	 et	 al.	 2010;	 Lai	 et	 al.	 2011;	
Wheway	et	 al.	 2015).	A	 study	by	Kim	and	 colleagues	 (2010)	 validated	49	putative	 genes	 that	
modulate	 ciliogenesis,	 as	 well	 as	 identification	 of	 regulatory	 proteins	 linking	 new	 pathways,	
endocytic	recycling	and	actin	dynamics,	with	ciliogenesis.	There	were	a	number	of	proteins	that	
overlapped	with	cell	cycle	entities,	which	verified	the	suspected	relationship	cilia	have	with	cell	
cycle,	migration	and	polarisation	(Christensen	et	al.	2008).	An	interesting	finding	from	Lai	et	al.	
(2011)	was	that	knockdown	of	different	constituents	from	the	same	complex	did	not	necessarily	
exhibit	the	same	phenotype.	For	example,	silencing	of	Ift46	resulted	in	shortened	cilia,	whereas	
knockdown	of	Ift88	prevented	ciliation,	despite	both	proteins	functioning	in	the	IFT-B	complex.	
The	difference	could	be	explained	by	additional	or	specific	roles	a	protein	has	within	or	outside	
of	their	respective	complex.	
	
Large-scale	 studies	 have	 implemented	whole	 genome	 screens	 or	 systems	biology	 approaches	
using	proteomics	techniques.	Wheway	et	al.	(2015)	instigated	a	whole	genome	screen	using	small	
interfering	 RNA	 (siRNA)	 to	 detect	 key	 cilia	 genes	 in	 murine	 inner	 medullary	 collecting	 duct	
(IMCD3)	cells	and	human	telomerase	reverse	transcriptase	retinal	pigmented	epithelial	 (TERT-
RPE1)	cells.	They	identified	112	ciliogenesis	genes	including	previously	unrelated	components	of	
the	ubiproteome,	splicing	factors	and	GPCRs.	This	study	determined	a	novel	interaction	between	
members	of	the	proteasome	and	cilia,	where	knock	down	of	these	subunits	resulted	in	increased	
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cilia	numbers.	This	highlighted	the	prominence	of	robust	proteostasis	in	mediating	ciliary	function	
(Wheway	et	al.	2015).	The	close	network	of	ciliary	proteins	was	further	displayed	by	Boldt	and	
colleagues	(2016)	using	a	powerful	technique	of	tandem	affinity	purification	experiments	coupled	
to	mass	spectrometry.	Using	217	baits	for	well	characterised	ciliary	proteins,	they	were	able	to	
model	 a	 unique	 interacting	 landscape	 consisting	 of	 1319	 proteins	 in	 52	 complexes	 and	 4905	
interactions.	Their	work	supported	previous	links	to	vesicle	transport,	signalling,	ubiquitination	
and	cytoskeletal	regulation	(Mick	et	al.	2015;	Hernandez-Hernandez	et	al.	2013;	Christensen	et	
al.	2008;	J.	Kim	et	al.	2010).	544	non-ciliary	proteins	were	identified,	supporting	the	belief	that	
gold	standard	ciliary	proteins	have	interconnecting	roles	outside	of	the	cilium	(Boldt	et	al.	2016;	
Bizet	et	al.	2015).	
	
Within	the	Cilia	consortium,	the	aim	has	not	only	been	to	recognise	novel	identifications	but	also	
create	 a	 gold	 standard	 set	 of	 cilia	 interacting	 genes.	 The	 SYSCILIA	 gold	 standard	 v1	 (SCGSv1)	
consists	 of	 303	 genes,	 66	 of	 which	 are	 specific	 to	 motile	 cilia,	 and	 are	 comprised	 from	 27	
experimental	ciliary	studies	(van	Dam	et	al.	2013).	The	SCGSv1	dataset	was	stringently	curated	
from	genes	with	a	definite	ciliary	role	that	have	been	experimentally	identified	and	validated.	The	
latest	published	ciliome	 is	 the	CiliaCarta	database,	consisting	of	benchmarked	and	statistically	
integrated	data	from	genome-wide	studies,	literature	and	annotations	(van	Dam	et	al.	2017).	This	
more	extensive	dataset	contains	a	total	of	836	genes.	Of	note,	these	large-scale	screening	and	
curation	studies	are	consistently	identifying	genes	with	unknown	ciliary	function,	suggesting	that	
there	are	still	biological	processes	yet	to	be	uncovered.	
	
The	 studies	 described	 above	have	 augmented	our	 knowledge	of	 how	 the	 components	 of	 the	
ciliome	 interact,	 revealing	 interconnecting	 complexes	 and	 new	 relationships	 with	 different	
cellular	processes.	They	have	also	created	a	valuable	resource	for	dissecting	the	protein	network	
in	the	context	of	ciliopathies,	and	allowing	prediction	of	novel	candidates	for	disease,	as	well	as	
generating	possible	targets	for	therapies.	This	highly	coordinated	and	interconnected	network	of	
proteins	helps	explain	why	ciliopathies	are	phenotypically	similar	with	various	overlapping	clinical	
features.	It	also	provides	an	explanation	for	how	mutations	in	interacting	proteins	can	manifest	
the	same	disease	or	different	diseases	arise	from	variants	in	the	same	gene.	An	example	of	the	
latter	is	CEP290,	a	gene	mutated	in	6	distinct	ciliopathies	(BBS,	JBTS,	MKS,	NPHP,	LCA,	and	SLS;	
table	 1.3)	 (Coppieters	 et	 al.	 2010).	 A	 theory	 for	 its	 multifaceted	 involvement	 is	 that	 CEP290	
directly	 interacts	 with	 different	 complexes	 linked	with	 each	 ciliopathy	 (Zaghloul	 and	 Katsanis	
2009).	For	example,	CEP290	interacts	with	RPGRIP1	and	RPGR	resulting	in	LCA	(Rachel,	Li,	et	al.	
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2012);	proteins	of	the	transition	zone	including	CC2D2A	and	TMEM67,	which	cause	MKS	and	JBTS	
(Gorden	et	al.	2008;	Garcia-Gonzalo	et	al.	2011);	components	of	the	BBSome	and	BBS6	causing	
BBS	(Barbelanne	et	al.	2015;	Rachel,	May-Simera,	et	al.	2012);	and	IQCB1	resulting	in	NPHP	and	
SLS	(Barbelanne	et	al.	2013)	(figure	1.3).	
	
	
Figure	1.3	–	The	multifaceted	interactions	of	CEP290,	which	may	explain	its	role	in	different	ciliopathies.	
Solid	 lines	 refer	 to	 direct	 interactions	 between	 CEP290	 and	 associating	 proteins.	 Dotted	 lines	 refer	 to	
interactions	not	directly	involving	CEP290.	Proteins	are	also	grouped	by	disorders	they	are	implicated	in,	
where	BBS	=	Bardet-Biedl	 Syndrome,	 LCA	=	 Leber	 congenital	 amaurosis,	 SLS	=	Senior-Løken	Syndrome,	
NPHP	=	Nephronophthisis,	MKS	=	Meckel-Gruber	 Syndrome,	 JBTS	=	 Joubert	 Syndrome.	 Image	 adapted	
from	Rachel	et	al.	2012.	
	
1.8	Bardet-Biedl	Syndrome	
Bardet-Biedl	 Syndrome	 (BBS)	 is	 a	 pleiotropic	 genetic	 disorder	 that	 exhibits	 both	 genetic	 and	
phenotypic	 heterogeneity.	 It	 is	 a	 rare	 disease,	 estimated	 to	 affect	 1	 in	 160,000	 individuals	 in	
Northern	Europe	(Waters	and	Beales	2011).	The	prevalence	is	greater	in	isolated	communities	
such	as	Kuwait	(1	in	13,500)	(Farag	and	Teebi	2008)	or	Newfoundland	(1	in	17,000)	(Green	et	al.	
Chapter	1:	Introduction	
	
46	
1989),	where	there	is	an	increased	level	of	consanguinity	or	a	smaller	gene	pool.	BBS	was	first	
described	 in	 the	 early	 20th	 century.	 Georges	 Bardet	 reported	 the	 clinical	 features	 of	 retinal	
deterioration,	polydactyly,	obesity	and	hypogonadism	in	2	siblings	(Bardet	1920).	Independently,	
Arthur	Biedl	published	findings	for	siblings	displaying	the	same	clinical	features	as	Bardet’s,	with	
additional	mental	retardation	(Biedl	1922).	These	5	features	became	the	diagnostic	criteria	for	
Bardet-Biedl	syndrome.	It	wasn’t	until	some	50	years	later	that	renal	dysfunction	was	reported	
(Bauman	and	Hogan	1973),	and	was	later	suggested	to	be	an	additional	cardinal	feature	of	BBS	
(Harnett	et	al.	1988;	Green	et	al.	1989;	Churchill	et	al.	1981).	
	
Throughout	 early	 clinical	 reports	 on	 BBS,	 a	 large	 amount	 of	 phenotypic	 heterogeneity	 was	
described	(Green	et	al.	1989;	Klein	and	Ammann	1969),	often	making	it	challenging	to	correctly	
diagnose	patients.	For	example,	in	a	population-based	survey	by	Klein	and	Ammann	(1969),	45.6%	
of	patients	were	reported	to	display	a	‘complete’	BBS	phenotype,	whereas	others	manifested	an	
‘incomplete’	 (4/5	 cardinal	 features,	 exclusive	 of	 renal	 dysfunction),	 ‘abortive’	 (2/5	 cardinal	
features)	or	undetermined	condition.	Therefore,	a	set	of	diagnostic	criteria	was	set	out	where	
4/5	traits	were	required	for	a	BBS	diagnosis	(Schachat	and	Maumenee	1982).	Moreover,	there	
were	often	difficulties	 in	diagnosing	patients	at	a	young	age	due	 to	 the	progressive	nature	of	
some	 symptoms.	 The	 age	 of	 onset	 for	 retinal	 dysfunction	 and	 renal	 abnormalities	 can	 vary	
considerably.	 Polydactyly	 is	 the	 only	 dysmorphic	 cardinal	 feature	 seen	 at	 birth,	 which	 is	 not	
uncommon	 or	 distinct	 to	 BBS.	 To	 facilitate	 an	 earlier	 diagnosis	 age,	 a	 number	 of	 secondary	
features	 have	 been	 incorporated	 into	 the	 diagnostic	 criteria.	 These	 features	 include	
developmental	 delay,	 speech	 disorders,	 behavioural	 traits,	 diabetes	 mellitus,	 strabismus/	
cataracts,	 orodental	 abnormalities,	 cardiovascular	 anomalies,	 syndactyly/brachydactyly,	 and	
fibrocystic	 liver	 disease	 (Waters	 and	Beales	 2011;	 Beales	 et	 al.	 1999).	 Therefore,	 Beales	 et	 al	
(1999)	 suggested	 updated	 criteria,	 where	 at	 least	 4	 cardinal	 features,	 or	 a	 combination	 of	 3	
cardinal	plus	2	secondary	features	are	required	for	BBS.	
	
1.8.1	Identification	of	BBS	loci	
Initially,	the	genetic	model	for	BBS	was	not	clear.	Bergsma	and	Brown	(1975)	discussed	whether	
BBS	could	be	inherited	through	a	polygenic	model,	as	it	was	not	understood	how	a	multisystem	
disorder	could	arise	from	a	single	gene.	On	the	other	hand,	BBS	features	were	clearly	distinct	and	
relatively	consistent,	so	it	was	suspected	that	the	BBS	gene	would	map	to	a	single	locus	(Katsanis,	
Lupski,	et	al.	2001).	The	model	was	complicated	further	when,	upon	linkage	analysis	of	affected	
families,	many	loci	were	identified.	BBS2	was	the	first	BBS	locus	uncovered,	which	was	mapped	
Chapter	1:	Introduction	
	
47	
to	chromosome	16	in	a	large	consanguineous	Bedouin	family	(Kwitek-Black	et	al.	1993).	This	was	
shortly	 followed	 by	 BBS1	 to	 chromosome	 11	 (Leppert	 et	 al.	 1994),	 BBS3	 to	 chromosome	 3	
(Sheffield	et	al.	1994)	and	BBS4	to	chromosome	15	(Carmi	et	al.	1995).	Further	genetic	analysis	
of	distantly	related	Newfoundland	families	determined	that	there	was	evidence	for	more	BBS	loci	
(Young,	Woods,	et	al.	1999),	revealing	the	identification	of	BBS5	(Young,	Penney,	et	al.	1999)	and	
BBS6	(Katsanis	et	al.	2000).	
	
From	2003	onwards	there	was	a	steady	identification	of	novel	BBS	loci	by	linkage	analysis	(BBS7)	
(Badano	et	al.	2003),	homozygosity	mapping	(BBS8-BBS16)	(Ansley	et	al.	2003;	Nishimura	et	al.	
2005;	 Stoetzel	 et	 al.	 2006;	 Leitch	 et	 al.	 2008;	 S.	 K.	 Kim	 et	 al.	 2010;	Metzler	 2011)	 and	more	
recently	whole	exome	and	whole	genome	sequencing	(BBS17-BBS20,	and	BBS21,	respectively)	
(Marion,	Stutzmann,	et	al.	2012;	Scheidecker	et	al.	2014;	Aldahmesh	et	al.	2014;	Schaefer	et	al.	
2016;	Heon	et	al.	2016).	Due	to	the	advent	of	next	generation	sequencing	(NGS)	technologies,	
the	diagnosis	rate	has	increased	from	80%	to	~90%	determined	cases	in	the	last	half	a	decade	
(Prof	P.	Beales,	personal	communication).	
	
The	distribution	of	BBS	gene	variants	can	vary	amongst	different	ethnic	populations.	The	majority	
of	pathogenic	variants	are	located	in	BBS1	and	BBS10,	which	are	found	at	an	incidence	of	23%	
and	 20%,	 respectively	 (Mykytyn	 et	 al.	 2002;	 Forsythe	 and	 Beales	 2013)	 (table	 1.4).	 Within	
European	populations,	BBS1	p.M390R	is	the	most	common	variant,	where	an	arginine	residue	
replaces	a	methionine	at	the	390th	amino	acid	in	BBS1.	This	variant	accounts	for	~80%	of	all	BBS1	
findings	and	is	thought	to	have	risen	from	an	ancient	haplotype	(Mykytyn	et	al.	2003;	Beales	et	
al.	2003).	The	incidence	of	other	genes	is	rare,	where	some	genes,	such	as	BBS15/WDPCP,	have	
only	been	seen	in	a	single	family	(S.	K.	Kim	et	al.	2010).	Variants	in	BBS4,	BBS5	and	BBS8	are	more	
commonly	seen	in	Middle	Eastern	families	(Forsythe	and	Beales	2013).	
	
	
		
Table	1.4	–	Summary	of	causative	BBS	genes,	including	frequency	of	gene	in	the	BBS	population	and	cellular	localisation.	BB=basal	body,	TZ=transition	zone,	IF=	intermediate	filaments.		
BBS	gene	
name	
Gene	
Alias	
Loci	 Frequency	 Known	Function	 Localisation	 References	
BBS1	 		 11q13.2	 23%	 Part	of	the	BBSome	complex	 BB	 (Leppert	et	al.	1994;	Mykytyn	et	al.	2002;	Jin	et	al.	2010)	
BBS2	 		 16q21	 8%	 Part	of	the	BBSome	complex	 BB	 (Kwitek-Black	et	al.	1993;	Jin	et	al.	2010)	
BBS3	 ARL6	 3q11.2	 2%	 GTPase	that	functions	with	BBSome	to	coat	proteins	
for	IFT	
BB,	TZ	 (Sheffield	et	al.	1994;	Fan	et	al.	2004;	Wiens	et	al.	
2010;	Jin	et	al.	2010)	
BBS4	 		 15q24.1	 2%	 Part	of	the	BBSome	complex	 BB	 (Carmi	et	al.	1995;	Jin	et	al.	2010)	
BBS5	 		 2q31.1	 <1%	 Part	of	the	BBSome	complex	 BB	 (Young,	Penney,	et	al.	1999;	Jin	et	al.	2010)	
BBS6	 MKKS	 20p12.2	 6%	 Forms	chaperonin	complex	for	BBSome	assembly	 BB	 (Katsanis	et	al.	2000;	Seo	et	al.	2010)	
BBS7	 		 4q27	 2%	 Part	of	the	BBSome	complex	 BB	 (Badano	et	al.	2003;	Jin	et	al.	2010)	
BBS8	 TTC8	 14q31.3	 1%	 Part	of	the	BBSome	complex	 BB	 (Ansley	et	al.	2003;	Jin	et	al.	2010)	
BBS9	 		 7p14.3	 6%	 Part	of	the	BBSome	complex	 BB	 (Nishimura	et	al.	2005;	Jin	et	al.	2010)	
BBS10	 		 12q21.2	 20%	 Forms	chaperonin	complex	for	BBSome	assembly	 BB	 (Stoetzel	et	al.	2006;	Seo	et	al.	2010)	
BBS11	 TRIM32	 9q33.1	 <1%	 E3	ubiquitin	ligase	 IF	 (Chiang	et	al.	2006)	
BBS12	 		 4q27	 5%	 Forms	chaperonin	complex	for	BBSome	assembly	 BB	 (Stoetzel	et	al.	2007;	Seo	et	al.	2010)	
BBS13	 MKS1	 17q22	 5%	 Regulates	ciliogenesis	and	centriole	migration	 BB	 (Tammachote	et	al.	2009;	Leitch	et	al.	2008)	
BBS14	 CEP290	 12q21.32	 1%	
Required	for	recruitment/targeting	of	key	centrosomal	
proteins.	Involved	in	regulation	of	BBSome		
BB,	
centrosome	 (Leitch	et	al.	2008;	Barbelanne	et	al.	2015)	
BBS15	 WDPCP	 2p15	 <1%	 Necessary	for	ciliogenesis	 Axoneme	 (S.	K.	Kim	et	al.	2010)	
BBS16	 SDCCAG8	 1q43	 <1%	 Unknown	
BB,	
centriole,	TZ	 (Metzler	2011;	Insolera	et	al.	2014)	
BBS17	 LZTFL1		 3p21.31	 <1%	 Regulates	BBSome	trafficking	and	HH	signalling	 BB,	cytosol	 (Marion,	Stutzmann,	et	al.	2012;	Seo	et	al.	2011)	
BBS18	 BBIP10	 10q25.2	 <1%	 Part	of	the	BBSome	complex.	Necessary	for	
microtubule	maintenance	
BB	 (Scheidecker	et	al.	2014;	Jin	et	al.	2010)	
BBS19	 IFT27	 22q12.3	 <1%	 Anterograde	IFT	 IFT-B	 (Aldahmesh	et	al.	2014;	Lucker	et	al.	2005)	
BBS20	 IFT172	 2p23.3	 <1%	 Anterograde	IFT	 IFT-B	 (Schaefer	et	al.	2016;	Lucker	et	al.	2005)	
BBS21	 C8ORF37	 8q22.1	 <1%	 Unknown	 BB	 (Heon	et	al.	2016;	Khan	et	al.	2016)	
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1.8.2	BBS	causality	and	localisation	
Despite	 successful	 cloning	 of	BBS1-BBS5	 at	 the	 turn	 of	 the	 century,	 the	 aetiology	 of	 BBS	 still	
remained	 elusive	 (Mykytyn	 et	 al.	 2002;	 Mykytyn	 et	 al.	 2001;	 Nishimura	 et	 al.	 2001).	 The	
breakthrough	occurred	in	2003	with	the	cloning	and	expression	experiments	of	BBS8	in	ciliated	
cells	and	Caenorhabditis	elegans	(Ansley	et	al.	2003).	TTC8	was	identified	as	BBS8	after	screening	
for	structural	protein	homology	with	BBS4,	both	of	which	contained	conserved	tetratricopeptide	
repeats	 (TPRs).	 TPRs	 are	 structural	motifs	 that	 are	 common	 in	 complexing	 proteins,	 and	 are	
known	 to	 be	 associated	with	 flagella	 and	 cilia	 (Xu	 et	 al.	 2015).	 Ansley	 and	 colleagues	 (2003)	
noticed	the	structural	similarity	with	the	prokaryotic	protein	PilF,	required	for	multimerisation	
and	localisation	of	the	bacterial	pilus	(Koo	et	al.	2008).	They	therefore	speculated	that	BBS8	might	
localise	to	mammalian	cilia.	The	investigation	determined	that	BBS8	was	a	centrosomal	protein,	
mimicking	localisation	of	y-tubulin	at	MTOCs,	and	was	tightly	associated	with	the	basal	body	in	
ciliated	IMCD3	cells.	These	findings	were	mimicked	with	the	C.	elegans	othologues	of	BBS1,	BBS2,	
BBS7	and	BBS8,	demonstrating	that	BBS	was	likely	caused	by	a	defective	basal	body.	
	
1.8.3	Complexes,	roles	and	interactions	
The	majority	of	BBS	proteins	are	known	to	function	in	complexes	and	networks,	which	can	help	
explain	why	mutations	disrupting	single	proteins	in	the	complex	can	result	 in	the	same	clinical	
phenotype.	 Through	 investigation	 of	 structural	 homology,	 it	 was	 observed	 that	 certain	 BBS	
proteins	shared	tertiary	similarity	and	interaction	motifs.	BBS1/BBS2/BBS7	are	formed	from	β-
propellers	and	BBS4/BBS8	both	have	conserved	TPR	domains,	raising	the	possibility	that	these	
proteins	share	functional	likeness	and	interact	within	complexes.	Unexpectedly,	it	was	found	that	
at	least	6	proteins	associated	with	BBS4	through	tandem	affinity	purification	experiments,	namely	
BBS1,	 BBS2,	 BBS5,	 BBS7,	 BBS8	 and	 BBS9	 (Nachury	 et	 al.	 2007).	 Subsequently,	 an	 additional	
protein,	BBIP10	(BBS18)	was	found	to	associate,	forming	the	fully	assembled	BBSome	complex	
(Loktev	et	al.	2008).	It	has	been	established	that	this	core	complex	is	required	for	recruitment	of	
cargo	 to	 the	 ciliary	membrane,	 through	 interaction	 with	 RABIN8	 and	 RAB8,	 and	may	 have	 a	
stabilising	 role	 in	 IFT	 (Wei	et	al.	2012;	 Jin	et	al.	2010)	 (figure	1.4).	Although	BBSome	proteins	
assemble	into	a	unit,	they	are	known	to	have	specific	roles	either	 independently	or	within	the	
complex.	BBS1	interacts	directly	with	ARL6,	which	recruits	the	BBSome	to	the	ciliary	membrane	
(Jin	et	al.	2010;	Mourão	et	al.	2014).	BBS4	is	required	for	anchoring	of	the	BBSome	to	the	basal	
body,	due	to	direct	 interaction	with	the	centriolar	satellite	protein,	PCM1	(Kim,	2004).	BBS5	is	
thought	to	have	a	specific	role	 in	photoreceptors	due	to	 light-dependent	phosphorylation	and	
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interaction	with	 phototransduction	 protein,	 Arrestin1	 (Smith,	 2013).	 External	 to	 the	 BBSome,	
BBIP10	 (BBS18)	 was	 shown	 to	 be	 required	 for	 polarisation,	 stabilisation	 and	 acetylation	 of	
microtubules	(Loktev	et	al.	2008).	
	
It	is	thought	that	the	BBSome	is	not	required	for	ciliogenesis,	as	knockdown	of	most	members	do	
not	affect	ciliary	assembly,	with	the	exception	of	BBS1	and	BBIP10	(BBS18)	(Loktev	et	al.	2008;	Jin	
et	al.	2010).	Furthermore,	murine	models	are	viable	and	express	cilia	when	Arl6,	Bbs2,	BBS4,	and	
Bbs7	are	separately	knocked	out,	which	is	not	the	case	for	Bbs1	(Mykytyn	et	al.	2004;	Nishimura	
et	al.	2004;	Zhang	et	al.	2011;	Zhang	et	al.	2013).	This	suggests	that	BBS1	has	an	independent	
essential	 role	 in	 cilium	 assembly.	 Moreover,	 the	 importance	 of	 BBS1	 is	 reflected	 in	 human	
genetics,	where	homozygous	null	mutations	have	been	identified	in	all	subunits	of	the	BBSome,	
apart	from	BBS1	(Jin	et	al.	2010).	Disease	causing	mutations	in	BBS1	most	commonly	present	with	
the	p.M390R	missense	variant	on	at	least	one	allele	(Mykytyn	et	al.	2002).	
	
A	second	complex	was	discovered	featuring	three	BBS	proteins,	MKKS	(BBS6),	BBS10	and	BBS12,	
with	 homology	 to	 the	 TCP-1	 Ring	 Complex	 (TRiC)	 chaperonin	 family	 (also	 called	 chaperone	
containing	 TCP-1	 (CCT)).	 As	 mutations	 in	 these	 chaperonin-like	 genes	 result	 in	 the	 same	
phenotype	as	the	BBSome	genes,	a	close	interaction	was	expected	between	the	two	complexes.	
Seo	and	colleagues	(2010)	demonstrated	that	the	3	chaperonin-like	proteins	were	required	for	
BBSome	assembly	and	formed	a	complex	with	6	other	TRiC/CCT	chaperones	that	localised	to	the	
centrosome.	BBS6,	BBS10	or	BBS12	did	not	exhibit	typical	ATPase	activity	required	for	protein	
folding	by	chaperone	proteins,	but	were	necessary	to	stabilise	BBS2	and	BBS7	and	coordinate	the	
formation	of	the	BBSome	(figure	1.4)	(Seo	et	al.	2010).	Thus,	their	role	may	be	to	mediate	the	
association	of	BBSome	proteins	with	the	6	TRiC/CCT	chaperones.	
	
By	 contrast,	 the	 ciliary	 function	 of	 the	 outstanding	 BBS	 proteins	 remains	 elusive.	BBS11	 was	
identified	as	the	RING	finger	E3	ubiquitin	 ligase,	TRIM32	 (Chiang	et	al.	2006).	BBS11	has	been	
shown	 to	 be	 associated	 with	 SHH	 repressor,	 GLIS2,	 (Ramachandran	 et	 al.	 2014)	 and	 other	
ubiquitin	 ligases	 were	 shown	 to	 localise	 to	 primary	 cilia,	 indicating	 a	 potential	 role	 in	 ciliary	
function	(Boldt	et	al.	2016).	However,	little	else	is	known	about	its	BBS-specific	role.	Mutation	of	
LZTFL1/BBS17	 was	 described	 in	 a	 consanguineous	 family	 exhibiting	 atypical	 BBS,	 featuring	
obesity,	hypogonadism,	cognitive	impairment,	situs	inversus	and	insertional	polydactyly	(Marion,	
Stutzmann,	et	al.	2012).	BBS17	interacts	with	BBS2,	BBS7	and	BBS9	of	the	BBSome	and	has	also	
been	implicated	in	trafficking	of	Smoothened	(SMO),	a	SHH	signalling	transducer,	to	the	ciliary	
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membrane	(Seo	et	al.	2011).	BBS19	and	BBS20	are	the	only	BBS	genes	that	localise	within	an	IFT	
complex.	It	has	been	determined	that	BBS19	functions	outside	of	the	IFT-B	complex	assembly	to	
assist	with	BBSome	assembly	and	exit	from	the	cilia	(Liew	et	al.	2014;	Eguether	et	al.	2014).	
	
Figure	1.4	–	Molecular	assembly	and	interactions	of	the	BBSome.	1)	The	components	of	the	BBSome	(BBS1,	
BBS2,	BBS4,	BBS5,	BBS7,	BBS8,	BBS9,	and	BBS18)	are	assembled	sequentially	by	the	TRiC	chaperonin-like	
complex	(BBS6,	BBS10,	and	BBS12),	thought	to	be	initiated	by	interaction	with	BBS7	and	BBS2	first	(Seo	et	
al.	2010).	2)	Once	assembled,	the	BBSome	is	targeted	to	the	basal	body	due	to	an	 interaction	between	
BBS4	 and	 PCM1.	 3)	 The	 BBSome	 functions	 through	 interactions	with	 ARL6/BBS3,	 RABIN8	 and	 RAB8	 to	
recruit	protein	cargo	to	the	ciliary	membrane	for	intraflagellar	transport.	
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1.8.4	Molecular	basis	of	BBS	
Through	manipulation	of	BBS	genes	in	experiments	utilising	ciliated	cells	and	model	organisms,	
our	 knowledge	 of	 BBS	 has	 augmented	 in	 recent	 years.	 Although	 the	 precise	 aetiology	
differentiating	all	21	genes	is	not	entirely	understood,	here	I	will	outline	the	molecular	basis	of	
the	cardinal	BBS	features.	
	
1.8.4.1	Retinal	dystrophy	
Retinal	dystrophy	 is	 the	most	prevalent	BBS	 feature,	predicted	 to	be	present	 in	93%	of	 cases	
(Forsythe	 and	 Beales	 2013).	 Patients	 are	 thought	 to	 have	 functional	 eyesight	 at	 birth,	 but	
progressive	visual	decline	begins	early,	typically	leading	to	registered	blindness	before	adulthood	
(Beales	 et	 al.	 1999).	 Retinal	 dystrophy	 in	 BBS	 is	 usually	 diagnosed	 as	 rod-cone	 dystrophy,	
describing	 the	 deterioration	 of	 rod	 photoreceptor	 first,	 followed	 by	 decline	 of	 cone	
photoreceptors.	 Cone-rod	 dystrophy	 is	 less	 commonly	 described	 (Mockel	 et	 al.	 2011).	 Rod	
photoreceptors	are	responsible	for	light	sensitivity;	thus,	the	first	retinal	symptom	of	rod-cone	
dystrophy	tends	to	be	nyctalopia	(night	blindness).	Subsequent	loss	of	visual	acuity	and	colour	
vision	follows	with	global	retinal	degeneration.	In	a	survey	of	109	BBS	patients	by	Beales	et	al.	
(1999),	the	mean	age	of	onset	for	night	blindness	and	subsequent	registration	of	blindness	was	
8.5	 years	 and	 15.5	 years,	 respectively.	 Secondary	 ocular	 features	 can	 include	 cataracts,	
strabismus,	nystagmus,	myopia,	astigmatism	and	macular	degeneration	(Green	et	al.	1989).	The	
pathobiology	of	retinal	dystrophy	in	BBS	is	reviewed	in	detail	in	chapter	6.	
	
1.8.4.2	Obesity	
Obesity	 is	 a	 result	 of	 energy	 imbalance	 caused	 by	 a	 greater	 calorific	 intake	 than	 metabolic	
expenditure.	 Childhood	 truncal	 obesity	 has	 been	 reported	 to	 affect	 72-92%	 of	 BBS	 patients	
(Forsythe	and	Beales	2013),	though	other	surveys	suggest	72%	are	overweight	and	52%	are	obese	
(Beales	 et	 al.	 1999).	 Obesity	 is	 diagnosed	 by	 the	World	 Health	 Organisation	 (WHO)	 through	
assessment	 of	 body	mass	 index	 (BMI),	 calculated	 by	 dividing	 body	weight	 by	 height	 squared	
(kg/m2).	The	BMI	healthy	weight	range	is	18.5-24.9	kg/m2,	whereas	25-29.9	kg/m2	is	classed	as	
overweight	and	>30	kg/m2	is	obese.	Although	there	is	a	high	prevalence	of	obesity	in	BBS	patients,	
some	argue	 that	 it	 is	 a	non-specific	phenotype	 in	 today’s	Western	 society	1,	 even	more	 so	 in	
subjects	likely	to	be	inactive	due	to	visual	decline	(Pietiläinen	et	al.	2008).	Regardless,	obesity	is	
																																																						
1	A	2008	WHO	survey	revealed	that	26%	of	American	men	and	29%	of	American	women	were	reported	as	obese	
(World	Health	Organisation	2008)	
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associated	 with	 morbidity	 and	 mortality	 in	 patients	 and	 can	 lead	 to	 secondary	 features	 of	
cardiovascular	disease,	cancer	and	type	II	diabetes.	
	
BBS-related	obesity	is	molecularly	distinct	from	nonsyndromic	obesity.	Studies	have	determined	
that	obesity	results	from	hyperphagia	triggered	by	leptin	resistance	and	defective	satiety	control	
in	 hypothalamic	 neurons.	BBS4	 null	mice	 exhibited	 hyperphagia,	 consuming	 between	 20-30%	
more	 than	 their	wild	 type	 littermates,	 and	displayed	elevated	 circulating	 leptin	 (Eichers	 et	 al.	
2006).	Leptin	sensitivity	could	not	be	restored	by	administration	of	 leptin	or	calorie	restriction	
suggesting	that	resistance	was	not	a	secondary	symptom	of	obesity,	but	intrinsic	to	BBS	(Seo	et	
al	2009).	Leptin	 resistance	was	confirmed	 in	a	study	of	50	BBS	patients,	who	had	significantly	
greater	 intraabdominal	 fat	mass,	 insulin	 resistance	and	blood	pressure	compared	to	100	BMI,	
age,	and	sex	matched	controls	(Feuillan	et	al.	2011).	This	finding	contributed	to	the	hypothesis	
that	BBS-dependent	obesity	 is	 driven	by	 leptin	 resistance	 caused	by	 aberrant	presentation	of	
GPCRs	responsible	for	control	of	satiety,	such	as	MCHR1	and	the	leptin	receptor,	LEP-R,	on	the	
cilia	of	hypothalamic	neurons	(Loktev	and	Jackson	2013;	Seo	et	al.	2009;	Berbari	et	al.	2008).	In	
support	of	this,	ablation	of	BBS	proteins	in	neurons	was	shown	to	significantly	reduce	expression	
of	POMC	transcripts,	a	gene	activated	downstream	of	leptin	binding,	which	signals	through	STAT3	
(Rahmouni	et	al.	2008).	Recently,	the	BBSome	was	shown	to	interact	via	BBS1	with	LEP-R,	which	
was	necessary	 for	 trafficking	of	 the	 leptin	 receptor	 to	 the	plasma	membrane	of	hypothalamic	
cells	(Guo	et	al.	2016;	Seo	et	al.	2009).	This	provided	a	possible	mechanism	that	leptin	resistance	
occurs	due	to	defective	trafficking	of	the	leptin	receptor	in	neural	cilia.	
	
Other	studies	have	suggested	that	adiposity	is	not	exclusively	driven	by	leptin	signalling	defects,	
but	BBS	patients	may	have	an	increased	propensity	for	adipogenesis	due	to	ciliary	defects	(Marion	
et	 al.	 2009;	 Marion,	 Mockel,	 et	 al.	 2012).	 Marion	 and	 colleagues	 (2009)	 determined	 that	
preadipocytes	 were	 transiently	 ciliated	 during	 adipogenesis,	 and	 ablation	 of	BBS10	 or	BBS12	
resulted	 in	 upregulation	 of	 proadipogenic	 pathways.	 It	 was	 suggested	 that	 the	 increased	
propensity	for	adipogenesis	was	driven	by	disrupted	Wnt	and	HH	signalling,	as	these	pathways	
are	potent	adipogenic	inhibitors	(Ross	et	al.	2000;	Kopinke	et	al.	2017).	
	
1.8.4.3	Polydactyly	
Polydactyly	is	the	growth	of	extra	digits	and	can	affect	a	single,	or	up	to	all	4,	limbs.	BBS	patients	
have	an	incidence	of	63-81%	polydactyly,	where	4-limbs	were	reported	in	21%	of	cases,	9%	hand	
polydactyly	 and	 21%	 foot	 polydactyly	 (Beales	 et	 al	 1999).	 It	 most	 commonly	 has	 a	 postaxial	
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presentation,	where	extra	digits	form	on	the	ulnar	side	of	the	hand	or	fibula	side	of	the	foot.	They	
may	 manifest	 as	 fully	 developed	 digits	 or	 subtly	 as	 a	 nubbin.	 Polydactyly	 is	 not	 distinct	 to	
ciliopathies	 and	 can	 present	 in	 1	 in	 1400	 live	 Caucasian	 births,	 with	 up	 to	 10	 times	 greater	
prevalence	 in	 African	 populations	 (Aucourt	 et	 al.	 2012).	 As	 a	 result,	 extra	 digits	 are	 routinely	
surgically	removed	after	birth,	which	highlights	the	importance	of	maintaining	a	detailed	clinical	
history	 to	 correctly	 diagnose	 patients.	 Other	 common	 limb	 abnormalities	 include	 syndactyly	
(fused	digits),	brachydactyly	(shortening	of	digits)	and	tapered	fingers	(Green	et	al.	1989).	
	
Abnormal	digit	development	results	from	defective	SHH	signalling	during	limb	bud	formation.	Shh	
null	mutations	in	mice	lack	any	digits,	whereas	loss	of	function	of	Gli3	induces	polydactyly	(Robert	
and	Lallemand	2006).	Gli3	contains	both	activator	and	repressor	domains,	which	are	activated	
through	proteolytic	cleavage.	Disruption	of	IFT	in	mice	led	to	polydactyly	of	all	four	limbs,	which	
suggested	that	IFT	was	involved	in	the	processing	of	Gli3	from	an	activator	to	repressor	form	(Liu	
et	 al.	 2005;	 Huangfu	 and	 Anderson	 2005).	 Interestingly,	 BBS	 mutant	 mice	 do	 not	 display	
polydactyly,	making	the	exact	role	of	BBS	proteins	in	limb	development	elusive.	
	
1.8.4.4	Genital	abnormalities	
Genital	anomalies	have	been	reported	to	affect	between	59-98%	of	BBS	patients	(Forsythe	and	
Beales,	2013).	The	primary	malformation	affecting	males	is	hypogonadism,	including	micropenis,	
maldescent	of	testes	and	hypospadias.	Abnormalities	in	females	are	generally	less	common,	but	
can	include	hydrometrocolpos,	vaginal	atresia,	vaginal	agenesis	and	polycystic	ovaries	(Deveault	
et	 al.	 2011).	 Reports	 of	 delayed	 puberty	 and	 irregular	menstruation	 cycles	 are	 also	 common	
(Beales	et	al.	1999).	
	
The	 mechanism	 causing	 genital	 abnormalities	 in	 BBS	 remains	 uncertain.	 The	 developmental	
defects	may	be	a	product	of	aberrant	SHH	signalling,	as	 Shh	 is	 required	 for	development	of	a	
genital	tubercle	and	androgen-independent	morphogenesis	in	mice	(Lin	et	al.	2009).	Anomalies	
may	 be	 attributed	 to	 improper	 hormone	 signalling.	 The	 GCPR	 KISSR1	 is	 known	 to	 localise	 to	
primary	 cilia	 of	 gonadotropin-releasing	 hormone	 (GnRH)	 neurons	 in	 the	 hypothalamus	
(Hilgendorf	et	al.	2016).	Signalling	by	Kisspeptin,	the	ligand	for	KISSR1,	is	involved	in	puberty	onset	
and	 adult	 reproductive	 function,	 and	 mutations	 in	 KISSR1	 can	 result	 in	 hypogonadotropic	
hypogonadism	(de	Roux	et	al.	2003).	Ablation	of	cilia	on	GnRH	neurons	was	shown	to	 reduce	
kisspeptin-mediated	neuronal	activity	(Koemeter-Cox	et	al.	2014).	
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1.8.4.5	Renal	dysfunction	
Renal	 anomalies	 are	 estimated	 to	 affect	 53%	 of	 patients	 (Forsythe	 and	 Beales	 2013).	 Renal	
abnormalities	 of	 BBS	 are	 defined	 as	 structural	 malformations,	 including	 renal	 cysts,	 fetal	
lobulation,	fibrosis,	calyceal	clubbing/blunting,	dysplastic	kidneys,	renal	calculi,	or	vesicoureteric	
reflux	(Harnett	et	al.	1988).	Other	symptoms	related	to	the	urorenal	system,	such	as	recurrent	
urinary	tract	infections,	polyuria	and	polydipsia	are	classed	as	secondary	BBS	features.	The	age	of	
onset	of	renal	abnormalities	can	span	from	late	childhood	onwards.	It	is	associated	with	mortality	
and	 morbidity,	 but	 transplantation	 for	 treatment	 of	 chronic	 kidney	 failure	 can	 successfully	
prolong	life	(Sharifian	et	al.	2007).	
	
The	 renal	 malformations	 observed	 in	 ciliopathies	 are	 thought	 to	 result	 from	 dysfunctional	
mechanosensation	in	the	renal	tubule,	caused	by	aberrant	trafficking	of	PC1	and	PC2.	As	seen	in	
ADPKD,	 failure	 to	 produce	 a	 functional	 PC1/PC2	 channel	 complex	 resulted	 in	 abnormal	 cell	
morphology	and	polarity,	which	led	to	cyst	formation	(Boucher	and	Sandford	2004;	Happé	et	al.	
2011;	Nauli	et	al.	2003).	Mechanosensation	is	required	for	Ca2+	influx	into	the	cell,	which	activates	
Ca2+-dependent	Wnt	signalling.	It	has	been	proposed	that	interruption	of	ciliary	function	switches	
renal	cells	towards	the	canonical	Wnt	signalling	pathway,	elevating	β-catenin	levels	(Simons	et	al.	
2005).	Cyst	formation	occurs	as	a	result	of	β-catenin	induced	overproliferation	(Lin	et	al.	2003;	
Saadi-Kheddouci	et	al.	2001).	A	direct	interaction	between	the	BBSome	(via	BBS1)	and	PC1	has	
been	established,	which	is	required	for	trafficking	of	PC1	to	the	ciliary	membrane	(Su	et	al.	2014).	
	
1.8.4.6	Learning	difficulties	
Learning	 difficulties	 are	 estimated	 to	 affect	 61%	of	 patients.	Other	 cognitive	 features	 include	
developmental	delay,	behavioural	issues,	mental	disability	and	speech	deficit	(Beales	et	al.	1999).	
~50%	of	children	attend	special	schools	and	can	exhibit	changeable	behaviour	with	outbursts	of	
frustration	(Forsythe	and	Beales,	2013).	There	are	reports	that	~50%	of	cases	have	neocortical	
and	 hippocampal	 volume	 loss,	 associated	 with	 impaired	 cognition,	 sensory	 perception	 and	
memory	(Baker	et	al.	2011;	Guemez-Gamboa	et	al.	2014).	
	
The	links	between	the	cilium	and	neurodevelopment	are	thought	to	be	related	to	SHH	or	other	
key	 signalling	 pathways.	 Ablation	 of	 primary	 cilia	 in	 murine	 neurons	 resulted	 in	 decreased	
hippocampal	proliferation	and	delayed	spatial	learning,	linked	to	loss	of	Shh	signalling	(Amador-
Arjona	et	al.	2011;	Tong	et	al.	2014).	Furthermore,	there	may	be	a	 link	between	somatostatin	
signalling	and	learning	difficulties.	Reduced	somatostatin	signalling	is	associated	with	neurological	
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and	 cognitive	 dysfunction	 and	 the	 receptor	 SSTR3	 is	 known	 to	 localise	 to	 primary	 cilia	 of	
hippocampal	 neurons	 (Händel	 et	 al.	 1999).	 Berbari	 et	 al.	 (2008)	 demonstrated	 that	 Sstr3	
localisation	was	dependent	on	the	BBSome,	as	Bbs2-/-	and	Bbs4-/-	mice	failed	to	express	Sstr3	on	
hippocampal	neurons.	
	
1.8.5	Genotype-Phenotype	Correlation	in	BBS	
As	 over	 20	 genes	 have	 been	 described	 to	 manifest	 BBS,	 it	 is	 perhaps	 not	 surprising	 that	
phenotypic	heterogeneity	is	a	common	hallmark	described	across	cohorts	(Deveault	et	al.	2011).	
There	 has	 been	 some	 attempt	 at	 categorising	 genes	 to	 establish	 a	 genotype-phenotype	
correlation	for	BBS,	particularly	with	ocular	features	(Héon	et	al.	2005;	Daniels	et	al.	2012;	Azari	
et	al.	2006).	For	example,	Heon	and	colleagues	(2005)	defined	ocular	phenotypes	of	34	patients	
with	retinal	dystrophy	carrying	mutations	in	BBS2,	BBS3	and	BBS4.	They	determined	that	myopia	
was	present	in	BBS3	and	BBS4	patients,	but	not	with	mutations	in	BBS2.	Correlations	have	also	
been	 demonstrated	 for	 renal	 disease,	 where	 5	 families	 with	 mutations	 in	 SDCCAG8	 (BBS16)	
exhibited	high	penetrance	early	onset	renal	failure	and	simultaneous	absence	of	polydactyly	(E	
Schaefer	et	al.	2011).	Furthermore,	Imhoff	et	al.	(2011)	conducted	an	investigation	with	33	BBS	
patients	of	a	French	cohort	to	uncover	genotype-phenotype	correlations.	They	proposed	a	link	
between	severity	of	renal	phenotype	with	different	BBS	complexes	affected.	70%	of	patients	with	
mutations	 affecting	 the	 chaperone-like	 BBS	 genes,	 BBS6,	 BBS10,	 and	 BBS12	 had	 renal	
abnormalities,	compared	to	15%	of	patients	with	variants	affecting	BBSome	genes	(Imhoff	et	al.	
2011).	 These	 research	 studies	 were	 typically	 limited	 by	 small	 cohort	 sizes	 and	 utilisation	 of	
patients	from	the	same	ethnic	background.	Larger	detailed	studies,	such	as	the	evaluation	of	105	
cases	by	Deveault	et	al	(2010),	did	not	identify	any	genotype-phenotype	correlation,	except	that	
patients	with	variants	in	BBS1	tended	to	have	later	onset	and	milder	severity.	
	
Limited	evidence	of	genotype-phenotype	correlation	in	BBS	is	even	apparent	between	patients	
with	a	genetic	diagnosis	 in	 the	same	gene,	or	with	the	same	disease-causing	variant	 (Estrada-
Cuzcano	et	al.	2012;	Beales	et	al.	2003).	This	phenomenon	extends	to	BBS	cases	within	the	same	
family,	 where	 there	 have	 been	 reports	 of	 siblings	 with	 clinical	 features	 of	 other	 ciliopathies	
alongside	 patients	 with	 BBS	 (Zaki	 et	 al.	 2011).	 It	 is	 widely	 considered	 that	 this	 phenotypic	
expressivity	is	accounted	for	by	secondary	genetic	modifiers.	These	may	present	at	a	second	site	
within	 the	 disease-causing	 loci,	 or	 in	 another	 gene	 that	 functions	 in	 the	 same	
complexes/networks	as	the	disease-causing	loci	(Zaghloul	and	Katsanis	2009;	Badano	et	al.	2006;	
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Beales	 et	 al.	 2003;	 Katsanis,	 Lupski,	 et	 al.	 2001;	 Katsanis,	 Ansley,	 et	 al.	 2001).	 This	 topic	 is	
discussed	in	detail	as	the	subject	of	chapter	3.	
	
1.8.6	Aetiology	of	BBS1	p.M390R	
The	variant	p.M390R	in	BBS1	is	the	most	common	variant	in	patients	of	European	descent,	and	
arguably	the	most	complex.	Many	studies	have	characterised	it	as	the	loci	that	manifests	a	less	
severe	form	of	BBS	(Deveault	et	al.	2011;	Daniels	et	al.	2012;	Estrada-Cuzcano	et	al.	2012),	where	
patients	have	been	reported	to	have	reduced	factors	of	obesity	and	cardiovascular	disease	than	
patients	 with	 mutations	 in	 BBS10	 (Feuillan	 et	 al.	 2011;	 Forsythe	 et	 al.	 2015).	 This	 may	 be	
attributed	 to	 the	 characteristics	of	 the	 variant	more	 than	 the	 loci.	 The	most	 common	variant	
found	in	BBS10	 is	a	frameshift	mutation	resulting	in	a	truncated	protein	(p.C91Lfs*5),	whereas	
p.M390R	 is	 a	 single	 base	 change	 that	 retains	 the	 full-length	 protein.	 Evaluations	 of	 retinal	
dystrophy	have	also	highlighted	the	vast	spectrum	of	severity	that	is	typical	in	patients	with	BBS1	
p.M390R	mutations.	Patients	carrying	 this	variant	have	been	 reported	 to	manifest	all	 cardinal	
features	of	BBS;	retinal	dystrophy	paired	with	one	other	feature,	such	as	obesity	or	polydactyly;	
and	nonsyndromic	rod-cone	dystrophy	(Cannon	et	al.	2008;	Azari	et	al.	2006;	Estrada-Cuzcano	et	
al.	2012).	Other	patients	only	presented	with	retinal	degeneration	into	their	fifth	decade	of	life,	
or	were	genotyped	as	unaffected	relatives	or	control	subjects	who	were	later	found	to	be	positive	
for	the	variant	(Azari	et	al.	2006;	Estrada-Cuzcano	et	al.	2012;	Beales	et	al.	2003).	
	
Genetic	 variants	 that	 drastically	 alter	 protein	 structure,	 such	 as	 nonsense,	 frameshift	 or	
mutations	affecting	the	splice	junctions,	induce	a	loss	of	function	response,	as	resulting	proteins	
will	 either	 be	 dysfunctional	 or	 degraded	 by	 NMD.	 In	 the	 case	 of	 missense	 variants,	 such	 as	
p.M390R,	the	full-length	protein	is	translated	and	the	aetiology	is	not	so	clear.	BBS1	p.M390R	is	
known	 to	 be	 a	 hypomorphic	 variant	 (Zaghloul	 et	 al.	 2010),	 where	 protein	 exhibits	 reduced	
performance	as	function	is	partially	lost.	The	disease	mechanism	of	the	variant	has	seldom	been	
studied.	 Mourão	 and	 colleagues	 (2010)	 published	 the	 first	 study	 investigating	 the	 protein	
structure	of	BBS1	and	its	interaction	with	ARL6,	essential	for	recruitment	of	the	BBSome	to	the	
ciliary	membrane	 (Jin	et	al.	2010),	 in	Chlamydomonas	 reinhardtii.	 The	authors	purified	 the	N-
terminal	of	BBS1,	which	bound	with	high	affinity	near	to	the	GTP	binding	pocket	of	ARL6-GTP.	
They	ascertained	that	the	binding	interface	between	BBS1	and	ARL6	is	highly	conserved	across	
different	species,	where	p.M390R	lies	in	a	conserved	β-propeller	domain	close	to	the	binding	site.	
Structural	assays	determined	that	the	p.M390R	protein	was	suitably	folded,	but	the	β-propeller	
was	partially	unstructured,	reducing	the	affinity	of	BBS1	for	ARL6-GTP	(Mourão	et	al.	2014).	This	
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would	 suggest	 that	 BBS	 is	 caused	 by	 insufficient	 recruitment	 of	 the	 BBSome	 to	 the	 ciliary	
membrane	by	ARL6	in	patients	with	BBS1	p.M390R	variants.	In	addition	to	this	conclusion,	it	is	
important	to	note	that	BBS1	has	direct	interactions	with	many	other	ciliary	proteins	and	cargo	
(Seo	et	al.	2009;	Loktev	and	Jackson	2013;	Jin	et	al.	2010;	Zhang	et	al.	2012).	The	direct	effect	of	
p.M390R	on	these	interactions	has	not	yet	been	elucidated.	
	
1.9	In-depth	Phenotyping	of	Rare	Diseases	
1.9.1	High	definition,	in-depth	phenotyping	at	Great	Ormond	Street	Hospital	
In	2013,	the	Centre	for	Translational	Omics	at	UCL	Great	Ormond	Street	Institute	of	Child	Health	
(UCL	GOS	 ICH)	 launched	an	 innovative	project;	High	definition,	 In-depth	phenotyping	at	Great	
Ormond	Street	Hospital,	coined	the	HIGH-5	project.	Funded	by	the	National	Institute	of	Health	
Research	(NIHR)	Great	Ormond	Street	Hospital	 (GOSH)	Biomedical	Research	Centre	(BRC),	 the	
project	 aimed	 to	 use	 next	 generation	 sequencing	 (NGS)	 technologies	 to	 elucidate	 the	
pathobiology	of	rare	diseases,	identify	genetic	modifiers	or	clinical	biomarkers,	and	personalise	
patient	 care.	 Patients	 were	 recruited	 into	 cohorts	 from	 7	 different	 genetic	 or	 multifactorial	
diseases.	15	patients	with	the	common	BBS1	c.1169T>G/	p.M390R	mutation	were	enrolled	into	
a	 BBS	 cohort,	 which	 attained	 additional	 funding	 support	 from	 the	 NIHR	 Rare	 Diseases	
Translational	Research	Collaboration	(TRC).	
	
The	present	study	operated	as	a	pilot	project	to	ascertain	suitable	methods	for	sample	collection,	
processing	and	storage.	Furthermore,	 it	provided	an	opportunity	to	trial	novel	state-of-the-art	
technologies	and	determine	analytical	methods	for	investigation	of	large	datasets.	The	HIGH-5	
project	 was	 possible	 due	 to	 the	 collaboration	 of	 researchers	 from	 different	 backgrounds,	
including	clinicians,	bioinformaticians,	geneticists,	computer	scientists,	and	analytical	scientists.	
	
1.9.2	Study	of	rare	diseases	
A	rare	disease,	sometimes	called	an	orphan	disease,	is	a	disorder	that	affects	a	small	percentage	
of	 a	 population.	 The	 definition	 of	 a	 rare	 disease	 is	 not	 universal.	 According	 to	 Rare	 Diseases	
Europe	 (EURORDIS),	 a	 disease	 is	 classified	 as	 rare	 if	 it	 affects	 less	 than	 1	 in	 2000	 individuals,	
whereas	 in	the	United	States	a	rare	disease	affects	 fewer	than	200,000	Americans	at	any	one	
time	(Azie	and	Vincent	2012).	It	is	predicted	that	in	Europe,	at	least	30	million	individuals	may	be	
suffering	 from	 any	 of	 6000	 rare	 diseases	 (EURORDIS	 2017),	 where	 rare	monogenic	 disorders	
affect	1	in	50	(Boycott	et	al.	2017).	Therefore,	the	burden	of	rare	diseases	is	high	and	cannot	be	
overlooked.		
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Recently,	awareness	by	advocacy	groups	and	research	funding	for	rare	diseases	has	 increased	
(Boycott	 et	 al.	 2017).	 This	 is	 partly	 due	 to	 overlapping	 features	 of	 rare	 diseases	 in	 common	
disorders,	where	mechanistic	insight	into	disrupted	pathways	may	reveal	therapeutic	targets	for	
more	 common	diseases.	 Ciliopathies	 are	 a	prime	example,	where	 collectively	 phenotypes	 are	
rare.	However,	 features	 such	as	obesity,	 retinal	dystrophy,	hearing	 loss,	 and	 renal	 failure,	 are	
individually	more	common	in	the	general	population.	In	addition,	rare	disease	research	augments	
our	 scientific	 knowledge	 of	 biological	 processes	 and	 mechanisms,	 which	 otherwise	 may	 be	
unfathomable.	On	the	other	hand,	research	of	rare	diseases	poses	some	challenges.	Due	to	the	
small	population	of	patients	within	a	given	geographical	area,	research	can	often	be	limited	by	
sample	size.	Furthermore,	high	levels	of	genetic	and	phenotypic	variability	within	rare	diseases	
can	complicate	patient	stratification	and	study	design.	
	
1.10	The	age	of	next	generation	sequencing	and	omic	analysis		
Next	generation	 sequencing	 (NGS)	 refers	 to	high	 throughput	nucleic	acid	 sequencing,	 such	as	
whole	exome	sequencing	(WES),	whole	genome	sequencing	(WGS),	and	RNA	sequencing	(RNA-
seq).	In	the	time	since	the	Human	Genome	Project	(HGP),	there	has	been	an	exponential	increase	
in	novel	 sequencing	 approaches	 and	bioinformatic	 tools	 to	 aid	discovery	 and	 clinical	 genetics	
(Ashley	2016).	It	is	thought	that	~50%	of	all	rare	genetic	diseases	now	have	a	molecular	diagnosis,	
which	is	predicted	to	increase	to	near	completion	over	the	next	decade	with	further	development	
of	NGS	technologies	(Boycott	et	al.	2013).	The	advent	of	NGS	is	aided	by	the	decreasing	cost	of	
sequencing.	This	has	dramatically	fallen	in	the	last	two	decades,	as	the	first	genome	by	the	HGP	
cost	 $100	 million,	 and	 now	 an	 individual’s	 genome	 can	 be	 sequenced	 for	 <$1500	 today	
(Wetterstrand	2016).	As	more	efficient	genome	sequencing	technologies	are	being	developed	by	
biotech	companies,	this	price	will	likely	decrease	to	less	than	$1000	in	the	near	future,	making	it	
an	affordable	research	and	diagnostic	tool	(Lupski	et	al.	2011).	
	
Development	 of	 high	 throughput	 sequencing	 and	 profiling	 technologies	 have	 not	 only	 been	
limited	to	assessment	of	nucleic	acids.	It	is	now	possible	to	characterise	an	individual’s	protein	or	
metabolite	composition,	epigenetic	marks	through	sequencing	of	DNA’s	methylation	patterns,	or	
microbiota	population	by	sequencing	DNA	of	gut	bacteria	(Topol	2014).	Collectively,	these	fields	
of	 research	 have	 been	 coined	 omics,	 encompassing	 genomics,	 transcriptomics,	 proteomics,	
metabolomics,	 epigenomics,	 and	microbiomics.	 Although	 individually	 each	 technology	 has	 its	
Chapter	1:	Introduction	
	
60	
advantage,	a	multi-omic	 integration	of	datasets	can	provide	enhanced	biological	 insight	to	aid	
interpretation,	and	offer	enrichment	of	data	for	a	more	comprehensive	analysis.	
	
1.10.1	Precision	medicine	
As	 sequencing	 has	 become	more	 affordable,	 large-scale	 population	 sequencing	 projects	 have	
been	 completed,	 including	 the	 1000	 genomes	 project,	 the	 NHLBI	 Exome	 Sequencing	 Project	
(ESP),	and	the	Broad	Institute’s	Exome	Aggregate	Consortium	(ExAC)	and	Genome	Aggregation	
Database	(GnomAD)	(Lek	et	al.	2016;	1000	Genomes	Project	Consortium	et	al.	2015).	Each	project	
has	demonstrated	that	a	vast	amount	of	genetic	variation	exists	between	different	populations,	
as	well	as	between	individuals.	On	average,	a	human	genome	was	found	to	contain	~3.5	million	
single	nucleotide	variants	(SNVs)	that	differed	from	the	reference	genome,	where	the	number	of	
rare	variants	was	much	higher	than	anticipated	(Conrad	et	al.	2010;	Lupski	et	al.	2011).	It	is	well	
understood	that	this	variation	may	affect	an	individual’s	susceptibility	to	disease	or	influence	their	
response	to	pharmacological	treatment	(Wray	et	al.	2007;	Goldstein	et	al.	2003).	Now	with	NGS	
and	omic	technologies,	a	new	era	of	medicine	 is	possible,	where	patients	can	be	treated	with	
respect	 to	 their	 genetic	 and	 environmental	 backgrounds.	 This	 has	 been	 referred	 to	 as	
‘personalised’,	‘individualised’,	or	‘precision’	medicine	(Ashley	2016;	Topol	2014).	
	
Precision	medicine	is	defined	as	“tailoring	of	medical	treatment	to	the	individual	characteristics	
of	each	patient”	(US	National	Research	Council	2011).	This	involves	stratification	of	patients	by	
genetic	diagnosis	or	molecular	phenotype,	rather	than	generalisation	of	patients	within	a	single	
disease	type.	This	personalised	approach	aims	to	aid	disease	prediction,	molecular	diagnosis,	and	
development	of	targeted	therapies	with	fewer	adverse	effects.	The	utility	of	precision	medicine	
in	rare	diseases	is	exemplified	by	treatment	of	cystic	fibrosis	(CF).	CF	is	caused	by	mutations	in	an	
epithelial	ion	transporter	encoded	by	CFTR.	Different	sites	of	variation	within	the	gene	results	in	
different	 loss	 of	 function	 outcomes.	 For	 example,	 a	 deletion	 of	 p.F508	 results	 in	 protein	
misfolding	and	subsequent	proteasomal	degradation,	whereas	a	missense	mutation	at	p.G551D	
leads	to	defective	channel	opening	at	the	epithelial	membrane	(Ashley	2016;	Brodlie	et	al.	2015).	
The	 small	 molecule	 Ivacaftor	 was	 developed	 as	 a	 CF	 treatment,	 which	 targets	 CFTR	 at	 the	
membrane,	keeping	the	channel	in	an	active,	open	state.	This	treatment	would	only	be	beneficial	
in	patients	with	CFTR	at	the	cell	surface,	and	thus	would	not	be	useful	in	patients	with	p.508del	
variants	 (Ramsey	et	al.	2011;	Brodlie	et	al.	2015).	This	demonstrates	 that	 individuals	with	 the	
same	 phenotype	 may	 require	 different	 therapeutic	 interventions,	 and	 thus	 highlights	 the	
importance	of	understanding	the	subject’s	genetic	background.	
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1.10.2	Integrative	personal	omics	profile	study:	Proof	of	principle	
One	of	the	first	applications	of	human	multi-omic	data	was	completed	by	Michael	Synder’s	lab,	
where	Synder	himself	was	the	subject	of	investigation	(Chen	et	al.	2012).	The	integrative	personal	
omics	 profile	 (iPOP)	 study	 followed	 Synder	 over	 a	 period	 of	 2	 years,	 serially	 sampling	 blood	
components	 at	 20	 different	 time	 points	 for	 a	 combination	 of	WGS,	 RNA-seq,	 proteomic	 and	
metabolomic	mass	 spectrometry,	 and	antibody	profiling.	 Interestingly,	 Synder	 contracted	 two	
viral	infections	over	the	sampling	period,	allowing	assessment	of	healthy	and	diseased	states.		
	
The	authors	used	WGS	to	identify	genetic	risk	factors	for	disease,	where	they	detected	variants	
associated	 with	 increased	 risk	 of	 basal	 cell	 carcinoma,	 coronary	 artery	 disease,	
hypertriglyceridemia,	 and	 type	 II	 diabetes	 (Chen	 et	 al.	 2012).	 They	 subsequently	 utilised	 this	
knowledge	 by	 recording	 measurements,	 such	 as	 fasting	 plasma	 glucose	 and	 glycated	
haemoglobin	(HbA1c),	to	monitor	the	possibility	of	type	II	diabetes.	Despite	Synder	presenting	a	
lack	of	physical	risk	factors	(such	as	high	BMI),	they	detected	a	spike	in	glucose	levels,	indicative	
of	type	II	diabetes	onset,	in	response	to	infection	by	a	respiratory	syncytial	virus.	As	a	result	of	
this	information,	he	was	able	to	alter	his	lifestyle	by	increasing	exercise	and	changing	his	diet	to	
bring	 his	 glucose	 levels	 back	 to	 normal	 (Chen	et	 al.	 2012).	 Further	 to	 the	 iPOP	 study,	 Synder	
shared	his	knowledge	with	family	members	who	were	similarly	at	risk,	encouraging	them	to	also	
change	their	lifestyle	choices	(Topol	2014).	The	study	also	demonstrated	the	benefits	of	a	multi-
omic	 strategy,	 where	 datasets	 were	 integrated	 to	 present	 a	 comprehensive	 analysis	 of	 both	
diseased	and	healthy	states.	Characterisation	of	the	transcriptome	and	proteome	allowed	them	
to	identify	biological	pathways,	some	of	which	were	only	detectable	through	a	combination	of	
both	datasets	(Chen	et	al.	2012).	
	
1.11	Introduction	to	omics	techniques	
1.11.1	Whole	genome	and	whole	exome	sequencing	
The	human	genome	consists	of	~3	billion	bases,	of	which	~1.5%	is	known	to	be	protein-coding	
(Topol	 2014).	 There	 are	 different	 commercially	 available	 technologies	 for	 DNA	 sequencing	
practices,	which	utilise	different	sequencing	chemistries.	Within	this	thesis,	Illumina	technology	
(Illumina	Inc,	San	Diego,	CA,	USA)	was	applied,	which	uses	a	sequencing	by	synthesis	approach.	
	
The	main	methodological	differences	between	WGS	and	WES	is	that	WES	isolates	DNA	that	aligns	
with	exonic	 regions	of	 the	genome	prior	 to	 sequencing.	This	 is	 completed	using	 specific	exon	
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capture	baits.	The	argument	 for	 favouring	WES	over	WGS	used	to	be	 lower	sequencing	costs,	
where	it	simply	wasn’t	realistic	for	research	groups	to	justify	the	cost	of	WGS.	As	it	is	cheaper,	
WES	is	typically	sequenced	to	a	deeper	coverage	(90X	instead	of	30X	for	WGS),	which	increases	
the	accuracy	of	variant	calling.	However,	as	discussed	previously,	the	cost	of	WGS	has	reduced	
drastically,	thus	many	more	studies	are	preferentially	using	WGS	over	WES	(Caulfield	et	al.	2017).	
Furthermore,	as	WES	only	sequences	exons,	other	areas	of	DNA	that	may	harbour	deleterious	
variants	 are	 overlooked;	 for	 example,	 regulatory	 elements	 in	 intergenic	 regions,	 including	
transcription	factor	binding	sites	or	enhancers	(Gerstein	et	al.	2012);	or	intronic	regions,	which	
may	harbour	mutations	that	induce	aberrant	splicing	(Cummings	et	al.	2016).	On	the	other	hand,	
the	connotation	that	WGS	sequences	the	entirety	of	the	genome	is	misleading.	Up	to	4%	of	the	
genome,	 equating	 to	 ~900	 genes,	 is	 not	 yet	 possible	 to	 sequence	 as	 they	 lie	 in	 telomeres	 or	
centromeres	(Topol	2014).	
	
1.11.1.1	Types	of	human	genetic	variation	
Single	nucleotide	variation	(SNV)	is	the	most	prevalent	class	of	variation,	mostly	lying	under	the	
term	single	nucleotide	polymorphism	(SNP).	A	polymorphism	is	defined	as	a	common	variant	that	
is	present	in	greater	than	1%	of	the	population.	A	great	proportion	of	SNPs	are	not	thought	to	
contribute	to	disease	or	phenotypic	variation,	and	thus	have	a	neutral	 impact	on	the	genome	
(Frazer	et	al.	2009).	It	is	because	of	their	neutral	behaviour	that	they	have	accumulated	to	a	high	
frequency	 in	 the	 population,	 as	 highly	 deleterious	 variants	 would	 be	 removed	 by	 natural	
selection.	However,	some	types	of	SNV	are	deleterious.	The	nature	of	the	SNV	depends	on	where	
the	site	of	variation	occurs	(i.e.	within	a	protein-coding	gene),	as	well	as	the	consequence	of	the	
base	substitution.	
	
Non-synonymous	nucleotide	changes	in	protein-coding	genes	that	effect	the	protein	function	are	
more	likely	to	be	deleterious.	There	are	different	classes	of	nucleotide	variants	that	are	involved	
in	human	disease	(table	1.5).	Nonsense	or	frameshift	mutations	are	more	likely	to	be	deleterious	
as	they	lead	to	a	truncated	protein	sequence.	If	the	variant	occurs	early	within	a	transcript,	the	
transcript	is	likely	to	undergo	NMD,	which	prevents	the	mRNA	being	translated.	If	a	truncating	
mutation	occurs	on	both	alleles,	the	result	is	a	null	phenotype	as	the	protein	is	not	expressed.	On	
the	 other	 hand,	 the	 pathogenicity	 of	 missense	 variation	 is	 more	 difficult	 to	 predict,	 as	 the	
transcript	with	a	missense	mutation	is	still	transcribed.	
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Table	1.5	–	Types	of	human	genetic	variation	that	affect	protein	coding	genes	
	
1.11.1.2	Classification	of	pathogenicity	
With	over	3	million	variants	in	a	single	human	genome,	it	is	challenging	to	determine	whether	a	
variant	is	likely	to	have	a	deleterious	or	phenotypic	effect.	When	reporting	potentially	disease-
causing	 mutations,	 correct	 classification	 of	 variants	 is	 critical	 to	 prevent	 publication	 of	 false	
positive	findings.	Databases	of	population	frequency	data	can	aid	classification	of	rare,	private	or	
common	 variants.	 Rare	 or	 private	 variants	 are	 more	 likely	 to	 be	 disease	 causing,	 as	 natural	
selection	 is	expected	 to	eradicate	deleterious	disease	variants	before	 they	 reach	a	high	allele	
frequency	 (Lupski	 et	 al.	 2011).	 Rare	 variants	 are	 typically	 defined	 as	 having	 a	 minor	 allele	
frequency	(MAF)	<1%,	whereas	private	mutations	are	novel,	in	the	sense	that	they	have	never	
been	 detected	 in	 prior	 sequencing	 experiments	 from	 the	 same	 population	 (Gao	 and	 Keinan	
2014).	Within	this	project,	ExAC	and	GnomAD	databases	have	been	utilised	(Lek	et	al.	2016).	ExAC	
contains	 over	 10	million	 variants	 identified	 by	 exome	 sequencing	 data	 obtained	 from	 60,706	
unrelated	individuals.	On	the	other	hand,	GnomAD	database	contains	data	obtained	from	15,496	
genome	sequences,	in	addition	to	123,136	exomes.	As	the	patients	within	this	study	were	all	of	
European	descent,	population	data	from	the	non-Finnish	European	population	within	ExAC	and	
GnomAD	were	also	used,	containing	33,370	and	63,369	sequences,	respectively	(Lek	et	al.	2016).	
	
A	rare	SNV	is	not	necessarily	pathogenic.	Functional	prediction	algorithms	have	been	developed	
to	 help	 establish	 the	pathogenicity	 of	 a	 variant	 based	on	 amino	 acid	 conservation,	molecular	
interactions	of	the	tertiary	structure.	Within	this	thesis,	Sorting	Intolerant	From	Tolerant	(SIFT)	
(Ng	 and	 Henikoff	 2003),	 PolyPhen-2	 (Adzhubei	 et	 al.	 2010),	 Protein	 Variation	 Effect	 Analyser	
(PROVEAN)	 (Choi	 et	 al.	 2012;	 Choi	 and	 Chan	 2015),	 and	 Combined	 Annotation-Dependent	
Depletion	(CADD)	(Kircher	et	al.	2014)	algorithms	were	used.	
Type	of	variation	 Description	
Missense	 Nucleotide	substitution	that	forms	the	codon	of	a	different	amino	acid	
Nonsense	 Nucleotide	substitution	that	forms	a	stop	codon,	inducing	early	termination	of	translation	
In-frame	
Deletion	or	insertion	of	one	or	more	codons,	resulting	in	loss	or	gain	of	amino	
acids	but	does	not	affect	the	reading	frame	
Frameshift	 Deletion	or	insertion	of	one	or	more	nucleotides	that	interrupts	the	reading	frame.	May	result	in	early	or	late	termination	of	translation	
Splice	site	loss	
Disruption	of	the	nucleotides	that	form	the	splice	acceptor	(AG)	or	donor	(GU)	
sites.	This	can	result	in	the	loss	or	gain	of	translated	mRNA.	
Splice	site	gain	
Creation	of	an	acceptor	or	donor	splice	site	with	greater	affinity	for	the	splicing	
machinery	than	the	genuine	splice	site.	This	can	result	in	the	loss	or	gain	of	
translated	mRNA.	
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SIFT	 utilises	 protein	 sequence	homology	 to	 ascertain	whether	 an	 amino	 acid	 substitution	will	
result	in	a	phenotypic	change.	This	method	assumes	that	the	change	of	a	conserved	amino	acid	
will	 be	 deleterious.	 The	 algorithm	 will	 also	 take	 the	 amino	 acid	 properties	 into	 account,	 for	
example,	if	a	conserved	polar	amino	acid	is	substituted	with	another	polar	residue,	the	change	
will	be	predicted	to	be	tolerated	(Ng	and	Henikoff	2003).	
	
PolyPhen-2	utilises	a	more	sophisticated	approach	for	prediction	of	damaging	variants.	 It	uses	
both	protein	sequence	and	structural	based	prediction	features.	The	structural	capability	allows	
elucidation	 of	whether	 the	 amino	 acid	 change	may	 affect	 intermolecular	 interactions,	 or	 the	
interface	with	complexing	ligands	or	proteins.	However,	the	structural	features	of	PolyPhen-2	can	
only	 be	 utilised	 if	 there	 is	 a	 known	 or	 homologous	 3D	 structure	 for	 the	 protein	 of	 interest	
(Adzhubei	et	al.	2010).	
	
PROVEAN	 is	 not	 restricted	 to	missense	 variants,	 but	 can	 also	 classify	 in-frame	 insertions	 and	
deletions	(indels).	Like	SIFT,	PROVEAN	uses	protein	homology	to	ascertain	the	deleterious	nature	
of	variants.	In	contrast	to	other	sequence	homology	based	algorithms,	PROVEAN	also	assesses	
the	neighbourhood	flanking	sequences,	allowing	evaluation	of	whether	the	amino	acid	lies	within	
conserved	protein	domains.	This	aimed	to	reduce	the	number	of	false	positives	reported	(Choi	et	
al.	2012).	
	
CADD	is	a	sophisticated	scoring	system,	which	allows	classification	of	coding	and	non-coding	SNVs	
and	indels.	The	algorithm	has	classified	the	deleteriousness	of	millions	of	observed	and	simulated	
variants	in	the	human	genome.	Deleteriousness	is	evaluated	by	comparison	of	different	metrics,	
including	 conservation	 scores,	 consideration	 of	 functional	 motifs	 and	 gene	 expression	
information,	 and	 knowledge	 of	 protein	 sequence/structure.	 CADD	 works	 by	 ranking	 the	
deleteriousness	of	an	input	variant	in	relation	to	all	possible	8.6	billion	substitutions	in	the	human	
reference	genome.	The	result	is	a	score	that	ranges	from	1	to	99,	where	higher	figures	relate	to	
a	more	deleterious	prediction.	A	recommended	cut-off	for	evaluation	of	deleterious	variants	is	
15-20	(Kircher	et	al.	2014).	
	
Of	 note,	 functional	 prediction	 algorithms	 should	 be	 interpreted	with	 caution	 as	 false	 positive	
rates	 are	 high;	 for	 example,	 SIFT	 has	 a	 20%	 false	 positive	 error	 rate	 (Ng	 and	Henikoff	 2003).	
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Algorithms	can	also	present	discordant	predictions.	Therefore,	it	is	advisable	to	use	the	strength	
of	multiple	prediction	methods.	
	
1.11.2	Transcriptomics	by	RNA-sequencing	
Whereas	 an	 organism’s	 DNA	 sequence	 is	 highly	 stable	 and	 relatively	 static,	 tangible	 cellular	
processes	are	far	from	it.	RNA	takes	the	form	of	DNA’s	messenger,	where	the	transcription	of	
DNA	 into	messenger	 RNA	 (mRNA)	 defines	 the	 cell	 identity.	 In	 contrast	 to	DNA,	 RNA	 is	 highly	
dynamic	and	reflects	a	snapshot	of	a	cellular	physiological	state.	The	whole	transcriptome	refers	
to	the	total	RNA	of	a	given	tissue	or	cell	type.	Although	there	are	different	types	of	RNA	molecule,	
mRNA	 transcripts	 were	 utilised	 within	 this	 thesis.	 Before	 the	 advent	 of	 NGS	 technologies,	
transcriptome	 studies	 implemented	 microarray	 or	 quantitative	 real-time	 PCR	 (qPCR).	 These	
techniques	are	targeted	and	use	specific	probes/primers,	thereby	requiring	existing	knowledge	
of	the	genome.	By	contrast,	RNA-seq	allows	the	complete	cataloguing	and	quantitation	of	mRNA	
transcripts	of	a	given	sample	within	a	single	 reproducible,	high-throughput	assay	 (Wang	et	al.	
2009).	 Transcript	 quantitation	 is	 determined	 as	 a	measure	 of	 read	 depth	 (Nagalakshmi	 et	 al.	
2010),	which	provides	a	direct	and	simple	read-out	for	gene	expression	levels.	
	
RNA-seq	can	be	used	to	answer	many	different	biological	questions	that	other	quantitative	RNA	
arrays	 cannot	 remedy.	 It	 allows	 determination	 of	 transcriptional	 architecture	 by	 providing	
information	about	transcriptional	start	sites,	the	location	of	5’	and	3’	ends,	alternative	splicing	
patterns,	and	post	transcriptional	modifications	(Ozsolak	and	Milos	2011).	Recently,	Cummings	
et	al.	(2017)	demonstrated	the	utility	of	RNA-seq	for	diagnosis	of	Duchenne	muscular	dystrophy	
patients	manifesting	variants	that	affected	splicing.	They	identified	both	coding	and	non-coding	
pathogenic	variants	that	resulted	in	aberrant	splicing,	including	two	heterozygous	synonymous	
variants	in	different	patients,	where	the	single	base	change	created	a	donor	splice	site	within	an	
exon,	but	did	not	change	the	amino	acid	sequence	(Cummings	et	al.	2017).	This	study	highlights	
the	need	for	sequencing	beyond	the	genome,	as	the	variants	within	this	study	would	otherwise	
not	have	been	possible	to	resolve	with	DNA	sequencing	methods	alone.	
	
As	the	whole	mRNA	transcriptome	of	a	tissue	is	sequenced,	RNA-seq	also	provides	a	vast	amount	
of	cellular	and	biological	information,	allowing	investigation	of	how	gene	expression	is	affected	
by	genetic	variation.	Differences	in	gene	expression	between	biological	groups	can	be	established	
by	 identification	 of	 differentially	 expressed	 genes,	 which	 enables	 quantification	 of	 different	
conditions,	such	as	response	to	treatment	or	disease.	
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1.11.3	Proteomics	
The	term	proteomics	originated	in	the	1990s	to	describe	the	study	and	detection	of	an	organism’s	
protein	composition,	as	well	as	analysis	of	their	structure	and	function	(James	1997).	In	contrast	
to	nucleic	acids,	proteins	are	notoriously	difficult	to	study,	as	each	can	differ	by	size,	molecular	
charge,	posttranslational	modifications	(PTMs),	or	structural	conformation.	Indeed,	from	23,000	
genes	in	the	human	genome,	there	are	an	estimated	100,000	protein	variants,	including	splice	
variants,	cleaved	polypetides	and	post-translationally	modified	proteins	(Wilhelm	et	al.	2014).	In	
recent	 years,	NGS	 technologies	have	 favoured	nucleic	 acids,	which	 takes	 advantage	of	 innate	
chemical	properties,	such	as	hybridisation.	However,	although	the	central	dogma	dictates	that	
DNA	makes	 RNA	makes	 protein,	 in	 reality	 this	 is	 not	 an	 equivalent	 process,	 as	 correlation	 of	
abundances	between	RNA	and	protein	have	been	reported	as	only	~40%	similar	(de	Sousa	Abreu	
et	 al.	 2009).	 As	 the	 functional	 product	 of	 a	 cell,	 reliable	 protein	 sequencing	 techniques	 are	
required	that	can	sensitively	detect	and	quantify	an	organism’s	proteome.	Protein	composition	
is	a	direct	indication	of	a	time-specific	snap	shot	of	a	cell.	By	investigation	of	the	proteome,	there	
is	an	opportunity	to	gain	 information	that	 is	 immediately	 instructive	of	a	tissue’s	pathobiology	
that	the	genome	and	transcriptome	cannot	offer.	
	
Proteomic	 techniques	 can	 either	 be	 targeted	 or	 untargeted,	 depending	 on	 the	 biological	
questions	that	need	to	be	answered.	An	untargeted	strategy	is	more	challenging	as	resolution	
and	assay	sensitivity	is	reduced	for	complex	mixtures.	On	the	other	hand,	targeted	proteomics	is	
limited	to	identification	of	optimised	proteins.	The	techniques	that	have	been	used	in	this	project	
are	outlined	below.	
	
1.11.3.1	Mass	spectrometry	
Although	 engineered	 for	 both	 targeted	 and	 untargeted	 capabilities,	 within	 this	 thesis,	 mass	
spectrometry	has	been	used	only	for	untargeted	analysis.	Over	the	last	20	years,	there	have	been	
new	technologies	released	to	enhance	the	sensitivity,	reliability,	and	simplicity	of	data	generation	
(Kuharev	et	al.	2015;	Cravatt	et	al.	2007;	Crutchfield	et	al.	2016).	Mass	spectrometry	has	evolved	
into	a	powerful	analytical	method	where	tissues,	cell	types	and	even	whole	organisms	have	had	
their	 proteomes	 identified	 (Nagaraj	 et	 al.	 2011;	 de	 Godoy	 et	 al.	 2008;	Wilhelm	 et	 al.	 2014).	
Concurrently,	 the	 study	 of	 proteins	 by	 mass	 spectrometry	 can	 produce	 variable	 results,	
influenced	by	 factors	such	as	sample	preparation,	undersampling,	and	storage;	 thus,	 judicious	
study	design	and	expertise	is	required	to	complete	reliable	experiments.	
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The	mass	spectrometer	detects	compounds	through	at	 least	two	distinct	characteristics;	mass	
and	charge.	The	mass	spectrometer	can	be	easily	coupled	to	other	separation	techniques,	such	
as	chromatography,	to	distinguish	between	compounds	by	chemical	properties	(Hawkridge	and	
Muddiman	 2009).	 At	 present,	 most	 mass	 spectrometers	 do	 not	 have	 the	 resolution	 to	
dependably	 recognise	 large	 proteins.	 Therefore,	 cleavage	 of	 proteins	 into	 peptides	 using	 the	
proteolytic	enzyme	trypsin	is	common	prior	to	mass	spectrometry	in	an	approach	called	‘bottom	
up’	proteomics.	Trypsin	is	particularly	suited	to	mass	spectrometry	since	it	specifically	cleaves	a	
protein	on	the	C-terminal	side	of	an	arginine	or	lysine	residue,	which	aids	peptide	identification	
(Meissner	and	Mann	2014).	The	value	of	any	profiling	technique	lies	with	accurate	quantitation.	
This	 can	 be	 a	 challenge	 for	 mass	 spectrometry,	 as	 it	 is	 not	 intrinsically	 quantitative,	 due	 to	
different	 ionisation	efficiencies	of	different	analytes	(Zhu	et	al.	2010).	To	overcome	this,	many	
quantitation	techniques	have	been	developed,	which	are	grouped	into	two	classes,	label-free	and	
isotopically	labelled	mass	spectrometry	(Schulze	and	Usadel	2010).	
	
1.11.3.2	Targeted	proteomic	techniques	
For	sensitive	and	reliable	mass	spectrometry,	readily	ionisable	and	low	complexity	samples	are	
required.	A	targeted	proteomic	strategy	provides	increased	assurance	of	sensitivity	where	mass	
spectrometry	 can	 fall	 short.	 Antibody	 based	 approaches	 are	 currently	 the	 gold	 standard	 for	
individual	 protein	 detection,	 as	 a	well-derived	 antibody	 has	 high	 affinity	 and	 specificity	 to	 its	
target	(Lollo	et	al.	2014).	Western	blotting	is	a	simple	and	widely	used	method	for	identification	
of	 a	 protein	 from	 a	 sample.	 Similarly,	 enzyme-linked	 immunosorbent	 assay	 (ELISA)	 uses	
antibodies	to	specifically	bind	to	a	protein,	but	can	quantify	this	analyte	through	addition	of	an	
enzyme-linked	secondary	antibody	that	chemically	emits	a	 fluorescent	signal.	Recently,	ELISAs	
have	been	developed	 into	multiplexed	assays	where	many	analytes	can	be	tested	 in	a	sample	
(Elshal	 and	 McCoy	 2006).	 However,	 the	 prosperity	 of	 this	 technique	 depends	 on	 antibody	
availability	for	each	analyte,	and	critically	developing	antibodies	that	do	not	cross-react.	
	
Within	 this	 thesis	 a	 novel	 targeted	 proteomics	 technology	 was	 trialled,	 called	 SOMAscan	
(SOMAlogic	 Inc,	 Boulder,	 CO,	USA).	 This	was	 inspired	by	 the	 specificity	of	 the	ELISA,	with	 the	
added	advantage	that	it	can	be	multiplexed	to	analyse	over	1000	proteins	(Gold	et	al.	2010).	This	
utilises	aptamers,	compounds	derived	from	nucleic	acid	structures	that	can	specifically	recognise	
protein	 epitopes	 (Lollo	 et	 al.	 2014).	 Over	 several	 years	 of	 development,	 SOMAscan	 was	
established	to	contain	over	1300	aptamers	with	high	specificity,	sensitivity,	and	no	risk	of	cross-
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reactivity	 commonly	 seen	with	antibody-dependent	assays	 (Gold	et	al.	2010).	This	 technology	
was	tested	and	evaluated	in	chapter	4.	
	
1.12	Pathway	analysis	
Complete	 sequencing	 of	 RNA	 is	 an	 effective	 and	 sensitive	 tool	 for	 quantitation	 of	 the	
transcriptome.	However,	with	reports	that	up	to	three	quarters	of	the	human	genome	is	capable	
of	being	transcribed	(Djebali	et	al.	2012),	this	sequencing	technique	produces	a	vast	wealth	of	
data	that	is	not	trivial	to	interpret.	Although	identification	of	differentially	expressed	transcripts	
or	 proteins	 can	 reduce	 this	 data	 into	 statistically	 significant	 changes,	 the	 resulting	 list	 of	
genes/protein	 provides	 limited	 biological	 insight.	 It	 is	 well	 known	 that	 gene	 products	 do	 not	
function	as	discrete	components,	but	in	large,	often	overlapping,	biological	processes.	Pathway	
analysis	 provides	 a	 method	 of	 classifying	 findings	 from	 RNA-seq	 or	 proteomic	 profiling	
experiments	 into	 statistically	 driven,	 informative	 groups.	 Not	 only	 does	 this	 reduce	 data	
complexity,	but	it	also	allows	identification	of	pathways	that	are	different	between	patient	and	
control	groups,	which	may	link	to	disease	pathology.	Multiple	knowledge	based	tools	are	available	
for	pathway	analysis.	Within	 this	 thesis,	gene	set	enrichment	analysis	 (GSEA),	Protein	Analysis	
Through	 Evolutionary	 Relationships	 (PANTHER)	 overrepresentation	 testing,	 and	 PANTHER	
statistical	enrichment	testing	were	implemented.	
	
1.12.1	Gene	Set	Enrichment	Analysis	
GSEA	was	developed	to	help	address	common	issues	related	to	working	with	large	transcriptome	
datasets.	 Statistical	 analysis	 to	 find	differentially	 expressed	genes	 can	 result	 in	 two	 scenarios;	
firstly,	one	may	be	inundated	with	thousands	of	significant	genes,	with	indeterminate	biological	
meaning;	or	secondly,	correction	for	multiple	testing	hypothesis	may	result	in	too	few	genes	for	
further	analysis.	Moreover,	cellular	systems	act	in	a	balance,	where	an	upregulation	of	a	single	
gene	may	impact	other	pathways.	Single	gene	analysis	would	be	incapable	of	providing	the	total	
cellular	processes	within	the	experiment.	Finally,	repetition	of	experiments	by	different	research	
groups	can	result	in	little	overlap	at	a	gene	level	(Fortunel	et	al.	2003).	Investigation	of	pathways	
or	networks	affected	may	provide	greater	understanding	that	is	more	reproducible	(Subramanian	
et	al.	2005).	
	
The	effectiveness	of	GSEA	relies	on	robust	reference	gene	sets.	There	are	over	10,000	gene	sets	
specifically	developed	for	use	with	GSEA	in	the	Molecular	Signatures	Database	(MSigDB)	(Liberzon	
et	al.	2011).	Within	this	project,	the	Hallmark	gene	sets	have	been	applied.	The	Hallmark	database	
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was	 developed	 by	MSigDB	 to	 reduce	 redundancy	 and	 heterogeneity	 between	 the	 exhaustive	
gene	sets	already	present	in	MSigDB	(Liberzon	et	al.	2015).	The	resulting	database	features	50	
reviewed	and	manually	annotated	gene	sets,	containing	7343	genes	in	total.	These	extensively	
cover	 cellular	 pathways	 involved	 in	 biological	 processes,	 molecular	 functions	 and	 cellular	
component,	such	as	proliferation,	signalling,	immunology,	metabolism,	development,	and	DNA	
damage	(Liberzon	et	al.	2015).	
	
1.12.2	PANTHER	Statistical	Overrepresentation	Test	
The	PANTHER	classification	system	is	an	open	access	database	containing	manually	curated	and	
computationally	generated	gene	sets	(Mi	et	al.	2013;	Mi	et	al.	2017).	The	database	is	comprised	
of	gene	ontology	(GO)	terms	(Gene	Ontology	Consortium	2015),	spanning	terms	associated	with	
molecular	function,	biological	processes,	and	cellular	components.	In	addition	to	these,	there	are	
gene	sets	associated	with	pathways,	including	their	own	PANTHER	pathways,	and	the	Reactome	
pathways	(Croft	et	al.	2011).	As	a	result,	PANTHER	encompasses	57,271	annotations	in	13,387	
genes	(Mi	et	al.	2017).	
	
Statistical	 overrepresentation	 analysis	 is	 a	 relatively	 simple	 test	 for	 identification	of	 pathways	
within	a	set	of	genes/proteins	with	a	given	threshold.	The	input	list	contains	genes/proteins	that	
are	separated	by	up	or	downregulation	and	usually	a	cut	off	of	fold	change	or	a	statistical	value,	
such	as	p-value	(Khatri	et	al.	2012).	The	input	list	is	then	compared	against	the	PANTHER	database	
of	annotated	genes	and	categorised	accordingly.	A	2x2	statistical	test	is	used	to	ascertain	whether	
the	number	of	genes	are	statistically	overrepresented	or	underrepresented	for	a	given	pathway	
compared	 to	what	 is	 expected	 for	 a	 random	sample	of	 genes	of	 the	 same	 size	 (Goeman	and	
Bühlmann	 2007).	 The	 output	 is	 the	 fold	 enrichment	 between	 the	 observed	 number	 of	 genes	
within	a	pathway	and	the	expected	number	from	the	2x2	test.	This	method	is	fairly	crude	as	it	
does	not	take	independent	changes	into	account,	and	thus	each	gene	has	equal	weighting	in	the	
analysis.	 Furthermore,	 it	 relies	 on	 manually	 selected	 genes	 according	 to	 selection	 criteria,	
disregarding	the	remaining	identifications	of	the	experiment	(Khatri	et	al.	2012).	
	
1.12.3	PANTHER	Statistical	Enrichment	Test	
The	final	pathway	analysis	used	in	this	study	was	the	PANTHER	statistical	enrichment	test.	It	works	
similarly	to	GSEA,	where	the	entire	list	of	genes	identified	by	sequencing	are	tested.	Genes	are	
ordered	by	fold	change	and	plotted	to	show	the	distribution	of	fold	change	over	the	whole	input	
set.	 Next,	 genes	 are	 categorised	 into	 pathways	 according	 to	 gene	 annotations	 within	 the	
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PANTHER	 database.	 Pathway	 classification	 for	 PANTHER	 enrichment	 analysis	 utilises	 the	
Reactome	pathways	knowledgebase	 (Croft	et	al.	2011),	a	database	of	hierarchically	organised	
processes,	containing	8701	annotated	genes	(Fabregat	et	al.	2016).	The	fold	change	of	all	genes	
within	a	given	pathway	are	then	compared	with	the	total	gene	set	to	determine	whether	they	are	
statistically	 positively	 or	 negatively	 enriched	 (figure	1.6).	 The	benefit	 of	 statistical	 enrichment	
over	 the	 overrepresentation	 test	 is	 that	 all	 genes	 are	 considered	 and	 up	 and	 downregulated	
genes	 are	 analysed	 simultaneously,	 allowing	 ascertainment	 of	 the	 coordinated	 differential	
regulation	of	a	pathway.	
	
1.12.4	Pathway	topology	mapping	
Identification	of	gene	products	that	function	in	pathways	only	provides	limited	information	about	
the	actual	interactions	that	exist	in	a	tissue.	Pathways	do	not	exist	as	separate	linear	entities,	but	
in	 fact	 are	 highly	 dynamic	 and	 cross-talking.	 Furthermore,	 the	 same	 protein	may	 function	 in	
different	pathways.	Classification	of	protein-protein	interactions	within	a	biological	pathway	or	
protein	 set	 provides	 valuable	 information	 about	 protein	 complexes	 and	 interconnecting	
networks.	Within	this	study,	STRING	database	was	used	to	identify	how	functional	gene	products	
may	interact.	STRING	functions	by	assessment	of	both	direct	physical	 interactions	and	indirect	
functional	associations	(Szklarczyk	et	al.	2015).	Interactions	stored	within	the	STRING	database	
exist	 from	 5	 sources.	 They	 may	 be	 known	 from	 experimental	 interactions,	 found	 in	 primary	
manually	 curated	 bases,	 determined	 through	 text	 mining,	 known	 interactions	 through	 co-
expression	 analysis,	 or	 interactions	 based	 on	 homology	 in	 one	 or	 more	 different	 organisms	
(Szklarczyk	et	al.	2015).	
	
1.13	Induced	pluripotent	stem	cells	
The	final	chapter	of	this	thesis	utilises	a	relatively	novel	phenomenon	that	has	transformed	the	
way	researchers	can	use	cell	culture	to	understand	disease	pathology;	induced	pluripotent	stem	
cells	(iPSCs).	Stem	cells	are	embryonic	cells	capable	of	self-renewal	and	differentiation	into	any	
of	 the	 three	 germ	 layers.	 Human	 embryonic	 stem	 cells	 (ESCs)	 have	 been	 used	 to	 model	
development	 and	 disease	 since	 they	 were	 first	 isolated	 by	 Thomson	 and	 colleagues	 in	 1998	
(Thomson	 et	 al.	 1998).	 However,	 due	 to	 the	 ethical	 impediments	 associated	 with	 ESCs,	
researchers	attempted	to	reverse	differentiated	cells	 through	addition	of	 transcription	 factors	
absolutely	 required	 for	 stem	 cell	 pluripotency.	 In	 2006,	 this	 was	 achieved	 by	 Takahashi	 and	
Yamanaka	through	retroviral	infection	of	the	transcription	factors	OCT4,	SOX2,	KLF4,	and	c-MYC	
in	murine	embryonic	fibroblasts	(Takahashi	and	Yamanaka	2006).	This	combination	of	genes	was	
Chapter	1:	Introduction	
	
71	
affectionately	 termed	 the	 Yamanaka	 cocktail,	 and	was	 subsequently	 used	 to	 reprogram	adult	
fibroblasts	 (Takahashi	 et	 al.	 2007).	 These	 iPSCs	 were	 established	 to	 be	 analogous	 to	 ESCs	 in	
morphology,	 gene	 expression,	 and	 their	 ability	 to	 differentiate	 into	 the	 three	 germ	 layers	
(Takahashi	 et	 al.	 2007;	 Yoshida	 and	 Yamanaka	 2010).	 iPSCs	 have	 been	 presented	 as	 an	
indispensable	 tool	 to	 help	 uncover	 disease	 mechanisms	 from	 patient	 cells,	 bypassing	 the	
dependency	on	animal	models.	iPSCs	can	be	derived	from	patients	and	differentiated	into	cells	
that	are	 inaccessible	by	biopsy,	 such	as	neurons	 (Wang	et	al.	2015;	Kim	et	al.	2014).	This	has	
allowed	researchers	to	effectively	study	disease	development,	determine	molecular	mechanisms	
of	disease,	or	trial	drug	and	gene	therapy	targets	(Yoshida	and	Yamanaka	2010;	Sterneckert	et	al.	
2014).	
	
iPSCs	used	in	this	thesis	were	derived	from	fibroblasts	and	reprogrammed	by	the	human	induced	
pluripotent	stem	cell	 initiative	 (HipSci)	as	 the	Wellcome	Trust	Sanger	 Institute,	Cambridge,	UK	
(Kilpinen	et	al.	2017).	This	initiative	has	reprogrammed	nearly	500	cell	lines	from	healthy	donors	
and	86	lines	from	patients	with	rare	genetic	diseases,	of	which	BBS	constitutes	50	lines	(Streeter	
et	 al.	 2017).	 Each	 line	 has	 been	 comprehensively	 assayed,	 creating	 phenomic,	 genomic,	
transcriptomic,	proteomic,	and	epigenomic	information,	the	majority	of	which	is	open	access	and	
available	 via	 their	 data	 portal	 (www.hipsci.org).	 iPSCs	 reprogrammed	 by	 HipSci	 from	 3	 BBS	
patients	 and	 2	 healthy	 controls	 have	 been	 used	 as	 a	model	 to	 investigate	 retinal	 dystrophy,	
presented	in	chapter	6.	
	
1.14	Objectives	of	this	thesis	
This	 project	 functioned	 alongside	 the	 pilot	 initiative	 for	 the	 NIHR	 GOSH	 BRC	 funded	 HIGH-5	
project,	which	had	three	general	aims	with	the	goal	of	personalising	patient	care.	These	were	to	
elucidate	 the	 pathobiology	 of	 rare	 diseases	 through	 NGS	 technologies,	 determine	 genetic	 or	
regulatory	 factors	 that	 may	 attribute	 to	 heterogeneity	 of	 rare	 diseases,	 and	 identify	 novel	
biomarkers	that	may	help	to	predict	or	pre-empt	disease	onset.	Experiments	within	this	thesis	
have	 been	 designed	 to	 address	 these	 aims	 with	 respect	 to	 the	 rare	 disorder,	 Bardet-Biedl	
Syndrome.	
	
15	BBS	patients	were	recruited	for	this	study,	where	all	individuals	shared	the	same	underlying	
diagnosed	variant,	BBS1	c.1169T>G/	p.M390R,	inherited	either	as	a	homozygous	or	compound	
heterozygous	SNV.	Recruitment	criteria	required	patients	to	consent	to	use	of	biological	material	
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for	 research	 purposes,	 namely	 a	 skin	 biopsy,	whole	 blood,	 and	 urine.	 Each	 type	 of	 biological	
material	was	probed	by	different	technologies	to	address	the	aims	of	this	project	(figure	1.7).	
	
Figure	1.5	–	Overall	study	outline	that	displays	how	biological	materials,	such	as	skin	biopsy,	urine,	or	whole	
blood,	were	investigated	by	different	technologies	for	each	thesis	chapter.	
	
Genomic	DNA	and	plasma	were	extracted	from	whole	blood,	which	were	used	for	whole	genome	
sequencing	 and	 proteomic	 profiling,	 respectively.	 Protein	 was	 also	 isolated	 from	 urine	 for	
proteomic	label-free	mass	spectrometry.	Patient-derived	dermal	fibroblast	cells	were	obtained	
from	skin	biopsies,	which	were	used	for	transcriptomic	and	proteomic	profiling.	These	cells	are	
responsible	 for	 extracellular	 matrix	 organisation	 in	 the	 dermis,	 as	 well	 as	 regulation	 of	 skin	
physiology	 (Sorrell	 and	Caplan	2004).	 Furthermore,	 they	 can	be	 readily	 cultured	 from	a	 small	
biopsy	obtained	by	a	minimally	invasive	procedure,	making	them	a	suitable	cell	type	for	a	pilot	
project,	 such	 as	 this	 one.	 Fibroblasts	 have	 the	 additional	 advantage	 that	 they	 can	 be	
reprogrammed	into	iPSCs.	In	addition	to	BBS	patient-derived	material,	plasma,	urine,	fibroblasts,	
and	iPSCs	were	obtained	from	clinically	healthy	control	individuals.	
	
Ultimately,	 within	 this	 thesis,	 genomic,	 transcriptomic,	 and	 proteomic	 technologies	 were	
implemented	in	a	multi-omic	strategy	to	investigate	the	following	objectives:	
	
• Determine	whether	interfamilial	heterogeneity,	which	presents	as	differences	in	disease	
onset	or	severity,	is	a	consequence	of	genetic	modifying	alleles	that	interact	with	BBS1	in	
the	primary	cilium.	Do	these	variants	contribute	to	enhance	the	mutational	burden	of	
BBS,	when	compared	to	control	individuals?	
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• Utilise	proteomic	profiling	technologies	to	discover	molecular	biomarkers	that	may	be	
used	to	measure	disease	progression	or	detect	secondary	features	of	BBS	from	urine	and	
plasma	biofluids.	
	
• Implement	 a	 multi-omic	 strategy	 via	 integration	 of	 transcriptomic	 and	 proteomic	
profiling	 to	 uncover	 differentially	 regulated	 pathways	 between	 BBS	 and	 control	
fibroblasts	that	may	elucidate	BBS	pathology.	
	
• Develop	a	tissue	specific	model	from	BBS	patient-derived	iPSCs	for	the	investigation	of	
retinal	dystrophy	in	vitro.	
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Chapter	2:	Materials,	Methods,	and	Patients	
	
2.1	Sample	Collection	
2.1.1	Ethics	
Samples	 were	 obtained	 from	 consented	 patients	 attending	 the	 Bardet-Biedl	 Syndrome	
multidisciplinary	clinic	at	Guy’s	Hospital	of	Guy’s	and	St	Thomas’	NHS	Foundation	Trust,	London.	
Recruitment	to	the	study	required	signed	consent	for	use	of	all	samples,	including	a	skin	biopsy,	
whole	blood	and	urine.	Ethical	consent	to	participate	in	the	research	study	was	granted	by	The	
National	Research	Ethics	Service	as	part	of	the	EU	rare	diseases	registry	for	Wolfram,	Alström,	
and	Bardet-Biedl	Syndromes	(EURO-WABB)	study,	supported	by	the	European	Commission	under	
the	Health	Programme	Framework	(Farmer	et	al.	2013).	Upon	collection	of	patient	samples,	they	
were	anonymised	and	appropriately	processed.	
	
2.1.2	Plasma	isolation	of	whole	blood	
Whole	blood	samples	from	15	patients	and	6	controls	were	obtained	in	the	fasted	state	and	were	
processed	on	the	same	day.	Up	to	5ml	of	blood	was	collected	in	an	ethylenediaminetetraacetic	
acid	(EDTA)	vacutainer	(Sarstedt)	and	mixed	well	to	ensure	chelation.	1ml	aliquots	of	whole	blood	
were	dispensed	in	clean	labelled	microcentrifuge	tubes	and	centrifuged	at	5000g	for	10	minutes	
at	4°C.	The	plasma	was	isolated	as	the	supernatant,	which	was	stored	in	500µl	aliquots	at	-80°C.	
	
2.1.3	Skin	biopsy	
A	skin	biopsy	was	taken	using	a	5mm	biopsy	punch.	The	biopsy	was	taken	from	the	back	of	the	
upper	 arm,	 which	 was	 sterilised	 with	 an	 alcohol	 wipe	 and	 Lignocaine	 local	 anaesthetic	 was	
administered.	The	biopsies	were	taken	by	Professor	Phil	Beales	or	Dr	Elizabeth	Forsythe	at	the	
BBS	clinic,	Guy’s	Hospital,	London.	Each	biopsy	was	cut	in	half	and	separately	placed	into	sterile	
Dulbecco’s	Modified	Eagle	Medium	(DMEM)	(Gibco)	supplemented	with	10%	fetal	bovine	serum	
(FBS)	(Gibco)	and	1%	Penicillin-Streptomycin	(10,000U/ml)	(Pen-Strep)	(Gibco).	One	half	of	the	
biopsy	 was	 couriered	 to	 the	 Wellcome	 Trust	 Sanger	 Institute,	 Cambridge,	 UK	 to	 be	
reprogrammed	 into	 induced	 pluripotent	 stem	 cells	 (iPSC),	 whereas	 the	 other	 was	 kept	 for	
fibroblast	culture	at	the	Institute	of	Child	Health,	UCL.	
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2.1.4	Urine	collection	
At	least	10ml	of	fasted	midstream	urine	was	collected	from	15	patients	and	6	controls.	On	the	
day	of	collection,	these	were	aliquoted	into	2ml	volumes	and	stored	at	-80	°C.	
	
2.2	Fibroblast	culture	
2.2.1	Culturing	fibroblasts	from	a	skin	biopsy	
All	cell	culture	work	was	carried	out	in	a	class	II	tissue	culture	hood	and	aseptic	technique	was	
implemented	throughout	the	procedure.		
	
2.2.1.1	Plating	the	skin	biopsy	
Using	a	scalpel,	the	biopsy	was	cut	through	the	epidermis	into	4-8	approximately	equal	segments.	
Each	 piece	 was	 compressed,	 skin	 side	 down,	 onto	 a	 T25	 tissue	 culture	 flask.	 To	 facilitate	
adherence,	the	tissue	was	left	at	room	temperature	for	10	minutes	before	2ml	of	DMEM,	10%	
FBS,	1%	Pen-Strep	was	added.	The	biopsies	were	incubated	for	4	hours	at	37°C,	5%	CO2,	after	
which	 an	 additional	 3ml	media	was	 added.	 Flasks	were	 kept	 at	 37°C,	 5%	 CO2,	monitored	 for	
growth	daily	and	media	changed	every	3-4	days.	Fibroblasts	started	to	appear	between	7-14	days	
and	were	passaged	when	colonies	surrounding	the	tissue	were	80-90%	confluent.		
	
2.2.1.2	Passaging	fibroblasts	
To	passage	fibroblasts	in	a	T25	flask,	the	spent	media	was	removed	and	cells	washed	with	5ml	1x	
Dulbecco’s	phosphate-buffered	saline	(DPBS).	To	detach	cells,	2.5ml	Trypsin-EDTA,	0.05%	(Gibco)	
was	added	and	incubated	for	up	to	5	minutes	at	37°C	or	until	cells	has	dissociated.	Once	~80%	of	
cells	 had	 detached,	 3ml	 of	 DMEM,	 10%	 FBS,	 1%	 Pen-Strep	 was	 added	 to	
inhibit	the	proteolytic	activity	of	trypsin.	The	trypsin-DMEM	mix	was	transferred	to	a	15ml	falcon	
and	 centrifuged	 at	 1000g	 for	 5	minutes,	 room	 temperature.	 The	 supernatant	was	 discarded,	
pellet	resuspended	in	DMEM	medium	and	split	at	a	ratio	of	1:3.	Table	2.1	shows	seeding	densities	
for	each	flask	type	used.	
Flask/	
plate	
Surface	
area	(cm2)	
Seeding	
density	
Cells	
at	confluency	
Volume	of	growth	
medium	(ml)	
Volume	of	trypsin-
EDTA,	0.05%	
Number	of	cryovials	
per	flask	
T25	 25	 0.7	x	106	 2.5	x	106	 5	 2.5	 1	
T75	 75	 2.1	x	106	 7.5	x	106	 15	 5	 3	
T175	 175	 4.6	x	106	 1.75	x	107	 35	 10	 7	
6-well	 9	 0.3	x	106	 1.2	x	106	 2	 1	 	
Table	2.1	–	Seeding	densities	for	fibroblasts	in	different	flasks	or	plates	used	
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2.2.1.3	Freezing	and	thawing	fibroblasts	
After	 trypsinisation	 and	 centrifugation	 (as	 above),	 the	 cell	 pellet	 from	 a	 T25	 flask	 was	
resuspended	in	1ml	freezing	media,	consisting	of	90%	supplemented	DMEM	and	10%	dimethyl	
sulfoxide	(DMSO)	(Sigma-Aldrich).	Cells	were	transferred	to	a	cryovial	and	initially	stored	in	a	Mr.	
Frosty	 freezing	 container	 (ThermoFisher)	 filled	with	 isopropanol	 at	 -80°C.	 This	 allowed	 gentle	
cryopreservation	 before	 long-term	 storage	 in	 liquid	 nitrogen	 (LN2).	 Each	 cryovial	 of	 cells	 was	
thawed	in	a	water	bath	at	37°C	and	resuspended	with	4ml	of	DMEM,	10%	FBS,	1%	Pen-Strep.	
After	 centrifugation	 for	 5	 minutes	 at	 1000g,	 the	 supernatant	 was	 discarded.	 The	 pellet	 was	
resuspended	in	5ml	supplemented	DMEM	and	transferred	to	a	T25	flask	prior	to	incubation	at	
37°C,	5%	CO2.	
	
2.2.2	Treated	and	untreated	fibroblasts	for	RNA	extraction	
Fibroblasts	from	15	patients	and	6	control	subjects	were	plated	in	2	wells	of	a	6-well	plate	at	a	
density	of	0.3	x	106	cells.	When	cells	reached	90%	confluency	in	both	wells,	they	were	separately	
processed	for	either	serum	starved	(treated)	or	serum	fed	(untreated).	
	
The	untreated	sample	was	washed	with	three	times	1x	DPBS.	On	the	final	wash,	the	cells	were	
dissociated	from	the	culture	dish	using	a	scraper	and	collected	in	a	microcentrifuge	tube.	A	pellet	
was	formed	by	centrifugation	at	1000g	for	5	minutes	at	4°C	and	supernatant	discarded.	QIAzol	
lysis	reagent	(QIAGEN)	was	added	to	the	pellet	and	homogenised	using	a	23G	needle	and	1ml	
syringe.	The	samples	were	either	processed	for	RNA	extracted	immediately	or	stored	at	-80°C	for	
processing	 later.	 Simultaneously,	 the	 second	well	was	 treated	with	 serum-depleted	media	 to	
induce	ciliogenesis.	The	well	was	washed	three	times	with	DPBS	and	2ml	of	DMEM,	0.5%	FBS,	1%	
Pen-Strep	was	added.	After	48	hours,	the	cells	were	washed	and	collected	by	scraping,	as	outlined	
above.	
	
2.2.3	Treated	and	untreated	fibroblasts	for	protein	extraction	
As	a	great	yield	of	protein	was	required	for	mass	spectrometry,	fibroblasts	from	15	patients	and	
6	control	subjects	were	grown	in	4x	T175	flasks.	Fibroblasts	were	seeded	in	each	T175	flask	at	a	
density	of	3.2	x	106	cells.	When	90%	confluency	was	attained,	2	flasks	were	washed	in	ice	cold	
DPBS	 three	 times.	 After	 the	 final	wash,	 5ml	 of	 DPBS	was	 added	 to	 each	 flask	 and	 cells	were	
collected	using	a	cell	scraper	and	transferred	to	a	15ml	falcon.	This	step	was	repeated	with	an	
additional	 5ml	 DPBS	 and	 centrifuged	 at	 4°C	 for	 5	 minutes	 at	 1000g.	 The	 supernatant	 was	
discarded	and	the	pellet	stored	at	-80°C	until	required	for	further	processing.	Simultaneously,	the	
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remaining	2	 flasks	were	washed	three	times	and	treated	with	serum	depleted	media	 (DMEM,	
0.5%	FBS,	1%	Pen-Strep)	for	48	hours.	Cells	were	collected	by	washing	and	scraping,	as	described	
above.	
	
2.3	Nucleic	acid	extraction	
2.3.1	Isolation	of	DNA	
Genomic	 DNA	 (gDNA)	 from	 whole	 blood	 was	 collected	 in	 EDTA	 vacutainers	 (Sarstedt)	 and	
extracted	by	the	laboratories	of	the	North-East	Thames	Regional	Genetics	Service,	Great	Ormond	
Street	Hospital,	Barclay	House,	London.	DNA	quality,	purity	and	quantity	were	assessed	in-house	
by	1%	agarose	gel	electrophoresis,	NanoDrop	1000	(ThermoFisher)	spectrophotometry	and	Qubit	
2.0	(ThermoFisher)	fluorometry	assay,	respectively.	
	
gDNA	from	5	iPSC	samples	was	extracted	for	Sanger	Sequencing	using	the	QIAamp	DNA	mini	kit	
(QIAGEN).	 Extraction	 was	 undertaken	 according	 to	 the	 manufacturer’s	 instructions.	 20µl	 of	
QIAGEN	protease	was	mixed	with	200µl	of	sample	and	200µl	AL	buffer,	and	incubated	at	56°C	for	
10	minutes	to	lyse	the	cells.	200µl	of	100%	ethanol	was	added	and	pulse-vortexed	for	15	seconds.	
The	entire	mixture	was	passed	through	a	QIAamp	mini	spin	column	by	centrifuging	at	6000g	for	
1	minute.	 The	 flow-through	was	 discarded	 and	 the	 column	 placed	 in	 a	 fresh	 collection	 tube,	
where	500µl	of	buffer	AW1	was	added	and	centrifuged	at	6000	g	for	1	minute.	The	column	was	
passed	 in	 another	 fresh	 collection	 tube,	 500µl	 of	 buffer	 AW2	was	 added	 and	 centrifuged	 at	
maximum	speed	 for	3	minutes.	 The	 flow-through	was	discarded	and	 column	 transferred	 to	 a	
1.5ml	 microcentrifuge	 tube.	 30µl	 of	 elution	 buffer	 AE	 was	 added	 and	 incubated	 at	 room	
temperature	for	5	minutes.	Finally,	DNA	was	isolated	by	6000g	centrifugation	for	1	minute	before	
quantitation	by	Qubit	2.0	fluorometry	assay.	
	
2.3.2	RNA	extraction	
RNA	was	extracted	 from	fibroblasts	and	differentiating	optic	cup	samples	using	 the	miRNeasy	
mini	 kit	 (QIAGEN)	 according	 to	 manufacturer’s	 instructions.	 Surfaces	 and	 equipment	 were	
cleaned	 with	 RNase	 AWAY	 decontamination	 reagent	 (ThermoFisher)	 before	 extraction.	
Homogenised	cells	in	QIAzol	were	thawed	at	room	temperature	and	were	shaken	vigorously	for	
15	seconds	with	140µl	of	chloroform	in	a	fume	hood.	After	incubation	at	room	temperature	for	
3	minutes,	samples	were	centrifuged	for	15	minutes	at	12,000g	at	4°C	to	generate	three	layers.	
The	upper	aqueous	phase	was	transferred	to	a	1.5ml	RNase	free	microcentrifuge	tube,	combined	
with	600µl	100%	ethanol	and	mixed	thoroughly	by	pipetting.	Each	sample	was	passed	through	an	
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RNeasy	Mini	spin	column	by	centrifugation	at	10,000g	for	15	seconds	at	room	temperature.	The	
column	was	retained	and	350µl	RW1	buffer	washed	the	column	after	centrifugation	at	10,000g	
for	 15	 seconds.	 RNase-free	 DNase	 I	 (QIAGEN)	mix	 was	 added	 to	 the	 column	 to	 remove	 any	
contaminating	DNA	and	incubated	for	15	minutes	at	room	temperature.	The	column	was	washed	
again	with	350µl	RW1	buffer	by	centrifugation	at	10,000g	 for	15	seconds.	Next,	x2	500µl	RPE	
buffer	was	added,	 the	 first	 centrifuged	 for	15	seconds	and	 the	second	 for	2	minutes,	both	at	
10,000g.	Finally,	30µl	of	RNase	free-water	was	added	to	the	column	to	elute	RNA	into	an	RNase-
free	microcentrifuge	tube.	Eluted	RNA	was	quantified	and	stored	at	-80°C.	
	
2.3.3	Assessment	of	nucleic	acid	quantity	and	purity	
DNA	and	RNA	samples	were	quantified	by	the	Qubit	2.0	fluorometer	using	the	Qubit	dsDNA	broad	
range	(BR)	or	RNA	BR	assay	kit	(ThermoFisher),	respectively.	The	protocol	for	each	nucleic	acid	
type	is	identical,	except	the	reagents	differ	between	kits.	To	produce	the	Qubit	working	solution,	
Qubit	 BR	 fluorescent	 reagent	 was	 diluted	 1:200	 in	 Qubit	 BR	 buffer	 and	 vortexed	 well.	 Two	
standards	were	prepared	by	diluting	10µl	of	each	standard	in	190µl	working	solution.	1µl	of	each	
sample	was	diluted	in	199µl	working	solution.	500µl	thin-walled	PCR	tubes	(ThermoFisher)	were	
used	and	samples	were	left	to	incubate	at	room	temperature	for	2	minutes.	The	concentration	
of	each	sample	was	calculated	by	the	fluorometer	obtained	from	the	standard	curve.	
	
Within	the	NanoDrop	1000	(ThermoFisher)	operating	software,	the	nucleic	acid	module,	followed	
by	either	DNA	or	RNA	was	selected.	The	NanoDrop	was	blanked	with	ddH2O	water	and	calibrated	
with	elution	buffer	prior	to	analysis	of	1µl	of	sample.	The	A260/A280	ratio	output	was	recorded	to	
assess	the	purity	of	each	sample.	A	ratio	of	~1.8	or	~2.0	was	considered	pure	enough	for	DNA	and	
RNA,	respectively.	
	
2.3.4	gDNA	agarose	gel	electrophoresis	
A	 1%	 gel	 was	 made	 by	 dissolving	 0.5g	 of	 UltraPure	 Agarose	 (Invitrogen)	 in	 50ml	 1x	
Tris/Borate/EDTA	 (TBE)	 buffer	 (BioRad)	 in	 a	 microwave.	 Once	 cooled	 to	 ~50°C,	 1µl	 Ethidium	
Bromide	(Sigma-Aldrich)	was	added	as	a	fluorescent	tag	and	mixed	well.	The	solution	was	poured	
into	a	casting	tray	with	combs.	Once	the	gel	was	set,	the	comb	was	removed	to	reveal	wells	and	
transferred	to	the	electrophoresis	tank	containing	1x	TBE	buffer.	1µl	of	genomic	DNA	was	mixed	
with	4µl	5x	Green	GoTaq	Flexi	buffer	(Promega)	and	5µl	of	each	sample	was	loaded	to	each	well	
on	the	gel.	4µl	of	Quick-Load	1kb	DNA	ladder	(New	England	Biosciences)	was	added	to	the	first	
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well	as	a	marker.	The	gel	was	run	at	110	volts	for	30	minutes.	Bands	were	visualised	using	the	Gel	
Doc	XR+	ultraviolet	(UV)	imaging	system	(Bio-Rad).	
	
2.4.	Protein	extraction	
2.4.1	Protein	extraction	from	urine	
Protein	was	isolated	from	the	urine	of	15	patient	and	6	control	subjects	for	liquid	chromatography	
mass	spectrometry	(LC-MS).	Urine	was	thawed	on	ice,	vortexed	well	and	centrifuged	at	13,000	
rpm	for	15	minutes.	1.5ml	of	supernatant	was	mixed	with	3ml	of	ddH2O	and	added	to	Amicon	
Ultra-4	centrifugal	filter	units	with	3kDa	molecular	weight	cut	off	(Merck	Millipore).	Urine	was	
filtered	 by	 ultracentrifugation	 at	 4,000	 rpm	 for	 50	 minutes.	 The	 protein	 concentrate	 was	
recovered.	 This	 ultrafiltration	 technique	 was	 utilised	 to	 concentrate	 the	 protein,	 as	 well	 as	
remove	low	molecular	weight	metabolites,	ions	and	detergents.	The	filter	was	washed	with	100µl	
of	50mM	ammonium	bicarbonate	and	added	to	the	concentrate.	Protein	was	quantified	by	Pierce	
bicinchoninic	acid	(BCA)	assay	(ThermoFisher).	
	
2.4.2	Protein	enrichment	by	ProteoMiner	kit	
Protein	was	isolated	from	the	plasma	of	2	patient	subjects,	BBS010	and	BBS011,	for	LC-MS.	To	
remove	 the	 most	 abundant	 plasma	 proteins	 from	 the	 samples,	 protein	 enrichment	 was	
implemented	using	 the	ProteoMiner	protein	enrichment	small-capacity	kit	 (Bio-Rad).	This	was	
followed	according	to	manufacturer’s	instructions.	
	
Plasma	was	thawed	on	ice,	vortexed	well	and	centrifuged	for	10	minutes	at	10,000	rpm.	200µl	of	
plasma	was	applied	 to	20µl	of	primed	beads	on	 the	ProteoMiner	column	and	 incubated	on	a	
rotational	shaker	for	2	hours	at	room	temperature.	The	column	was	centrifuged	at	1,000g	for	60	
seconds	and	flow-through	was	discarded	(one	sample	flow-through	was	retained	to	run	on	SDS	
PAGE).	200µl	wash	buffer	was	added	and	 incubated	 for	5	minutes	at	 room	temperature	on	a	
rotator	 to	ensure	proper	washing.	 The	wash	was	 removed	by	 centrifugation	at	1,000g	 for	60	
seconds.	The	wash	step	was	repeated	twice	more	(a	flow-through	from	each	wash	of	one	sample	
was	retained	for	SDS-PAGE).	The	column	was	incubated	with	200µl	deionised	water	for	1	minute	
and	centrifuged	at	1,000g	for	60	seconds.	To	elute	the	enriched	protein,	20µl	of	elution	reagent	
was	incubated	for	15	minutes	with	occasional	vortexing.	The	protein	was	eluted	by	centrifugation	
into	a	microcentrifuge	tube	at	1,000g	for	60	seconds.	The	elution	step	was	repeated	twice	more	
and	pooled	together.	Protein	was	quantified	by	BCA	assay.	
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2.4.3	Homogenisation	of	fibroblasts	
Cell	pellets	from	serum	starved	and	serum	fed	fibroblasts	of	15	patient	and	6	control	subjects	
were	 thawed	 on	 ice,	 resuspended	 in	 500µl	 50	 mM	 Ammonium	 bicarbonate	 pH	 7.8,	 2%	
Amidosulfobetaine	 (ASB)-14	 and	 added	 to	 0.5ml	 homogenisation	 tubes	 with	 1.4mm	 ceramic	
beads	 (Bertin	 Technologies).	 Samples	 were	 bead	 homogenised	 in	 the	 Minilys	 bench	 top	
homogeniser	(Bertin	Technologies)	for	3x	60	second	at	3000	rpm,	placed	on	ice	between	cycles.	
The	homogenate	was	transferred	to	a	fresh	microcentrifuge	tube	and	centrifuged	at	13,000	rpm	
for	10	minutes	at	4°C.	The	supernatant	was	kept	and	quantified	by	BCA	assay.		
	
2.4.4	Protein	quantitation	by	BCA	assay	
Protein	 was	 quantified	 using	 the	 Pierce	 BCA	 assay	 kit	 (ThermoFisher),	 which	 was	 completed	
according	to	manufacturer’s	instructions	in	a	96-well	microplate	suitable	for	absorbance	assays.	
Bovine	serum	albumin	 (BSA)	 standards	were	generated	by	serial	dilution	 to	create	a	standard	
curve	at	concentrations	of	2000,	1500,	1000,	750,	500,	250,	125	ng/µl.	Working	solution	was	
created	 by	 dilution	 of	 BCA	 reagent	 B	 (containing	 4%	 cupric	 sulphate)	 with	 BCA	 reagent	 A	
(containing	 sodium	 carbonate,	 sodium	 bicarbonate,	 bicinchonicic	 acid	 and	 sodium	 tartrate	 in	
0.1M	sodium	hydroxide)	at	a	50:1	 ratio.	2µl	of	 standard	or	sample	was	added	to	each	well	 in	
triplicate,	followed	by	200µl	of	working	solution.	The	plate	was	covered	and	incubated	at	37°C	
for	1	hour.	Protein	concentration	was	measured	at	555nm	and	595nm	by	an	 Infinite	200	PRO	
NanoQuant	plate	reader	(Tecan).	The	absorbance	reading	for	each	standard	was	used	to	generate	
a	standard	curve	in	Microsoft	Excel.	The	curve	was	used	to	calculate	the	concentration	of	each	
sample	and	the	volume	of	protein	required	for	downstream	analysis.	In-house	mass	spectrometry	
required	50µg	from	plasma,	25µg	from	urine	and	50µg	from	fibroblasts.	An	additional	300µg	from	
fibroblasts	was	sent	to	BGI	for	isobaric	tag	for	relative	and	absolute	quantitation	(iTRAQ)	mass	
spectrometry,	and	20µg	from	plasma	was	used	for	SOMAscan	assay	(SOMAlogic).	
	
2.5	Protein	preparation	for	unlabelled	liquid	chromatography	mass	
spectrometry	
2.5.1	Acetone	protein	precipitation	
Protein	 extracted	 from	 plasma	 and	 urine	 for	 in-house	 mass	 spectrometry	 were	 acetone	
precipitated	to	desalt	and	help	purify	the	samples.	The	correct	quantity	of	protein	calculated	from	
the	BCA	assay	standard	curve	was	aliquoted	to	new	microcentrifuge	tubes.	Ice	cold	acetone	was	
added	 to	 the	 protein	 at	 a	 ratio	 of	 3:1,	 vortexed	 well	 and	 incubated	 overnight	 at	 -20°C.	 The	
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remaining	protein	was	stored	at	-80°C.	The	next	day,	samples	were	centrifuged	at	13,000	rpm	for	
10	minutes	at	4°C	and	supernatant	discarded.	100µl	of	ddH2O	was	added	to	the	pellet,	vortexed	
and	 dried	 overnight	 using	 the	 Modulyo	 freeze-drier	 (Edwards).	 Dried	 pellets	 were	 further	
processed	for	mass	spectrometry.	
	
2.5.2	Digest	and	clean-up	of	protein	from	urine	
Freeze-dried	samples	were	reconstituted	in	20µl	of	100mM	Tris,	pH	7.8,	containing	8	M	urea	and	
2%	 ASB-14	 and	 incubated	 on	 a	 shaker	 at	 900	 rpm	 for	 1	 hour	 at	 room	 temperature.	 1.5µl	
dithioerythritol	(DTE)	(Sigma-Aldrich)	(3mg	DTE	in	100µl	50mM	Ammonium	bicarbonate,	pH	7.8)	
was	added	and	incubated	on	a	shaker	for	1	hour	at	900	rpm.	3µl	of	Iodoacetamide	(IAA)	(Sigma-
Aldrich)	 (36mg/ml	 in	50	mM	Ammonium	bicarbonate,	pH	7.8)	was	added	and	 incubated	on	a	
shaker	at	room	temperature	for	30	minutes	at	900	rpm	in	the	dark.	11.5µl	Trypsin	Gold	(Promega,	
mass	spectrometry	grade)	and	155µl	of	ddH2O	was	mixed	well	with	each	sample	and	incubated	
overnight	at	37°C.	
	
To	remove	salts	and	buffers	before	mass	spectrometry,	digests	were	cleaned	up	using	reverse	
phase	C18	columns.	Each	column	was	 first	washed	with	1ml	50%	acetonitrile	containing	0.1%	
trifluoroacetic	acid	(TFA),	then	primed	with	2x	1ml	0.1%	TFA.	Each	sample	was	diluted	1:1	with	
0.2%	 TFA,	 added	 to	 a	 primed	 column	 and	 allowed	 to	 slowly	 drip	 through.	 The	 sample	 was	
collected	and	reapplied	to	the	column.	Residual	salts	were	washed	away	by	addition	of	2x	1ml	of	
3%	 acetonitrile	 containing	 0.1%	 TFA.	 Cleaned	 peptides	 were	 collected	 from	 the	 column	 by	
addition	of	2x	250µl	of	50%	acetonitrile	 containing	0.1%	TFA.	The	peptides	were	 freeze-dried	
overnight	and	stored	at	-80°C	until	required	for	mass	spectrometry.		
	
2.5.3	Protein	preparation	from	plasma	
2.5.3.1	SDS-PAGE	
Protein	enriched	from	2	patient	plasma	samples	were	separated	via	sodium	docecyl	sulphate-
polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE)	 prior	 to	 enzymatic	 digestion	 into	 peptides.	 In	
addition,	3	flow-through	collections	retained	from	enrichment	via	ProteoMiner	were	separated	
by	SDS-PAGE.	
	
Freeze-dried	 samples	 after	 acetone	 precipitation	 were	 reconstituted	 in	 10µl	 of	 1x	 SDS-Tris	
(Sigma-Aldrich)	and	incubated	at	room	temperature	for	1	hour.	1.5µl	DTE	(3mg	DTE	in	100µl	1x	
SDS-Tris)	was	added	and	incubated	on	a	shaker	for	1	hour	at	900	rpm.	3µl	of	IAA	(36	mg/ml	in	
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50mM	Tris,	pH	7.8)	was	added	and	incubated	on	a	shaker	at	room	temperature	for	45	minutes	
at	900	rpm	in	the	dark.	A	further	15.5µl	of	1x	SDS-Tris	was	added	and	incubated	at	95°C	for	5	
minutes.	 The	 protein	 electrophoresis	 gel	 tank	 (Bio-Rad)	 was	 prepared	 and	 filled	 with	 1x	
Tris/Glycine/SDS	running	buffer	(ThermoFisher).	A	precast	4-15%	Mini-PROTEAN	TGX	stain-free	
gel	 (Bio-Rad)	 was	 placed	 into	 the	 buffer	 chamber,	 where	 5µl	 of	 colour	 prestained	 protein	
standard	(New	England	Biosciences)	was	added	to	the	first	well.	30µl	(~50	µg)	of	each	sample	was	
added	to	the	remaining	wells.	The	gel	was	run	at	200V	for	30	minutes.	Subsequently,	the	gel	was	
removed	and	placed	face	down	in	Coomassie	blue	stain	(40%	methanol,	7.5%	acetic	acid,	0.1%	
Coomassie	 in	 ddH2O)	 and	 incubated	 on	 a	 shaker	 for	 30	 minutes.	 The	 Coomassie	 blue	 was	
removed	and	gel	washed	three	times	in	destainer	(40%	methanol,	7.5%	acetic	acid	in	ddH2O)	for	
1	hour	each,	the	final	wash	was	left	overnight.	
	
Samples	for	mass	spectrometry	were	cut	into	bands	and	profiled	individually.	Each	sample	was	
cut	 into	 8	 pieces,	 where	 stronger	 bands	 were	 cut	 into	 smaller	 segments	 so	 that	 each	 piece	
contained	approximately	~6.25µg	of	protein.	Each	band	was	placed	in	a	separate	microcentrifuge	
tube	and	washed	in	200µl	of	50mM	ammonium	bicarbonate,	pH	7.8	three	times,	vortexed	well	
between	each	wash.	After	the	final	wash,	500µl	100%	acetonitrile	was	added	to	dehydrate	the	
gel	pieces	and	incubated	on	a	shaker	for	30	minutes	at	900	rpm.	The	acetonitrile	was	removed	
and	samples	dehydrated	completely	in	the	Vacufuge	concentrator	(Eppendorf)	on	V-AL	setting	
for	45	minutes	at	45°C.	
	
2.5.3.2	In-gel	trypsin	digest	and	clean	up	
60µl	of	Trypsin	Gold	(mass	spectrometry	grade)	was	added	to	each	band	and	incubated	at	room	
temperature	until	the	gel	bands	had	expanded	(approximately	30	minutes).	50mM	ammonium	
bicarbonate,	pH	7.8	was	added	to	each	band	until	covered,	mixed	well	and	 incubated	at	37°C	
overnight.	
	
To	clean	up	the	peptide	mixture,	200µl	of	1%	formic	acid	was	added	to	each	band,	vortexed	well	
and	incubated	on	the	shaker	for	20	minutes	at	900	rpm.	The	solution	was	transferred	to	a	fresh	
microcentrifuge	 tube	and	2x	300µl	50%	acetonitrile,	1%	formic	acid	was	added	to	each	band,	
shaking	for	20	minutes	and	pooling	each	wash.	Finally,	200µl	of	1%	formic	acid	was	added	directly	
to	the	washed	peptide	solution,	vortexed	well	and	freeze-dried	overnight.	The	spent	bands	were	
discarded	 and	 freeze-dried	 peptide	 samples	 were	 stored	 at	 -80°C	 until	 required	 for	 mass	
spectrometry.	
Chapter	2:	Materials,	Methods,	and	Patients	
	
83	
	
2.5.4	Protein	preparation	for	SOMAscan		
Extracted	protein	 from	the	plasma	of	15	patients	and	6	controls	was	prepared	 for	SOMAscan	
targeted	 proteomic	 profiling	 (SOMAlogic).	 20	 ng	 of	 protein	 was	 diluted	 with	 10µl/ml	 HALT	
protease	inhibitor	cocktail	(ThermoFisher)	in	SOMA	AB	buffer	(SOMAlogic).	Samples	were	sent	to	
UCL	genomics,	UCL	Great	Ormond	Street	Institute	of	Child	Health,	London,	UK	for	processing.	
	
2.5.5	Protein	preparation	for	iTRAQ	mass	spectrometry	
42	samples	consisting	of	300	µg	of	protein	each	was	sent	 to	Beijing	Genomics	 Institute	 (BGI),	
Hong	Kong,	China	for	iTRAQ	mass	spectrometry.	Protein	was	extracted	by	homogenisation	from	
21	 starved	 (treated)	 and	21	 fed	 (untreated)	 fibroblasts	 of	 15	patients	 and	6	 controls.	 Protein	
processing	was	completed	by	BGI.	Before	processing,	samples	were	pooled	into	14	groups	of	3	
(5x	3	treated	patients,	2x	3	treated	controls,	5x	3	untreated	patients,	2x	3	untreated	controls).	
Treated	 and	 untreated	 samples	 formed	 2	 distinct	 iTRAQ	 experiments.	 A	 bridge	 sample	 was	
included	in	both	for	normalisation	and	comparison	across	the	runs.	
	
Samples	were	acetone	precipitated	at	-20	°C	overnight,	dried,	and	reconstituted	in	lysis	buffer,	
consisting	of	2	mM	EDTA	and	1mM	phenylmethane	sulfonyl	fluoride	(PMSF),	a	serine	protease	
inhibitor.	Samples	were	reduced	with	10	mM	DTT	and	alkylated	with	55	mM	IAA.	Protein	was	
quantified	 using	 a	 Bradford	 assay,	 where	 absorbance	 was	 measured	 at	 595	 nm.	 Sample	
concentrations	were	calculated	 from	a	standard	curve	of	known	BSA	concentrations.	Samples	
were	checked	for	integrity	by	running	30	µg	of	protein	on	polyacrylamide	gel	electrophoresis.	100	
µg	of	protein	was	then	digested	with	10	µg	Trypsin	Gold	at	37	°C	for	12	hours.	Samples	were	
dried,	reconstituted	in	0.5	M	Triethylammonium	bicarbonate	buffer	and	iTRAQ	labelled	using	the	
iTRAQ	reagent	8-plex	kit	(SCIEX)	according	to	manufacturer’s	instructions.	Labelled	samples	were	
incubated	for	2	hours	and	8-plex	tagged	samples	pooled	into	1	run.	
	
Peptides	 were	 cleaned	 and	 fractionated	 before	 mass	 spectrometry	 using	 C18	 reverse-phase	
chromatography.	Digested	samples	were	diluted	in	2ml	5%	acetonitrile,	pH	9.8	and	loaded	on	a	
4.6x	250	mm	Gemini	C18	column	containing	5	µm	particles	(Phenomenex).	Peptides	were	eluted	
with	the	Shimadzu	LC-20AB	high	performance	liquid	chromatography	(HPLC)	pump	system	at	a	
flow	rate	of	1ml/min	with	a	gradient	of	5%	buffer	B	(95%	acetonitrile,	pH	9.8)	for	10	minutes,	5-
35%	buffer	B	for	40	minutes	and	35-95%	buffer	B	for	1	minute.	The	system	was	maintained	in	
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95%	buffer	B	 for	3	minutes	and	equilibrated	with	5%	buffer	B	 for	11	minutes.	Fractions	were	
collected	every	minute,	after	which	peptides	were	pooled	as	20	fractions	and	vacuum-dried.	
	
2.6	Sequencing	and	profiling	
2.6.1	Whole	genome	sequencing	
15	patient	and	30	control	DNA	samples	were	prepared	to	60μg	concentrations	and	distributed	to	
BGI,	 Hong	 Kong.	 BGI	 quantified	 and	 checked	 DNA	 integrity	 before	 commencing	 library	
preparation	 using	 the	 TruSeq	 DNA	 PCR-free	 Preparation	 Kit	 (Illumina),	 followed	 according	 to	
manufacturer’s	instructions.	The	samples	were	sequenced	on	the	Illumina	HiSeq	X	Ten	sequencer	
to	30X	coverage,	generating	90Gb	of	raw	data	per	sample.	BGI	returned	sequenced	samples	as	
fastq	files,	which	were	processed	in-house.	
	
2.6.2	Whole	exome	sequencing	
16	 patient	 and	 25	 control	 DNA	 samples	 were	 sent	 to	 PerkinElmer	 Inc,	 Connecticut,	 USA	 for	
sequencing.	The	samples	were	prepared	using	Agilent	SureSelect	exome	version	3	50Mb	library	
preparation	 kit	 and	 sequenced	 to	 90X	 coverage	 on	 the	 HiSeq	 1000	 sequencer.	 Perkin	 Elmer	
returned	sequenced	samples	as	fastq	files,	which	was	processed	in-house.	
	
2.6.3	RNA	sequencing	
RNA	extracted	from	starved	(treated)	and	fed	(untreated)	fibroblasts	of	15	patients	and	6	controls	
was	sequenced	at	UCL	Genomics,	UCL	Institute	of	Child	Health,	London,	UK.	RNA	integrity	and	
quantitation	was	assessed	using	the	4200	TapeStation	Instrument	(Agilent	Technologies).	250ng	
RNA	was	taken	for	RNA-seq	library	preparation.	Sample	libraries	were	prepared	to	43	bp	using	
the	NEBNext®	UltraTM	Directional	RNA	Library	Prep	for	Illumina	kit.	These	were	sequenced	with	
paired	ends	using	the	Illumina	NextSeq	500	sequencer	at	a	read	depth	of	16	million	reads	per	
sample.	RNA-seq	data	was	returned	as	fastq	files	for	bioinformatics	processing.	
	
2.6.4	Unlabelled	tandem	mass	spectrometry	
Peptides	were	reconstituted	in	3%	acetonitrile,	0.1%	TFA	and	centrifuged	for	5	minutes	at	13,000	
rpm	at	room	temperature.	20µl	was	transferred	to	quadrupole	time	of	flight	(QToF)	Trueview	vial	
(Waters)	 for	profiling.	 Protein	extracted	 from	urine	was	profiled	using	 the	Synapt	G2	Si	QToF	
tandem	 mass	 spectrometer	 (Waters),	 whereas	 the	 plasma	 fractions	 were	 profiled	 on	 the	
Micromass	 matrix	 assisted	 laser	 desorption/ionisation	 (MALDI)	 QToF	 Premier	 tandem	 mass	
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spectrometer	(Waters).	Elution	buffers	A	and	B	were	prepared	containing	95%	H2O,	5%	DMSO,	
0.1%	formic	acid	and	95%	acetonitrile,	5%	DMSO,	0.1%	formic	acid,	respectively.	Unlabelled	mass	
spectrometry	was	performed	at	 the	UCL	Biological	Mass	Spectrometry	Centre,	Great	Ormond	
Street	Institute	of	Child	Health,	London,	UK,	assisted	by	Miss	Jasmine	Gratton.	
	
2.6.4.1	Synapt	G2	Si	QToF	
For	urine	samples,	1µl	of	each	sample	were	pooled	together	to	make	a	quality	control	sample	
(referred	 to	 as	 the	 QC).	 The	 QC	 was	 injected	 as	 the	 first	 and	 last	 sample,	 as	 well	 as	 evenly	
dispersed	throughout	the	run.	A	total	of	4	QCs	were	run	and	all	other	samples	were	randomised	
before	injection.	
	
0.4	µg	of	urine	peptides	were	injected	per	sample	onto	a	20mm	NanoACQUITY	ultra-performance	
liquid	 chromatography	 (UPLC)	 Symmetry	 C18	 Trap	 column	 with	 5	 µm	 beads	 (Waters).	 The	
samples	were	loaded	and	eluted	under	the	conditions	in	table	2.2i	 into	the	Synapt	G2	Si	QToF	
fitted	with	a	ZSpray	source	(Waters)	and	ion	mobility	separation	(IMS).	Data	was	acquired	at	a	
resolution	of	20,000,	capillary	voltage	of	2.5-3kV	with	IMS	gas	flow	at	90ml/min,	IMS	velocity	of	
650	m/s	and	IMS	wave	height	of	40V.	MassLynx	software	version	4	(Waters)	was	used	for	data	
acquisition	and	transformed	data	for	analysis.	
	
2.6.4.2	MALDI	QToF	Premier	
2.5µg	of	 plasma	peptides	 for	 each	 fraction	was	 injected	onto	 the	 20mm	NanoACQUITY	UPLC	
Symmetry	 C18	 Trap	 column	 with	 5µm	 beads.	 Fractions	 were	 loaded	 and	 eluted	 under	 the	
conditions	in	table	2.2ii	from	the	column	into	the	QToF	Premier	tandem	mass	spectrometer	fitted	
with	a	MALDI	source.	Data	was	acquired	at	a	MALDI	laser	firing	rate	of	200,	resolution	of	8,500	
and	 capillary	 voltage	 of	 2.9kV.	 MassLynx	 software	 version	 4	 (Waters)	 was	 used	 for	 data	
acquisition	and	transformed	data	for	analysis.	
	
2.6.5	iTRAQ	TripleTOF	mass	spectrometry	
20	 fractions	 for	 each	 iTRAQ	 run	 were	 resuspended	 in	 5%	 acetonitrile,	 0.1%	 formic	 acid	 and	
centrifuged	at	20,000g	for	10	minutes.	Supernatant	was	loaded	at	a	concentration	of	0.5µg/µl	to	
a	LC-20AD	nanoHPLC	(Shimadzu)	onto	a	20mm	C18	trap	column.	The	samples	were	loaded	and	
eluted	under	the	conditions	in	table	2.2iii.	Peptide	spectra	were	acquired	by	the	TripleTOF	5600	
system	(AB	SCIEX)	fitted	with	a	Nanospray	III	source	(AB	SCIEX)	and	a	pulled	quartz	tip	emitter	
(New	Objectives).	Data	was	acquired	using	Analyst	1.6	software	(AB	SCIEX)	under	the	following	
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conditions:	 ion	 spray	 2.5kV,	 30	 psi	 curtain	 gas,	 15	 psi	 nebulizer	 gas,	 30,000	 resolution	 and	
interface	heater	temperature	of	150°C.	Raw	data	was	converted	into	.mgf	files	for	bioinformatics	
analysis,	which	was	completed	by	BGI,	Hong	Kong.	
	
i)	Synapt	G2	Si	QToF	(Waters)	conditions	[1]	
Stage	 Time	(min)	 Flow	rate	(µl/min)	 %	buffer	A	 %	buffer	B	
Trapping	 1	 15	 99	 1	
Elution	
Initial	 0.3	 97	 3	
40	 0.3	 60	 40	
42	 0.3	 15	 85	
45	 0.3	 97	 3	
	 	 	 	 	
ii)	Premier	MALDI	QToF	(Waters)	conditions	[1]	
Stage	 Time	(min)	 Flow	rate	(µl/min)	 %	buffer	A	 %	buffer	B	
Trapping	 1	 10	 97	 3	
Elution	
Initial	 0.3	 97	 3	
35	 0.3	 45	 55	
36	 0.3	 1	 99	
41	 0.3	 97	 3	
	 	 	 	 	
iii)	TripleTOF	5600	(AB	SCIEX)	conditions	[2]	
Stage	 Time	(min)	 Flow	rate	(µl/min)	 %	buffer	A	 %	buffer	B	
Trapping	 4	 8	 95	 5	
Elution	
Initial	 0.3	 95	 5	
41	 0.3	 65	 35	
46	 0.3	 20	 80	
49	 0.3	 95	 5	
Table	2.2	–	Chromatography	trapping	(sample	loading)	and	elution	conditions	before	ionisation	into	Synapt	
G2	Si	(i),	QToF	Premier	(ii)	and	TripleTOF	(iii)	mass	spectrometers.	[1]	Buffer	A	=	95%	H2O,	5%	DMSO,	0.1%	
Formic	acid,	buffer	B	=	95%	acetonitrile,	5%	DMSO,	0.1%	Formic	acid.	[2]	Buffer	A	=	95%	H2O,	0.1%	Formic	
acid,	buffer	B	=	95%	acetonitrile,	0.1%	Formic	acid.	
	
2.7	Data	processing	
2.7.1	Whole	genome	and	whole	exome	sequencing	
Fastq	files	were	checked	for	quality	using	fastQC	(Babraham	Bioinformatics),	which	was	run	using	
Java.	Reads	were	then	aligned	to	the	reference	genome	using	Burrows-Wheeler	Aligner	(BWA)	
(Li	and	Durbin	2009).	WGS	and	WES	reads	were	aligned	to	Genome	Reference	Consortium	human	
(GRCh)	genome	build	38	and	37,	respectively.	Alignment	created	Sequence	Alignment	Map	(SAM)	
files,	which	were	converted	 into	BAM	files	 (a	binary	version	of	SAM)	using	SAMtools	 (Li	et	al.	
Chapter	2:	Materials,	Methods,	and	Patients	
	
87	
2009).	Picard	Tools	(Broad	Institute)	was	used	to	mark	duplicate	reads	 in	WES	data,	before	all	
samples	were	realigned	and	recalibrated	by	Genome	Analysis	Tool	Kit	 (GATK)	 (McKenna	et	al.	
2010).	Genotypes	were	called	using	Haplotype	caller,	which	is	built	in	to	GATK,	and	further	quality	
controls	were	implemented.	Finally,	a	variant	call	file	(vcf)	for	each	sample	was	generated,	which	
were	used	for	variant	analysis.	
	
All	WGS	files	were	processed	by	Dr	Federico	Minneci	using	a	pipeline	devised	by	Dr	Chela	James	
and	Miss	Nital	Jani	(GOSgene	Bioinformatics	Team,	UCL	GOS	Institute	of	Child	Health,	London).	
WES	files	were	processed	by	Dr	Chela	James.	
	
2.7.2	RNA	sequencing	
Fastq	files	were	quality	checked	using	fastQC	before	read	alignment	to	GRCh38	by	TopHat	and	
Bowtie	(Trapnell	et	al.	2009).	TopHat	outputted	BAM	files,	which	were	checked	again	for	quality	
by	RSeQC	(Wang	et	al.	2012),	before	read	filtering	to	mapping	quality	≥4	by	SAMtools.	Only	genes	
that	 had	more	 than	 10	 reads	 in	 4	 or	more	 samples	were	 retained	 for	 further	 analysis.	 From	
filtered	 BAM	 files,	 reads	 were	 counted	 using	 featureCounts	 (Liao	 et	 al.	 2014),	 which	 were	
inputted	into	differential	gene	expression	analysis.	RNA-sequencing	processing	was	completed	
by	Dr	Georg	Otto	(GOSgene	Bioinformatics	Team,	UCL	GOS	Institute	of	Child	Health,	London).	
	
2.7.3	Protein	identification	and	quantitation	of	unlabelled	MS	data	
Protein	identification	and	quantitation	was	completed	using	Progenesis	QI	for	proteomics	(QIP)	
(Waters).	 Peptide	 spectra	 from	 samples	 within	 the	 same	 run	 were	 uploaded	 into	 a	 single	
Progenesis	QIP	experiment,	where	 spectra	were	aligned	 to	a	 reference	 spectra	 to	generate	a	
score	>80%.	Ions	with	a	retention	time	<10	minutes	and	>48	minutes	were	removed.	Peptides	
with	a	charge	>10	were	removed.	Peptides	were	identified	from	raw	MS/MS	spectra	using	an	MSE	
search,	which	were	screened	against	the	Human	Swiss-Prot	database,	canonical	sequences	only	
(from	 January	 2015,	 containing	 20,198	 sequences).	 Proteins	 with	 no	 unique	 peptide	
identifications	or	a	peptide	length	<5	were	omitted.	Proteins	were	quantified	by	ion	abundance	
quantification	 in	 Progenesis	QIP.	 Samples	were	 separated	 into	biological	 groups	 to	 compared	
between	patients	and	controls.	Plasma	fractions	were	processed	per	fraction	creating	8	individual	
experiments,	which	were	 combined	after	quantitation.	 Statistical	 significance	was	ascertained	
using	 an	ANOVA	 test	 and	 false	 discovery	 rates	 (FDR)	were	 generated	 to	 account	 for	multiple	
testing.	Differences	with	a	FDR<0.05	were	considered	statistically	significant.	
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2.7.4	Protein	identification	and	quantitation	of	iTRAQ	data	
Mascot	version	2.3.02	was	used	to	 identify	proteins	 from	raw	MS/MS	spectra.	Uniprot,	Homo	
sapiens	 was	 used	 as	 the	 input	 database,	 containing	 134,169	 sequences.	 At	 least	 one	 unique	
peptide	 was	 required	 for	 a	 successful	 identification.	 Proteins	 were	 quantified	 using	 IQuant	
software	 (Wen	 et	 al.	 2014).	 Statistical	 analysis	 for	 differentially	 expressed	 proteins	 between	
biological	groups	was	also	completed	by	BGI,	Hong	Kong.	Protein	identifications,	quantitation	and	
significantly	regulated	proteins	were	returned	as	.csv	files	for	further	analysis	and	interpretation.	
	
2.7.5	Differential	Gene	Expression	
Expression	analysis	was	implemented	using	R	version	3.3.2	and	the	R	package,	edgeR	(Robinson	
et	al.	2010).	Statistical	significance	for	differentially	expressed	genes	was	determined	by	fitting	a	
negative	binomial	model	to	read	counts	of	each	gene,	followed	by	the	generalised	linear	model	
(GLM)	 likelihood	 ratio	 test	 (McCarthy	 et	 al.	 2012).	 Differentially	 expressed	 gene	 tests	 were	
conducted	by	disease,	treatment,	and	disease	x	treatment	interaction	for	all	multi-omic	datasets.	
Disease	comparisons	consisted	of	BBS	vs.	control	gene	expression	for	serum	fed	fibroblasts	and	
BBS	vs.	control	gene	expression	for	serum	starved	fibroblasts.	Comparison	by	treatment	involved	
comparison	of	 gene	expression	 for	 starved	 vs.	 fed	BBS	 fibroblasts	 and	 starved	 vs.	 fed	 control	
fibroblasts.	 A	 covariate	 ‘sex’	 adjustment	 was	 used	 to	 correct	 for	 gene/protein	 expression	
differences	 caused	 by	 sex.	 Differential	 expression	 ratio	 and	 log2	 fold	 change	 (FC)	 for	 each	
comparison	was	calculated.	Differential	expression	analysis	 for	RNA-seq	was	carried	out	by	Dr	
Georg	Otto	(GOSgene	Bioinformatics	Team,	UCL	GOS	Institute	of	Child	Health,	London).	Genes	
were	considered	significantly	differentially	expressed	with	an	FDR<0.05.	
	
2.7.6	Pathway	analysis	
Differentially	expressed	genes	from	RNA,	as	well	as	proteins	from	UPLC-MS/MS	and	iTRAQ-MS	
were	 further	 analysed	 using	 Protein	 Analysis	 Through	 Evolutionary	 Relationships	 (PANTHER)	
database,	 version	 11	 (Mi	 et	 al.	 2017).	 Statistical	 overrepresentation	 analysis	 and	 statistical	
enrichment	test	on	test	sets	were	completed	using	multiple	comparison	Bonferroni	correction,	
with	an	adjusted	p-value	statistical	 significance	threshold	of	<0.05.	Protein-protein	 interaction	
plots	were	generated	using	STRING	version	10.5	(Szklarczyk	et	al.	2015).	
	
2.7.7	Gene	Set	Enrichment	Analysis	
GSEA	is	based	on	a	comparison	of	a	test	dataset	against	a	known	gene	set	of	biologically	curated	
genes	 (Mootha	 et	 al.	 2003).	 The	 enrichment	 score	 (ES)	 is	 calculated	 by	 the	 GSEA	 algorithm	
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‘walking’	down	list	and	increasing	the	running	ES	sum	when	a	test	gene	corresponds	to	the	gene	
set,	and	decreases	if	it	is	not	in	the	list.	A	positively	enriched	gene	set	will	obtain	a	positive	ES,	
whereas	a	negatively	correlated	gene	set	will	be	negative	(figure	2.1).	GSEA	creates	a	normalised	
enrichment	score	(NES)	by	taking	into	account	the	original	size	of	the	expression	dataset,	so	that	
GSEA	can	be	reliably	compared	across	different	experiments	(Subramanian	et	al.	2005).	Statistical	
analysis	 is	 also	 encompassed	within	 the	GSEA	 framework,	where	 false	discovery	 rate	 (FDR)	 is	
calculated	 to	 control	 for	 false	 positive	 findings.	 The	 benefit	 of	 GSEA	 over	 pathway	
overrepresentation	analysis	is	that	GSEA	uses	the	entire	expression	dataset,	and	does	not	purely	
rely	on	differentially	expressed	findings	(Irizarry	et	al.	2009).	
	
	
Figure	2.1	–	Graphical	representation	of	gene	set	enrichment	analysis	for	positively	(left)	and	negatively	
(right)	enriched	gene	sets.	The	top	of	 the	plot	shows	the	running	enrichment	score	 (ES)	as	 the	analysis	
progresses	down	the	ranked	dataset.	The	peak	of	the	graph	is	the	ES	for	the	dataset,	where	peaks	at	the	
front	of	the	plot	are	positively	enriched	(positive	ES)	and	peaks	at	the	end	of	the	plot	are	negative	enriched	
(negative	 ES).	 The	 horizontal	 black	 lines	 in	 the	middle	 of	 the	 plot	 represents	 each	 gene	 analysed,	 and	
indicates	whether	it	is	positively	or	negatively	correlated	with	the	gene	set.	The	leading	edge	is	the	group	
of	genes	that	contribute	most	to	the	ES.	
	
Gene	 set	 enrichment	 analysis	 (GSEA)	 (Subramanian	 et	 al.	 2005;	 Mootha	 et	 al.	 2003)	 was	
implemented	for	all	comparisons	with	RNA-seq	and	 iTRAQ	data	using	the	Molecular	Signature	
Database	(MSigDB)	Hallmark	database	of	50	gene	sets,	version	6	(Liberzon	et	al.	2015).	Analysis	
was	completed	using	the	GSEA	preranked	tool,	and	were	ranked	according	to	log2	fold	change	
between	biological	groups.	NES,	FDR	values,	and	GSEA	profiles	were	generated	for	the	top	20	
positive	 and	 negative	 significantly	 enriched	 gene	 sets.	 Gene	 sets	 were	 considered	 to	 be	
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significantly	enriched	with	an	FDR<0.25	(as	recommended	by	GSEA	(Subramanian	et	al.	2005)).	
GSEA	desktop	application	software	version	3	was	provided	by	the	Broad	Institute.	Transcriptome	
and	 proteome	 GSEA	 was	 completed	 by	 Dr	 Georg	 Otto	 and	 Dr	 Xueting	 Wang,	 respectively	
(GOSgene	Bioinformatics	Team,	UCL	GOS	Institute	of	Child	Health,	London).	
	
2.8	Identification	of	modifying	alleles	from	NGS	data	
2.8.1	Identification	of	modifying	alleles	
A	4-tier	 categorisation	 strategy	was	developed	 to	 keep	 genetic	 variants	 that	may	modify	 BBS	
disease	expressivity.	Variants	from	15	BBS	patients	were	filtered	from	WGS	vcfs	uploaded	into	
Ingenuity	 Variant	 Analysis	 (IVA)	 software	 (QIAGEN).	 Calls	 were	 initially	 filtered	 to	 reduce	 the	
number	of	candidate	variants.	First,	only	variants	in	exonic	regions	were	considered	for	analysis.	
Next,	a	genetic	control	filter	was	added	that	removed	variants	seen	in	30	control	genomes	(20	
healthy	and	10	very	early	onset-inflammatory	bowel	disease	(VEO-IBD)	subjects).	A	confidence	
filter	removed	variants	with	call	quality	<20	and	calls	found	within	the	top	5%	most	exonically	
variable	100base	windows	in	healthy	public	genomes.	Finally,	a	panel	of	genes	known	to	cause	
primary	ciliopathies	was	added.	These	qualifying	variants	were	separated	 into	4	 tiers,	 starting	
with	 the	most	 stringent	 criteria,	which	gradually	 relaxed.	At	each	 stage	of	analysis,	either	 the	
population	 frequency	based	on	ExAC	European	 frequency	data	 (Tier	1&2,	MAF<1%;	Tier	3&4,	
MAF<5%)	or	the	prediction	of	deleterious	calls	by	PROVEAN	or	PolyPhen-2	was	manipulated.	To	
help	assign	functionality	when	PolyPhen-2	and	PROVEAN	were	discordantly	called,	a	CADD	score	
>20	 filter	was	 added,	where	 variants	 <20	were	 classified	 as	benign.	 To	qualify	 as	deleterious,	
variants	had	to	be	called	by	2	out	of	3	functional	prediction	algorithms.	The	quality	of	variants	
was	checked	by	visualising	BAM	files	on	Integrative	Genome	Viewer	(IGV)	software.	
	
2.8.2	Burden	testing	
Mutational	burden	analysis	was	completed	using	two	data	sets	generated	from	whole	genome	
and	whole	exome	sequencing.	The	subjects	sequenced	by	WGS	consisted	of	14	patients	(BBS011	
was	excluded	as	a	monozygotic	twin)	and	30	unrelated	European	control	individuals.	WES	cases	
included	16	unrelated	patients,	10	of	which	had	a	definitive	molecular	diagnosis.	The	WES	control	
group	consisted	of	25	unrelated	individuals.	All	control	subjects	were	either	clinically	healthy	or	
presented	a	disease	unconnected	to	any	ciliopathy.	
	
Qualifying	variants	were	filtered	using	Ingenuity	Variant	Analysis	(IVA).	First,	variants	from	WGS	
samples	were	prefiltered	to	only	include	variants	in	exonic	regions.	The	confidence	filter	was	set	
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as	described	previously.	In	WES	subjects,	variants	were	removed	with	a	read	depth	<10.	Variants	
with	MAF<1%	of	total	ExAC	population	frequency	data	were	kept.	Calls	were	kept	 if	predicted	
pathogenic	or	 likely	pathogenic	according	 to	computed	American	College	of	Medical	Genetics	
(ACMG)	guidelines	 (Richards	et	 al.	 2015)	or	disease-associated	according	 to	 the	Human	Gene	
Mutation	Database	(HGMD)	(Stenson	et	al.	2017)	or	a	CADD	score	>20.	Variants	that	exhibited	a	
frameshift,	 in-frame	indel,	start/stop	codon	loss,	splice	site	loss,	or	missense	change	predicted	
deleterious	 by	 SIFT	 or	 PolyPhen-2	 functional	 prediction	 software,	 were	 also	 retained.	 Finally,	
variants	were	 kept	 if	 found	within	 a	 gene	 list;	 either	 genes	 known	 to	 nonmotile	 ciliopathies,	
primary	cilia	genes	within	 the	SCGSv1	or	a	control	gene	panel	associated	with	Charcot-Marie-
Tooth	disease	(supplemental	data,	table	A.1,	table	A.2,	table	A.3).	
	
All	qualifying	variants	were	exported	to	Microsoft	Excel	for	analysis.	The	number	of	alleles	was	
counted	within	patient	and	control	groups,	where	heterozygous	and	homozygous	variants	were	
assigned	a	count	of	1	and	2,	respectively.	The	number	of	qualifying	variants	were	calculated	for	
WGS	and	WES	separately	and	then	combined.	A	separate	analysis	was	performed	where	primary	
driving	mutations	(PDMs)	were	removed	from	each	patient	with	a	definitive	molecular	diagnosis	
(WGS	=	28	PDM	alleles,	WES	=	20	PDM	alleles).	The	mean	number	of	alleles	per	individual	was	
calculated	 for	 each	 experiment	 and	 compared	 between	 patient	 and	 control	 groups	 using	 a	
Fisher’s	Exact	test	(GraphPad	Software).	Tests	were	considered	to	be	statistically	significant	with	
a	p-value<0.05.	
	
The	number	 of	WGS	 variants	 between	patient	 and	 control	 groups	was	 assessed	 for	 technical	
abnormalities.	The	number	of	variants	was	counted	for	each	patient	or	control	individual	at	each	
stage	of	filtering	in	IVA	and	the	mean	calculated	in	Microsoft	Excel.	Statistical	differences	between	
patient	and	control	means	were	obtained	by	Student’s	T	test	(GraphPad	Software).	Tests	were	
considered	to	be	statistically	significant	with	a	p-value<0.05.	
	
2.9	Induced	pluripotent	stem	cell	culture	
2.9.1	Reprogramming	of	fibroblasts	into	induced	pluripotent	stem	cells	
Patient	skin	biopsies	were	sent	to	the	Wellcome	Trust	Sanger	Institute	to	be	reprogrammed	into	
induced	 pluripotent	 stem	 cells	 (iPSCs)	 by	 the	 Human	 induced	 pluripotent	 stem	 cell	 initiative	
(HipSci)	project.	 Fibroblasts	were	 cultured	 from	 the	biopsy	by	 the	 same	method	as	described	
previously.	 Fibroblasts	 were	 transduced	 using	 Cytotune	 2.0	 Sendai	 virus	 (ThermoFisher)	
containing	 the	 Yamanaka	 cocktail	 of	OCT4,	 SOX2,	 c-MYC	 and	 KLF4	 (Takahashi	 and	 Yamanaka	
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2006)	and	maintained	until	 iPSC	colonies	appeared.	iPSC	colonies	were	picked	and	grown	on	a	
feeder-free	matrix	of	Vitronectin	XF	for	3-4	weeks	before	shipping.	
	
iPSC	samples	underwent	rigorous	quality	control	checks,	including	regular	tests	for	mycoplasma	
contamination.	iPSC	pellets	were	assayed	for	chromosomal	or	unexpected	genetic	abnormalities	
and	required	a	high	Pluritest	score	(Müller	et	al.	2011)	before	banking.	
	
2.9.2	Maintenance	of	iPSC	colonies	
iPSC	colonies	were	maintained	on	a	Vitronectin	XF	(StemCell	technologies)	matrix	and	Essential	8	
(E8)	medium	(Life	technologies).	Vitronectin	plates	were	prepared	by	diluting	40µl	Vitronectin	XF	
in	960µl	DPBS	 for	each	well	of	 a	6-well	plate.	Plates	were	 stored	at	4°C	 for	up	 to	3	days	and	
incubated	at	room	temperature	for	1	hour	before	use.	Before	cells	were	added	to	vitronectin	
coated	wells,	the	vitronectin/DPBS	mix	was	aspirated	and	air	dried	for	up	to	1	minute.	
	
E8	media	was	prepared	by	diluting	2ml	E8	supplement	in	98ml	filtered	E8	basal	media,	which	was	
used	 within	 10	 days	 of	 preparation.	 E8	 media	 was	 stored	 at	 4°C	 and	 equilibrated	 to	 room	
temperature	for	1	hour	before	use.	
	
2.9.2.1	Thawing	iPSC	colonies	
To	increase	cell	recovery	during	thawing,	10µM	Y-27632	ROCK	inhibitor	(Sigma-Aldrich)	in	E8	at	
a	 concentration	 of	 1:1000	 was	 used.	 A	 cryovial	 of	 iPSC	 colonies	 was	 thawed	 at	 37°C	 and	
immediately	added	dropwise	to	the	E8/Y-27632	mix,	careful	to	not	disrupt	the	colonies.	The	cells	
were	 centrifuged	 at	 200g	 for	 3	 minutes.	 The	 supernatant	 was	 discarded	 and	 pellet	 gently	
resuspended	in	2ml	of	E8/Y-27632.	The	2ml	suspension	was	added	to	a	vitronectin	treated	well	
of	a	6-well	plate	and	incubated	at	37°C,	5%	CO2.	Media	was	changed	daily	with	fresh	E8	media	
and	passaged	every	5-7	days	once	colonies	were	~80%	confluent.	
	
2.9.2.2	Passaging	iPSC	colonies	
iPSC	 colonies	 were	 dissociated	 using	 0.5mM	 EDTA	 by	 diluting	 UltraPure	 0.5M	 EDTA	 (Life	
Technologies)	 with	 DPBS	 at	 a	 1:1000	 dilution.	 Spent	 medium	 was	 aspirated	 and	 cells	 gently	
washed	with	2ml	DPBS.	1ml	of	0.5mM	EDTA	was	added	to	the	colonies	and	incubated	at	room	
temperature	for	4	minutes.	EDTA	was	aspirated	and	colonies	were	gently	collected	in	a	falcon	
with	 4x	 1ml	 E8	media	without	 resuspension	 by	 pipetting.	 Colonies	were	 left	 to	 settle	 for	 2-3	
minutes	and	supernatant	carefully	aspirated.	The	pellet	was	resuspended	in	E8	media,	ensuring	
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distribution	of	equally	sized	colonies	and	was	typically	split	at	a	ratio	of	1:6	in	a	new	vitronectin	
coated	plate.	Plates	were	kept	at	37°C,	5%	CO2.	Colonies	were	carefully	monitored	and	media	
changed	daily.	
	
2.9.2.3	Freezing	iPSC	colonies	
iPSC	colonies	from	1	well	of	a	6-well	plate	were	frozen	in	1ml	freezing	media	consisting	of	90%	
knock-out	 serum	 replacement	 (KSR)	 (ThermoFisher)	 and	 10%	 DMSO	 (Sigma-Aldrich).	 Both	
freezing	media	and	Mr.	Frostie	freezing	container	filled	with	isopropanol	were	kept	at	4°C	until	
use.	After	detachment	by	EDTA	and	centrifugation,	the	iPSC	pellet	was	resuspended	in	freezing	
media	and	transferred	to	a	cryovial.	These	were	transferred	to	a	pre-chilled	Mr.	Frosty	(kept	at	
4°C)	for	storage	at	-80°C	for	24	hours,	before	being	moved	to	LN2	for	long	term	storage.	
	
2.9.3	Differentiation	into	3D	optic	cups	
2.9.3.1	Experimental	outline	
The	 experimental	 design	 for	 differentiation	 was	 developed	 to	 maximise	 the	 number	 of	
differentiations	 for	 each	 line.	 This	was	because	differentiation	of	 separate	 cell	 lines,	 and	 also	
within	differentiation	attempts	for	the	same	line,	were	sometimes	 inconsistent.	To	counteract	
this,	 a	 new	 differentiation	 was	 initiated	 upon	 every	 passaging	 event,	 thereby	 increasing	 the	
chance	that	the	differentiation	was	successful	(figure	2.2).	
	
Figure	2.2	–	An	outline	of	the	design	adopted	for	maintenance	and	differentiation	of	iPSCs.	This	shows	3	6-
well	plates	were	maintained	between	every	passage.	When	~80%	confluent,	differentiation	was	initiated	
for	2	plates	and	the	other	plate	was	passaged	or	harvested	for	RNA	extraction.	
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This	also	provided	the	opportunity	to	assess	for	variability	between	each	differentiation	within	a	
single	 line.	 5-6	 differentiations	 were	 initiated	 for	 each	 line.	 The	 strategy	 also	 took	 into	
consideration	regular	sampling,	which	was	required	to	track	the	process	of	differentiation.	Each	
differentiation	started	with	2	confluent	6-well	plates.	
	
2.9.3.2	Embryoid	body	(EB)	formation		
Differentiation	was	instigated	on	2x	6-well	plates	of	iPSCs	with	good	pluripotent	morphology	and	
low	rates	of	spontaneous	differentiation.	The	first	day	of	differentiation	was	referred	to	as	day	0.	
For	this	study,	EBs	were	generated	using	a	static	suspension	method.	
	
Embryoid	body	media	 Day	0	-	4	
Reagent	 Volume	 Manufacturer	
DMEM/F12	(1:1)	with	L-glutamine	 80ml	 ThermoFisher	
Knock	out	serum	replacement	 20ml	 ThermoFisher	
MEM	non-essential	amino	acids	 1ml	 ThermoFisher	
50	mM	2-mercaptoethanol	 0.7µl	 ThermoFisher	
10	µM	Y-27632	ROCK	inhibitor	on	day	0	 1:1000	 Sigma-Aldrich	
Table	2.3	–	The	recipe	for	embryoid	body	media.	
	
Embryoid	 body	 media	 (EBM)	 was	 prepared	 by	 filter	 sterilising	 the	 components	 in	 table	 2.3.	
Colonies	were	dissociated	with	EDTA	as	described	previously.	After	centrifugation	at	200g	for	1	
minute,	 the	 supernatant	was	 removed	and	 the	 total	pellet	 from	12	wells	was	 resuspended	 in	
24ml	EBM	and	12ml	each	was	transferred	into	2x	T25	flasks.	Flasks	were	incubated	at	37°C,	5%	
CO2	and	EB	media	changed	daily	until	day	4.		
	
2.9.3.3	Changing	to	neural	induction	media	and	laminin	plating		
On	day	4	of	differentiation,	media	was	changed	from	EBM	to	neural	induction	media	(NIM).	NIM	
was	prepared	by	filter	sterilising	all	components	in	table	2.4,	except	N2	supplement,	which	was	
added	after	filtering.	Media	was	changed	daily.	
	
On	day	6	of	differentiation,	EBs	were	 transferred	 to	 laminin	coated	6-well	plates.	These	were	
prepared	on	day	5	by	dilution	of	40µl	 laminin	 (Sigma-Aldrich,	 stock	 concentration	1mg/ml)	 in	
1160µl	DMEM	(ThermoFisher).	200µl	of	laminin/DMEM	was	spread	in	the	centre	of	each	well	of	
2x	6-well	plates	and	incubated	overnight	at	37°C.	
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Neural	Induction	Media	(NIM)	 Day	4	-	16	
Reagent	 Volume	 Manufacturer	
DMEM/F12	(1:1)	with	L-glutamine	 100ml	 ThermoFisher	
MEM	non-essential	amino	acids	 1ml	 ThermoFisher	
N2	Supplement	 1ml	 ThermoFisher	
Heparin	 100µl	(2mg/ml	stock)	 Sigma-Aldrich	
Table	2.4	–	The	recipe	for	neural	induction	media.	
	
On	day	6,	the	laminin	was	aspirated	from	each	well	and	replaced	with	2ml	NIM.	EBs	from	2x	T25	
flasks	were	collected	in	1x	15ml	falcon	and	left	to	settle	to	the	bottom	of	the	falcon.	Spent	media	
was	carefully	aspirated,	retaining	the	last	~3ml	of	media	containing	the	EBs.	200µl	of	resuspended	
EBs	were	evenly	distributed	to	each	well,	giving	~70-100	EBs	per	well.	Plates	were	incubated	for	
48	 hours	 at	 37°C	 to	 allow	 EBs	 to	 adhere	 to	 laminin,	 and	 media	 was	 changed	 every	 2	 days	
thereafter.		
	
2.9.3.4	Changing	to	retinal	differentiation	media	
Retinal	differentiation	media	(RDM)	was	prepared	by	filter	sterilising	all	components	in	table	2.5	
except	 B27,	 which	 was	 added	 after	 sterilisation.	 3ml	 of	 RDM	 replaced	 NIM	 at	 day	 16	 of	
differentiation,	where	spent	media	was	replenished	every	other	day.	
	
Retinal	Differentiation	Media	(RDM)	 Day	16	-	42	
Reagent	 Volume	 Manufacturer	
DMEM,	high	glucose,	L-glutamine	 70ml	 ThermoFisher	
F12	Nutrient	mixture	(Ham)	 30ml	 ThermoFisher	
B27	(without	vitamin	A)	 2ml	 ThermoFisher	
MEM	non-essential	amino	acids	 1ml	 ThermoFisher	
Table	2.5	–The	recipe	for	retinal	differentiation	media.	
	
2.9.3.5	Mechanical	lifting	of	neural	retina	domains	
On	day	28	of	differentiation,	identifiable	neural	retina	(NR)	domains	were	manually	lifted	to	grow	
in	suspension.	Spent	RDM	was	aspirated	for	1	well,	washed	with	2ml	DPBS	and	replaced	with	1ml	
RDM.	 Lifting	 was	 aided	 by	 the	 in-hood	 microscope	 EVOS	 XL	 core	 cell	 imaging	 system	
(ThermoFisher).	NR	domains	were	identifiable	by	their	distinctive	horseshoe	shape.	These	were	
lifted	using	a	10µl	pipette	tip	and	collected	in	a	15ml	falcon.	Care	was	taken	to	ensure	that	NR	
domains	were	undamaged	and	few	other	cells	were	lifted.	This	process	of	lifting	domains	in	1ml	
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RDM	was	completed	up	to	three	times	for	each	well.	Collected	NR	domains	were	left	to	settle	
and	supernatant	was	removed.	NR	domains	from	2	plates	were	evenly	distributed	across	2x	fresh	
6-well	plates	to	grow	in	suspension.	
	
Plates	 were	 regularly	 examined	 over	 the	 differentiation	 period,	 where	 cultures	 with	 poor	
morphology	were	removed.	It	was	observed	that	over	time	a	 layer	of	cells	would	grow	on	the	
surface	 of	 the	 plate,	 where	 some	 optic	 cups	 would	 also	 attach.	 Therefore,	 optic	 cups	 were	
collected	and	transferred	to	fresh	plates	every	10	days,	and	any	adherent	cups	would	be	manually	
lifted.	
	
2.9.3.6	Addition	of	exogenous	factors	to	retinal	differentiation	media	
At	day	42,	FBS	was	added	to	RDM	to	promote	cell	viability.	RDM	+	FBS	was	prepared	by	filter	
sterilising	all	components	in	table	2.6	except	B27,	which	was	added	after	sterilisation.	
	
Retinal	Differentiation	Media	+	FBS	(RDM+FBS)	 Day	42	-	70	
Reagent	 Volume	 Manufacturer	
DMEM,	high	glucose,	L-glutamine	 65ml	 ThermoFisher	
F12	Nutrient	mixture	(Ham)	 25ml	 ThermoFisher	
B27	(without	vitamin	A)	 2ml	 ThermoFisher	
Foetal	bovine	serum	(FBS)	 10ml	 ThermoFisher	
Taurine	(100µM)	 1ml	 Sigma-Aldrich	
Table	2.6	–	The	recipe	for	retinal	differentiation	media	with	extra	supplementation	from	FBS	and	taurine.	
	
At	 day	 70,	 1µM	 retinoic	 acid	 (RA)	 was	 added	 to	 RDM	 +	 FBS	 to	 encourage	 photoreceptor	
maturation.	1µl	of	10mM	RA	stock	was	freshly	added	to	each	10ml	of	RDM	+	FBS	media.	At	day	
98,	the	concentration	of	RA	was	lowered	to	0.5µM,	thus	0.5µl	of	RA	stock	was	added	to	every	
10ml	media.	
	
2.9.3.7	Sample	collection	
Where	possible,	samples	from	each	differentiation	were	collected	at	day	0,	6,	16,	37,	60,	98,	147	
and	198.	When	 samples	were	 collected,	 it	was	 aimed	 to	 take	 a	 representative	 sample	of	 the	
whole	differentiation.	The	optic	cups	that	had	the	best	morphology	were	retained	for	long	term	
culture.	
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2.10	Polymerase	Chain	Reaction	
2.10.1	Reverse	Transcription	from	RNA	to	cDNA	
cDNA	was	generated	by	the	SuperScript	II	Reverse	Transcriptase	(RT)	kit	(ThermoFisher).	500µg	
of	RNA	was	incubated	at	60°C	for	5	minutes	with	1µl	of	Oligo(dT)12-18	(ThermoFisher),	1µl	dNTP	
mix	 (10mM	each)	 (ThermoFisher)	and	RNase	free	water	 to	make	a	total	of	12	µl.	4µl	5x	First-
strand	buffer,	2µl	0.1	M	DTT	and	1µl	RNaseOUT	(40	units/µl)	(ThermoFisher)	were	added,	gently	
mixed	and	incubated	for	2	minutes	at	42°C.	1µl	of	SuperScript	II	RT	was	mixed	and	incubated	for	
50	minutes	at	42°C,	before	a	final	incubation	at	70°C	for	15	minutes	to	inactive	the	reaction.	To	
test	 for	 DNA	 contamination,	 negative	 controls	 for	 each	 sample	were	 included	where	 RT	was	
omitted.	cDNA	samples	were	stored	at	-20°C	until	required.	
	
2.10.2	Designing	primers	
Primers	used	for	products	run	on	agarose	gel	were	design	in	Primer3Plus	(Untergasser	et	al.	2007)	
and	verified	for	specificity	using	University	of	California	Santa	Cruz	(UCSC)	genomes	in-silico	PCR	
(UCSC	 Genome	 Browser	 2017).	 Primers	 binding	 to	 cDNA	 were	 designed	 to	 span	 exon-exon	
junctions	where	possible.	Primer	pairs	were	synthesised	by	Sigma-Aldrich	and	tested	on	positive	
and	negative	controls	before	experiments	were	carried	out.	
	
2.10.3	Polymerase	chain	reaction	
For	all	polymerase	chain	reactions	(PCRs)	the	GoTaq	G2	Flexi	kit	(Promega)	was	used.	In	each	PCR	
tube	or	well	of	a	96-well	plate,	the	following	were	mixed:	17.75µl	nuclease	free	water,	6µl	GoTaq	
buffer,	 2.4µl	 25	 mM	magnesium	 chloride,	 0.6µl	 dNTPs	 (10	 mM	 each),	 0.3µl	 of	 each	 primer	
(100µM),	5%	DMSO,	0.15µl	GoTaq	polymerase	and	1µl	of	gDNA	or	cDNA	(25ng).	PCR	mixes	were	
placed	in	the	T100	Thermo	cycler	(Bio-Rad)	where	most	experiments	were	run	using	the	following	
touchdown	programme:	first,	samples	were	denatured	at	95°C	for	3	minutes.	This	was	followed	
by	10	amplification	cycles,	where	samples	fluctuated	between	a	30	second	denaturing	step	at	
95°C	and	a	30	second	annealing	step,	which	started	at	64°C	and	decreased	by	1°C	with	every	cycle	
down	to	54°C.	Samples	were	incubated	for	1	minute	at	72°C,	before	the	elongation	cycle	began,	
featuring	24	cycles	between	95°C	and	54°C.	Finally,	samples	were	incubated	at	72°C	for	8	minutes	
for	the	final	extension.	For	primers	specific	to	PAX6,	a	touchdown	programme	cycling	from	60°C	
to	50°C	was	used.	
	
For	each	set	of	primers	 (table	2.7)	 for	a	PCR	experiment,	a	negative	control	using	RNase	 free	
water	instead	of	DNA	was	prepared.	For	RT-PCR	experiments	using	cDNA,	primers	designed	to	
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target	GAPDH	were	used	as	a	positive	control	to	test	that	cDNA	production	was	successful	and	
gDNA	contamination	was	absent.	
	
2.10.4	Primers	
	
Gene	 Primer	sequence	
Product	size	(bp)	
Gene	Purpose	
cDNA	 gDNA	
GAPDH	F	 ATGTTCGTCATGGGTGTGAA	
89	 181	 Housekeeping	gene	
GAPDH	R	 GGTGCTAAGCAGTTGGTGGT	
BBS1	ex.12	F	 ATCCCCTGTCTTGCTTTCCT	
NA	 225	 Disease	gene	
BBS1	ex.12	R	 TGCTTCATTTCCACCTCCTC	
VSX2	F	
ATTCAACGAAGCCCACTACCCAG
A	
229	 14542	 Neural	retina	marker	
VSX2	R	 ATCCTTGGCTGACTTGAGGATGG
A	
CRX	F	 TATTCTGTCAACGCCTTGGCCCTA	
253	 4877	 Photoreceptor	specific	
CRX	R	 TGCATTTAGCCCTCCGGTTCTTGA	
SOX2	F	 CCCCCGGCGGCAATAGCA	
448	 448	
Neural	induction	
marker	SOX2	R	 TCGGCGCCGGGGAGATACAT	
OCT4	F	 GTGACAGAGACAGGGGGAAA	
196	 196	 Pluripotency	marker	
OCT4	R	 AGCGATCAAGCAGCGACTAT	
PAX6	F	 CGGAGTGAATCAGCTCGGTG	 259	(-5a),	
301	(+5a)	 1186	 Eye	field	marker	PAX6	R	 CCGCTTATACTGGGCTATTTTGC	
NANOG	F	 CAAAGGCAAACAACCCACTT	
158	 158	 Pluripotency	marker	
NANOG	R	 TCTGCTGGAGGCTGAGGTAT	
RX	F	 GAATCTCGAAATCTCAGCCC	
279	 279	 Eye	field	marker	
RX	R	 CTTCACTAATTTGCTCAGGAC	
LHX2	F	 CAAGATCTCGGACCGCTACT	
284	 1242	 Eye	field	marker	
LHX2	R	 CCGTGGTCAGCATCTTGTTA	
MITF	F	 CTCGAAAACCCCACCAAGTA	
123	 123	
Retinal	pigmented	
epithelium	(RPE)	
marker	MITF	R	 CTGGTTTGGACATGGCAAG	
RCVRN	F	 TCCAGCTTCTGGTTGGTCTT	
328	 328	 Photoreceptor	specific	
RCVRN	R	 CTGCCCACTCTTCCTCACTC	
Table	2.7	–	Forward	(F)	and	reverse	(R)	primer	sequences	including	the	expected	product	size	from	a	cDNA	
or	gDNA	template.	
	
2.10.5	2%	agarose	gel	electrophoresis	
A	 2%	 gel	 was	 made	 by	 dissolving	 4g	 of	 UltraPure	 Agarose	 (Invitrogen)	 with	 200ml	 1x	
Tris/Borate/EDTA	 (TBE)	 buffer	 (BioRad)	 in	 a	 microwave.	 Once	 cooled	 to	 ~50°C,	 4µl	 Ethidium	
Bromide	(Sigma-Aldrich)	was	added	as	a	fluorescent	tag	and	mixed	well.	The	solution	was	poured	
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into	a	casting	tray	with	combs.	Once	the	gel	was	set,	the	comb	was	removed	to	reveal	wells	and	
transferred	to	the	electrophoresis	tank	containing	1x	TBE	buffer.	5µl	of	cDNA	PCR	product	was	
mixed	with	5µl	5x	Green	GoTaq	Flexi	buffer	(Promega)	and	10µl	of	each	sample	was	loaded	to	
each	well	on	the	gel.	4µl	of	HyperLadder	50bp	(Bioline)	DNA	molecular	weight	marker	was	added	
to	the	first	well	as	a	marker.	The	gel	was	run	at	110	volts	for	45	minutes.	Bands	were	visualised	
using	the	UVP	BioDoc-It	Imaging	system	(Analytik	Jena).	
	
2.10.6	Quantitative	PCR	
For	quantitative	PCR	(qPCR),	TaqMan	gene	expression	primer	and	probes	were	utilised	(Applied	
Biosystems)	and	experiments	were	performed	in	triplicate.	All	TaqMan	gene	expression	assays	
contained	primers	spanning	exon-exon	 junctions	and	probes	conjugated	with	5’	FAM	reporter	
and	 3’	 MGB-NFQ	 quencher	 (table	 2.8).	 TaqMan	 master	 mix	 contained	 AmpliTaq	 Gold	 DNA	
polymerase,	 Uracil-DNA	 glycosylase	 (UDG),	 ROX	 passive	 reference	 and	 optimised	 buffer	
components.	In	each	well	of	a	MicroAmp	Optical	96-well	reaction	plate	(Applied	Biosciences),	1µl	
of	20x	TaqMan	gene	expression	assay,	10µl	2x	TaqMan	gene	expression	master	mix,	4µl	cDNA	
template	 (total	of	100	ng)	and	5µl	of	RNase	 free	water	were	combined.	The	plate	was	sealed	
before	being	placed	in	the	StepOnePlus	qPCR	system	(Applied	Biosystems)	and	run	on	a	standard	
qPCR	cycle.		
	
The	thermal	cycling	conditions	were	as	follows:	samples	were	incubated	for	2	minutes	at	50°C	to	
allow	UDG	activity,	then	for	10	minutes	at	95	°C	to	quench	UDG	activity	and	activate	AmpliTaq	
Gold.	This	was	followed	by	thermo	cycling	between	a	15	second	denaturing	step	at	95°C	and	a	1	
minute	annealing/	extension	step	at	60°C.	If	the	target	gene	was	present,	the	DNA	polymerase	
cleaved	the	reporter	from	the	TaqMan	probe,	which	emitted	a	fluorescent	signal.	Baseline	and	
threshold	 for	 amplification	 curves	 were	 calculated	 automatically	 by	 the	 sequence	 detection	
system	 in	 the	 StepOne	 software	 and	 checked	 manually.	 Samples	 were	 quantified	 using	 the	
comparative	 ∆∆Ct	 quantitation	 method,	 which	 was	 implemented	 using	 Microsoft	 Excel.	
Quantitations	 were	 first	 normalised	 to	 an	 endogenous	 control,	 namely	 SNRPD3	 or	 ACTB,	 to	
generate	the	∆Ct.	The	∆∆Ct	of	each	sample	was	calculated	by	normalisation	to	a	calibrator	sample,	
usually	the	sample	from	the	earliest	day	of	differentiation	in	the	experiment.	Relative	fold	change	
was	determined	 through	calculation	of	2(-∆∆Ct).	 For	housekeeping	gene	 test,	 samples	were	not	
normalised	to	an	endogenous	control	but	to	day	0	of	the	iPSC	differentiation.	
	
	
Chapter	2:	Materials,	Methods,	and	Patients	
	
100	
Gene	 Reporter/Quencher	 Gene	Purpose	
Amplicon	
length	
Assay	ID	
SNRPD3	 FAM/MGB-NFQ	 Reference	gene	 68	 Hs00188207_m1	
LDHA	 FAM/MGB-NFQ	 Reference	gene	 66	 Hs01378790_g1	
TBP	 FAM/MGB-NFQ	 Reference	gene	 91	 Hs00427620_m1	
PGK1	 FAM/MGB-NFQ	 Reference	gene	 73	 Hs00943178_g1	
GAPDH	 FAM/MGB-NFQ	 Reference	gene	 93	 Hs02758991_g1	
ACTB	 FAM/MGB-NFQ	 Reference	gene	 63	 Hs01060665_g1	
HPRT1	 FAM/MGB-NFQ	 Reference	gene	 82	 Hs02800695_m1	
NANOG	 FAM/MGB-NFQ	 Pluripotency	marker	 101	 Hs04399610_g1	
PAX6	 FAM/MGB-NFQ	 Eye	field	marker	 76	 Hs00240871_m1	
RAX	 FAM/MGB-NFQ	 Eye	field	marker	 106	 Hs00429459_m1	
MITF	 FAM/MGB-NFQ	 RPE	marker	 81	 Hs01117294_m1	
VSX2	 FAM/MGB-NFQ	 Neural	retina	marker	 125	 Hs01584047_m1	
CRX	 FAM/MGB-NFQ	 Photoreceptor	specific	 73	 Hs00230899_m1	
RCVRN	 FAM/MGB-NFQ	 Photoreceptor	specific	 70	 Hs00610056_m1	
Table	2.8	–	List	of	TaqMan	probes	and	assay	IDs	used	for	qPCR.	
	
2.10.7	Sanger	sequencing	of	p.M390R	
Primers	were	designed	at	least	50bp	either	side	of	the	codon	for	amino	acid	position	390	in	BBS1	
exon	12.	Genomic	DNA	extracted	from	5	iPSC	samples	was	inputted	into	a	touchdown	PCR	with	
BBS1	primers	(described	previously).	The	primers	were	assessed	for	specificity	by	running	the	PCR	
product	 on	 a	 2%	 agarose	 gel	 (described	 previously).	 Excess	 primers	 and	 nucleotides	 were	
removed	by	addition	of	2µl	ExoSap-IT	PCR	product	cleanup	reagent	 (Affymatrix)	 to	5µl	of	PCR	
product.	 Samples	 were	 incubated	 at	 37°C	 for	 15	 minutes	 followed	 by	 80°C	 for	 15	 minutes.	
Samples	prepared	to	a	concentration	of	3ng/µl	were	sent	with	BBS1	primers	at	3.2pmol/µl	 to	
Source	 Bioscience,	 Nottingham,	 UK	 for	 Sanger	 sequencing.	 Sanger	 sequencing	 traces	 were	
visualised	using	Sequencher	v.5.2.3	software	(Gene	Codes	Corporation).	
	
2.11	Immunofluorescence	and	imaging	
2.11.1	Collection	and	cryosectioning	optic	cups	at	day	98,	147	and	198	
Where	possible,	5-10	optic	cups	were	collected	when	differentiations	reached	day	98,	147	and	
198.	These	were	washed	in	PBS	and	fixed	in	4%	Paraformaldhyde	(PFA)	(VWR)	for	20	minutes	at	
room	 temperature.	 After	 3x	 10	 minute	 PBS	 washes,	 the	 optic	 cups	 were	 cryoprotected	 by	
incubation	 in	 30%	 sucrose	 solution	 at	 room	 temperature	 for	 1	 hour.	 The	 cups	 were	 then	
embedded	 in	 optimal	 cutting	 temperature	 (OCT)	 compound	 (VWR)	 and	 fast	 frozen	 in	 a	
methylbutane/dry	 ice	 slurry.	 They	 were	 stored	 at	 -80°C	 until	 cryosectioning	 and	 immuno-
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histochemical	staining.	Embedded	optic	cups	were	equilibrated	to	-20°C	before	cryosectioning	to	
a	thickness	of	5	µm	with	the	Leica	Biosystems	cryostat.	
	
2.11.2	Fixing	of	cultured	cells	
Fibroblasts	and	iPSC	colonies	for	immunocytochemical	staining	were	grown	in	8-well	Nunc	Lab-
Tek	II	chamber	slide	systems	(ThermoFisher).	Cells	were	washed	in	PBS	and	fixed	in	4%	PFA	for	
15	minutes	at	room	temperature.	Cells	were	washed	3	times	in	PBS	for	5	minutes	each	before	
immunofluorescent	staining.	
	
2.11.3	Immunofluorescence	staining	
Slides	of	cryosectioned	optic	cups	were	dried	at	room	temperature	overnight	and	washed	3	times	
in	DPBS	for	5	minutes	prior	to	staining.	Samples	were	permeabilised	by	incubation	in	0.1%	Triton	
X-100	 (Sigma-Aldrich),	 0.1%	 Tween-20	 (ThermoFisher)	 in	 PBS	 for	 10	 minutes	 at	 room	
temperature.	After	washing	with	3	times	with	PBS	for	5	minutes	each,	samples	were	blocked	in	
3%	BSA	(Sigma-Aldrich),	10%	donkey	serum	(Sigma-Aldrich)	in	PBST	(PBS,	0.1%	Tween)	for	1	hour	
at	room	temperature.	Antibody	diluent	was	prepared	with	0.3%	BSA,	1%	donkey	serum	in	PBST.	
Primary	 antibodies	 were	 diluted	 as	 indicated	 and	 samples	 were	 incubated	 with	 primary	
antibodies	overnight	at	4°C.	Samples	were	washed	in	3	times	in	PBS	for	5	minutes	each	prior	to	
application	 of	 species-specific	 secondary	 antibodies.	 Either	 anti-IgG	 Alexa	 Fluor	 594	 or	 488	
(ThermoFisher)	were	used	as	appropriate,	which	were	diluted	1:1000	in	PBST	and	incubated	for	
1	 hour	 at	 room	 temperature	 in	 the	 dark.	 Samples	 were	 washed	 in	 PBS	 and	 coverslips	 were	
mounted	with	ProLong	Gold	antifade	mountant	with	DAPI	(ThermoFisher).	
	
2.11.4	Antibodies	
The	 following	 antibodies	 were	 used	 to	 stain	 the	 primary	 cilium,	 basal	 body	 and	 anterograde	
intraflagellar	transport	machinery:	anti-mouse	acetylated	tubulin	at	1:500	(Sigma-Aldrich),	anti-
rabbit	BBS5	at	1:100	 (Proteintech)	and	anti-rabbit	 IFT88	at	1:300	 (Proteintech).	 The	 following	
antibodies	were	used	to	establish	pluripotency	of	iPSCs:	anti-goat	NANOG	at	a	dilution	of	1:100	
(R&D	Systems),	anti-goat	SOX2	at	1:200	(R&D	Systems)	and	anti-mouse	OCT-4	at	1:100	(Santa	
Cruz	Biotechnology).	The	following	antibodies	were	used	to	follow	development	in	iPSC	derived	
optic	cups:	anti-mouse	CRX	at	a	dilution	of	1:800	(Sigma-Aldrich),	anti-rabbit	Recoverin	at	1:800	
(Merck	Millipore),	anti-mouse	BRN3	at	1:200	(Merck	Millipore),	anti-goat	VSX2	at	1:200	(Santa	
Cruz	Biotechnology),	anti-rabbit	rhodopsin	4D2	at	1:500	(Abcam)	and	anti-mouse	cone-arrestin	
7G6	 at	 1:10,000	was	 a	 kind	 gift	 from	 Professors	Mike	 Cheetham	 and	 Alison	 Hardcastle	 (UCL	
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Institute	 of	Ophthalmology,	 London,	UK).	 Donkey	 anti-mouse,	 donkey	 anti-rabbit	 and	 donkey	
anti-goat	 Alexa	 Fluor	 488	 or	 Alexa	 Fluor	 594	 secondary	 antibodies	 from	 ThermoFisher	 were	
utilised	at	a	dilution	of	1:1000.	
	
2.11.5	Imaging	
All	 fluorescence	 images	 were	 obtained	 using	 the	 Carl	 Zeiss	 Z1	 imager	 at	 20x,	 40x	 or	 63x	
magnification	and	captured	with	 the	AxioCam	MRm	camera.	For	 images	at	63x	magnification,	
immersion	oil	 (Sigma-Aldrich)	was	used.	 Images	were	taken	using	AxioVision	4.8	software	and	
exported	 to	 Fiji	 image	 processing	 package	where	 scale	 bars	 were	 calculated	 for	 each	 image.	
Images	at	x20,	40x	or	63x	magnification	were	assigned	50µm,	20µm	or	20µm	bars,	respectively.	
	
2.11.6	Calculating	the	percentage	of	ciliated	fibroblasts	
Serum	starved	and	serum	fed	fibroblasts	from	5	lines	were	immunocytochemically	stained	with	
acetylated	 tubulin	 to	 identify	 primary	 cilia.	 6	 images	 representative	 of	 each	 line	were	 taken,	
resulting	in	30	images	for	each	condition.	Nuclei	were	identifiable	by	DAPI	counterstain,	which	
were	 counted	 for	 each	 image	 using	 an	 ImageJ	 macro.	 Similarly,	 primary	 cilia	 number	 was	
identified	using	a	second	ImageJ	macro.	The	mean	number	of	ciliated	cells	for	each	condition	was	
calculated	by	dividing	the	number	of	cilia	by	the	number	of	nuclei	per	image	and	averaging	over	
30	images.	ImageJ	macros	were	written	by	Miss	Grace	Freke.	
	
2.11.7	Transmission	Electron	Microscopy	(TEM)	
Optic	cups	from	patient	line	BBS001	(aetc_1)	at	day	198	were	fixed	in	3%	glutaraldehyde,	1%	PFA	
and	 0.08	 M	 sodium	 cacodylate-HCl	 buffered	 to	 pH	 7.4.	 Following	 this,	 the	 optic	 cups	 were	
processed	 for	 transmission	 electron	 microscopy	 (TEM)	 and	 imaged	 by	 Dr	 Peter	 Munro	 (UCL	
Institute	of	Ophthalmology,	London,	UK).	They	were	washed	twice	in	0.1M	sodium	cacodylate-
HCl,	pH	7.4	for	5	minutes	each	and	incubated	for	2	hours	in	1%	aqueous	osmium	tetroxide.	They	
were	dehydrated	in	alcohol,	passing	through	once	at	50-90%	alcohol,	and	3	times	at	100%,	for	10	
minutes	each,	before	incubation	overnight	in	equal	parts	araldite	and	propylene	oxide.	Optic	cups	
were	embedded	in	araldite	resin	and	cured	at	60	°C	overnight.	Sections	were	prepared	at	0.75µM	
and	stained	with	1%	toluidine	blue-borax	and	Reynolds	lead	citrate.	The	apical	layer	of	the	optic	
cups	was	imaged	by	JEOL	1010	transmission	electron	microscope	at	80	kV	and	captured	using	the	
Gatan	Orius	CCD	camera.	
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2.12	Software	and	Databases	
With	millions	of	genetic	variants,	tens	of	thousands	of	transcripts,	and	thousands	of	proteomics	
data	points,	the	greatest	challenge	of	large	omic	datasets	is	how	to	reduce	the	data	size	to	allow	
accurate	 and	 biologically	 meaningful	 inferences.	 This	 can	 be	 aided	 through	 use	 of	 different	
software,	analytical	techniques,	and	open	source	databases.	The	software	and	databases	utilised	
within	this	thesis	are	presented	in	table	2.9.	
	
2.13	Raw	Data	
The	 raw	data	 for	 transcriptomic	and	proteomic	experiments,	as	well	as	outputs	 for	GSEA	and	
other	 pathway	 analyses,	 can	 be	 found	 on	 the	 USB	 stick	 attached	 to	 this	 thesis.	 A	 table	
demonstrating	the	file	names	and	locations	can	be	found	in	the	supplemental	material	section,	
table	S.1.	
	
	
		
Software,	database,	
open	source	software	
Supplier/	provider	 Version	 Website	 Use	in	thesis	 Reference	
Ingenuity	Variant	
Analysis	(IVA)	 QIAGEN	 -	
https://www.qiagenbioinformatics.com/products/ingenuity-
variant-analysis/	 Chapter	3	 -	
Progenesis	QI	for	
Proteomics	(QIP)	
Nonlinear	Dynamics	by	Waters	
Corporation	 v.2.0	 http://www.nonlinear.com/progenesis/qi-for-proteomics/	 Chapter	4	 -	
Exome	aggregate	
consortium	(ExAC)	
Broad	Institute	 v.0.3.1	 http://exac.broadinstitute.org	 Chapter	3	 (Lek	et	al.	2016)	
Genome	aggregation	
database	(GnomAD)	
Broad	Institute	 v.2	 http://gnomad.broadinstitute.org	 Chapter	3	 (Lek	et	al.	2016)	
Sorting	Intolerant	From	
Tolerant	(SIFT)	 J.	Craig	Venter	Institute	 v.1.03	 http://sift.jcvi.org	 Chapter	3	 (Ng	and	Henikoff	2003)	
PolyPhen-2	 Harvard	University	 v.2.2.2	 http://genetics.bwh.harvard.edu/pph2/	 Chapter	3	 (Adzhubei	et	al.	2013)	
Protein	Variation	Effect	
Analyser	(PROVEAN)	 J.	Craig	Venter	Institute	 v.1.1.3	 http://provean.jcvi.org/index.php	 Chapter	3	
(Choi	et	al.	2012;	Choi	and	
Chan	2015)	
Combined	Annotation-
Dependent	Depletion	
(CADD)	
University	of	Washington	 v.1.3	 http://cadd.gs.washington.edu	 Chapter	3	 (Kircher	et	al.	2014)	
PANTHER	Classification	
system	
Gene	Ontology	Phylogenic	
Annotation	Project	
v.12.0	 http://pantherdb.org/	 Chapter	4	&	
5	
(Mi	et	al.	2013;	Mi	et	al.	
2017)	
Gene	Ontology	 Gene	Ontology	Consortium	 -	 http://geneontology.org/	 Chapter	4	
(Ashburner	et	al.	2000;	
Gene	Ontology	
Consortium	2015)	
Reactome	 Reactome	consortium	 v.54.0	 http://reactome.org	 Chapter	5	
(Matthews	et	al.	2009;	
Croft	et	al.	2011)	
Gene	set	enrichment	
analysis	(GSEA)	
Broad	Institute	 v.3.0	 http://software.broadinstitute.org/gsea/index.jsp	 Chapter	5	 (Subramanian	et	al.	2005;	
Mootha	et	al.	2003)	
Molecular	Signatures	
Database	(MSigDB)	
Hallmark	
Broad	Institute	 v.6.0	 http://software.broadinstitute.org/gsea/index.jsp	 Chapter	5	 (Liberzon	et	al.	2015)	
STRING	 STRING	consortium	 v.10.5	 https://string-db.org	
Chapter	3,	4	
&	5	 (Szklarczyk	et	al.	2015)	
Table	2.9	–	Software,	databases,	and	open	source	software	utilised	within	this	thesis.
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2.14	Patients	and	controls	
2.14.1	Recruitment	criteria	
Patients	were	 recruited	 to	 the	 study	 from	April	 to	December	2014.	All	 clinical	data	described	
below	was	relevant	at	the	time	of	recruitment.	The	conditions	for	recruitment	were	as	follows:	
• patients	possess	 a	definitive	molecular	 diagnosis	 comprised	of	 the	 common	p.M390R	
mutation	in	BBS1.	Patients	may	be	homozygous	for	p.M390R	or	compound	heterozygous	
with	p.M390R	on	one	allele	and	an	additional	segregating	pathogenic	allele	elsewhere	in	
BBS1	
• patients	were	white	European	from	non-consanguineous	families	
• patients	must	have	attended	the	multidisciplinary	BBS	clinic	at	Guy’s	Hospital,	London	for	
genetic	and	phenotypic	assessment	
• patients	consented	to	use	of	a	skin	biopsy,	whole	blood,	and	urine	for	research	purposes	
	
2.14.2	Clinical	details	
The	clinical	details	for	each	patient	is	outlined	here	and	detailed	in	table	2.10.	
	
2.14.2.1	BBS001	
Gender:	Female		 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	30-39	
Retinal	pigmentation	was	observed	at	the	age	of	7	and	rod-cone	dystrophy	diagnosed	at	13	years.	
The	patient	had	a	clinically	obese	BMI	of	35.6	when	samples	for	this	study	were	taken	and	has	
moderate	 learning	 difficulties.	 She	 suffered	 from	 recurrent	 renal	 and	 urinary	 tract	 infections	
(UTIs),	 including	vesicoureteral	reflux	and	pyelonephritis	with	renal	abscess	formation.	Despite	
this,	 she	 has	 no	 structural	 renal	 dysfunction	 to	 classify	 as	 a	 primary	 BBS	 feature.	 Physical	
secondary	features	of	BBS	include	mild	cataract,	brachydactyly,	epicanthic	folds	and	a	high	palate.	
	
2.14.2.2	BBS002	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	60+	
Patient	BBS002	has	been	registered	blind	since	his	20s	due	to	advanced	rod-cone	dystrophy.	The	
patient	was	born	with	foot	polydactyly	and	suffers	from	mild	learning	difficulties.	At	the	time	of	
recruitment	to	the	study,	he	had	a	clinically	obese	BMI	of	38.5.	He	had	type	II	diabetes	mellitus	
and	hypertension,	likely	as	a	secondary	feature	to	obesity.	
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2.14.2.3	BBS003	
Gender:	Female		 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	40-49	
Patient	BBS003	suffers	from	severe	rod-cone	dystrophy	and	was	born	with	polydactyly	of	the	left	
hand.	She	presented	with	persistent	fetal	lobulation,	a	structural	defect	of	the	kidney.	At	the	time	
of	 study	 recruitment,	 the	 patient	 had	 a	 severely	 obese	 BMI	 of	 41	 and	 also	 displayed	 severe	
learning	difficulties.	Secondary	development	defects	include	brachydactyly,	syndactyly	and	a	high	
arched	palate.	She	also	had	hypothyroidism	and	hypertension.	
	
2.14.2.4	BBS004	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	c.723+1G>A	 	 Age:	20-29	
Patient	BBS004	has	severe	rod-cone	dystrophy	and	moderate	learning	difficulties	but	displays	no	
other	symptoms	indicative	of	BBS.	He	was	identified	as	a	patient	due	to	a	sibling	who	presents	a	
more	 typical	phenotype.	At	 the	 time	of	 study	 recruitment,	BBS004	had	an	overweight	BMI	of	
25.6,	but	was	not	clinically	obese.		
	
2.14.2.5	BBS005	
Gender:	Female		 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	60+	
Night	blindness	was	first	reported	in	this	patient	at	the	age	of	8	years.	Deterioration	of	eyesight	
has	rendered	this	patient	completely	blind.	She	was	borderline	obese	at	the	time	of	recruitment	
with	a	BMI	of	30.2	and	was	born	with	polydactyly	of	the	feet	and	the	right	hand.	BBS005	also	
experienced	renal	cysts	and	cardiac	issues	including	angina	pectoris	and	hypertension.	She	had	
some	urorenal	abnormalities,	including	pyelonephritis	and	nephrolithiasis	(kidney	stones).		
	
2.14.2.6	BBS006	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	p.G73*	 	 Age:	40-49	
BBS-related	symptoms	were	first	diagnosed	in	this	patient	at	the	age	of	11	and	he	was	registered	
blind	 from	 rod-cone	 dystrophy	 at	 21	 years.	 4-limb	 polydactyly	 was	 present	 at	 birth	 and	 has	
orodental	abnormalities	including	high	arched	palate,	hypodontia	and	dental	crowding.	Weight	
gain	was	noticeable	at	an	early	age	and	had	a	clinically	obese	BMI	of	36.2	at	recruitment.	Other	
secondary	features	of	BBS	include	cataracts,	hypercholesterolemia,	polyuria	and	polydipsia.		
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2.14.2.7	BBS007	
Gender:	Female		 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	40-49	
Patient	BBS007	was	diagnosed	with	BBS	in	her	40s	due	to	a	 late	onset	of	rod-cone	dystrophy.	
Despite	this,	her	vision	has	diminished	quickly.	This	patient	had	a	severely	obese	BMI	of	51.3	at	
recruitment	 and	 presents	 stage	 III	 chronic	 kidney	 disease.	 Developmental	 features	 include	
moderate	 learning	difficulties,	postaxial	 foot	polydactyly,	midface	 retrusion,	a	high	palate	and	
dental	crowding.		
	
2.14.2.8	BBS008	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	40-49	
Patient	BBS008	has	profound	rod-cone	dystrophy	and	was	registered	blind	in	his	20s.	At	the	time	
of	recruitment,	he	was	clinically	obese	with	a	BMI	of	35.1.	He	was	born	with	polydactyly	of	the	
feet	 and	 has	mild	 learning	 difficulties.	 BBS008	 has	 type	 I	 diabetes	mellitus,	 cataracts,	 dental	
crowding	and	suffers	from	recurrent	UTIs.		
	
2.14.2.9	BBS009	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	30-39	
Patient	 BBS009	 presents	mild	 rod-cone	 dystrophy	 but	 shows	 a	 progression	 decline	 of	 colour	
vision.	Polydactyly	of	the	feet	was	present	at	birth.	He	was	clinically	obese	with	a	BMI	of	31.3	at	
the	time	of	recruitment.	
	
2.14.2.10	BBS010	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	p.Y284Sfs*5	 	 Age:	50-59	
Patient	BBS010	is	a	monozygotic	(MZ)	twin	with	patient	BBS011	and	brother	of	BBS012.	He	has	
severe	rod-cone	dystrophy	and	is	registered	to	have	severely	impaired	vision.	He	was	born	with	
4-limb	polydactyly	and	presents	moderate	learning	difficulties.	Secondary	BBS	features	include	
cataracts,	high	palate	and	dental	crowding.	At	the	time	of	recruitment,	he	was	clinically	obese	
with	a	BMI	of	31.2.	
	
2.14.2.11	BBS011	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	p.Y284Sfs*5	 	 Age:	50-59	
Patient	BBS011	has	severe	rod-cone	dystrophy	and	early	cataract	formation.	 In	contrast	to	his	
MZ	twin,	he	was	not	born	with	polydactyly.	He	has	moderate	learning	difficulties	and	was	clinically	
obese	with	a	BMI	of	33	at	recruitment.	
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2.14.2.12	BBS012	
Gender:	Female		 Genotype:	BBS1	p.M390R/	p.Y284Sfs*5	 	 Age:	50-59	
Patient	BBS012	is	the	affected	sibling	of	BBS010	and	BBS011.	In	comparison	to	her	siblings,	she	
had	later	onset	of	rod-cone	dystrophy	and	milder	learning	difficulties.	She	was	clinically	obese	at	
recruitment	 with	 a	 BMI	 of	 33.4.	 Secondary	 features	 include	 cataracts,	 high	 palate,	 dental	
crowding	and	nephrolithiasis.		
	
2.14.2.13	BBS013	
Gender:	Female		 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	20-29	
Patient	BBS013	was	diagnosed	at	the	age	of	3	years	due	to	onset	of	visual	decline,	but	unusually	
did	not	present	with	night	blindness.	BBS013	has	mild	 learning	difficulties	 and	was	born	with	
polydactyly.	Secondary	BBS	features	include	cardiac,	endocrine	and	urorenal	abnormalities.	
	
2.14.2.14	BBS014	
Gender:	Female		 Genotype:	BBS1	p.M390R/	p.G73*	 	 Age:	30-39	
Patient	BBS014	was	diagnosed	with	 rod-cone	dystrophy	at	7	years.	 She	was	born	with	4-limb	
polydactyly	and	has	mild	learning	difficulties.	BBS014	had	stage	V	chronic	kidney	disease,	which	
required	transplantation.	At	the	time	of	recruitment,	she	was	reported	to	be	obese,	but	her	BMI	
was	 not	 recorded.	 Secondary	 endocrine	 features	 include	 uterine	 leiomyoma	 and	 polycystic	
ovaries.	
	
2.14.2.15	BBS015	
Gender:	Male	 	 Genotype:	BBS1	p.M390R/	p.M390R	 	 Age:	40-49	
Night	 blindness	was	 first	 reported	 in	 BBS015	 at	 the	 age	of	 9	 years,	 developing	 into	 rod-cone	
dystrophy	 in	 later	 life.	 He	 presents	 with	 hypogonadism	 and	 some	 urorenal	 abnormalities,	
including	polyuria	and	polydipsia.	At	the	time	of	recruitment,	he	was	reported	to	be	overweight,	
with	a	BMI	of	27.
		
Patient	
ID	
Gender	 Allele	1	 Allele	2	
Primary	features	 Secondary	features	
Retinal	
dystrophy	
Obesity	
(BMI)	
Hypo-
gonadism	
Postaxial	
Polydactyly	
Renal	
dysfunction	
Learning	
difficulties	
Count	
Eye	
abnormalities	
Developmental	
features	
Endocrine	
Orodental	
abnormalities	
Cardiac	issues	
Urorenal	
abnormalities	
Count	
BBS001	 Female	
BBS1	
p.M390R	
BBS1	
p.M390R	
Severe	
Yes	
(35.6)	
-	 -	 -	 Moderate	 3	 Cataract	
Brachydactyly,	
epicanthic	folds	
-	 High	palate	 -	
Vesicoureteral	
reflux,	recurrent	
UTI,	
pyelonephritis	
4	
BBS002	 Male	
BBS1	
p.M390R	
BBS1	
p.M390R	
Severe	
Yes	
(38.5)	
-	 Feet	 -	 Mild	 4	 Cataract	 -	
Type	II	diabetes	
mellitus	
-	 Hypertension	 -	 3	
BBS003	 Female	
BBS1	
p.M390R	
BBS1	
p.M390R	
Severe	
Yes	
(41.0)	
-	 Hand	
Persistent	
fetal	
lobulation	
Severe	 5	 -	
Brachydactyly,	
Syndactyly	
Hypothyroidism	 High	palate	 Hypertension	 -	 4	
BBS004	 Male	
BBS1	
p.M390R	
BBS1	
c.723+1G>A	
Severe	
OW	
(25.6)	
-	 -	 -	 Moderate	 2	 -	 -	 -	 -	 -	 -	 0	
BBS005	 Female	
BBS1	
p.M390R	
BBS1	
p.M390R	
Severe	
Yes	
(30.2)	
-	 3-limb	 Renal	cysts	 -	 4	 Cataract	 -	 -	
Dental	
crowding	
Hypertension,	
angina	pectoris	
Pyelonephritis,	
polyuria,	
nephrolithiasis	
4	
BBS006	 Male	
BBS1	
p.M390R	
BBS1	p.G73*	 Severe	
Yes	
(36.2)	
Yes	 4-limb	 -	 Mild	 5	 Cataract	 -	
Hyper-
cholesterolemia	
Hypodontia,	
high	palate,	
dental	
crowding	
-	
Polyuria,	
polydipsia	
4	
BBS007	 Female	
BBS1	
p.M390R	
BBS1	
p.M390R	
Mild	
Yes	
(51.3)	
-	 Feet	 Stage	III	CKD	Moderate	 5	 Strabismus	
Midface	
retrusion	
Hypothyroidism	
High	palate,	
dental	
crowding	
-	 -	 4	
BBS008	 Male	
BBS1	
p.M390R	
BBS1	
p.M390R	
Severe	
Yes	
(35.1)	
-	 Feet	 -	 Mild	 4	
Cataract,	
Strabismus	
-	
Type	I	diabetes	
mellitus	
Dental	
crowding	
-	 Recurrent	UTI	 4	
		
BBS009	 Male	
BBS1	
p.M390R	
BBS1	
p.M390R	
Mild	
Yes	
(31.3)	
-	 Feet	 -	 -	 3	 -	 -	 -	 -	 -	 Recurrent	UTI	 1	
BBS010	 Male	
BBS1	
p.M390R	
BBS1	
p.Y284Sfs*5	
Severe	
Yes	
(31.2)	
-	 4-limb	 -	 Moderate	 4	 Cataract	 -	 -	
High	palate,	
dental	
crowding	
-	 -	 2	
BBS011	 Male	
BBS1	
p.M390R	
BBS1	
p.Y284Sfs*5	
Severe	
Yes	
(33)	
-	 -	 -	 Moderate	 3	 Cataract	 -	 -	 -	 -	 -	 1	
BBS012	 Female	
BBS1	
p.M390R	
BBS1	
p.Y284Sfs*5	
Mild	
Yes	
(33.4)	
-	 -	 -	 Mild	 3	 Cataract	 -	 -	
High	palate,	
dental	
crowding	
-	 Nephrolithiasis	 3	
BBS013	 Female	
BBS1	
p.M390R	
BBS1	
p.M390R	
Mild	
Yes	
(37.3)	
-	 4-limb	 -	 Mild	 4	 -	 -	
Polycystic	
ovaries,	diabetes	
insipidus	
-	
Aortic	valve	
stenosis,	Aortic	
regurgitation	
Recurrent	UTI,	
polysplenia	
3	
BBS014	 Female	
BBS1	
p.M390R	
BBS1	p.G73*	 Severe	
Yes	
(BMI	
N/k)	
-	 4-limb	 Stage	V	CKD	 Mild	 5	 -	 -	
Uterine	
leiomyoma,	
polycystic	
ovaries	
-	 -	 Recurrent	UTI	 2	
BBS015	 Male	
BBS1	
p.M390R	
BBS1	
p.M390R	
Severe	
OW	
(27)	
Yes	 -	 -	 -	 2	 -	 -	 -	 -	 -	
Polyuria,	
polydipsia	
1	
Table	2.10	–	Patient	clinical	information.	Grey	highlighted	headings	indicate	cardinal	features	of	BBS,	whereas	secondary	features	are	on	the	right-hand	side	of	the	table.	A	
count	for	primary	and	secondary	features	is	displayed	for	each	patient.	N/k	indicates	a	feature	that	was	not	recorded;	OW	=	overweight.
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2.14.3	Control	individuals	
Throughout	this	project,	biological	replicates	from	BBS	patients	were	compared	against	a	set	of	
clinically	healthy	non-obese	control	 individuals	(detailed	in	table	2.11).	Urine	and	plasma	from	
control	 samples	CTRL019	 and	CTRL021-26	were	utilised	 as	 biological	 replicates	 for	 biomarker	
discovery	in	chapter	4.	Fibroblasts	obtained	from	CTRL019-020	and	CTRL030-033	were	profiled	
by	RNA-seq	and	iTRAQ	mass	spectrometry	in	chapter	5.	Finally,	iPSC	cell	lines	from	CTRL037	and	
CTRL038	were	reprogrammed	from	healthy	individuals,	which	were	provided	for	use	in	chapter	
6	by	the	HipSci	project	(Wellcome	Trust	Sanger	Institute,	Cambridge,	UK).	
	
Sample	ID	 Gender	 Age	 Ethnicity	 Material/cells	obtained	
CTRL019	 Female	 40-49	 European	 Urine/	plasma/	fibroblasts	
CTRL020	 Female	 30-39	 European	 Fibroblasts	
CTRL021	 Female	 20-29	 European	 Urine/	plasma	
CTRL022	 Male	 30-39	 European	 Urine/	plasma	
CTRL023	 Female	 30-39	 European	 Urine/	plasma	
CTRL024	 Male	 20-29	 European	 Urine/	plasma	
CTRL025	 Male	 30-39	 European	 Urine/	plasma	
CTRL026	 Male	 50-59	 European	 Urine/	plasma	
CTRL030	 Female	 20-29	 European	 Fibroblasts	
CTRL031	 Female	 30-39	 European	 Fibroblasts	
CTRL032	 Female	 20-29	 European	 Fibroblasts	
CTRL033	 Male	 30-39	 European	 Fibroblasts	
CTRL037	 Male	 65-69	 European	 iPSCs	
CTRL038	 Female	 40-44	 European	 iPSCs	
Table	2.11	–	Sample	information	about	control	individuals	used	within	this	study.	
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Chapter	3:	Use	of	next	generation	sequencing	data	to	investigate	
the	presence	of	genetic	modifiers	in	BBS	
	
3.1.	Background	
A	genetic	modifier	is	defined	as	a	gene	that	has	the	potential	to	alter	the	expression	of	another	
gene	at	the	primary	locus	(Cutting	2010).	In	the	case	of	disease	modifiers,	these	can	transform	
the	expressivity	or	manifestation	of	a	primary	driving	mutation,	with	little	or	no	effect	in	a	healthy	
individual	(Génin	et	al.	2008).	Modifiers	can	either	act	in	close	proximity	to	the	primary	gene	as	a	
cis-modifier,	or	can	be	modulated	by	a	genetic	variant	 far	 from	the	primary	 locus,	as	a	 trans-
modifier	(Harper	et	al.	2015).	
	
3.1.1.	Genetic	modifiers	in	ciliopathies	
Ciliopathies	are	an	intriguing	group	of	diseases.	The	proteins	involved	are	closely	organised	in	a	
single	organelle,	and	yet	pathogenic	defects	in	ciliopathy	related	genes	can	cause	a	vast	spectrum	
of	disease.	These	can	present	as	a	variety	of	seemingly	unrelated	phenotypes,	at	varying	levels	of	
severity.	 The	 diversity	 observed	 at	 the	 phenotypic	 level	 is	 accredited,	 in	 part,	 to	 the	 genetic	
background	of	each	patient,	where	it	is	proposed	that	disease	expressivity	is	controlled	by	genetic	
modifiers	(Beales	et	al.	2003;	Katsanis,	Lupski,	et	al.	2001;	Zaghloul	and	Katsanis	2009;	Badano	et	
al.	2006;	Zaki	et	al.	2011).	Since	the	early	genotyping	of	pathogenic	variants	in	BBS	proteins	there	
has	been	 identification	of	additional	alleles	 in	a	second	BBS	 locus	 in	a	small	subset	of	 families	
(Beales	et	al.	2003;	Zaki	et	al.	2011;	Katsanis,	Ansley,	et	al.	2001).	Following	this	phenomenon,	
modifiers	have	been	described	in	several	different	ciliopathies,	such	as	additional	heterozygous	
AHI1	or	NPHP6	alleles	found	in	patients	with	NPHP1	nephronophthisis,	modifying	the	phenotype	
from	 isolated	 neuropathy	 towards	 a	 JBTS-like	 syndrome	 (Tory	 et	 al.	 2007).	 In	 addition,	 BBS	
proteins	 have	been	 shown	 to	 alter	 phenotypic	 expression	 in	 other	 ciliopathies,	 particularly	 in	
CEP290	related	syndromes	(Zhang	et	al.	2014;	Rachel	et	al.	2012).		
	
A	particularly	relevant	example	 is	of	three	siblings	of	northern	European	descent,	all	of	whom	
were	homozygous	for	BBS1	p.M390R	alleles.	However,	two	of	the	siblings	were	heterozygous	for	
an	additional	missense	allele	in	BBS2,	which	exhibited	a	more	severe	retinal	phenotype	in	these	
two,	compared	to	the	third	sibling	(Beales	et	al.	2003).	Moreover,	there	have	been	remarkable	
cases	 where	 siblings	 have	 displayed	 characteristics	 of	 distinct	 syndromes,	 such	 as	 one	 child	
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exhibiting	BBS	inclusive	of	renal	dysfunction,	whereas	their	two	siblings	displayed	the	molar	tooth	
sign	 indicative	 of	 JBTS,	 without	 obesity	 or	 nephropathy	 (Zaki	 et	 al.	 2011).	 These	 findings	
demonstrate	the	close	interconnectivity	of	the	ciliary	proteome	and	highlight	the	delicate	nature	
of	 these	 syndromes,	 where	 an	 additional	 allele	 could	 easily	 alter	 the	 degree	 of	 phenotypic	
expressivity.	
	
Upon	the	discovery	of	these	triple	allelic	combinations,	it	was	hypothesised	that	an	effect	would	
only	be	seen	between	alleles	from	interacting	proteins	(Katsanis	2004).	This	hypothesis	supported	
the	relatively	high	frequency	of	variants	detected	in	both	BBS2	and	BBS6	(Katsanis,	Lupski,	et	al.	
2001;	Katsanis	2004;	Beales	et	al.	2003),	as	these	proteins	directly	interact	via	their	respective	
complexes,	 the	BBSome	and	chaperone	complex.	More	 recently,	modifying	variants	have	also	
been	predicted	to	affect	BBS	phenotypic	expressivity,	identified	in	CCDC28B	(Badano	et	al.	2006;	
Cardenas-Rodriguez	et	al.	2013),	TTC21B	(Davis	et	al.	2011)	and	RPGRIP1L	(Khanna	et	al.	2009).	
Although	 it	 has	 been	 shown	 that	 CCDC28B	 directly	 interacts	 with	 the	 BBSome,	 TTC21B	 and	
RPGRIP1L	 have	 yet	 to	 demonstrate	 an	 experimentally	 determined	 interaction	 with	 BBSome	
proteins.	 It	 is	 not	 yet	 understood	 whether	 modifiers	 in	 any	 ciliary	 gene	 can	 exhibit	 a	 trans-
modifying	effect	to	any	non-interacting	ciliary	protein	(Boldt	et	al.	2016).	
	
3.1.2.	Identification	of	modifiers	
Although	modifiers	 are	 predicted	 to	 explain	 the	 substantial	 variability	 observed	 in	Mendelian	
disorders,	relatively	few	numbers	of	potential	modifiers	have	been	identified	so	far	(Génin	et	al.	
2008).	The	reason	for	this	can	be	attributed	to	the	techniques	for	modifier	identification,	which	
can	 be	 difficult	 to	 replicate	 and	 validate.	 Detection	 of	 cis-modifiers	 can	 be	 relatively	 straight	
forward	compared	to	trans-modifiers,	as	they	can	be	detected	through	linkage	analysis	(Wright	
et	 al.	 2011).	 Cis-modifiers	 act	 within	 close	 range	 of	 the	 primary	 driving	 mutation,	 and	 thus	
segregate	with	the	disease	variant.	The	presence	or	absence	of	a	cis-modifier	can	occasionally	
explain	variability	 in	disease	penetrance	 (Azaiez	et	al.	2004;	Shawky	2014).	By	contrast,	trans-
modifiers	 exhibit	 their	 effects	 in	 other	 regions	 of	 the	 genome	 and	 can	 often	 appear	 as	
multifactorial-like	 diseases	 (Génin	 et	 al.	 2008).	 Association	 studies,	 and	 more	 recently,	 next	
generation	sequencing	data	are	being	utilised	in	an	attempt	to	identify	modifier	alleles	(Gonzaga-
Jauregui	et	al.	2015;	Li	and	Leal	2008).	
	
In	contrast	to	identification	of	the	primary	disease	locus,	modifier	alleles	are	more	challenging	
(Boyle	 2007).	 Firstly,	 the	 majority	 of	 modifiers	 in	 ciliopathies	 are	 reported	 as	 heterozygous	
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variants,	 and	 thus	 cannot	 be	 determined	 through	 genetic	 segregation.	 Sibling	 or	 twin	
investigations	can	provide	additional	insight	into	the	function	of	a	potential	modifier,	if	discordant	
phenotypes	 are	 observed	 with	 the	 presence	 or	 absence	 of	 a	 third	 allele.	 Additionally,	 these	
studies	 can	 further	 assist	 in	 discriminating	 between	 variability	 caused	 by	 genetic	 or	
environmental	contributing	factors	(Czyz	et	al.	2012).		
	
Secondly,	 quantifying	 the	 severity	 of	 a	 modifier	 can	 prove	 challenging	 (Khanna	 et	 al.	 2009),	
especially	when	it	is	hypothesised	that	they	implement	temporal	changes,	such	as	age	of	onset	
or	developmental	defects.	These	changes	are	particularly	difficult	to	validate	through	functional	
assays,	as	some	developmental	 features	may	express	differently	 in	model	organisms,	as	 is	the	
case	 with	 the	 lack	 of	 polydactyly	 phenotype	 in	 BBS	 mouse	 models	 (Davis	 et	 al.	 2007).	
Furthermore,	 prediction	 of	 phenotype	 is	 made	 harder	 by	 variable	 transcript	 expressivity,	 as	
discrepancies	may	exist	for	the	same	mutant	transcript	in	different	tissue	types	(Shaheen	et	al.	
2016).	 This	 phenomenon	 is	 thought	 to	 account	 for	 some	 of	 the	 disparity	 observed	 for	 splice	
variants,	 such	 as	 the	 common	 deep	 intronic	CEP290	 variant	 that	 causes	 isolated	 retinopathy	
(Parfitt	et	al.	2016).	
	
A	further	challenge	is	to	obtain	a	sufficient	sample	size	and	a	comparable	control	group	(Boyle	
2007),	an	 issue	that	 is	exacerbated	 in	a	rare	disease	cohort.	Furthermore,	potential	modifying	
variants	should	not	be	excluded	if	common	in	the	general	population,	as	these	alleles	can	still	
augment	 an	 aberrant	 pathway	 when	 expressed	 in	 trans	 with	 a	 disease	 locus	 (Zaghloul	 and	
Katsanis	 2009).	 Moreover,	 predicting	 the	 outcome	 of	 a	 potential	 modifier	 presents	 another	
obstacle,	as	they	can	act	in	either	a	protective	or	deleterious	manner	(Harper	et	al.	2015;	Kousi	
and	Katsanis	2015).	
	
3.1.3.	Characterisation	of	ciliopathy	modifiers	
Current	 published	 BBS	 modifiers	 were	 identified	 in	 large	 patient	 cohorts	 of	 heterogeneous	
ciliopathy	patients	(Badano	et	al.	2006).	Typically,	patient	DNA	was	screened	for	an	enrichment	
of	predicted	loss	of	function	variants	in	known	ciliopathy	genes	(Khanna	et	al.	2009;	Davis	et	al.	
2011).	 After	 identification,	 potential	 modifiers	 were	 tested	 to	 establish	 functionality	 through	
large	scale	functional	assays	using	either	a	secondary	cell	 line	known	to	ciliate,	such	as	kidney	
derived	IMCD3	cells,	or	zebrafish	morphants	(Davis	et	al.	2011;	Wheway	et	al.	2015).	Zebrafish	
models	 are	 commonly	 used	 to	 archetype	 ciliopathies	 as	 they	 display	 relevant	 physiological	
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features	 and	 introduction	of	 human	wild	 type	mRNA	can	 robustly	 rescue	mutant	phenotypes	
(Khanna	et	al.	2009;	Ross	et	al.	2005;	Cardenas-Rodriguez	et	al.	2013).	
	
Zaghloul	et	al.	(2010)	undertook	a	challenging	project	to	morphometrically	screen	125	common	
alleles,	previously	considered	benign	or	reported	as	modifiers	in	BBS	(Zaghloul	et	al.	2010).	Out	
of	 the	 125	 alleles	 screened,	 14	 were	 reported	 as	 benign,	 45	 as	 unrescuable	 null	 alleles,	 15	
hypomorphs,	and	35	alleles	predicted	to	exhibit	a	dominant	negative	function.	This	demonstrates	
that	common	alleles	have	the	potential	to	be	detrimental,	and	the	importance	of	testing	variants	
in	a	model	system.	Further	studies	have	corroborated	that	the	characteristics	of	the	variant,	not	
just	 the	 gene,	 is	 critical	 to	 expected	 phenotypic	 outcome.	 Davis	 et	 al.	 tested	 48	 previously	
unreported	polymorphisms	in	TTC21B,	a	member	of	the	IFT-B	complex	that	can	cause	NPHP	and	
JS.	The	effect	of	mutant	alleles	on	ciliogenesis	was	assayed	in	IMCD3	cells	and	varied	from	benign,	
hypomorphic	 or	 null	 effects,	 likely	 depending	 on	 their	 position	 in	 the	 gene	 and	 proximity	 to	
conserved	tetratricopeptide	domains	(Davis	et	al.	2011).	
	
Although	the	majority	of	ciliopathy	modifiers	have	been	linked	to	a	negative	effect	on	phenotype	
presentation,	an	 intriguing	study	deemed	to	 increase	the	complexity	of	ciliopathies	 further	by	
revealing	 a	 protective	 effect	 of	 a	 triple	 allelic	 mouse.	 Separately,	 mice	 exhibiting	 BBS6-/-	 or	
homozygous	 Cep290	 truncating	 mutations	 mimicked	 a	 severe	 ciliopathy	 phenotype.	
Astoundingly,	researchers	found	that	generation	of	a	triple	allelic	mouse	for	these	loci	reduced	
retinal	defects	and	olfactory	abnormalities	compared	to	homozygous	mutants	alone	(Rachel	et	
al.	2012).	This	study	further	demonstrates	the	intricate	and	unpredictable	relationships	present	
in	the	primary	cilium.	
	
3.1.4.	Mutational	burden	
In-depth	sequencing,	either	at	the	exome	or	genome	level,	has	enabled	the	development	of	new	
approaches	for	identification	of	disease	associated	genes.	One	of	these	approaches	is	known	as	
mutational	burden	testing,	which	attempts	to	quantify	the	mutational	load	of	a	disease	based	on	
the	total	presence	of	pathogenic	variants	in	relevant	genes	(Guo	et	al.	2016).	Mutational	load	is	
defined	 by	 the	 accumulation	 of	 deleterious	mutations	 in	 the	 general	 population.	 A	 landmark	
study	 determined	 that	 mutational	 load	 would	 tend	 to	 be	 attributed	 to	 more	 common,	 less	
damaging	variants,	as	very	harmful	mutations	would	quickly	be	eliminated	from	the	population	
(Kimura	et	al.	1963).	Recently,	 rare	mutations	have	been	recognised	to	accumulate	 in	disease	
genes	 of	 certain	 disease	 populations,	 such	 as	 patients	 with	 Charcot-Marie-Tooth	 disease	
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(Gonzaga-Jauregui	 et	 al.	 2015),	 schizophrenia	 (Girard	 et	 al.	 2015)	 and	 atrioventricular	 septal	
defect	(AVSD)	(Alessandro	et	al.	2016).	It	is	hypothesised	that	this	increased	mutational	burden	
cumulatively	acts	to	further	destabilise	the	network	of	affected	biological	pathways	and	influence	
disease	penetrance	or	 expressivity	 (Gonzaga-Jauregui	 et	 al.	 2015).	Due	 to	 the	 interconnected	
relationship	of	proteins	within	the	primary	cilium,	it	is	possible	that	ciliopathies,	such	as	BBS,	will	
adhere	 to	 the	mutational	burden	model	 and	help	explain	phenotypic	heterogeneity	observed	
through	patient	cohorts	(Shaheen	et	al.	2016).	
	
3.1.5.	Aims	of	chapter	
In	this	study,	a	cohort	of	15	BBS	patients	with	mutations	in	BBS1	has	been	investigated.	These	
patients	were	selected	due	to	their	similar	genotypes,	namely	either	homozygous	BBS1	p.M390R	
or	compound	heterozygous	for	p.M390R	with	a	second	deleterious	allele	elsewhere	in	the	BBS1	
locus.	Despite	all	presenting	with	pathogenic	variants	 in	 the	same	gene,	 there	 is	 considerable	
interfamilial	 heterogeneity	 shown	 throughout	 the	 cohort.	 This	 heterogeneity	 presents	 as	
differences	in	onset	of	disease,	severity,	or	the	presence/absence	of	a	clinical	feature	of	BBS.	
	
I	have	hypothesised	that	the	difference	in	phenotypic	presentation	between	patients	is	due	to	
modifier	 alleles	 that	 can	 be	 uncovered	 from	 whole	 genome	 sequencing	 data.	 In	 particular,	
potentially	modifying	variants	would	be	present	in	genes	that	encode	proteins	that	interact	with	
BBS1	in	the	primary	cilium.	
	
Detection	 of	 modifying	 alleles	 can	 be	 more	 complex	 than	 identification	 of	 disease	 causing	
variants.	Association	studies	have	yielded	some	success	for	Mendelian	disorders	(Cutting	2010;	
Génin	et	al.	2008),	though	large	cohort	sizes	are	required,	which	was	not	possible	for	this	study.	
Therefore,	in	this	chapter	I	describe	the	development	of	a	4-tier	categorisation	system	based	on	
predicted	functional	outcomes	of	mutations	and	their	population	frequencies	to	assess	the	role	
of	 the	 modifier	 genes	 in	 disease	 pathology.	 A	 combination	 of	 three	 functional	 prediction	
programmes	has	been	used,	PROVEAN	(Choi	and	Chan	2015),	PolyPhen-2	(Adzhubei	et	al.	2013),	
and	Combined	Annotation	Dependent	Depletion	(CADD)	scoring	(Kircher	et	al.	2014)	to	predict	
the	outcome	of	the	sequence	variants.	As	a	result,	13	out	of	15	patients	were	found	to	exhibit	at	
least	one	potential	modifying	variant	that	functions	in	interacting	networks	with	BBS1.	Further	
selection	criteria	involved	identification	of	known	ciliopathy	modifiers	from	the	literature,	such	
as	 mutations	 in	 TTC21B	 (Davis	 et	 al.	 2011)	 and	 RPGRIP1L	 (Khanna	 et	 al.	 2009),	 as	 well	 as	
localisation	of	encoding	modifier	proteins	within	the	primary	cilium.	
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The	 second	 stage	 of	 this	 chapter	 addresses	 whether	 the	 presence	 of	 modifying	 variants	
contribute	to	the	overall	mutational	burden	of	BBS.	To	undertake	mutational	burden	testing,	the	
mean	aggregate	of	qualifying	variants	was	compared	between	patient	and	control	cases	 for	a	
relevant	gene	panel.	The	hypothesis	that	there	 is	an	enrichment	of	pathogenic	variants	 in	the	
patient	 group	 compared	 to	 the	 control	 subjects	 was	 investigated.	 Qualifying	 variants	 were	
defined	as	 rare	 (MAF<1%)	 and	predicted	pathogenic	by	 SIFT,	 PolyPhen-2,	 or	CADD>20.	 Three	
gene	 panels	 were	 examined;	 the	 ciliopathy	 disease	 panel	 (n=73;	 appendix,	 table	 A.1),	 an	
extended	set	of	primary	cilia	genes	curated	by	the	SYSCILIA	consortium	(SYSCILIA	gold	standard	
v1	(SCGSv1)	panel	n=235;	appendix,	table	A.2)	(van	Dam	et	al.	2013),	and	a	control	gene	panel	
associated	with	an	unrelated	neuropathy,	Charcot-Marie-Tooth	disease	(n=74;	appendix,	table	
A.3).	 Additional	 data	 from	whole	 exome	 sequencing	 of	 16	 BBS	 patients	 and	 25	 controls	 was	
included	in	the	mutational	burden	analysis.	These	were	analysed	separately	and	then	integrated	
with	WGS	data	to	enhance	statistical	power.	Fishers	exact	testing	was	performed	to	determine	
the	statistical	significance	of	the	burden	tests.	Overall,	this	analysis	uncovered	that	mutational	
burden	exists	only	with	the	presence	of	the	pathogenic	driving	mutation	in	BBS,	and	there	is	no	
evidence	that	modifying	variants	contribute	to	the	total	mutational	load	of	the	disease.	
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3.2.	Results	
3.2.1.	Quality	control	for	whole	genome	sequencing	
Prior	 to	whole	 genome	 sequencing,	DNA	was	 assessed	 for	 quality	 and	 concentration,	 using	 a	
Qubit	 2.0	 fluorometer	 (Thermo	 Fisher	 Scientific)	 and	 Nanodrop-1000	 spectrophotometer	
(Thermo	Scientific).	Concentration	and	nanodrop	output	featuring	A260/A280	absorbency	ratios	are	
displayed	in	table	3.1.	The	ratio	of	absorbency	can	help	determine	the	purity	of	DNA,	where	a	
ratio	of	1.8	is	considered	pure.	A260/A280	ratios	for	BBS001-BBS015	range	between	1.71	to	2.03.	
Nonetheless,	samples	that	deterred	from	a	ratio	of	1.8	were	accepted	for	sequencing	by	Beijing	
Genomics	 Institute	 (BGI).	 The	 integrity	 of	 total	 genomic	 DNA	 was	 assessed	 through	
electrophoresis	on	a	1%	agarose	gel	(figure	3.1).	Sample	BBS007	was	flagged	by	BGI	as	slightly	
degraded,	but	sequencing	was	completed	with	the	understanding	that	sequencing	quality	may	
be	affected.		
Patient	no.	 Concentration	(ng/µl)	 A260/A280	
BBS001	 108.2	 1.71	
BBS002	 39.5	 1.83	
BBS003	 66.1	 1.85	
BBS004	 50.1	 1.91	
BBS005	 142	 1.79	
BBS006	 81.8	 1.97	
BBS007	 53.8	 1.82	
BBS008	 58.9	 1.85	
BBS009	 51.4	 2.03	
BBS010	 73.5	 1.83	
BBS011	 63.4	 1.84	
BBS012	 65	 1.89	
BBS013	 61.4	 1.76	
BBS014	 78.6	 1.91	
BBS015	 77.8	 1.95	
Table	3.1	–	Concentrations	of	BBS	patient	genomic	DNA	samples	with	corresponding	A260/A280	absorbency	
ratios.	
	
Whole	genome	sequencing	was	also	completed	on	30	samples	that	were	used	as	a	control	set.	
20	 samples	 were	 obtained	 from	 parents	 of	 10	 trios,	 where	 the	 probands	were	 Silver-Russell	
Syndrome	(SRS)	patients.	The	parents	used	in	this	study	were	asymptomatic,	nonrelated	and	of	
European	ethnicity.	The	other	10	control	samples	were	obtained	from	patients	with	very	early	
onset	inflammatory	bowel	disease	(VEO-IBD),	which	had	no	overlapping	symptoms	with	BBS,	and	
were	also	nonrelated	and	of	European	ethnicity.	The	quality	of	all	30	samples	was	assessed	by	
the	same	method	previously	utilised	for	the	15	BBS	patients	(completed	by	Miss	Stefanie	Dowle	
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and	Dr	Jochen	Kammermeier,	UCL	GOS	Institute	of	Child	Health,	London)	and	were	sequenced	by	
the	same	sequencing	technology	at	Beijing	Genome	Institute	(BGI).	Similarly,	Dr.	Louise	Ocaka	
(UCL	GOS	Institute	of	Child	Health,	London)	executed	whole	exome	sequencing	quality	control	
analysis	 and	 sequencing	 was	 completed	 by	 PerkinElmer	 Inc	 (Connecticut,	 USA).	 Batch	 and	
sequencing	information	for	all	samples	are	presented	in	the	appendix	(table	A.4).	
	
Figure	3.1	–	1%	agarose	gel	of	 total	 genomic	DNA	 for	BBS001-015	 to	 test	DNA	 integrity.	 *BBS007	was	
reported	by	BGI	as	slightly	degraded.	
	
3.2.2.	Identification	of	modifiers	
The	 hypothesis	 that	 phenotypic	 heterogeneity	 in	BBS1	 p.M390R	 patients	 is	 accounted	 for	 by	
genetic	modifiers	was	initially	investigated.	Possible	modifiers	were	identified	by	looking	at	whole	
genome	data	generated	from	BBS001-BBS015	in	Ingenuity	Variant	Analysis	(IVA).	In	total,	there	
were	11,590,993	variants	detected	across	all	15	genomes.	Due	to	the	unmanageable	number	of	
variants	observed,	several	filtering	methods	were	implemented	to	reduce	the	variant	count	(table	
3.2).		
	
Filtering	criteria	 Number	of	variants	 Number	of	genes	
Total	variants	 11,590,993	 23,904	
Exonic	only	 85,351	 16,640	
Variants	not	seen	in	controls	 11,843	 6,736	
Confidence	 11,672	 6,710	
Ciliopathy	panel	 89	 41	
Table	3.2	–	Filtering	criteria	and	resulting	number	of	calls	via	IVA	analysis.	Confidence	filter	removes	calls	
with	low	quality	(call	quality	<20)	and	those	within	the	most	exonically	variable	regions	in	the	genome.	
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A	 factor	 that	markedly	 reduced	 the	number	 of	 variants	was	 the	 exclusion	of	 variants	 in	 non-
protein	coding	regions.	Although	these	may	impact	disease	pathogenicity,	these	were	excluded	
from	this	study	as	their	functionality	 is	challenging	to	predict.	Next,	to	reduce	calls	further,	30	
control	samples	were	included	in	the	analysis,	where	variants	were	excluded	if	seen	in	any	control	
sample.	A	confidence	filter	reduced	the	number	of	calls	further	by	removing	low	quality	variants.	
In	order	to	assess	genes	that	may	affect	ciliary	function,	a	list	containing	73	genes	known	to	cause	
the	spectrum	of	ciliopathies	were	screened	(appendix,	table	A.1).	
	
3.2.2.1.	Development	of	the	4-tier	categorisation	system		
Further	classification	of	variants	was	required	to	aid	the	discovery	of	potential	disease	modifiers.	
To	efficiently	manage	the	variants	obtained	from	IVA,	I	developed	a	4-tier	categorisation	system,	
which	featured	relaxed	and	stringent	tiers	for	extensive	identification.	This	classification	system	
aimed	 to	 encompass	 potential	 modifiers	 of	 varying	 characteristics	 without	 producing	 an	
unmanageable	 number	 of	 variants	 for	 further	 investigation.	 The	 first	 tier	 contained	 the	most	
stringently	called	variants	and	at	each	stage	the	filters	were	relaxed,	allowing	more	variants	to	be	
called	(figure	3.2).	
	
At	each	stage	of	analysis,	either	the	population	frequency	based	on	ExAC	European	frequency	
data	 (Tier	 1	 and	2,	MAF<1%;	 Tier	 3	 and	4,	MAF<5%)	or	 the	prediction	of	 deleterious	 calls	 by	
PROVEAN	or	 PolyPhen-2	was	manipulated.	 To	 help	 assign	 functionality	when	 PolyPhen-2	 and	
PROVEAN	were	discordantly	called,	a	CADD	score	>20	filter	was	added,	where	variants	<20	were	
classified	as	innocuous	(Kircher	et	al.	2014).	To	qualify	as	deleterious,	variants	had	to	be	called	by	
2	out	of	3	functional	prediction	algorithms.	
	
Tier	 1	 analysis	 identified	 12	 rare	 nonsynonymous	 variants	 (MAF<1%)	 in	 8	 genes	 that	 were	
predicted	deleterious	or	were	high	impact	variants	such	as	frame	shift,	nonsense	or	splice	site	
loss.	Included	in	this	group	of	variants	were	the	underlying	pathogenic	variants	in	BBS1	that	were	
previously	diagnosed	(highlighted	 in	table	3.3i,	 tier	1).	Of	note,	BBS1	p.M390R	has	a	relatively	
high	allele	frequency	for	a	rare	disease-causing	variant,	with	a	MAF	of	0.3%	from	a	heterozygous	
allele	count	of	347/126644	from	the	Gnomad	European	dataset.	BBS1	p.M390R	was	predicted	as	
benign	 by	 PolyPhen-2,	 which	 demonstrates	 the	 importance	 of	 using	 multiple	 functional	
prediction	algorithms.		
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Figure	3.2	–	Strategy	 for	genetic	modifiers	4-tier	categorisation	where	deleterious	prediction	and	allele	
frequency	were	manipulated.	The	number	of	detected	variants	and	genes	are	displayed	at	each	tier.	The	
numbers	in	square	brackets	are	inclusive	of	primary	driving	mutations	in	BBS1.	
	
Next,	 Tier	 2	 analysis	 generated	 rare	 nonsynonymous	 variants	 that	 were	 predicted	 to	 be	
innocuous	by	at	least	2	out	of	PROVEAN,	PolyPhen-2	or	CADD	(score<20)	(table	3.3ii).	These	were	
included	 in	 the	 analysis	 because	modifiers	may	 not	 be	 disease	 causing	 by	 themselves,	 but	 in	
combination	with	a	pathogenic	background	could	alter	the	disease	expressivity	(Cutting	2010).	
Here,	14	heterozygous	missense	variants	in	9	different	genes	were	identified.		
	
For	tier	3	and	4	(table	3.3iii;	3.3iv),	the	objective	was	to	widen	the	net	to	detect	variants	that	were	
less	rare	(MAF<5%),	as	some	known	modifiers	of	ciliopathies	are	described	as	common	(Khanna	
et	al.	2009;	Zaghloul	et	al.	2010).
		
Table	3.3(i)	Tier	1:	<1%	ExAC	European	frequency	(MAF<0.01),	predicted	damaging	by	2	or	more	functional	prediction	algorithms,	where	†	denotes	primary	driving	mutation	
Gene	
Symbol	
Variant	 Affected	patients	
Translation	
Impact	
PolyPhen-2	 PROVEAN	
CADD	
score	
ExAC	
European	
Frequency	(%)	
Gnomad	
European	
Frequency	(%)	
Association	of	gene	with	
disease	
NPHP4	 p.R735W	 BBS005	 Missense	 Possibly	
Damaging	
Deleterious	 32	 0.026	 0.026	 NPHP	(OMIM:	606966),		
SLS	(OMIM:	606996)	
SDCCAG8	 p.R82C	 BBS013	 Missense	
Possibly	
Damaging	 Deleterious	 23.8	 0.008	 0.011	
BBS	(OMIM:	615993);		
SLS	(OMIM:	613615)	
C2ORF71	 p.S1085L	 BBS007	 Missense	
Possibly	
Damaging	 Deleterious	 17.67	 0.004	 0.006	 RP	(OMIM:	613428)	
TTC21B	 p.L1002V[1]	 BBS006;	BBS008	 Missense	
Possibly	
Damaging	 Deleterious	 25.2	 0.800	 0.874	 NPHP	(OMIM:	613820);		
JATD	(OMIM:	613819)	
TTC21B	 p.R616C	 BBS006	 Missense	 Benign	 Deleterious	 20.7	 0.304	 0.289	
ARL6	 p.T32M	 BBS005	 Missense	
Probably	
Damaging	 Deleterious	 33	 0.000	 0.000	 BBS	(OMIM:	600161)	
BBS1†	 p.G73*	 BBS006;	BBS014	 Stop	Gain	 	 	 36	 0.000	 0.000	
BBS	(OMIM:	209900)	
BBS1†	 c.723+1G>
A	
BBS004	 Splice	Site	
Loss	
	 	 27	 0.000	 0.000	
BBS1†	 p.Y284fs*5	 BBS010;	BBS011;	
BBS012	
Frameshift	 	 	 34	 0.001	 0.002	
BBS1†	 p.M390R	
All	(BBS001,	002,	
003,	005,	007,	008,	
009,	013,	015	as	
homozygous)	
Missense	 Benign	 Deleterious	 28.2	 0.227	 0.274	
CEP164	 p.Q1410*	 BBS014	 Stop	Gain	 	 	 40	 0.109	 0.135	 NPHP	(OMIM:	614845)	
XPNPEP3	 p.P493A	 BBS012	 Missense	 Probably	Damaging	 Deleterious	 24	 0.169	 0.174	 NPHP-like	(OMIM:	613159)	
	
		
Table	3.3(ii)	Tier	2:	<1%	ExAC	European	frequency	(MAF<0.01),	predicted	innocuous	by	2	or	more	functional	prediction	algorithms	
Gene	
Symbol	
Variant	
Affected	
patients	
Translation	
Impact	
PolyPhen-2	 PROVEAN	
CADD	
score	
ExAC	
European	
Frequency	(%)	
Gnomad	
European	
Frequency	(%)	
Association	of	gene	with	
disease	
USH2A	 p.S5188G	 BBS014	 Missense	 Benign	 Neutral	 22.7	 0.314	 0.367	
RP	(OMIM:	613809);	
USH	(OMIM:	276901)	
USH2A	 p.K5026E	 BBS014	 Missense	 Benign	 Neutral	 <10	 0.315	 0.367	
USH2A	 p.R4848Q	 BBS014	 Missense	 Benign	 Neutral	 10.5	 0.320	 0.368	
USH2A	 p.G4838E	 BBS014	 Missense	 Benign	 Neutral	 <10	 0.330	 0.378	
USH2A	 p.Q4541P	 BBS002	 Missense	 Benign	 Neutral	 16.94	 0.001	 0.001	
WDR35	 p.I285F	 BBS002	 Missense	 Benign	 Deleterious	 <10	 0.055	 0.074	 JATD	(OMIM:	614091)	
WDPCP	 p.R290H	 BBS010;	BBS011;	BBS012	 Missense	 Benign	 Neutral	 <10	 0.000	 0.001	 BBS	(OMIM:	615992)	
BBS12	 p.S429T[2]	 BBS009	 Missense	 Benign	 Neutral	 <10	 0.094	 0.062	 BBS	(OMIM:	615989)	
PKHD1	 p.G698D	 BBS010;	BBS011	 Missense	 Benign	 Neutral	 <10	 0.015	 0.015	 Polycystic	kidney	and	hepatic	disease	(OMIM:	263200)	
CEP164	 p.P127L	 BBS013	 Missense	 Benign	 Neutral	 19.55	 0.223	 0.168	 NPHP	(OMIM:	614845)	
PKHD1	 p.I3309V	 BBS010;	BBS011	 Missense	 Possibly	
Damaging	
Neutral	 15.02	 0.016	 0.039	 Polycystic	kidney	and	hepatic	
disease	(OMIM:	263200)	
PKHD1	 p.V3263A	 BBS014	 Missense	 Benign	 Neutral	 23.5	 0.267	 0.315	
CDH23	 p.D1806E	 BBS009	 Missense	 Probably	
Damaging	
Neutral	 18.96	 0.585	 0.646	 USH	(OMIM:	601067)	
BBS4	 p.V266G	 BBS013	 Missense	 Benign	 Deleterious	 14.75	 0.001	 0.001	 BBS	(OMIM:	615982)	
	
		
Table	3.3(iii)	Tier	3:	<5%	ExAC	European	frequency	(MAF<0.05),	predicted	damaging	by	2	or	more	functional	prediction	algorithms	
Gene	
Symbol	
Variant	 Affected	patients	
Translation	
Impact	
PolyPhen-2	 PROVEAN	
CADD	
score	
ExAC	
European	
Frequency	(%)	
Gnomad	
European	
Frequency	(%)	
Association	of	gene	with	disease	
NPHP4	 p.E618K	 BBS013	 Missense	
Probably	
Damaging	 Neutral	 23.3	 1.507	 1.440	
NPHP	(OMIM:	606966),		
SLS	(OMIM:	606996)	
CC2D2A	 p.K507E	 BBS009	 Missense	 Probably	
Damaging	
Neutral	 27.1	 1.080	 1.038	 JBTS	(OMIM:	612285);		
MKS	(OMIM:	612284)	
PCDH15	 p.N637S	 BBS014	 Missense	
Possibly	
Damaging	 Neutral	 21.5	 3.155	 2.727	 USH	(OMIM:	601067/602083)	
BBS10	 p.D142N	 BBS008;	BBS010;	
BBS011;	BBS012	
Missense	 Possibly	
Damaging	
Neutral	 28.3	 1.291	 1.245	 BBS	(OMIM:	615987)	
CEP290	 p.I2134T	 BBS005	 Missense	 Probably	Damaging	 Neutral	 29	 1.693	 0.688	
BBS	(OMIM:	615991);	JBTS	
(OMIM:	610188);	LCA	(OMIM:	
611755);	MKS	(OMIM:	611134);	
SLS	(OMIM:	610189)	
AHI1	 p.R548H	 BBS015	 Missense	 Benign	 Deleterious	 24.1	 1.545	 1.716	 JBTS	(OMIM:	608629)	
		
Table	3.3(iv)	Tier	4:	<5%	ExAC	European	frequency	(MAF<0.05),	predicted	innocuous	by	2	or	more	functional	prediction	algorithms	
Gene	
Symbol	
Protein	
Variant	
Affected	
patients	
Translation	
Impact	
PolyPhen-2	 PROVEAN	
CADD	
score	
ExAC	
European	
Frequency	(%)	
Gnomad	
European	
Frequency	(%)	
Association	of	gene	with	
disease	
NPHP4	 p.R740H	 BBS003	 Missense	 Benign	 Neutral	 <10	 4.079	 3.304	 NPHP	(OMIM:	606966),		SLS	(OMIM:	606996)	
USH2A	 p.E478D	 BBS005	 Missense	 Benign	 Neutral	 23.8	 1.720	 1.790	 RP	(OMIM:	613809);		
USH	(OMIM:	276901)	
TMEM67	 p.D261N	
BBS005;	
BBS009	 Missense	 Benign	 Neutral	 <10	 1.700	 1.548	
JBTS	(OMIM:	610688);		
MKS	(OMIM:	607361);		
NPHP	(OMIM:	613550)	
PCDH15	 p.P1718S	 BBS005	 Missense	 Benign	 Neutral	 <10	 2.752	 1.603	 USH	(OMIM:	601067/602083)	
TCTN1	 p.I412V	 BBS002	(Hom)	 Missense	 Benign	 Neutral	 <10	 1.005	 0.926	 JBTS	(OMIM:	614173)	
TCTN2	 p.R200Q	
BBS003;	
BBS008	 Missense	 Benign	 Neutral	 <10	 1.242	 1.240	 JBTS	(OMIM:	616654)	
RPGRIP1L	 p.A229T[3]	 BBS003	 Missense	 Benign	 Neutral	 15.69	 2.783	 2.716	 JBTS	(OMIM:	611560);		
MKS	(OMIM:	611561)	
TCTN1	 p.M1I	
BBS002	
(Hom)	 Start	Loss	 	 Neutral	 <10	 2.201	 0.996	 JBTS	(OMIM:	614173)	
RPGRIP1L	 p.A1183G	 BBS013	 Missense	 Possibly	
Damaging	
Neutral	 10.95	 1.539	 1.558	 JBTS	(OMIM:	611560);		
MKS	(OMIM:	611561)	
Table	3.3	–	Putative	modifying	variants	identified	through	the	4-tier	categorisation	strategy.	Modifiers	that	are	known	to	act	in	BBS	were	uncovered:	TTC21B	p.L1002V[1]	(Davis	
et	al.	2011);	BBS12	p.S429T[2]	 (Zaghloul	et	al.	2010);	RPGRIP1L	p.A229T[3]	 (Khanna	et	al.	2009).	Disease	definitions:	Bardet-Biedl	Syndrome,	BBS;	Nephronophthisis,	NPHP;	
Senior-Loken	 Syndrome,	 SLS;	 Retinitis	 Pigmentosa,	 RP;	 Jeune	 Asphyxiating	 Thoracic	 Dysplasia,	 JATD;	 Joubert	 Syndrome,	 JBTS;	 Leber	 Congenital	 Amaurosis,	 LCA;	Meckel	
Syndrome,	MKS;	Usher	syndrome,	USH.	
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Tier	3	analysis	revealed	6	heterozygous	missense	variants	predicted	to	be	deleterious.	Finally,	tier	
4	analysis,	where	functional	predictions	were	innocuous,	identified	an	additional	9	variants	in	7	
genes.	2	of	these	were	homozygous	mutations	in	TNTN1,	both	found	in	patient	BBS002.	
	
The	number	of	 variants	per	patient	 at	 each	 tier	 is	 summarised	 in	 table	3.4.	Notably,	 patients	
BBS001	and	BBS004	have	no	additional	qualifying	variants	other	than	the	underlying	pathogenic	
alleles.	On	the	other	hand,	patient	BBS005	and	BBS014	have	the	greatest	number	of	potential	
modifying	alleles,	with	6	alleles	in	6	genes	and	7	alleles	in	4	genes,	respectively.	
	
Patient	ID	 Allele	1	 Allele	2	
Number	of	potentially	modifying	
alleles		
Affected	genes	
Tier	1	 Tier	2	 Tier	3	 Tier	4	 Total	 Number	 Gene	names	
BBS001	 BBS1	
p.M390R	
BBS1	
p.M390R	
0	 0	 0	 0	 0	 0	 		
BBS002	 BBS1	p.M390R	
BBS1	
p.M390R	 0	 2	 0	 4	 6	 3	
USH2A;	WDR35;	
TCTN1	
BBS003	
BBS1	
p.M390R	
BBS1	
p.M390R	 0	 0	 0	 3	 3	 3	
NPHP4;	TCTN2;	
RPGRIP1L	
BBS004	
BBS1	
p.M390R	
BBS1	
c.723+1G>A	 0	 0	 0	 0	 0	 0	 		
BBS005	 BBS1	
p.M390R	
BBS1	
p.M390R	
2	 0	 0	 3	 6	 6	 ARL6;	NPHP4;	CEP290;	
USH2A;	TMEM67	
BBS006	 BBS1	
p.M390R	
BBS1	p.G73*	 2	 0	 0	 0	 2	 1	 TTC21B	
BBS007	 BBS1	p.M390R	
BBS1	
p.M390R	 1	 0	 0	 0	 1	 1	 C2ORF71	
BBS008	
BBS1	
p.M390R	
BBS1	
p.M390R	 1	 0	 1	 1	 3	 3	 TTC21B;	BBS10;	TCTN2	
BBS009	
BBS1	
p.M390R	
BBS1	
p.M390R	 0	 2	 1	 1	 4	 4	
BBS12;	CDH23;	
CC2D2A;	TMEM67	
BBS010†	 BBS1	
p.M390R	
BBS1	
p.Y284fs*5	
0	 3	 1	 0	 4	 3	 WDPCP;	PKHD1;	
BBS10	
BBS011†	 BBS1	
p.M390R	
BBS1	
p.Y284fs*5	
0	 3	 1	 0	 4	 3	 WDPCP;	PKHD1;	
BBS10	
BBS012†	 BBS1	
p.M390R	
BBS1	
p.Y284fs*5	
1	 1	 1	 0	 3	 3	 WDPCP;	XPNPEP3;	
BBS10	
BBS013	 BBS1	
p.M390R	
BBS1	
p.M390R	
1	 2	 1	 1	 5	 5	
SDCCAG8;	CEP164;	
BBS4;	NPHP4;	
RPGRIP1L	
BBS014	
BBS1	
p.M390R	 BBS1	p.G73*	 1	 5	 1	 0	 7	 4	
CEP164;	USH2A;	
PKHD1;	PCDH15	
BBS015	 BBS1	
p.M390R	
BBS1	
p.M390R	
0	 0	 1	 0	 1	 1	 AHI1	
Table	3.4	–	A	summary	of	the	number	of	potentially	modifying	variants	per	patient	that	were	detected	at	
each	tier.	The	number	and	names	of	affected	genes	are	also	presented.	†	denotes	related	individuals	where	
BBS010	and	BBS011	are	monozygotic	twins	and	BBS012	is	their	sibling.	
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3.2.2.2.	Location	of	modifiers	within	the	cilium	
Exclusive	of	the	primary	driving	mutations	in	BBS1,	37	variants	were	identified	in	23	ciliopathy	
genes.	The	image	represents	the	localisation	of	each	protein	that	is	encoded	by	qualifying	genes	
within	the	cilia	(figure	3.3)	as	established	by	the	SYSCILIA	project	(van	Dam	et	al.	2013)	(appendix,	
table	A.2).	
	
Figure	3.3	–	The	 location	of	proteins	encoded	by	qualifying	genes	within	 the	primary	cilium,	where	the	
presence	of	a	variant	 is	 illustrated	by	a	silhouette.	Each	silhouette	is	coded	by	tier	(colour)	and	zygosity	
(50%	 =	 heterozygous;	 100%	 =	 homozygous).	 Tiered	 strategy	 is	 as	 previously	 described,	where	 tier	 1	 =	
MAF<1%,	 predicted	 deleterious;	 tier	 2	 =	 MAF<1%,	 predicted	 innocuous;	 tier	 3	 =	 MAF<5%,	 predicted	
deleterious;	tier	4	=	MAF<5%,	predicted	innocuous.	
	
This	demonstrates	that	the	majority	of	affected	genes	(7/23)	localise	to	the	basal	body,	where	
the	BBS	proteins	within	 the	BBSome	also	 localise	 (Wei	 et	 al.	 2012).	However,	 the	 image	 also	
illustrates	a	global	effect	of	variants	on	the	cilium,	as	almost	all	structural	elements	of	the	cilium	
are	affected.	Furthermore,	three	variants	lie	in	tissue	specific	genes,	such	as	CDH23	and	PCDH15,	
which	localise	to	the	connecting	cilium	of	photoreceptors	and	stereocilium	of	cochlear	cells	(van	
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Dam	 et	 al.	 2013).	 These	 variant	 findings	 may	 contribute	 to	 an	 overall	 mutational	 burden	 in	
ciliopathy	genes	for	these	patients.	
	
Moreover,	to	determine	the	effect	that	these	modifiers	may	have	at	a	functional	level,	the	STRING	
database	 (Szklarczyk	 et	 al.	 2015)	 was	 utilised	 to	 predict	 direct	 and	 indirect	 protein-protein	
interactions	with	BBS1,	which	were	assembled	into	a	network	(figure	3.4).	This	interaction	map	
demonstrates	 the	 close-knit	 relationship	 between	 these	 genes.	 BBS1	 is	 known	 through	
experimental	means	or	curated	databases	to	 interact	directly	with	BBS10,	ARL6,	BBS4,	BBS12,	
and	CEP290.	A	further	7	interactions	are	predicted	to	interact	by	knowledge	obtained	from	text	
mining	 (namely,	WDPCP,	 TTC21B,	 NPHP4,	 RPGRIP1L,	 CC2D2A,	 AHI1,	 and	 TMEM67).	 Through	
investigation	 of	 indirect	 interactions,	 BBS1	 is	 predicted	 to	 network	 with	 all	 remaining	 gene	
products	 through	 intermediate	 proteins,	 predominantly	 via	 CEP290.	 The	 only	 exception	 is	
C2ORF71,	which	has	no	known	interactors.	
	
	
Figure	3.4	–	The	interacting	network	of	BBS1	with	the	protein	products	of	genes	identified	through	4-tier	
categorisation.	 Interactions	 are	 experimentally	 determined	 (pink	 connectors),	 from	 literature	 mining	
(green	 connectors)	 or	 from	 curated	 databases	 (blue	 connectors).	 Direct	 interactions	 with	 BBS1	 are	
indicated	by	solid	lines,	whereas	indirect	interactions	through	intermediates	are	denoted	as	detached	lines.	
Image	adapted	from	information	provided	by	the	STRING	database.	
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3.2.2.3.	Known	modifiers	
Following	identification	of	these	variants,	a	literature	search	was	executed	to	determine	whether	
patients	were	harbouring	any	established	modifier	mutations.	In	total,	three	known	hypomorphic	
variants	were	found.	Namely,	BBS12	p.S429T	 in	patient	BBS009	(Zaghloul	et	al.	2010),	TTC21B	
p.L1002V	in	patients	BBS006	and	BBS008	(Davis	et	al.	2011),	and	RPGRIP1L	p.A229T	in	patient	
BBS003	 (Khanna	 et	 al.	 2009).	 This	 demonstrates	 that	 the	 4-tier	 strategy	 was	 successful	 in	
uncovering	variants	known	to	influence	BBS	expressivity.	
	
Furthermore,	a	previously	reported	variant	 in	AHI1	p.R548H	was	detected	 in	BBS015,	but	was	
disregarded	as	pathogenic	in	a	study	of	JBTS	patients	as	it	did	not	segregate	exclusively	with	the	
disease	 (Parisi	 et	 al.	 2006).	 	 However,	 lack	 of	 segregation	 does	 not	 exclude	 this	 variant	 from	
having	 a	 role	 as	 a	 modifier.	 Similarly,	 the	 heterozygous	 variant	 in	NPHP4	 p.R735W	 found	 in	
patient	 BBS005	 was	 previously	 identified	 in	 a	 nephronophthisis	 patient,	 though	 it	 was	 not	
determined	whether	this	variant	was	a	main	contributor	to	the	disease	(Hoefele	et	al.	2005).	
	
In	addition	to	finding	known	modifiers	in	the	literature,	two	variants	identified	in	this	study	were	
also	 previously	 predicted	 to	 be	 benign	 through	 morphometric	 analysis.	 Specifically,	 BBS10	
p.D142N	found	in	BBS008	and	the	siblings	BBS010,	BBS011	and	BBS012	(Zaghloul	et	al.	2010),	as	
well	as	TTC21B	p.R616C	in	patient	BBS006	(Davis	et	al.	2011).	
	
A	variant	that	may	be	of	interest	is	ARL6	(BBS3)	p.T32M	that	was	uncovered	in	patient	BBS005.	
This	is	a	rare	variant	that	has	never	been	reported	in	an	individual	of	European	descent.	Gnomad	
database	 reports	 a	 frequency	of	 2/245868	 in	 the	 total	 population,	MAF=8.1x10-6,	 due	 to	 two	
heterozygous	 variants	 identified	 in	 the	 South	 Asian	 population.	 Furthermore,	 this	 variant	 is	
adjacent	 to	 an	 amino	 acid	 change	 known	 to	 cause	 BBS	 (p.T31M).	 Indeed,	 ARL6	 p.T31	 was	
screened	 by	 Zaghloul	 and	 colleagues,	 which	 exhibited	 a	 dominant	 negative	 effect	 when	
substituted	to	either	methionine	or	arginine	(Zaghloul	et	al.	2010).	Further	investigation	of	the	
variant	p.T31M	discovered	that	this	residue	is	in	a	highly	conserved	GTP	binding	pocket	of	ARL6,	
where	the	nucleotide	binding	sequence	is	known	as	the	P-loop	[G-N(x4)-G-K-T/S]	(Fan	et	al.	2004)	
(figure	3.5).	Although	not	directly	part	of	the	P-loop,	this	variant	could	still	play	a	crucial	role	in	
maintaining	the	structure	of	the	GTP	binding	pocket.	
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Figure	3.5	–	Conservation	of	ARL6	p.T32M.	The	amino	acid	p.T32	
is	conserved	through	vertebrates	and	adjacent	 to	 the	 functional	
phosphate	 binding	 	 loop	 (P-loop).	 The	 variant	 p.T32M	 is	
highlighted	in	yellow.	
	
	
3.2.2.4.	Candidate	modifiers	
From	the	tiered	modifier	analysis,	potential	variants	have	been	assessed	and	table	of	the	more	
likely	 candidate	 mutations	 has	 been	 compiled	 (table	 3.5).	 These	 have	 been	 chosen	 after	
assessment	of	the	commonality,	functional	prediction,	the	 location	of	affected	proteins	within	
the	 primary	 cilium,	 and	 the	 network	 of	 interactions	 in	 close	 proximity	 with	 BBS1.	 Where	
applicable,	known	modifiers	have	also	been	included.	A	confidence	grading	of	low	or	high	was	
assigned	 to	each	 candidate	depending	on	 the	 strength	of	 evidence	as	 a	modifier	 of	BBS.	 The	
justification	 for	 each	 confidence	 rating	 is	 further	 examined	 in	 the	 discussion	 section	 of	 this	
chapter.	
	
Patient	ID	 Gene	 Variant	 Tier	 Confidence	 Confidence	justification	
BBS002	 TCTN1	 p.M1I	 4	 Low	 Uncertain	significance	
BBS003	 RPGRIP1L	 p.A229T	 4	 High	 Known	modifier	
BBS005	 ARL6	 p.T32M	 1	 High	
Highly	conserved/next	to	known	BBS	
variant/direct	interaction	with	BBS1	
BBS006	 TTC21B	 p.L1002V	 1	 High	 Known	modifier	
BBS007	 C2ORF71	 p.S1085L	 1	 Low	 Uncertain	significance	
BBS008	 TTC21B	 p.L1002V	 1	 High	 Known	modifier	
BBS009	 BBS12	 p.S429T	 2	 High	 Known	modifier	
BBS010/011†	 PKHD1	
p.I3309V	 2	 Low	 Uncertain	significance	
p.G698D	 2	 Low	 Uncertain	significance	
BBS010/011/012†	 WDPCP	 p.R290H	 2	 Low	 Uncertain	significance	
BBS012†	 XPNPEP3	 p.P493A	 1	 Low	 Uncertain	significance	
BBS013	 BBS4	 p.V266G	 2	 High	 Direct	interaction	with	BBS1	
BBS014	 CEP164	 p.Q1410*	 1	 High	 Deleterious	nonsense	variant	
BBS015	 AHI1	 p.R548H	 3	 High	 Known	modifying	gene	
Table	3.5	–	The	candidate	modifying	variant	for	each	patient	with	a	confidence	grading	of	high	or	low.		
†	denotes	related	individuals	where	BBS010	and	BBS011	are	monozygotic	twins	and	BBS012	is	their	sibling.	
	
3.2.3.	Mutational	burden	analysis	
The	 second	 hypothesis	 of	 this	 chapter,	 that	 enhanced	 background	 variation	 attributes	 to	
mutational	burden	and	contributes	to	disease	severity	in	patients,	was	subsequently	investigated.	
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It	was	explored	whether	there	was	an	accumulation	of	mutational	load	in	BBS	patients	compared	
to	controls,	using	both	whole	genome	and	exome	datasets.	These	datasets	were	first	considered	
separately	and	then	combined	to	observe	the	effect	of	a	larger	sample	size	on	the	analysis.	Only	
rare	 variants	 (MAF<1%)	 predicted	 pathogenic	 by	 SIFT	 or	 PolyPhen-2	 or	 CADD	 score>20	were	
considered.	First,	variant	counting	was	restricted	to	a	panel	of	genes	known	to	cause	ciliopathies	
of	 the	primary	cilium	(n=73).	The	panel	was	 then	expanded	to	encompass	a	broader	 range	of	
genes	from	the	primary	cilium	network,	referred	to	as	SYSCILIA’s	SCGSv1	panel	(n=235)	(van	Dam	
et	al.	2013).	As	the	ethnicity	of	the	WES	BBS	patients	was	not	exclusively	European,	the	total	ExAC	
population	frequency	data	was	utilised.	
	
3.2.3.1.	Mutational	burden	of	patients	from	WES	data	
The	WES	patient	data	were	taken	from	a	set	of	16	patients	exhibiting	BBS	who	were	sequenced	
to	 identify	 the	 disease-causing	 alleles	 (appendix,	 table	 A.4).	Mutational	 analysis	 for	 a	 genetic	
diagnosis	 was	 implemented	 by	 GOSgene,	 UCL	 GOS	 Institute	 of	 Child	 Health,	 who	 confirmed	
disease	causing	variants	in	10	patients	(table	3.6).	The	remaining	6	were	unresolved	without	a	
genetic	diagnosis.	
	
Sample	ID	
Gene	
Symbol	
Allele	1	 Allele	2	
WES_508	 BBS12	 p.G540V	 p.V409M	
WES_511	 BBS12	 p.L530P	 p.L530P	
WES_512	 MKKS	 p.T259fs*21	 p.T259fs*21	
WES_513	 MKKS	 p.T259fs*21	 p.T259fs*21	
WES_514	 BBS12	 p.L530P	 p.L530P	
WES_519	 BBS12	 p.C426Y	 p.E365fs*18	
WES_521	 BBS1	 p.R570*	 p.I200_T201del	
WES_522	 MKKS	 p.I339fs*3	 p.I339fs*3	
WES_524	 TTC8	 c.116+2T>C	 c.116+2T>C	
WES_525	 BBS12	 p.S21*	 p.S21*	
WES_506	 No	diagnosis	confirmed	
WES_507	 No	diagnosis	confirmed	
WES_502	 No	diagnosis	confirmed	
WES_518	 No	diagnosis	confirmed	
WES_520	 No	diagnosis	confirmed	
WES_523	 No	diagnosis	confirmed	
Table	3.6	–	Known	genetic	diagnoses	for	10	of	16	patients	sequenced	by	WES.	
	
The	first	set	of	burden	analysis	conducted	was	with	all	16	WES	patients	compared	against	a	set	
of	25	non-ciliopathy	control	individuals	(appendix,	table	A.4).	There	was	a	significant	enrichment	
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of	variants	in	patients	compared	to	controls	(mean	variant	count	4.8	vs.	3.1	respectively;	p=0.006)	
(table	3.7i).	
	
As	an	autosomal	recessive	disease,	there	are	two	pathogenic	segregating	alleles	per	patient	that	
are	diagnosed	to	be	the	main	contributor	to	disease.	In	this	study,	the	combination	of	these	alleles	
has	 been	 defined	 as	 the	 pathogenic	 driving	 mutation	 (PDM).	 By	 definition,	 patients	 with	 a	
definitive	molecular	diagnosis	are	expected	to	have	additional	burden	on	disease	genes	that	is	
augmented	from	the	typical	background	level	of	variation	seen	in	the	general	population.	Next,	
it	was	tested	whether	there	was	still	an	enrichment	of	background	pathogenic	variants	when	the	
PDMs	were	excluded	from	analysis.	When	PDMs	were	removed,	the	mean	number	of	pathogenic	
variants	 reduced	 to	 a	 level	 that	 was	 similar	 to	 controls	 (table	 3.7ii).	 This	 suggested	 that	 the	
significant	difference	 seen	 in	 table	3.7i	was	being	driven	by	 the	PDMs	and	 that	 there	was	no	
additional	mutational	burden	without	PDMs	within	the	73	ciliopathy	genes	tested.	
	
The	hypothesis	that	the	PDMs	were	the	significant	factor	in	the	analysis	was	further	supported	
when	the	group	was	separated	into	cases	with	and	without	a	definitive	molecular	diagnosis.	The	
count	of	variants	in	10	diagnosed	cases	(including	PDMs)	was	significantly	greater	with	a	mean	of	
5.5	alleles	per	patient	compared	to	3.1	for	controls	(p=0.001).	However,	when	the	PDMs	were	
removed	 the	 mean	 variant	 count	 diminished	 to	 a	 comparable	 count	 as	 the	 6	 undiagnosed	
patients	 alone	 (3.5	 and	 3.7,	 respectively)	 (table	 3.7iii).	 Both	 of	 these	 were	 not	 significantly	
different	to	controls	(p=0.524	and	0.439,	respectively),	demonstrating	that	the	driving	mutations	
for	the	undetermined	cases	may	be	in	genes	not	found	in	the	ciliopathy	panel.	
	
	
Filtering	
criteria	
Data	comparison	
Mean	number	
of	variant	alleles	
per	patient	
Mean	number	of	
variant	alleles	
per	control	
Fisher	Exact	
p-value	
i)	 +PDM	 16	BBS	vs.	25	controls	 4.8	 3.1	 0.006*	
ii)	 -PDM	 16	BBS	vs.	25	controls	 3.6	 3.1	 0.419	
	 		 	 	 	 	
iii)	
+PDM	 10	diagnosed	vs.	25	controls	 5.5	 3.1	 0.001*	
-PDM	 10	diagnosed	vs.	25	controls	 3.5	 3.1	 0.524	
	 6	undiagnosed	vs.	25	controls	 3.7	 3.1	 0.439	
	
Table	3.7	–	Burden	analysis	comparison	against	WES	patient	and	control	datasets	with	ciliopathy	
gene	panel	(n=73),	with	and	without	primary	driving	mutation	included	in	the	analysis	(PDM).		
*	denotes	statistically	significant	p-value	where	α=0.05.	
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3.2.3.2.	Mutation	burden	of	WGS	data	
An	identical	burden	analysis	strategy	for	the	WES	dataset	was	implemented	with	the	WGS	data	
generated	from	14	BBS	patients	compared	with	30	non-ciliopathy	control	individuals.	As	genetic	
material	from	monozygotic	twins	is	highly	similar,	BBS011	was	excluded	from	the	burden	analysis	
to	prevent	artificial	bias	created	from	pseudo	duplicate	samples.	As	the	14	WGS	patients	all	had	
a	molecular	diagnosis	 in	BBS1,	 it	was	expected	 that	 the	burden	analysis	with	PDMs	would	be	
similar	to	the	WES	analysis.	However,	the	number	of	variants	per	patient	was	closely	matched	to	
controls,	with	mean	counts	of	3.7	and	3.6,	respectively	(p=0.863)	(table	3.8i).	This	did	not	mimic	
the	high	significance	observed	between	WES	patient	and	control	sets.	To	investigate	the	effect	
the	PDMs	in	BBS1	were	having	on	the	outcome	of	the	burden	test,	these	alleles	were	excluded	
from	 further	 analysis.	 As	 a	 result,	 there	 was	 a	 large	 decrease	 in	 mean	 variants	 per	 patient	
compared	to	control	(1.7	vs.	3.6,	respectively),	which	elicited	a	highly	significant	p-value	of	0.0004	
(table	3.8ii).	
	
	
Filtering	
criteria	
Data	comparison	
Mean	number	of	
variant	alleles	per	
patient	
Mean	number	
of	variant	alleles	
per	control	
Fisher	Exact	
p-value	
i)	 +PDM	 14	patients	vs.	30	controls	 3.7	 3.6	 0.863	
ii)	 -PDM	 14	patients	vs.	30	controls	 1.7	 3.6	 0.0004*	
	
Table	3.8	–	Burden	analysis	comparison	against	WGS	patient	and	control	datasets	with	ciliopathy	
gene	panel	(n=73),	with	and	without	primary	driving	mutation	included	in	the	analysis	(PDM).	*	
denotes	statistically	significant	p-value	where	α=0.05.	
	
3.2.3.3.	Combination	of	WES	and	WGS	
Next	the	two	datasets	were	integrated	to	give	a	combined	analysis	of	30	patients	vs.	55	controls.	
A	 collective	 average	 for	 BBS	 patients	 was	 4.3	 variants	 compared	 to	 3.4	 variants	 for	 controls	
(p=0.035)	(table	3.9i).	With	the	exclusion	of	the	PDMs	from	the	analysis,	the	mean	variant	count	
per	patient	was	not	significantly	lower	than	the	controls	(unlike	the	result	seen	with	WGS	alone)	
(table	3.9ii).	
	
	
Filtering	
criteria	
Data	comparison	
Mean	number	of	
variant	alleles	per	
patient	
Mean	number	
of	variant	alleles	
per	control	
Fisher	Exact	
p-value	
i)	 +PDM	 WES	+	WGS	combined	 4.3	 3.4	 0.035*	
ii)	 -PDM	 WES	+	WGS	combined	 2.7	 3.4	 0.109	
	
Table	3.9	–	Burden	analysis	comparison	against	integrated	datasets	with	ciliopathy	gene	panel	
(n=73),	with	and	without	primary	driving	mutation	included	in	the	analysis	(PDM).	*	denotes	
statistically	significant	p-value	where	α=0.05.	
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3.2.3.4.	Mutational	burden	within	a	larger	gene	panel	
The	results	of	the	ciliopathy	panel	suggested	that	there	was	no	mutational	burden	in	the	73	genes	
when	the	PDMs	were	subtracted.	The	next	line	of	investigation	was	to	expand	the	gene	list	to	
encompass	an	additional	162	genes	from	the	SYSCILIA	project,	which	have	central	roles	within	
the	primary	cilia	but	are	not	directly	associated	with	ciliopathies	(van	Dam	et	al.	2013).	
	
The	results	of	mutational	burden	testing	with	a	larger	gene	panel	mimicked	prior	analyses.	When	
PDMs	 were	 included	 in	 the	 calculations,	 there	 were	 significantly	 more	 variants	 in	 the	 WES	
patients	compared	to	controls	(mean	of	12.8	vs.	10.6	variants,	respectively;	p=0.006)	(table	3.10i).	
However,	 like	 the	 ciliopathy	 panel,	 there	 was	 no	 additional	 mutational	 burden	 compared	 to	
controls	when	the	PDMs	were	subtracted	from	the	analysis.	Similarly,	there	was	no	enrichment	
of	variants	in	WGS	patients	compared	to	controls	when	PDMs	were	present	(mean	of	9.3	vs.	9.9	
variants,	respectively;	p=0.522).	When	the	PDMs	were	removed	from	the	analysis,	there	was	a	
significant	 decrease	 in	 the	 mean	 number	 of	 variants	 compared	 to	 controls	 (7.2	 vs.	 9.9,	
respectively;	p=0.006)	(table	3.10ii).	In	contrast	to	the	ciliopathy	panel,	there	was	no	significant	
difference	between	patients	and	controls	when	data	sets	were	combined,	both	with	and	without	
PDMs	(table	3.10iii).	This	analysis	demonstrated	that	even	within	a	 larger	primary	cilia	specific	
gene	panel,	there	was	no	mutational	burden	observed	for	these	patients	compared	to	controls.	
	
	
Filtering	
criteria	
Data	comparison	
Mean	number	of	
variant	alleles	per	
patient	
Mean	number	
of	variant	alleles	
per	control	
Fisher	Exact	
p-value	
i)	
+PDM	 WES		
16	BBS	vs.	25	controls	
12.8	 10.6	 0.006*	
-PDM	 11.6	 10.6	 0.350	
	 	 	 	 	 	
ii)	
+PDM	 WGS	
14	patients	vs.	30	controls	
9.2	 9.9	 0.522	
-PDM	 7.2	 9.9	 0.006*	
	 	 	 	 	 	
iii)	
+PDM	
WES	+	WGS	combined	
11.2	 10.2	 0.206	
-PDM	 9.6	 10.2	 0.378	
	
Table	3.10	–	Burden	analysis	comparison	with	SCGSv1	gene	panel	(n=235),	with	and	without	
primary	driving	mutation	included	in	the	analysis	(PDM).	*	denotes	statistically	significant	p-value	
where	α=0.05.	
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3.2.3.5.	Burden	analysis	with	control	gene	panel	
To	establish	whether	the	significant	differences	observed	(or	not	observed)	were	specific	to	the	
ciliopathy	and	SCGSv1	panels,	a	similarly	sized	unrelated	disease	panel	was	utilised.	This	featured	
74	genes	associated	with	the	inherited	motor	neuropathy,	Charcot-Marie-Tooth	(CMT)	disease	
(table	3.11;	appendix,	A.3).	This	gene	list	has	previously	been	investigated	by	Gonzaga-Jauregui	
and	colleagues	who	observed	mutational	burden	in	a	group	of	CMT	patients	compared	to	controls	
(Gonzaga-Jauregui	et	al.	2015).	
	
The	 average	 number	 of	 variants	were	 concordant	 between	 patient	 and	 controls	 (table	 3.11),	
though	some	variability	was	observed	between	WES	and	WGS	sets	(combined	mean	of	1.9	and	
2.5,	 respectively).	 This	 inconsistency	 could	 be	 due	 to	 sequencing	 artefacts	 distinct	 to	 one	
technique	 over	 the	 other.	 As	 there	 was	 no	 significant	 difference	 in	 the	 number	 of	 variants	
between	patients	and	controls,	this	analysis	offers	evidence	that	the	differences	observed	in	the	
burden	testing	are	specific	to	ciliopathy	genes.	
	
	
Filtering	criteria	 Data	comparison	
Mean	number	of	
variant	alleles	per	
patient	
Mean	number	of	
variant	alleles	per	
control	
Fisher	Exact	
p-value	
	 CMT	gene	panel	
WGS	only	 1.8	 2.0	 0.723	
WES	only	 2.6	 2.4	 0.678	
Combined	data	sets	 2.2	 2.15	 0.931	
	
Table	3.11	–	Comparison	between	WGS,	WES,	and	combined	datasets	with	a	control	gene	panel	
(n=74)	
	
3.2.3.6.	Technical	investigations	
The	unexpected	finding	presented	here	was	the	observation	that	there	were	significantly	fewer	
variants	in	BBS	patients	than	controls	when	BBS1	PDMs	were	removed	from	the	WGS	cohort.	I	
set	out	to	determine	whether	this	could	be	a	technical	issue	caused	by	more	variants	overall	in	
the	controls	 than	patients.	Although	the	sequencing	company,	 technology,	and	bioinformatics	
analysis	were	identical	for	all,	it	was	possible	that	batch	effects	may	exist	as	the	15	BBS	patients,	
20	SRS,	and	10	VEO-IBD	controls	were	sequenced	in	different	batches.	To	investigate	potential	
technological	 inconsistencies,	 the	 number	 of	 total	 variants	 was	 counted	 separately	 for	 each	
individual.	It	was	then	recorded	how	many	variants	were	considered	after	each	filter	was	applied	
in	IVA.	The	mean	number	of	qualifying	variants	for	patients	and	controls	were	calculated	and	a	
Student’s	t-test	conducted	to	assess	whether	there	were	significantly	more	variants	in	the	control	
than	 patient	 cohort.	 The	 number	 of	 qualifying	 variants	with	 the	 respective	 filtering	 criteria	 is	
presented	in	figure	3.6.	
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On	average	for	total	variants,	there	were	~300	more	variants	in	the	control	group	than	the	BBS	
cohort	 (figure	 3.6A).	 However,	 at	 α=0.05	 there	was	 not	 sufficient	 evidence	 to	 reject	 the	 null	
hypothesis	 that	 the	 group	means	 differ	 significantly	 (p=0.078;	 supplemental	 data	 table	 S.40).	
Further	 testing	 was	 completed	 throughout	 the	 filtering	 process,	 where	 the	 conclusion	 that	
differences	were	not	statistically	significant	was	 found	at	each	 level	 (figure	3.6B	and	3.6C).	As	
previously	shown,	when	the	PDMs	were	subsequently	removed	from	the	analysis,	there	was	a	
significant	decrease	in	the	number	of	variants	per	patient	compared	to	controls	(figure	3.6C).	
	
Figure	3.6	–	The	mean	number	of	variants	 throughout	 IVA	filtering	 for	BBS	patients	 (blue)	and	controls	
(red).	A)	mean	number	of	total	variants	without	filtering.	B)	mean	number	of	variants	with	MAF<1%	ExAC	
population	frequency	filter	applied	(left),	and	with	the	addition	of	predicted	deleterious	by	SIFT,	PolyPhen-
2	or	CADD>20	(right).	C)	SCGSc1	(n=235)	and	Ciliopathy	(n=73)	gene	panels	were	added	with	and	without	
the	presence	of	PDMs	in	the	analysis.	Error	bars	correspond	to	95%	confidence	intervals	and	statistically	
significant	differences	when	α=0.05	are	indicated.	
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All	 samples	 were	 whole	 genome	 sequenced	 to	 an	 average	 coverage	 of	 30X.	 Although	 the	
sequencing	is	expected	to	be	robust	across	different	batches,	there	can	be	some	variability	due	
to	 sequencing	errors	caused	by	GC	 rich	or	 repetitive	 regions	of	 the	genome.	 It	was	 therefore	
inspected	whether	there	were	any	irregularities	in	sequence	coverage	over	71	genes	from	the	
ciliopathy	 panel	 for	 patients	 and	 controls	 (OFD1	 and	 RPGR	 found	 on	 chromosome	 X	 were	
removed	from	this	analysis,	as	they	would	add	sex	bias)	(Figure	3.7).	
	
All	 subjects	had	high	 sequence	coverage	over	 the	 ciliopathy	panel,	 exceeding	30X	 in	all	 cases	
(figure	3.7A).	On	average,	BBS	patients	had	a	higher	coverage	compared	to	control	subjects	(36X	
and	33X,	respectively),	demonstrating	that	both	were	sequenced	to	the	expected	standard.	The	
coverage	was	also	assessed	at	an	individual	level	by	calculating	the	percentage	of	bases	covered	
at	different	read	depths	(figure	3.7B).	On	average,	76%	of	bases	were	covered	with	depth	greater	
than	30X	for	BBS	patients,	compared	to	69%	for	controls.	Both	groups	had	an	average	of	96%	of	
bases	 covered	 with	 coverage	 greater	 than	 20X.	 Taken	 together,	 these	 data	 show	 no	 clear	
technical	sequencing	abnormalities	in	both	datasets,	and	they	were	sequenced	to	a	high	quality.	
This	 supports	 the	 conclusion	 that	 the	mutational	 burden	 testing	was	 not	 driven	 by	 technical	
anomalies.	
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Figure	3.7	–	Mean	coverage	data	to	assess	the	quality	of	WGS	data	at	a	gene	(A)	and	individual	(B)	level.	A)	
The	mean	coverage	calculated	across	each	gene	in	the	ciliopathy	panel	for	15	BBS	patients	(blue)	and	30	
controls	 (red).	B)	The	percentage	of	bases	averaged	over	 the	ciliopathy	gene	panel	covered	 to	a	depth	
greater	than	30X	(blue),	between	20-30X	(red),	between	10-20X	(green)	and	less	than	10X	(purple),	for	BBS	
patients	(left)	and	control	individuals	(right).	
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3.3.	Discussion	
	
3.3.1.	Identification	of	potential	modifier	alleles	
In	this	study,	whole	genome	sequencing	was	utilised	to	uncover	potential	modifying	alleles	that	
could	 explain	 the	 phenotypic	 heterogeneity	 commonly	 observed	 in	 BBS	 patients.	 A	 4-tier	
categorisation	 system	 was	 devised	 to	 filter	 over	 11	 million	 variants	 down	 to	 41	 potential	
modifying	mutations.	In	addition	to	the	underlying	pathogenic	mutations	in	BBS1,	13	out	of	15	
patients	possessed	potential	secondary	mutations	with	MAF<5%.	7	of	these	patients	had	variants	
identified	that	were	predicted	to	be	deleterious	by	functional	prediction	algorithms,	as	well	as	
defined	 as	 rare	 (MAF<1%).	 Furthermore,	 the	 tiered	 system	 identified	 previously	 established	
hypomorphic	modifying	mutations	 in	BBS12,	TTC21B	and	RPGRIP1L	 in	4	patients.	From	the	41	
candidate	modifiers,	 each	affected	gene	was	 considered	 for	 their	distribution	 throughout	 the	
primary	cilium	and	assessed	for	their	direct	interaction	with	BBS1.	As	a	result	of	this,	as	well	as	
acknowledgement	 of	 predicted	 pathogenicity	 and	 rare	minor	 allele	 frequencies,	 a	 shortlist	 of	
candidate	modifier	variants	was	constructed	(table	3.5).	
	
3.3.1.1.	High	confidence	candidate	modifier	alleles	
For	 comprehensive	 characterisation	of	 these	 candidate	modifying	 variants,	 functional	 analysis	
should	be	undertaken,	as	well	as	further	assessment	of	these	candidates	in	a	larger	population	of	
BBS	patients.	However,	as	this	is	beyond	the	scope	of	this	project,	I	have	selected	a	number	of	
variants	where	evidence	exists	 in	 literature	and	databases	 to	support	 their	 role	as	a	modifier.	
These	are	classed	as	high	confidence	modifiers	and	discussed	here	in	detail.	
	
BBS003:	RPGRIP1L	
RPGRIP1L	p.A229T	was	identified	in	BBS003,	who	presents	with	severe	BBS	including	early	onset	
RP	and	 renal	defects.	RPGRIP1L	 is	mutated	 in	MKS	and	 JBST,	but	has	been	 shown	 to	act	as	a	
modifier	 specifically	 for	 RP	 in	 other	 ciliopathies	 (Khanna	 et	 al.	 2009).	 Khanna	 and	 colleagues	
(2009)	identified	p.A229T,	a	common	polymorphic	variant	in	RPGRIP1L	that	was	enriched	in	18	
ciliopathy	patients	of	European	descent	compared	to	3016	control	alleles.	4	of	these	18	ciliopathy	
cases	were	BBS	patients.	Furthermore,	through	morphogenic	zebrafish	experiments,	RPGRIP1L	
p.A229T	was	 validated	 to	 act	 as	 a	 hypomorph.	 In	 particular,	 this	 variant	was	 only	 present	 in	
ciliopathy	cases	where	RP	is	a	diagnostic	feature,	such	as	BBS	or	SLS.	The	manuscript	continued	
to	 suggest	 that	 the	 absence	 of	 this	 variant	may	 protect	 from	RP	 in	 other	 ciliopathy	 patients.	
However,	this	claim	is	not	supported	by	the	fact	that	p.A229T	is	absent	from	the	14	remaining	
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BBS	 patients	 in	 this	 study	 who	 also	 suffer	 from	 RP.	 The	 proposed	 mechanism	 involved	 the	
collaborative	relationship	between	RPGRIP1L	and	RPGR,	which	was	abrogated	by	substitution	to	
p.T229.	 The	 study	 by	 Khanna	 et	 al.	 suggested	 that	 this	 interaction	may	 play	 a	 larger	 role	 in	
photoreceptors,	 due	 to	 the	 significant	 role	 of	 RPGR	 in	 RP	 (Ayyagari	 et	 al.	 2002).	 It	 may	 be	
postulated	 that	 this	 phenomenon	 also	 affect	 kidney	 cells,	 as	 both	 RPGRIP1L	 and	 RPGR	 are	
expressed	in	renal	tissue	and	aberrations	can	lead	to	ciliopathies	featuring	nephropathy	(Wolf	et	
al.	 2007;	 Delous	 et	 al.	 2007;	 Patil	 et	 al.	 2010).	 Despite	 this	 variant	 being	 fairly	 common	 and	
predicted	innocuous,	this	evidence	indicates	that	it	may	play	a	pivotal	role	in	the	severity	of	BBS	
in	patient	BBS003.	
	
BBS005:	ARL6	(BBS3)	
Out	of	all	15	patients,	BBS005	has	the	greatest	number	of	qualifying	variants,	with	6	mutations	in	
6	genes.	The	most	convincing	candidate	modifier	is	the	variant	in	the	GTP-binding	protein	ARL6.	
A	direct	interaction	between	ARL6	and	BBS1	has	been	shown	by	X-ray	crystallography,	which	is	
required	for	recruitment	of	the	BBSome	to	ciliary	membrane	(Mourão	et	al.	2014).	Mourão	et	al.	
(2014)	hypothesised	 that	 the	p.M390R	variant	destabilises	 this	 interaction	with	ARL6,	 thus	an	
additional	hit	in	ARL6	could	exacerbate	this	disruption	further.	Moreover,	the	adjacent	residue	to	
T32	 is	another	threonine,	which	contributes	to	a	conserved	nucleotide	binding	site	called	a	P-
loop.	Mutation	of	p.T31M	is	known	to	cause	BBS	by	disruption	of	GTP	binding	(Fan	et	al.	2004).	
Structural	analysis	by	Fan	et	al.	(2004)	determined	that	p.T32	is	also	within	the	nucleotide	binding	
pocket	of	ARL6,	and	thus	a	substitution	to	a	methionine	could	sufficiently	alter	the	structure	of	
this	pocket	and	disrupt	GTP	binding.	The	rarity	of	the	mutation	(MAF<0.001%	of	total	Gnomad	
database)	 and	 position	 within	 a	 functional	 domain	 of	 the	 protein	 could	 render	 p.T32M	 as	 a	
deleterious	variant,	perhaps	more	so	in	collaboration	with	BBS1	p.M390R.	
	
BBS006,	BBS008:	TTC21B	
TTC21B	 is	 mutated	 in	 NPHP	 and	 the	 skeletal	 ciliopathy	 JATD,	 and	 encodes	 an	 intraflagellar	
transport	protein	in	the	IFT-A	particle	(Davis	et	al.	2011).	Tiered	modifier	analysis	identified	3	hits	
in	TTC21B	that	affect	2	patients,	where	2	of	these	hits	are	the	same	variant	(p.L1002V)	in	BBS006	
and	BBS008.	This	mutation	was	identified	as	a	modifier	by	Davis	et	al.	(2011)	after	it	was	found	
as	a	 second	site	hit	 in	5	ciliopathy	patients.	An	mRNA	construct	of	p.L1002	was	 subsequently	
expressed	 in	 the	 photoreceptors	 of	 a	 Ttc21b	 knock-down	 rat	 retina.	 It	 was	 observed	 that	
p.L1002V	could	not	fully	rescue	TTC21B	mislocalisation	within	the	cilia	caused	by	the	gene	knock	
down,	but	did	partially	restore	ciliary	length.	Due	to	the	partial	rehabilitation	of	the	phenotype,	
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this	 variant	was	 considered	 to	have	 a	hypomorphic	 effect.	 In	 a	 similar	 experiment,	Davis	 and	
colleagues	(2011)	determined	that	the	third	hit	in	TTC21B	(p.R616C),	identified	in	BBS006,	was	
benign.	
	
BBS009:	BBS12	
A	final	known	modifier,	BBS12	p.S429T,	was	identified	in	patient	BBS009.	BBS12	is	a	member	of	
a	chaperone	complex	required	for	assembly	of	the	BBSome	(Seo	et	al.	2010).	This	point	mutation	
was	interpreted	by	PROVEAN	and	PolyPhen-2	to	be	neutral/benign	and	had	a	CADD	score<10.	
The	reason	for	this	prediction	is	due	to	the	substitution	from	a	serine	to	a	threonine,	which	both	
contain	polar	side	chains.	Regardless,	BBS12	p.S429T	was	screened	in	a	zebrafish	morphometric	
experiment	and	was	found	to	have	a	hypomorphic	affect	(Zaghloul	et	al.	2010).	This	demonstrates	
how	modifying	 variants	may	 not	 be	 deleterious	when	 expressed	 alone	 but	 induce	 a	 variable	
phenotype	when	in	combination	with	the	primary	driving	mutation.	
	
BBS013:	BBS4	
In	patient	BBS013,	another	suitable	candidate	modifier	was	identified	in	BBS4	(p.V226G),	which	
is	a	fellow	member	of	the	BBSome	with	BBS1,	and	has	previously	been	highlighted	as	a	candidate	
for	oligogenicity	in	BBS	(Katsanis	et	al.	2002).	Additional	roles	for	BBS4	are	known,	including	the	
interaction	 with	 centriolar	 satellite	 proteins.	 One	 such	 interactor	 is	 pericentriolar	 material	 1	
(PCM1),	which	is	required	for	correct	localisation	of	proteins	to	the	centrosome	for	cilia	assembly	
(Kim	 et	 al.	 2004;	 Chamling	 et	 al.	 2014).	 The	 BBS4	 protein	 has	 a	 well	 conserved	 structure,	
consisting	of	13	tandem	tetratricopeptide	repeat	(TPR)	motifs	(Kim	et	al.	2004).	These	motifs	are	
found	in	many	proteins	involved	in	complex	formation,	and	critically,	are	highly	enriched	in	ciliary	
proteins	 (Xu	et	 al.	 2015;	Davis	 et	 al.	 2011).	 The	amino	acid	 change	p.V226G	 found	 in	patient	
BBS013	lies	within	the	6th	TPR	of	BBS4	and	thus	may	abrogate	the	binding	properties	of	BBS4	for	
assembly	of	centriolar	satellite	or	BBSome	complexes.	
	
BBS014:	CEP164	
Except	 for	 two	 variants,	 the	 majority	 of	 candidate	 modifying	 variants	 discovered	 were	
heterozygous	 missense	 mutations.	 One	 exception	 is	 a	 heterozygous	 nonsense	 mutation	 in	
CEP164	 (p.Q1410*),	 identified	 in	BBS014.	CEP164	 is	 linked	 to	NPHP	with	extra-renal	 features,	
such	as	RP	and	obesity	(Chaki	et	al.	2012).	Hence,	this	variant	is	a	good	candidate	as	a	modifier	
for	BBS014	as	this	patient	had	stage-5	chronic	kidney	disease.	CEP164	encodes	for	a	centrosomal	
protein	that	is	required	for	primary	cilium	formation,	as	well	as	having	important	roles	in	the	DNA	
Chapter	3:	Genetic	modifiers	in	BBS	
	
142	
damage	 response	 pathway	 and	 cell	 cycle	 progression	 (Graser	 et	 al.	 2007;	 Slaats	 et	 al.	 2014).	
Furthermore,	CEP164	interacts	with	SDCCAG8	(Chaki	et	al.	2012),	a	centrosomal	protein	that	has	
been	 shown	 to	 cause	 BBS	 (Schaefer	 et	 al.	 2011).	 As	 a	 nonsense	 mutation,	 this	 shortened	
transcript	could	disrupt	the	function	of	the	protein,	especially	since	this	truncation	prevents	the	
translation	of	a	known	phosphorylation	site	(Zhou	et	al.	2013).	
	
BBS015:	AHI1	
Patient	 BBS015	 has	 a	 fairly	 mild	 presentation	 of	 BBS	 but	 suffered	 from	 early	 onset	 retinal	
dystrophy.	The	only	variant	 that	was	 identified	 in	this	patient	was	 in	AHI1	 (p.R548H),	which	 is	
mutated	in	JBTS	with	high	penetrance	for	retinal	dystrophy	(Valente	et	al.	2006;	Parisi	et	al.	2006).	
AHI1	has	been	suspected	of	demonstrating	modifying	effects	in	other	ciliopathies,	including	NPHP	
(Tory	et	al.	2007;	Louie	et	al.	2010)	and	LCA	(Coppieters	et	al.	2010).	It	also	exhibited	a	vital	role	
in	 the	 formation	 of	 the	 outer	 segments	 of	 photoreceptors	 and	 suppression	 of	 Ahi1	 in	 mice	
resulted	in	early	photoreceptor	degeneration	(Louie	et	al.	2010;	Westfall	et	al.	2010).	Therefore,	
it	is	possible	that	p.R548H	acted	as	a	modifying	variant	specifically	towards	rod-cone	dystrophy	
and	enhanced	retinal	degeneration	in	BBS015.	
	
3.3.1.2.	Low	confidence	candidate	modifier	alleles	
Some	of	the	variants	chosen	as	candidate	alleles	have	little	evidence	for	their	potential	role	as	
modifiers.	 This	 may	 be	 due	 to	 tissue	 specific	 gene	 expression	 that	 contradicts	 the	 patient	
phenotype,	 or	 too	 little	 is	 known	 about	 the	 gene.	 These	 were	 classified	 as	 low	 confidence	
modifier	alleles	and	are	outlined	here.	
	
BBS002:	TCTN1	
In	 patient	 BBS002,	 a	 homozygous	 start	 loss	 variant	 was	 discovered	 in	 a	 transcript	 of	 TCTN1	
(p.M1I).	TCTN1	is	a	regulator	of	the	Hedgehog	pathway	(Reiter	and	Skarnes	2006).	In	addition	to	
this	 role,	 TCTN1	 regulates	 ciliogenesis	 in	 certain	 tissues	 and	 controls	 the	 localisation	of	 some	
transition	zone	proteins,	such	as	MKS1	and	TMEM67	(Garcia-Gonzalo	et	al.	2011).	Mutations	in	
TCTN1	can	cause	the	developmental	ciliopathy,	JBTS	(Huppke	et	al.	2015).	There	are	at	least	5	
protein	 coding	 transcripts	 for	 TCTN1,	 where	 the	 p.M1I	 variant	 only	 interrupts	 one	 transcript	
(RefSeq	transcript	ID:	NM_001173975)	and	falls	in	an	intronic	region	between	exon	1	and	2,	or	in	
the	3’	untranslated	region	(UTR)	of	the	remaining	transcripts.	Although	it	is	known	that	TCTN1	
expression	differs	in	different	tissue	types	(Garcia-Gonzalo	et	al.	2011),	there	is	no	evidence	of	
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whether	 NM_001173975	 has	 a	 distinct	 role	 that	 is	 not	 achieved	 by	 the	 other	 4	 transcripts.	
Therefore,	it	is	uncertain	whether	the	loss	of	a	start	site	will	actually	present	a	phenotype.	
	
BBS007:	C2ORF71	
Patient	BBS007	is	1	of	3	patients	to	suffer	from	kidney	failure	in	this	cohort.	However,	the	only	
qualifying	variant	 identified	 in	this	patient	was	a	heterozygous	substitution	 in	C2ORF71,	which	
has	only	been	found	to	cause	nonsyndromic	autosomal-recessive	RP	(Collin	et	al.	2010).	 It	has	
been	suggested	that	C2ORF71	is	consistent	with	a	gene	that	is	expressed	specifically	in	the	outer	
segment	or	connecting	cilium	of	photoreceptors	(Nishimura	et	al.	2010).	However,	the	Human	
Protein	 Atlas	 (Uhlén	 et	 al.	 2015)	 shows	 some	 expression	 in	 other	 tissue	 types,	 including	 the	
kidney,	 where	 there	 is	 weak	 expression	 in	 the	 tubules	 but	 high	 expression	 in	 the	 glomeruli	
(Human	Protein	Atlas	2017a).	
	
BBS010,	BBS011,	BBS012:	PKHD1,	WDPCP,	XPNPEP3	
The	 discovery	 of	 genetic	modifiers	 can	 be	 facilitated	 by	 examining	 discordant	 siblings,	where	
segregation	analysis	can	be	utilised	for	discovery	of	unique	variants	that	may	explain	a	phenotype	
in	one	sibling	and	not	the	other	(Génin	et	al.	2008).	In	this	study,	patients	BBS010	and	BBS011	
are	 monozygotic	 (MZ)	 twins	 and	 BBS012	 is	 an	 older	 sibling.	 Interestingly,	 despite	 the	 same	
underlying	pathogenic	variants	 in	BBS1,	BBS010	was	 the	only	patient	 to	display	polydactyly	at	
birth	and	BBS012	had	later	onset	retinal	degeneration	with	no	learning	difficulties.		
	
WDPCP	(BBS15)	was	shown	to	cause	BBS	after	a	homozygous	mutation	was	found	to	segregate	
in	a	patient	by	Kim	et	al.	(2010).	Although	this	has	been	the	only	case	with	published	data	linking	
WDPCP	with	BBS,	it	has	been	shown	that	WDPCP	is	required	for	ciliogenesis,	as	well	as	other	key	
regulatory	processes	such	as	maintaining	cell	polarity	(Cui	et	al.	2013).	WDPCP	p.R290H	was	the	
only	candidate	variant	consistent	across	all	3	siblings,	but	predicted	to	be	benign	as	position	290	
is	not	well	conserved	in	orthologues.	Although	this	does	not	exclude	this	variant	as	a	potential	
modifier,	there	is	currently	no	evidence	that	it	would	have	a	significant	effect	on	expressivity.	It	
is	of	note	 that	 this	 variant	 is	extremely	 rare,	as	only	1	out	of	244598	alleles	are	 found	 in	 the	
Gnomad	database.	
	
Although	there	was	no	distinction	between	BBS010	and	BBS011	to	explain	the	manifestation	of	
polydactyly,	 there	 were	 two	 variants	 in	 PKHD1	 that	 were	 not	 present	 in	 BBS012	 (p.I3309V;	
p.G698D).	However,	this	variant	was	assigned	low	confidence	due	to	expression	primarily	in	renal	
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and	 hepatic	 cells	 (GTEx	 Portal	 2017;	 Human	 Protein	 Atlas	 2017b;	 Aguet	 et	 al.	 2016),	 where	
mutations	in	PKHD1	cause	polycystic	kidney	and	hepatic	disease	(Zhang	et	al.	2004).	The	MZ	twins	
do	not	present	a	renal	phenotype,	ergo	this	variant	does	not	seem	a	likely	candidate.	
	
In	 contrast	 to	 the	MZ	 twins,	 BBS012	 has	 a	 variant	 in	XPNPEP3	 (p.P493A),	which	 interestingly	
localises	 to	 the	mitochondria	 of	 renal	 cells	 and	 causes	 a	NPHP-like	 ciliopathy.	 Suppression	 of	
XPNPEP3	exhibits	a	deleterious	effect	on	the	cilium	and	thus	is	predicted	to	have	a	dual	role	at	
the	 basal	 body	 (O’Toole	 et	 al.	 2010).	 BBS012	 does	 not	 present	 renal	 defects	 except	 for	
nephrolithiasis,	which	is	not	considered	a	symptom	of	BBS.	Due	to	the	presence	of	this	mutation	
in	 the	 less	 severe	 sibling,	 it	 could	be	possible	 that	 the	variant	acts	protectively	and	 slows	 the	
progression	of	symptoms	like	retinal	degeneration.	XPNPEP3	is	undoubtedly	an	interesting	gene	
that	 requires	 more	 investigation	 to	 determine	 the	 link	 between	 the	 primary	 cilium	 and	
mitochondria.	
	
3.3.1.3.	Undiscovered	modifiers	
As	described	above,	there	are	some	fitting	candidate	modifiers	that	may	explain	the	phenotypic	
heterogeneity	 observed	 throughout	 the	 cohort.	However,	 there	were	 2	 patients	who	did	 not	
present	any	modifiers,	and	others	exhibited	less	suitable	candidates	that	could	not	explain	the	
differences	in	expressivity.	For	example,	I	could	not	find	a	genetic	explanation	for	why	the	MZ	
twins	were	discordant	 for	polydactyly.	This	may	be	an	obvious	statement,	 since	MZ	 twins	are	
supposedly	genetically	identical.	However,	this	assumption	needs	to	be	re-evaluated,	as	somatic	
mutations	 can	 develop	 in	MZ	 twins	 postzygotically	 (Silva	 et	 al.	 2011;	 Youssoufian	 and	 Pyeritz	
2002).	Indeed,	somatic	mutations	can	occur	during	any	stage	of	development	and	may	be	tissue	
specific	(Lupski	2010).	Therefore,	a	somatic	mutation	that	caused	polydactyly	in	BBS010	may	not	
be	detectable	in	genomic	DNA	extracted	from	peripheral	blood.	
	
One	of	the	benefits	of	whole	genome	sequencing	is	that	the	data	are	contiguous	and	areas	that	
are	difficult	to	capture	in	WES	can	be	sequenced.	However,	complications	with	WGS	technology	
still	exist.	For	example,	some	repetitive	regions	are	challenging	to	sequence	at	sufficient	depth	to	
pass	quality	control	tests	(Dewey	et	al.	2014).	Moreover,	WGS	also	allows	 investigation	of	the	
non-coding	DNA	accounting	 for	~98%	of	 the	genome.	Emerging	projects	 such	as	ENCODE	has	
revealed	that	regulatory	variation	can	play	a	role	in	explaining	disease	variability	due	to	mutations	
within	expression	quantitative	trait	loci	(eQTLs);	regions	of	the	genome	shown	to	influence	gene	
expression	(Gerstein	et	al.	2012;	Ward	and	Kellis	2012).	For	the	purpose	of	this	study,	analysis	
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was	 restricted	 to	 functional	 coding	 regions.	At	present	 resources	 for	 identification	of	disease-
related	regulatory	variation	is	limited,	making	it	challenging	to	determine	the	functional	outcome	
of	the	non-coding	genome.	Identification	of	eQTLs	requires	comparison	by	association	in	a	large	
sample	size.	This	could	not	be	accomplished	in	this	study	due	to	insufficient	numbers.	
	
The	gene	panel	that	was	utilised	contained	73	genes	known	to	exhibit	the	spectrum	of	ciliopathies	
specific	 to	 the	 primary	 cilium.	 However,	 the	 primary	 cilium	 is	 a	 vast	 network	 of	 interacting	
proteins,	estimated	to	feature	over	800	genes	(van	Dam	et	al.	2017),	where	novel	ciliary	gene	
discovery	is	a	common	occurrence	(Boldt	et	al.	2016;	Wheway	et	al.	2015;	van	Dam	et	al.	2013).	
Therefore,	it	is	possible	that	a	modifier	may	be	present	in	any	of	the	cilia	genes	not	screened	in	
this	study.	The	reason	that	a	larger	panel	was	not	screened	was	because	a	vast	number	of	variants	
would	have	been	unrealistic	to	individually	evaluate.	
	
The	purpose	of	this	study	was	to	assess	whether	the	phenotypic	heterogeneity	of	BBS	is	altered	
by	genetic	 factors.	However,	expressivity	could	also	be	 impacted	by	 lifestyle	or	environmental	
influences,	such	as	gender,	diet,	physical	activity	etc.	(Hunter	2005).	Undoubtedly,	environment	
can	affect	the	degree	of	obesity	and	metabolic	syndrome.	On	the	other	hand,	there	are	other	
genetic	 factors	 not	 investigated	 here	 that	may	 explain	 low	 genotype-phenotype	 correlations.	
These	include	larger	variation	types	that	may	modify	gene	expression,	such	as	copy	number	and	
structural	variation	(Lindstrand	et	al.	2016).	Indeed,	all	15	patients	were	assayed	for	copy	number	
changes	using	a	SNParray.	In	addition,	in	silico	methods	of	structural	variant	detection	were	also	
applied	to	the	WGS	data,	using	the	programmes	LUMPY	(Layer	et	al.	2014)	and	CNVnator	(Abyzov	
et	al.	2011).	A	screen	of	the	resulting	data	with	the	ciliopathy	gene	panel	identified	no	candidate	
modifying	copy	number	or	structural	variations.		
	
3.3.2.	Future	experiments	for	validation	of	modifiers	
Further	probing	will	be	required	to	determine	what	affect	the	candidate	modifier	mutations	have	
on	 downstream	 gene	 expression	 and	 protein	 function.	 The	 effect	 of	 secondary	 modifying	
variation	will	need	to	be	resolved	through	further	genetic	or	functional	analysis.	
	
3.3.2.1.	Screening	in	larger	cohort	
One	of	the	limitations	of	this	experiment	was	a	small	sample	size,	an	inevitable	feature	of	studying	
a	rare	disease.	As	a	result,	it	is	more	challenging	to	speculate	the	effect	of	a	potential	modifier	on	
the	disease	phenotype	when	only	found	in	one	patient.	However,	with	a	larger	cohort,	it	may	be	
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possible	to	stratify	patients	according	to	identified	modifiers	and	their	phenotypes.	The	utility	of	
this	 technique	was	 displayed	when	 15	 out	 of	 117	 JBTS	 patients	were	 discovered	 to	manifest	
retinal	dystrophy	and	renal	dysfunction	as	a	result	of	modifying	mutations	in	AHI1	(Parisi	et	al.	
2006).	 A	 larger	 experiment	 would	 also	 provide	 greater	 power	 that	 would	 be	 required	 for	
statistical	testing.	
	
3.3.2.2.	Functional	validation	
In	vivo	validation	method	
Zebrafish	assays	are	one	model	that	has	shown	successful	utility	for	validation	of	modifiers,	such	
as	those	in	TTC21B,	RPGRIP1L,	and	CCDC28B	(Khanna	et	al.	2009;	Zaghloul	et	al.	2010;	Lindstrand	
et	 al.	 2014;	 Leitch	 et	 al.	 2008;	 Cardenas-Rodriguez	 et	 al.	 2013).	 Practicality	 comes	 from	 their	
number,	 short	 gastrulation,	 and	 transparent	 embryos	 that	makes	 it	 possible	 to	monitor	 their	
development	 in	 real	 time.	 In	 addition,	 gene	 expression	 can	 easily	 be	 manipulated	 through	
injection	of	an	antisense	morpholino	oligonucleotide	(MO)	to	suppress	a	specific	gene	of	interest	
(Zaghloul	and	Katsanis	2011).	Typically,	zebrafish	are	easier	to	breed	than	mice,	especially	when	
engineering	specific	knock-in	mutations,	which	would	not	be	time	or	cost	effective	 for	a	 large	
panel	of	modifying	variants.	Primary	cilia	pathways	are	conserved	in	zebrafish	and	the	main	organ	
systems	affected	in	BBS	are	equivalent	to	mammalian	models	(Song	et	al.	2016).	The	ciliopathy	
phenotype	has	also	been	well	characterised,	consisting	of	a	down-curved	body	axis,	kidney	cysts,	
gastrulation	defects,	as	well	as	a	shortened	and	widened	body	axis	(Tobin	and	Beales	2008;	Oishi	
et	al.	2006).		
	
For	future	validation	of	candidate	modifying	variants	uncovered	in	this	study,	the	zebrafish	would	
be	a	valuable	model.	Expression	of	target	genes	can	be	suppressed	through	injection	of	a	specific	
MO	and	 subsequently	 rescued	with	wild	 type	mRNA.	To	 investigate	 the	effect	of	 a	modifying	
mutation,	the	chosen	variant	can	be	incorporated	into	the	rescue	mRNA.	The	consequence	of	the	
modifier	can	be	determined	by	comparing	the	impact	of	the	mutant	and	wild	type	rescue	mRNAs.	
Mutant	alleles	that	rescue	the	phenotype	to	the	same	degree	as	the	wild	type	mRNA	are	regarded	
as	benign	variants.	However,	mutant	mRNAs	that	fail	or	only	partially	rescue	the	phenotype	are	
classed	as	null	or	hypomorphic	variants,	respectively.	Furthermore,	mutants	that	exacerbate	the	
phenotype	further	than	knock	down	alone	are	defined	as	dominant	negative	variants.	Through	
this	 method	 of	 knock	 down	 and	 rescue,	 many	 gene/modifier	 combinations	 can	 be	 assayed	
effectively	in	a	reliable	in	vivo	model	(Zaghloul	et	al.	2010;	Zaghloul	and	Katsanis	2011).	
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In	vitro	validation	methods	
Modifier	validation	 in	 in	 vitro	models	would	also	be	highly	useful.	The	benefit	of	 in	 vitro	over	
zebrafish	 experiments	 is	 that	 it	 is	 possible	 to	 directly	 visualise	 cilia	 via	 immunohistochemical	
staining.	 This	 can	 provide	 greater	 understanding	 of	 the	 functional	 role	 of	 the	 modifier,	 for	
example,	 whether	 it	 induces	 mislocalisation	 of	 proteins	 or	 impaired	 ciliogenesis.	 Here	 knock	
down	 is	 achieved	 through	 addition	 of	 specific	 short-hairpin	 RNAs	 and	 rescued	 by	 transiently	
transfecting	with	wild	 type	or	mutant	constructs	 (Davis	et	al.	2011).	The	categorisation	of	 the	
modifier	can	be	assessed	under	the	same	criteria	as	above	(i.e.	hypomorphic,	null,	etc).	
	
For	a	patient-specific	understanding	of	how	a	modifier	may	function,	induced	pluripotent	stem	
cell	 (iPSC)	 models	 could	 be	 used.	 The	 benefit	 of	 patient-derived	 cells	 is	 that	 the	 genetic	
background	 is	 the	 same.	 Furthermore,	 tissue	 specific	 effects	 can	 be	 explored	 through	
differentiation	of	iPSCs	into	relevant	cell	types,	such	as	renal	cells	(Xia	et	al.	2013),	neurons	(Wang	
et	al.	2015),	or	photoreceptors	(Zhong	et	al.	2014).	The	effect	of	the	modifier	can	be	determined	
through	mutation	correction	techniques,	such	as	CRIPSR-Cas9	(Kim	et	al.	2014).	
	
3.3.3.	Mutational	Burden	Analysis	
Mutational	burden	analysis	is	the	assessment	of	the	number	of	variants	within	disease	relevant	
genes	for	a	patient	cohort	compared	to	a	control	group.	If	the	mutational	burden	hypothesis	is	
true,	 there	 should	be	an	enrichment	of	 functional	 variants	 in	 the	disease	group	 compared	 to	
controls.	 It	 is	 thought	 that	 this	 cumulative	 burden	 within	 a	 pathway	 could	 destabilise	 the	
biological	system	and	provoke	an	enhanced	disease	phenotype	(Gonzaga-Jauregui	et	al.	2015).	
As	the	primary	cilium	contains	an	intricate	network	of	tightly	regulated	protein	complexes,	this	
organelle	provided	a	fitting	system	where	this	model	would	be	expected	to	work	well.	
	
Two	 sets	 of	 ciliopathy	 patient	 cohorts	were	 assessed	 for	mutational	 burden	 against	 controls,	
featuring	 patients	 sequenced	 by	 either	 whole	 exome	 (16	 patients	 vs.	 25	 controls)	 or	 whole	
genome	sequencing	(14	patients	vs.	30	controls).	The	experimental	justification	of	using	two	data	
sets	was	that	these	could	be	combined	for	a	greater	statistical	power	(30	patients	vs.	55	controls).	
These	were	 also	 analysed	 separately	 under	 identical	 criteria	 to	 detect	whether	 findings	were	
replicable	 in	different	patient	 cohorts.	Only	nonsynonymous	variants	predicted	pathogenic	by	
SIFT	or	PolyPhen-2	or	CADD>20	were	considered	at	a	population	frequency	less	than	1%	of	ExAC	
database.	
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3.3.3.1.	Mutational	burden	associated	with	PDMs	in	WES	data	
The	first	set	of	analyses	used	WES	data,	and	determined	that	there	was	a	significant	enrichment	
in	the	mean	number	of	qualifying	variants,	specifically	in	ciliopathy	cases	and	not	controls.	This	
was	demonstrated	for	73	ciliopathy	genes	(p=0.006)	and	an	extended	panel	of	235	primary	cilia	
genes	from	the	SYSCILIA	consortium	(p=0.006)	(van	Dam	et	al.	2013).	A	control	set	of	a	similarly	
sized	disease	gene	panel	that	did	not	overlap	with	primary	cilia	genes	was	also	tested.	These	74	
genes	 were	 associated	 with	 the	 neuropathy	 CMT,	 and	 have	 previously	 been	 affiliated	 with	
increased	 mutational	 burden	 in	 a	 cohort	 of	 40	 CMT	 patients	 vs.	 5748	 control	 individuals	
(Gonzaga-Jauregui	 et	 al.	 2015).	 For	my	 analysis,	 the	mean	 number	 of	 qualifying	 variants	was	
consistent	 between	 control	 and	 patient	 groups	 (p=0.678),	 which	 suggests	 that	 the	 statistical	
enrichment	of	variants	was	specific	to	primary	cilia	genes.	
	
Under	 an	 autosomal	 recessive	 disease	model,	 it	 is	 expected	 that	 two	 segregating	 deleterious	
alleles	are	necessary	and	sufficient	alone	to	drive	disease	pathogenicity.	10	out	16	patients	had	a	
definitive	molecular	diagnosis.	When	these	20	known	pathogenic	alleles	were	removed	from	the	
analysis,	there	was	no	longer	a	statistical	increase	in	the	number	of	qualifying	variants	compared	
to	controls	(p=0.419).	This	demonstrated	that	the	significant	difference	observed	was	an	artificial	
artefact,	contributed	to	only	by	the	PDMs.	This	observation	was	further	supported	when	patients	
were	segregated	 into	those	with	and	without	a	definitive	diagnosis.	The	undiagnosed	patients	
exhibited	 a	 similar	 average	 (3.5	 variants)	 to	 the	 diagnosed	 patients	 when	 the	 PDMs	 were	
subtracted	(3.7	variants).	Thus,	when	compared	to	the	control	group,	there	was	no	evidence	of	
mutational	burden	without	the	effect	of	the	PDMs.	This	discovery	supports	previous	findings	in	
31	ciliopathy	patients	vs.	64	controls	(Shaheen	et	al.	2016).	Here,	rare	(MAF<0.01)	and	pathogenic	
(CADD>20)	alleles	were	counted	in	89	ciliopathy	genes	and	no	mutational	load	beyond	the	causal	
variants	was	detected.	
	
3.3.3.2.	Differences	found	between	WES	and	WGS	burden	analysis	
The	WES	patient	data	was	not	corroborated	by	 the	WGS	patient	burden	analysis.	 Indeed,	 the	
mean	number	of	variants	were	matched	for	patients	(with	PDMs)	and	controls	for	the	ciliopathy	
panel	(3.7	vs.	3.6,	respectively;	p=0.863)	and	less	than	controls	for	the	SCGSv1	panel	(9.2	vs.	9.9,	
respectively;	p=0.522).	For	both	panels,	there	were	significantly	fewer	variants	in	patients	when	
PDMs	were	removed	(ciliopathy,	p=0.0004;	SCGSv1,	p=0.006).	This	is	opposite	to	what	would	be	
expected	 if	 the	 burden	 analysis	 hypothesis	 were	 true.	 Initially,	 it	 was	 considered	 that	 this	
abnormality	could	be	a	technical	error	caused	by	discordances	across	different	batches	of	WGS.	
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This	thought	was	strengthened	by	the	observation	that	there	were	slightly	fewer	variants	in	the	
CMT	 panel	 in	 patients	 compared	 to	 controls.	 However,	 small	 amounts	 of	 variation	 between	
individuals	to	a	certain	degree	would	be	expected,	as	determined	by	Fisher’s	exact	test,	which	
suggested	that	the	difference	observed	was	due	to	chance.	
	
Further	 investigation	 into	 technical	 error	 was	 carried	 out	 by	 counting	 the	 mean	 number	 of	
variants	at	each	stage	of	the	filtering	analysis.	This	showed	that	there	were	overall	more	variants	
in	the	control	data	than	the	patients.	However,	the	large	statistical	variance	illustrated	by	95%	
confidence	 intervals,	 suggested	 that	 the	difference	 is	due	 to	biological	 variability,	 rather	 than	
technical	variability.	This	finding	was	investigated	by	a	Student’s	t-test,	which	further	supported	
that	the	variability	was	due	to	chance	(p=0.078).	
	
One	of	 the	advantages	of	WGS	 technology	 is	 that	 reads	are	 contiguous,	which	allows	greater	
accuracy	for	mapping	and	uniformity	of	sequence	coverage.	Therefore,	it	is	more	likely	that	WGS	
would	outperform	WES	 for	 reliability	 across	batches,	 as	WES	 reads	 can	differ	 in	hybridisation	
efficiency	 resulting	 in	 technical	 artefacts	 in	 low	 coverage	 areas.	 As	 no	 abnormalities	 were	
observed	across	the	WES	data	sets,	this	led	to	the	conclusion	that	the	difference	between	the	
WGS	patients	and	controls	was	biological	and	not	caused	by	technical	artefacts.	
	
3.3.3.3.	Combination	of	datasets	
The	 datasets	 from	 WES	 and	 WGS	 were	 integrated	 to	 increase	 the	 sample	 size	 for	 a	 better	
representation	of	the	BBS	population.	Where	previously	there	were	a	similar	number	of	variants	
in	WGS	patients	(with	PDMs)	and	controls,	the	combined	set	increased	the	number	of	variants	in	
favour	 of	 the	 patients	 (ciliopathy	 panel,	 p=0.035).	 Although	 it	 could	 be	 considered	 that	 the	
integration	enhanced	the	experimental	power	to	statistically	distinguish	between	the	patient	and	
control	 sets,	 this	 data	 should	 be	 interpreted	with	 caution.	 The	 significance	 observed	may	 be	
artificial,	which	 has	 skewed	 the	 analysis	 due	 to	 a	 strong	 contrast	 between	WES	 patients	 and	
controls.	This	demonstrates	the	importance	of	analysing	the	two	datasets	separately	first,	for	the	
differences	between	the	WGS	and	WES	datasets	would	have	been	masked.	
	
3.3.4.	Conclusions	of	burden	analysis	
The	key	biological	differences	between	the	WGS	and	WES	patient	cohorts	were	the	underlying	
causal	 variants.	 The	 variants	 in	 10	 diagnosed	 WES	 patients	 consisted	 largely	 of	 frameshift,	
nonsense,	or	splice	site	mutations,	where	9	out	of	11	alleles	were	not	found	in	Gnomad	database	
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of	138,632	individuals.	On	the	other	hand,	the	WGS	cohort	were	selected	for	sequencing	due	to	
the	presence	of	the	common	p.M390R	allele	in	BBS1,	for	which	436	out	of	277,150	control	alleles	
were	reported	in	Gnomad.	With	this	knowledge,	it	was	surmised	that	the	discordance	between	
the	analyses	for	these	2	datasets	is	due	to	the	differences	in	patient	genotype.	This	deduction	has	
led	 to	 two	 conclusions	 to	be	established	 relating	 to	burden	 testing	 in	BBS.	 Firstly,	mutational	
burden	analysis	has	shown	that	there	was	no	enrichment	of	variants	in	patients	when	PDMs	were	
subtracted.	Therefore,	this	result	suggests	that	the	number	of	variants	and	disease	expressivity	
do	not	correlate.	Secondly,	a	significant	increase	in	patients	(with	PDMs)	compared	to	controls	
was	only	seen	for	private	or	very	rare	PDMs.	Thus,	a	significant	increase	was	not	observed	for	
patients	with	p.M390R	allele	as	this	is	a	relatively	common	variant	(Beales	et	al.	2003;	Mykytyn	
et	al.	2002).	These	two	conclusions	are	discussed	below.	
	
3.3.4.1.	Number	of	variants	does	not	correlate	with	disease	expressivity	
The	 results	 indicate	 that	PDMs	are	 the	driving	 factors	 that	 lead	 to	a	significant	enrichment	of	
pathogenic	 variants	 in	 WES	 patients	 vs.	 controls.	 When	 the	 PDMs	 were	 removed	 from	 the	
analysis,	the	mean	number	of	variants	resembled	the	mean	of	the	controls.	This	suggests	that	the	
PDM	alone	is	driving	disease	expressivity.	On	the	other	hand,	it	has	been	shown	that	a	single	locus	
mutation	 does	 not	 sufficiently	 explain	 the	 clinical	 heterogeneity	 observed	 in	 BBS.	 Studies	
including	this	one,	have	provided	evidence	of	modifying	mutations	that,	to	a	degree,	determine	
phenotypic	 expressivity	 (Cardenas-Rodriguez	 et	 al.	 2013;	 Zaghloul	 et	 al.	 2010;	 Badano	 et	 al.	
2006).	The	burden	analysis	suggests	 that	modifying	mutations	do	not	occur	 in	addition	to	the	
background	level	of	variation,	but	are	inherited	by	chance	as	part	of	the	background.	Contrary	to	
burden	analysis	of	other	diseases	(Gonzaga-Jauregui	et	al.	2015;	Ji	et	al.	2016;	Girard	et	al.	2015),	
evidence	suggests	that	BBS	expressivity	is	driven	by	a	small	number	of	rare	deleterious	variants,	
which	induce	a	large	detrimental	effect.	In	conclusion,	it	is	not	the	number	of	variants	that	control	
disease	expressivity,	but	the	functional	effect	that	the	mutations	have	at	the	protein	level.	
	
3.3.4.2.	Private	mutations	drive	statistical	significance	in	burden	testing	
Large	scale	sequencing	projects,	such	as	the	1000	genomes	or	ExAC	projects,	have	determined	
that	there	 is	an	abundance	of	rare	and	private	mutations	at	a	background	level	 in	the	general	
population	(Xue	et	al.	2012;	Lek	et	al.	2016).	The	burden	analysis	in	this	study	has	determined	
that	a	level	of	background	variation	is	present	within	all	investigated	individuals,	which	resides	at	
around	3	background	variants	per	person	for	the	ciliopathy	gene	panel.	
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The	hypothesis	of	mutational	burden	is	that	there	is	an	accumulation	of	variants	in	the	patients	
compared	to	controls,	which	drives	disease	expressivity.	Testing	 in	 this	study	determined	that	
there	was	only	a	statistical	increase	of	variants	in	patients	when	the	PDMs	were	included	in	the	
WES	analysis	and	not	for	WGS	patients.	The	nature	of	the	WES	patient’s	PDMs	is	that	they	are	
private/novel	or	very	rare	variants,	and	predicted	to	be	pathogenic,	either	by	a	missense	mutation	
in	a	highly	conserved	region	or	a	protein	truncating	variant.	The	definition	of	a	private	mutation	
is	a	variant	that	is	discovered	for	the	first	time	in	a	population,	but	is	not	necessarily	de	novo	(Gao	
and	Keinan	2014).	Through	negative	selection,	very	deleterious	private	mutations	are	typically	
removed	 from	 the	 population	 (Gazave	 et	 al.	 2013).	 This	 study	 has	 demonstrated	 that	 these	
private	mutations	have	an	increased	burden	on	BBS	compared	to	the	p.M390R	allele,	which	by	
comparison	is	relatively	common.	
	
Unlike	the	WES,	the	WGS	patients	exhibited	a	similar	mean	number	of	variants	(with	PDMs)	as	
the	control	group.	This	led	to	the	conclusion	that	the	p.M390R	allele	was	mimicking	a	background	
variant,	 as	 possession	 of	 this	 mutation	 did	 not	 differentiate	 the	 patients	 from	 controls.	 This	
explains	why	there	was	a	significant	difference	when	PDMs	were	removed	from	the	analysis.	As	
the	number	of	variants	were	similar	between	the	patients	and	controls,	the	removal	of	p.M390R	
created	an	artificial	bias	that	led	to	a	statistical	difference.	
	
BBS1	p.M390R	manifests	in	up	to	30%	of	all	BBS	patients	(Mykytyn	et	al.	2003).	Individuals	with	
p.M390R	are	arguably	some	of	the	most	complex	BBS	cases.	Family	members	homozygous	for	
p.M390R	 can	 express	 widely	 different	 onsets	 of	 disease,	 severity	 or	 even	 be	 asymptomatic	
(Beales	et	al.	2003;	Shaheen	et	al.	2016;	Azari	et	al.	2006;	Estrada-Cuzcano	et	al.	2012).	The	basis	
of	p.M390R	as	a	background	variant	relies	on	its	fairly	high	population	frequency	in	Europeans	
(MAF=0.3%).	The	commonality	of	the	allele	is	supported	by	the	fact	that	all	homozygous	patients	
in	this	study	are	from	non-related	parents;	typically,	in	rare	disease	cases	homozygous	variants	
arise	from	consanguineous	families	(Shawky	et	al.	2013).	Studies	have	suggested	that	p.M390R	
resides	on	an	ancient	haplotype	that	has	propagated	through	the	European	population	by	genetic	
drift	or	a	selective	advantage	in	the	heterozygous	form	(Beales	et	al.	2003;	Mykytyn	et	al.	2003).	
Perhaps	 it	 could	 act	 as	 a	 beneficial	 allele	 in	 times	 of	 famine,	 as	 it	 has	 been	 suggested	 that	
heterozygous	carriers	are	prone	to	obesity	(Croft	et	al.	1995).	Furthermore,	patients	with	BBS1	
p.M390R	 mutations	 exhibit	 a	 spectrum	 of	 severity,	 where	 with	 modern	 treatments	 some	
individuals	are	able	to	raise	families.	Therefore,	there	is	limited	opportunity	for	the	allele	to	be	
negatively	 selected	 against.	 Moreover,	 as	 p.M390R	 is	 an	 ancient	 mutation,	 it	 may	 have	 less	
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influence	on	disease	susceptibility	(Lupski	et	al.	2011).	This	strengthens	the	case	that	p.M390R	
patients	 have	 modifying	 mutations	 that	 control	 the	 penetrance	 or	 phenotypic	 variability,	 as	
demonstrated	in	the	first	section	of	this	chapter.	
	
3.3.5.	Further	investigations	and	experimental	limitations	
Firstly,	it	must	be	considered	that	a	small	sample	size	may	influence	the	statistical	testing	due	to	
an	 underpowered	 study	 design.	 Therefore,	 further	 investigations	must	 be	 undertaken	with	 a	
larger	 group	 of	 patient	 and	 control	 subjects	 in	 order	 to	 provide	 greater	 evidence	 of	 the	
conclusions	made	in	this	study.	
	
In	order	to	determine	whether	the	hypothesis	that	p.M390R	mimics	a	background	variant	is	true,	
I	would	need	to	validate	my	findings	with	a	larger	cohort	of	patients	carrying	the	p.M390R	allele.	
Another	 line	 of	 investigation	 would	 be	 to	 determine	 whether	 asymptomatic	 patients	 exhibit	
protective	 variants.	 For	 example,	 asymptomatic	 carriers	may	 have	 an	 enrichment	 of	 variants	
compared	to	syndromic	patients,	which	safeguard	against	 the	onset	of	BBS.	This	 investigation	
could	 be	 difficult	 to	 conduct,	 as	 it	 is	 unknown	 how	many	 healthy	 individuals	 are	 harbouring	
homozygous	p.M390R	alleles	and	there	are	no	homozygous	variants	in	control	databases,	such	
as	Gnomad.	Thus,	a	large-scale	sequencing	study	would	be	required.	
	
The	availability	of	a	larger	cohort	would	strengthen	the	study	design	for	burden	testing	as	more	
sophisticated	analyses	could	be	completed	with	greater	statistical	power	(Guo	et	al.	2016;	Ionita-
Laza	et	al.	2011).	Studies	with	large	numbers	have	shown	that	it	is	possible	to	pinpoint	the	variants	
that	are	contributing	the	most	to	the	statistical	significance	of	the	burden	test	(Lin	2016).	This	
can	 help	 identify	 causative	 variants	 in	 undiagnosed	 patients	 or	 discover	 potential	 modifying	
alleles	 (Zhao	 et	 al.	 2016;	 Lee	 et	 al.	 2014).	 Especially	 for	 a	 rare	 disease,	 there	 are	 practical	
limitations	for	undertaking	an	experiment	of	this	magnitude.	In	order	to	complete	these	analyses,	
potentially	hundreds	of	case	subjects	would	be	required	for	a	heterogeneous	disease,	such	as	
BBS	(Guo	et	al.	2016).	
	
For	 this	 analysis,	 a	 relatively	 simplistic	 testing	 method	 was	 utilised.	 Two	 gene	 lists	 were	
investigated	 in	 order	 to	 encompass	 the	 complex	 interacting	 network	 of	 the	 primary	 cilium.	
However,	it	is	possible	that	a	large	gene	set	was	suppressing	some	mutational	load,	which	gave	
the	impression	that	patients	have	no	additional	burden	compared	to	controls.	Some	genes	may	
not	be	amenable	to	mutation	testing	as	they	have	a	high	genic	tolerance	i.e.	the	gene	can	endure	
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multiple	predicted	deleterious	mutations	but	not	exhibit	 an	effect	 (Petrovski	 et	 al.	 2013).	 For	
genes	in	a	mutational	burden	panel,	the	challenge	is	to	decide	between	the	biological	importance	
of	a	gene	and	its	genic	tolerance.	Furthermore,	the	true	deleterious	nature	of	a	variant	cannot	
be	 ascertained	 through	 computational	 means.	 In	 this	 study,	 the	 variants	 were	 filtered	 by	
functional	 prediction	 software,	 retaining	 calls	 predicted	 deleterious	 by	 SIFT	 or	 PolyPhen-2	 or	
CADD>20.	However,	the	use	of	these	algorithms	would	have	overestimated	the	deleterious	calls,	
as	variants	can	be	 retained	 if	 calling	methods	are	discordant.	Either	manual	or	computational	
analysis	would	be	required	to	accurately	isolate	deleterious	calls	by	more	than	one	algorithm.	
	
3.3.6.	Final	conclusion	
Overall,	the	modifier	and	burden	testing	experiments	suggest	that	looking	only	at	the	number	of	
variants	 is	 not	 sufficient	 to	determine	differences	 in	disease	expressivity.	Within	 the	modifier	
section	 of	 this	 study,	 the	 frequency	 of	 identified	 candidate	 modifiers	 did	 not	 correlate	 with	
disease	severity.	For	example,	patient	BBS007	is	one	of	the	more	severe	patients	in	the	cohort	
who	presents	renal	abnormalities.	This	patient	only	had	1	qualifying	variant.	Furthermore,	there	
was	no	evidence	of	mutational	burden	without	the	presence	of	the	primary	driving	mutations	in	
patients	when	compared	to	controls.	 Importantly,	 in	order	to	validate	the	observations	 in	this	
study,	further	testing	in	larger	cohorts,	as	well	as	functional	assays	would	be	required.	
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Chapter	4:	Utilisation	of	proteomic	profiling	techniques	for	
identification	of	biomarkers	in	BBS	
	
4.1	Background	
4.1.1	Biomarkers	
A	biomarker	is	a	measurable	biological	characteristic	that	can	indicate	normal	physiology,	disease	
state	or	pharmacological	response	to	treatment	(Biomarkers	Definitions	Working	Group.	2001).	
A	clinically	informative	biomarker	can	help	clinicians	make	decisions	for	treatments	or	facilitate	
monitoring	of	disease	progression,	either	to	aid	diagnosis	or	in	response	to	therapy.	Biomarkers	
can	take	many	forms,	for	example,	they	may	be	a	molecular	marker	identified	from	a	biosample,	
a	recording	such	as	blood	pressure,	or	an	imaging	scan.	Within	this	chapter,	the	focus	shall	be	
molecular	biomarkers	comprised	of	protein	or	peptides.	Established	proteomic	biomarkers	are	
commonly	identified	in	accessible	biofluids,	including	plasma	(Hathout	et	al.	2015)	and	urine	(Park	
et	al.	2016).	
	
A	common	goal	is	to	identify	protein	biomarkers	that	can	be	routinely	used	in	clinics	(Rifai	et	al.	
2006).	Cancer-specific	markers	have	shown	the	greatest	clinical	utility,	such	as	prostate	specific	
antigen	 (PSA),	which	 is	 indicative	 of	 prostate	 cancer.	 PSA	 is	 specifically	 expressed	 in	 prostate	
tissue,	but	is	elevated	in	serum	upon	tumorigenesis,	where	abundance	correlates	with	disease	
progression	(Stamey	et	al.	1987).	Furthermore,	elevated	levels	of	plasma	CD340	were	found	to	
be	indicative	of	an	aggressive	form	of	HER2/neu	specific	breast	cancer.	This	marker	can	also	be	
used	 to	warrant	 treatment	with	 trastuzumab,	which	 targets	 the	HER2	 receptor	 (Lüftner	et	al.	
2003).	Both	of	these	protein	biomarkers	are	detectable	due	to	increased	secretion	of	proteins	
from	diseased	tissue,	so	that	they	are	abnormally	elevated	 in	biofluids.	Research	studies	 for	a	
range	of	non-cancer	disease	biomarkers	have	also	been	described,	including	Duchenne	muscular	
dystrophy	(Hathout	et	al.	2015),	Parkinson	disease	(Shi	et	al.	2015),	rheumatoid	arthritis	(Park	et	
al.	2016),	diabetes	(Riaz	2015;	Soggiu	et	al.	2012)	and	renal	diseases	(Rao	et	al.	2007;	Kamińska	
et	al.	2016;	Zhao	et	al.	2015).	Identified	markers	required	comprehensive	biomarker	validation	
before	they	could	be	translated	into	the	clinic.	
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4.1.1.1	Biomarkers	for	Bardet-Biedl	Syndrome	
For	 BBS	 patients,	 DNA	 sequencing	 allows	 identification	 of	 the	 genetic	 marker	 of	 disease.	
However,	 patients	 habitually	 express	 phenotypic	 variability	 and	 despite	 studies,	 a	 genotype-
phenotype	correlation	is	largely	unestablished	(Daniels	et	al.	2012;	Deveault	et	al.	2011;	Carmi	et	
al.	1995;	Hjortshøj	et	al.	2010).	The	mutual	finding	of	these	studies	is	that	patients	with	mutations	
in	BBS1	are	generally	less	severe	than	other	genotypes.	However,	heterogeneity	exists	within	the	
BBS1	genotype,	where	patients	with	the	same	mutation	can	manifest	different	clinical	features	
(Beales	et	al.	2003).		
	
In	clinic,	patients	are	monitored	through	measurement	of	markers	unspecific	to	BBS.	Currently,	
circulating	C	reactive	protein	(CRP)	is	the	standard	marker	to	monitor	disease	progression.	CRP	is	
an	 acute	 phase	 protein,	 where	 plasma	 abundance	 correlates	 with	 inflammation	 (Gabay	 and	
Kushner	1999).	This	is	used	as	an	indicator	of	secondary	factors	to	obesity,	as	low-grade	chronic	
inflammation	underpins	cardiovascular	disease	(CVD),	insulin	resistance,	and	subsequent	type	II	
diabetes	(Mirhafez	et	al.	2016).	However,	CRP	is	a	generic	marker	of	disease	and	does	not	provide	
information	of	the	consequence	of	inflammation.	Therefore,	there	is	a	need	for	markers	that	may	
help	predict	the	onset	of	phenotypic	features,	such	as	renal	failure	or	metabolic	syndrome,	to	
allow	early	treatment	or	management	of	disease.	Within	this	study,	11	patients	were	clinically	
obese,	 patients	 BBS003	 and	 BBS007	 were	 morbidly	 obese,	 and	 BBS004	 and	 BBS015	 were	
overweight.	 Therefore,	within	 this	 chapter	obesity	was	 the	primary	phenotypic	 feature	under	
investigation.	
	
Obesity	is	a	highly	prevalent	feature	of	BBS,	where	an	overweight	to	morbidly	obese	BMI	(25-40+	
kg/m2)	was	reported	to	affect	92.5%	of	patients	in	a	survey	containing	105	cases	by	Deveault	et	
al.	 (2010).	Of	 these,	17.6%	were	overweight	 (25-29.9	kg/m2),	64.9%	were	obese	 (BMI	30-39.9	
kg/m2)	and	17.6%	morbidly	obese	(BMI	<40	kg/m2).	As	a	consequence	of	high	adiposity,	patients	
exhibited	detrimental	secondary	features,	such	as	elevated	triglyceride	levels,	high	cholesterol,	
hypertension,	 cardiovascular	 abnormalities,	 diabetes	 mellitus,	 and	 non-alcoholic	 fatty	 liver	
disease	(phenotype	frequency:	50%,	72.6%,	32.4%,	19.1%,	17.1%	and	18%	of	cases,	respectively)	
(Deveault	 et	 al.	 2011).	 These	 features	 overlap	 closely	 with	 metabolic	 syndrome,	 which	 is	
predicted	to	affect	30-40%	of	people	in	the	UK	by	age	65	(Han	and	Lean	2016).	However,	BBS	
subjects	are	thought	to	be	molecularly	distinct	from	obese	subjects;	BBS	patients	are	known	to	
exhibit	 leptin	 resistance,	higher	adiposity	and	greater	abdominal	 visceral	 fat	 in	 comparison	 to	
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BMI-matched	controls	(Feuillan	et	al.	2011).	Taken	together,	these	features	can	attribute	to	high	
morbidity	and	mortality	in	BBS	patients	if	improperly	managed.	
	
4.1.1.2	Strategy	for	biomarker	identification	
The	 goal	 of	 biomarker	 discovery	 is	 to	 uncover	 an	 easily	 measureable	 molecule	 related	 to	 a	
pathophysiological	 pathway	 that	 presents	 prognostic	 or	 diagnostic	 value.	 Regardless	 of	many	
publications	describing	new	biomarkers,	only	a	handful	are	considered	reliable	enough	for	use	in	
clinic	 (Poste	 2011).	 The	path	 from	discovery	 to	 validation	 is	 a	multi-step	 process	 (figure	 4.1),	
where	 success	 lies	 in	 correct	 stratification	 of	 patients,	 independent	 preclinical	 validation,	
verification	 in	 large	 cohorts,	 and	 appropriate	 control	 groups.	 The	 initial	 discovery	 stage	 will	
typically	 utilise	 a	 relatively	 small	 number	 of	 samples	 and	may	 identify	 thousands	 of	 potential	
markers.	 At	 each	 step	 of	 the	 process,	 the	 biomarker	 specificity	 and	 sensitivity	 is	 validated.	
Consequently,	 the	 sample	 size	 increases	 and	 false	 positive	markers	 are	 eliminated,	 leaving	 a	
handful	of	high	confidence	markers	that	may	be	translated	into	the	clinic	(Rifai	et	al.	2006).	
Figure	4.1	–	The	hierarchy	for	biomarker	discovery	(adapted	from	(Rifai	et	al.	2006)).	The	steps	of	biomarker	
identification	are	inversely	proportional	between	the	number	of	samples	and	detectable	analytes.	
	
4.1.2	Proteomic	profiling	of	biofluids	
4.1.2.1	Urine	
Urine	 is	 the	product	of	soluble	components	of	blood	filtered	by	the	glomerulus	of	the	kidney.	
Although	the	main	constituents	of	urine	are	water,	urea,	ions,	and	creatinine,	soluble	molecules	
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such	 as	 proteins,	 hormones	 and	 metabolites	 are	 also	 detectable.	 Urine	 is	 an	 advantageous	
biofluid	for	study	as	it	 is	readily	and	abundantly	available,	and	can	be	obtained	non-invasively.	
Furthermore,	as	it	has	been	filtered	by	the	glomerulus,	it	has	relatively	low	complexity.	Disease	
associated	 protein	 markers	 have	 previously	 been	 identified	 for	 diabetes,	 renal	 abnormalities	
including	autosomal	dominant	polycystic	kidney	disease	(ADPKD),	and	CVD	(Soggiu	et	al.	2012;	
Rao	et	al.	2007;	Gonzales	et	al.	2009;	Dear	et	al.	2013;	Pocsfalvi	et	al.	2015).	
	
Studies	have	been	undertaken	to	determine	the	protein	composition	of	urine.	Some	have	utilised	
the	presence	of	extracellular	vesicles	 (EVs)	 that	are	 found	 in	urine.	These	are	vesicles	 ranging	
from	5-1000	nm	in	diameter	and	categorised	into	subtypes	depending	on	their	size;	exosomes	
(50-100	nm),	microvesicles	(up	to	1000	nm)	and	apoptotic	bodies.	EVs	are	used	to	traffic	secreted	
proteins,	 lipids,	 and	 RNA	 between	 cells,	 and	 thus	 provide	 a	 valuable	 insight	 into	 intercellular	
communication	 (Raposo	 and	 Stoorvogel	 2013).	 Furthermore,	 cells	 can	 release	 EVs	 under	
pathological	 conditions,	 hence	 soluble	 luminal	 proteins	 may	 provide	 additional	 insight	 into	
disease.	A	multistep	fractionation	study	culminating	 in	mass	spectrometry	uncovered	that	 the	
urine	proteome	consists	of	at	least	2362	proteins	(Kentsis	et	al.	2009).	In	a	separate	investigation,	
1132	 proteins	were	 discovered	 to	 exist	 as	 part	 of	 a	 fraction	 containing	 only	 urinal	 exosomes	
(Gonzales	et	al.	2009).	
	
4.1.2.2	Plasma	
Isolated	plasma	is	the	cell-free	component	of	blood.	 Its	physiological	role	 is	to	maintain	blood	
pressure	 and	 act	 as	 a	 transport	 system	 for	 blood	 cells	 and	 soluble	 macromolecules.	 Plasma	
contains	proteins	secreted	by	tissues,	typically	of	sizes	less	than	45kDa,	as	larger	molecules	are	
filtered	 by	 the	 kidney	 (Anderson	 and	Anderson	 2002).	 The	 plasma	 proteome	 is	 comprised	 of	
immunoglobulin,	hormones,	cytokines,	lysosomal	proteins,	and	other	non-hormone	proteins	that	
temporarily	travel	via	the	circulatory	system.	Moreover,	plasma	may	also	carry	proteins	that	have	
leaked	or	were	aberrantly	secreted	from	diseased	cells,	as	well	as	foreign	proteins	from	infectious	
organisms	(Anderson	and	Anderson	2002).	
	
In	theory,	plasma	is	one	of	the	most	promising	biofluids	for	biomarker	discovery,	due	to	the	fact	
that	 proteins	 can	 be	 secreted	 into	 the	 blood	 by	 diseased	 cells	 (Parker	 and	 Borchers	 2014).	
Clinically,	it	is	suitable	since	it	can	be	obtained	through	routine	procedure.	However,	proteomic	
analysis	of	plasma	is	a	formidable	challenge	due	to	the	vast	range	of	protein	concentrations;	the	
circulating	 proteome	 is	 estimated	 to	 cover	 12	 logs	 of	 concentration,	 where	 serum	 albumin	
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equates	 to	 approximately	 55%	of	 plasma	mass	 (Anderson	 and	Anderson	2002).	 Furthermore,	
proteomic	analysis	indicates	that	the	remaining	proportion	of	plasma	may	represent	up	to	3400	
plasma	proteins	(Gold	et	al.	2010).	Analysis	of	a	highly	complex	sample	complicates	the	sample	
preparation,	 where	 long	 depletion	 and	 fractionation	 methods	 are	 required	 for	 sensitive	 and	
reliable	 analysis.	 These	 steps	 can	 increase	 sample	 variability	 and	 decreases	 throughput	
(Alshammari	et	al.	2015).	
	
4.1.3	Proteomic	techniques	for	biomarker	identification	
Biomarkers	may	be	present	at	a	low	abundance	and	thus	a	sensitive	detection	method	is	required	
(Hawkridge	and	Muddiman	2009).	Two	methods	of	detection	have	been	utilised	 in	this	study;	
label-free	mass	spectrometry	and	targeted	proteomic	analysis.	
	
4.1.3.1	Ultra-performance	liquid	chromatography	mass	spectrometry	
For	 mass	 spectrometry	 experiments	 within	 this	 chapter,	 ultra-performance	 liquid	
chromatography	 (UPLC)	 coupled	 to	 a	 quadrupole	 time	 of	 flight	 (Q-ToF)	 mass	 spectrometer	
(Waters	Corporation)	was	utilised	for	an	untargeted,	label-free	strategy.	Quadrupole	and	ToF	are	
both	types	of	mass	analysers,	which	are	coupled	together	to	allow	generation	of	MS/MS	spectra	
by	 tandem	 mass	 spectrometry	 (MS/MS).	 This	 enhances	 resolution	 for	 accurate	 peptide	
identification.	As	mass	spectrometry	separates	analytes	by	mass	and	charge,	samples	are	ionised	
and	desolvated	upon	 injection	 into	 the	 instrument.	Different	 variations	of	 ionisation	methods	
have	been	developed	(Ashcroft	1997),	but	samples	for	this	study	were	ionised	by	electrospray	
ionisation	(ESI)	for	urine	analysis,	or	by	matrix	assisted	 laser	desorption/ionisation	(MALDI)	for	
plasma	analysis.	The	ionisation	chambers	were	coupled	to	the	Synapt	G2	Si	QToF	or	QToF	Premier	
mass	spectrometers,	respectively	(both	by	Waters	Corporation).	
	
In	UPLC	Q-ToF	mass	spectrometry,	the	sample	is	loaded	on	to	the	chromatography	column	where	
it	is	subsequently	eluted	by	pH	and	molecular	weight	over	45	minutes.	The	sample	flows	into	the	
mass	 spectrometer,	 where	 it	 undergoes	 ionisation	 and	 desolvation	 by	 ESI	 or	 MALDI.	 Once	
charged	through	the	loss	of	one	or	more	electron,	the	analyte	enters	the	vacuum	system	of	the	
first	(quadrupole)	mass	analyser,	where	the	sample	is	separated	by	molecular	weight	and	charge.	
The	MS1	 spectra	 is	 produced	by	 the	detector.	 The	 tandem	MS/MS	 spectra	 is	 generated	by	 a	
selection	of	ions	from	MS1	entering	the	collision	chamber.	Here,	ions	are	fragmented	by	collision	
induced	dissociation	(CID),	where	accelerated	neutrally	charged	atoms,	such	as	helium,	collide	
with	analytes	to	induce	bond	breakage.	These	fragments	progress	to	MS2,	where	once	again	ions	
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are	separated	by	mass	and	charge,	and	detected	on	the	second	mass	analyser.	Analytes	may	have	
different	 charges,	 so	 ions	 are	 normalised	 through	 calculating	 the	mass	 to	 charge	 ratio	 (m/z).	
Typically,	MS/MS	allows	fragmentation	of	peptides	to	their	amino	acid	constituents,	and	thus	the	
spectra	can	be	used	to	identify	peptide	sequence	(figure	4.2).	
Figure	4.2	–	Schematic	representation	of	a	quadrupole	time	of	flight	mass	spectrometer.	Sample	enters	the	
instrument	and	 is	 ionised	by	ESI	or	MALDI.	Peptide	 ions	are	separated	by	mass	and	charge	through	the	
quadrupole	 mass	 analyser	 in	MS1	 stage.	 Ions	 are	 selected	 for	MS/MS	 and	 enter	 the	 collision	 cell	 for	
fragmentation.	Fragment	ions	are	separated	by	mass	and	charge	by	the	ToF	mass	analyser	(MS2),	which	
are	detected	by	the	detector.	An	example	MS1	spectrum	of	a	sample	(left)	and	a	peptide	fragmentation	
spectrum	by	MS/MS	(indicated	by	*,	right)	is	also	shown,	demonstrating	how	peptide	identification	can	be	
determined	from	MS/MS	data.	
	
Although	MS/MS	aids	peptide	identification,	not	all	peptides	are	selected	to	enter	the	collision	
cell	 for	 fragmentation	 (Glish	 and	Vachet	 2003).	 As	 only	 peptides	 that	 are	 fragmented	 can	 be	
reliably	 identified,	 this	 leads	 to	 a	misrepresentation	 of	 the	 exact	 peptide	 composition	 of	 the	
sample.	 Recently,	MSE	was	 developed	 by	Waters	 Corporation,	 where	 the	mass	 spectrometer	
rapidly	cycles	between	high	and	low	energy	states	during	CID.	At	the	low	collision	energy	state	
the	ions	are	distinctly	separated,	where	upon	induction	of	high	collision	energy	the	ions	undergo	
maximal	fragmentation.	This	enables	all	detectable	ions	to	be	fragmented	without	selection	bias	
and	thus	increases	reproducibility	(Plumb	et	al.	2006).	MSE	and	high	definition	MSE	(HDMSE)	were	
used	for	plasma	and	urine	analysis,	respectively	within	this	chapter.	
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4.1.3.2	Peptide	identification	and	quantification	from	MS	data	
Progenesis	QI	for	Proteomics	(QIP)	(Non-linear	Dynamics,	Waters	Corporation)	is	computational	
software	for	label-free	liquid	chromatography	(LC)-MS	proteomics	data	analysis.	It	is	designed	to	
allow	comprehensive	processing	of	raw	MS	data	by	normalisation,	peptide	identification,	protein	
quantitation,	 and	 statistical	 analysis	 of	 biological	 groups	within	 a	 single	 programme	 (Qi	 et	 al.	
2012).	The	functionality	of	Progenesis	QIP	is	reviewed	here.	
	
4.1.3.3	Peptide	identification	
A	peptide	sequence	can	be	obtained	from	efficient	peptide	fragmentation	generated	by	tandem	
MS.	For	peptide	identification,	the	ion	fragment	spectra	produced	by	MS/MS	is	searched	against	
the	 human	 proteome	 database.	 The	 quality	 of	 fragmentation	 is	 reflected	 by	 a	 peptide	
identification	 score.	 Peptides	with	 high	 fragmentation	 efficiency,	 and	 thus	 a	 clear	 amino	 acid	
read-out,	 are	 assigned	 a	 high	 peptide	 score	 greater	 than	 8.	 However,	 peptides	 that	 did	 not	
fragment	well	in	the	collision	chamber	receive	a	lower	peptide	score	(figure	4.3).	
	
Figure	4.3	–	The	profile	of	a	well	fragmented	peptide	versus	a	low	efficiency	fragmentation	profile.	From	
the	 top	 peptide,	 an	 accurate	 amino	 acid	 sequence	 can	 be	 achieved	 and	 a	 high	 identification	 score	 is	
granted.	The	peptide	profile	at	the	bottom	demonstrates	poor	fragmentation.	
	
4.1.3.4	Label-free	quantitation	
The	 accurate	 quantification	 of	 proteins	 identified	 in	 a	 sample	 is	 crucial	 for	 statistical	 analysis	
between	 2	 biological	 groups.	 This	 is	 challenging	 since	 mass	 spectrometry	 is	 not	 intrinsically	
quantitative,	due	to	 ionisation	efficiency	differing	between	one	analyte	and	another	(Ho	et	al.	
2003).	As	a	consequence,	the	intensity	peak	of	an	ion	is	not	comparable	within	the	same	run,	but	
can	be	compared	relative	to	the	same	ion	in	a	different	run	(Zhu	et	al.	2010;	Wang	et	al.	2012).	
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This	 method	 is	 called	 relative	 quantification	 and	 is	 used	 within	 this	 chapter	 for	 label-free	
quantitation.	
	
Label-free	methods	are	the	least	cumbersome	approach	to	protein	quantification,	which	makes	
them	 beneficial	 for	 large-scale	 discovery	 experiments	 (Griffin	 et	 al.	 2010).	 Each	 sample	 is	
prepared	and	analysed	separately	without	the	need	for	expensive	labelling	compounds.	However,	
to	reduce	the	variability	of	this	technique,	there	must	be	control	over	sample	preparation	and	
instrument	stability.	As	this	can	be	difficult	to	control,	it	is	not	uncommon	for	the	same	sample	
to	result	in	differences	in	peak	intensities	(Nilsson	et	al.	2010).	Therefore,	spectra	normalisation	
and	peak	alignment	is	crucial	to	ensure	reliable	results.	
	
A	 sophisticated	 approach	 for	 peptide	 quantitation	 is	 employed	 by	 Progenesis	 QIP,	 called	 ion	
abundance	quantification.	This	technique	averages	and	normalises	unique	peptide	ion	peaks	and	
calculates	 the	abundance	 from	 the	volume	of	each	peak.	The	 first	 step	 requires	alignment	of	
spectra	 to	 remove	 variability	 of	 retention	 time	 acquired	 for	 the	 same	 ion	over	 different	 runs	
(figure	 4.4).	 Consequently,	 high	 reproducibility	 of	 the	 instrument	 is	 essential	 for	 accurate	
quantification.	 The	 abundances	 are	 calculated	 from	 these	 aligned	 runs,	 only	 for	 ions	 that	 are	
unique	and	shared	between	runs.	Therefore,	if	the	ion	is	only	found	once,	it	cannot	be	quantified.	
This	 approach	 enhances	 the	 rate	 of	 protein	 quantification	 by	 up	 to	 40%	 (Schulze	 and	Usadel	
2010).	The	main	disadvantage	is	the	requirement	for	expensive	computational	software,	and	that	
missing	ions	cannot	be	quantified.	
	
4.1.3.5	Challenges	of	Mass	spectrometry	
Protein	mixtures	from	biological	samples	can	be	highly	complex;	not	only	in	number,	which	can	
range	from	2000	proteomics	from	urine	to	over	10,000	proteins	for	cellular	mixtures	(Kentsis	et	
al.	2009;	Geiger	et	al.	2012),	but	also	due	to	posttranslational	modifications,	complexing	proteins,	
isoforms,	or	variants	(Larance	and	Lamond	2015).	Therefore,	experimental	conditions	must	be	
well	controlled	to	ensure	that	experimental	variability	 is	not	mistaken	for	biological	variability.	
Complex	 mixtures	 are	 prone	 to	 undersampling,	 which	 can	 be	 prevented	 through	 extensive	
fractionation	prior	to	profiling.	
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Figure	4.4	–	Example	of	an	ion	intensity	plot	from	Progenesis	QIP,	where	each	spot	is	a	peptide	ion	plotted	
by	m/z	 vs.	 retention	 time.	 Colours	 represent	 the	 level	 of	 alignment	with	 a	 chosen	 reference	 run:	well	
aligned	(green),	ok	(orange),	may	need	reviewing	(red).	This	example	has	an	alignment	score	of	94.7%.	Ion	
intensity	peaks	(bottom)	shows	the	intensity	of	peptide	ions	for	the	reference	run	(pink)	compared	to	the	
target	run	(green).	The	relative	abundance	is	calculated	from	the	area	of	each	peak.	
	
Undersampling	refers	to	when	the	analysis	is	not	representative	of	the	entire	sample	(Nilsson	et	
al.	2010).	For	example,	a	mass	spectrometer	will	profile	an	injected	portion	(~0.5	µl)	of	a	peptide	
mixture,	which	will	originate	from	a	larger	stock	of	resuspended	peptides.	The	analysis	will	only	
be	able	to	detect	analytes	present	within	the	0.5	µl	of	peptides,	where	low	abundant	peptides	
may	not	be	sampled.	This	is	why	some	mass	spectrometry	experiments	have	low	reproducibility	
rates	(Griffin	et	al.	2010).	Undersampling	can	be	combatted	through	multiple	replicates	of	the	
same	 sample	 until	 new	 peptides	 are	 no	 longer	 discovered,	 or	 through	 reducing	 sample	
complexity	by	fractionation	techniques	(Jafari	et	al.	2012).	
	
During	mass	spectrometry,	a	peptide	mixture	is	separated	by	mass	and	charge.	However,	if	the	
instrument	is	overwhelmed	by	analytes	with	very	similar	mass	and	charge,	the	resulting	spectrum	
will	contain	a	peak	for	the	most	abundant	analyte,	masking	the	low	abundance	ones	(Hawkridge	
and	 Muddiman	 2009).	 This	 is	 why	 a	 second	 form	 of	 separation	 is	 required	 prior	 to	 mass	
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spectrometry	 to	 reduce	 the	 sample	 complexity.	 As	 utilised	 in	 this	 project,	 ultra-performance	
liquid	 chromatography	 (UPLC)	 columns	 are	 commonly	 coupled	 to	mass	 spectrometry	 for	 this	
purpose	(Dunn	et	al.	2011).	The	column	contains	a	stationary	phase	(such	as	C18	alkyl	groups)	
and	the	sample	is	eluted	through	the	column	using	different	concentrations	of	a	polar	solvent	
(such	as	acetonitrile)	under	high	pressure.	The	mixture	is	separated	based	on	the	chemical	affinity	
with	the	stationary	phase	and	the	solvent	mobile	phase	(Ardrey	2003).	Different	analytes	are	then	
profiled	by	the	mass	spectrometer	with	respect	to	their	retention	time	(the	time	it	takes	for	the	
analyte	to	be	eluted	from	the	column).		
	
Fractionation	takes	advantage	of	the	different	chemical	properties	of	proteins,	and	can	separate	
by	size,	affinity,	charge	or	pH.	Samples	can	be	fractionated	by	chromatography	‘on-line’	(coupled	
to	the	mass	spectrometer),	where	different	solvents	are	used	to	separate	analytes	by	pH	(Dunn	
et	al.	2011).	Off-line	uncoupled	fractionation	may	utilise	other	chromatography	techniques	(such	
as	ion	exchange	or	size	exclusion	chromatography)	or	gel	electrophoresis	(Sajic	et	al.	2015).	In	
this	project,	proteins	were	fractionated	by	SDS-PAGE,	which	separates	proteins	by	their	molecular	
weight	(Jafari	et	al.	2012).	Fractionation	can	occur	either	at	the	protein	level	or	as	peptides,	where	
the	outcomes	will	differ	depending	on	which	method	is	chosen.	
	
The	quality	and	sensitivity	of	the	mass	spectrometer	can	be	monitored	through	the	course	of	the	
run	to	flag	any	potential	anomalies.	A	quality	control	(QC)	sample	can	be	prepared	from	a	pool	of	
all	samples	within	the	experiment.	This	QC	is	then	analysed	multiple	times	and	at	regular	intervals	
throughout	the	course	of	the	run.	Upon	analysis,	all	samples	and	QCs	can	be	plotted	in	a	principle	
component	 space	 to	 observe	 the	 distribution	 of	 data	 points	 (figure	 4.5).	 As	 the	QC	 runs	 are	
technical	 replicates,	 these	 should	 cluster	 on	 the	 principle	 component	 analysis	 (PCA)	 plot.	
Furthermore,	as	a	pool	of	all	samples,	the	QC	cluster	should	lie	in	the	centre	of	the	plot,	with	all	
other	 samples	distributed	around	 it	 (figure	4.5B).	On	 the	other	hand,	 if	 the	QC	 replicates	are	
scattered	on	the	PCA,	this	suggests	that	the	mass	spectrometer	had	reduced	sensitivity	and	the	
data	is	not	reliable	for	further	analysis	(figure	4.5A).	
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Figure	4.5	–	Principle	component	analysis	(PCA)	of	metabolomic	analysis	by	mass	spectrometry	taken	from	
Theodoridis	et	al.	2008	(with	permission).	Black	triangles	refer	to	samples,	whereas	red	triangles	are	QC	
samples	run	at	regular	intervals	throughout	the	course	of	the	experiment.	A)	QCs	are	scattered	indicating	
poor	instrument	performance	and	high	variability.	B)	Tight	clustering	of	QCs	demonstrates	sensitive	system	
performance.	The	QC	cluster	is	in	the	centre	of	the	plot	as	it	is	a	representative	pool	of	all	samples.	
	
4.1.3.6	Alternative	proteomic	technique:	SOMAlogic	
Inspired	by	the	specificity	and	sensitivity	of	ELISAs,	SOMAlogic	Inc.	identified	that	for	a	complex	
proteomic	 study,	 large-scale	multiplexing	 of	 assays	 is	 required.	 However,	 ELISAs	 have	 limited	
multiplexing	 ability	 due	 to	 inherent	 cross-reactivity	 of	 antibodies.	 The	 answer	 was	 found	 in	
oligonucleotide	comprised	three-dimensional	molecules,	first	described	over	20	years	ago,	called	
aptamers	 (Gold	 1995).	 The	 nucleic	 acid	 equivalent	 of	 monoclonal	 antibodies,	 aptamers	
specifically	recognise	a	protein	epitope,	which	 is	possible	due	to	nucleic	acids	 innate	ability	to	
fold	into	3D	structures.		
	
Aptamers	 are	 derived	 through	 an	 in	 vitro	 process	 called	 systemic	 evolution	 of	 ligands	 by	
exponential	enrichment	 (SELEX)	and	have	historically	been	used	 for	 therapeutics	and	catalysis	
(Brody	and	Gold	2000).	Aptamers	are	comprised	of	RNA	secondary	structures	and	single	stranded	
DNA,	which	can	be	individually	engineered	to	specifically	complex	with	respective	protein	targets.	
SOMAlogic	have	modified	 the	aptamer	selection	process	by	generating	slow	off-rate	modified	
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aptamers	 (referred	to	as	SOMAmers),	which	have	a	greater	affinity	 for	 the	target	 than	typical	
aptamers	 (Lollo	 et	 al.	 2014).	 Specificity	 to	 the	 target	 can	be	 altered	 through	modifications	of	
deoxyuridine	bases,	 controlled	by	additions	of	benzyl,	napthyl,	 tryptophan	or	 isobutyl	groups,	
which	mimic	 amino	 acid	 side	 chains	 (Gold	 et	 al.	 2010).	 As	 a	 result	 of	 years	 of	 optimisation,	
SOMAlogic	have	been	able	to	develop	aptamers	that	strongly	associate	with	1310	proteins	and	
due	to	no	cross-reactivity,	these	can	be	multiplexed	to	detect	and	quantify	these	proteins	in	one	
high-throughput	assay,	namely	SOMAscan.	
	
An	advantage	of	 SOMAscan	 is	 that	 it	 utilises	 robust	nucleic	 acid	hybridisation	properties,	 and	
employs	the	same	chemistry	as	a	microarray	(Gold	et	al.	2010).	The	oligonucleotide	SOMAmer	is	
able	 to	 distinctly	 fold	 into	 a	 unique	 structure,	 which	 specifically	 binds	 to	 the	 target	 protein.	
Through	 simple	 binding	 and	 washing	 steps,	 the	 target	 is	 cleaved	 and	 the	 remaining	 unique	
SOMAmer	is	hybridised	to	a	complementary	probe	library.	The	output	is	a	fluorescent	signal	that	
quantitatively	reflects	the	protein	constituents	of	the	original	sample	(Kraemer	et	al.	2011).	
	
The	SOMAscan	array	is	highly	reproducible,	sensitive,	low	cost	and	is	high	throughput	with	a	fast	
turnaround.	Unlike	mass	spectrometry,	the	SOMAscan	is	not	limited	by	protein	abundance;	and	
can	detect	over	8	logs	of	concentration	in	one	sample	(Lollo	et	al.	2014).	This	results	in	a	simpler	
sample	preparation	protocol,	as	fractionation	steps	are	not	required.		
	
SOMAscan	 is	 limited	 only	 by	 its	 optimisation	 and	 library	 of	 SOMAmer	 probes.	 At	 the	 time	 of	
writing,	the	SOMAscan	was	optimised	for	detection	of	plasma	proteins,	but	the	scope	is	vast	for	
optimisation	of	SOMAmers	distinct	to	many	different	tissue-specific	proteins	(Gold	et	al.	2010).	
The	 SOMAmers	 are	 not	 designed	 to	 discriminate	 between	 posttranslational	 modifications	
(PTMs).	PTMs	could	either	block	the	epitope	or	induce	a	conformational	change	in	the	protein,	
which	would	compromise	SOMAmer	binding	and	prevent	protein	detection	(Hathout	et	al.	2015).	
Similarly,	 proteins	 cannot	 be	 detected	 if	 the	 epitope	 is	 blocked	by	 a	 complexing	 protein	 or	 a	
cofactor.	Small	linear	polypeptides,	typically	with	a	molecular	weight	less	than	5kDa,	may	not	be	
detected	by	SOMAmers,	since	these	oligonucleotides	are	designed	to	recognise	globular	proteins.	
Finally,	difficulty	may	be	found	when	distinguishing	between	close	homologues,	including	those	
generated	by	alternative	splicing,	if	the	epitope	is	identical	between	proteins	(Lollo	et	al.	2014).	
These	weaknesses	observed	by	SOMAscan	are	strengths	for	mass	spectrometry.	
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4.1.4	Aims	of	investigation	
Biomarkers	can	be	beneficial	for	both	patient	and	clinician	to	encourage	changes	in	lifestyle	or	to	
aid	 administration	 of	 treatment.	 Currently,	 there	 are	 no	 specific	 molecular	 biomarkers	 to	
measure	disease	progression	or	detect	secondary	features	of	BBS.	The	current	biomarker	used	in	
clinic	is	CRP,	a	generic	indictor	of	inflammation.	The	aim	of	this	chapter	was	to	profile	plasma	and	
urine	 biofluids	 from	 BBS	 patients	 to	 uncover	 putative	markers	 specific	 to	 BBS,	 or	 specific	 to	
phenotypic	features	of	BBS.	This	was	achieved	through	use	of	proteomic	untargeted	and	targeted	
techniques.	Furthermore,	statistical	analysis	was	utilised	to	determine	if	differentially	expressed	
proteins	were	present	between	15	BBS	patients	and	6	healthy	non-obese	controls.	Although	this	
was	a	small	sample	size,	this	is	suitable	for	preliminary	investigations	to	identify	potential	markers	
(Rifai	et	al.	2006).	Importantly,	significantly	differentially	expressed	candidate	markers	must	be	
validated	in	future	investigations.	
	
BBS	 patients	 are	 phenotypically	 heterogeneous,	 of	 which	 the	 patients	 in	 this	 cohort	 are	 no	
exception.	For	statistical	comparison,	ideally	the	biological	groups	need	to	be	as	homogeneous	
as	 possible.	 There	 are	 two	 phenotypes	 that	 are	most	 prevalent	 in	 this	 study’s	 cohort:	 retinal	
dystrophy	(affecting	15/15	patients)	and	obesity	(affecting	13/15	patients).	In	addition	to	obesity,	
some	 patients	 exhibited	 secondary	 features,	 such	 as	 type	 II	 diabetes	 in	 patient	 BBS002	 and	
hypercholesterolemia	in	BBS006,	as	well	as	factors	associated	with	CVD,	including	hypertension	
in	 BBS002,	 BBS003	 and	 BBS005,	 angina	 pectoris	 in	 BBS005,	 and	 aortic	 valve	 abnormalities	 in	
BBS013	(full	patient	details	are	available	in	table	2.9).	Therefore,	comparisons	between	patient	
and	control	were	conducted	with	a	view	to	 identify	markers	related	to	obesity	and	secondary	
phenotypes	associated	with	obesity.	
	
Additionally,	 the	 aim	 was	 to	 evaluate	 different	 proteomic	 techniques	 for	 use	 within	 future	
multiOmic	 studies.	 Protein	 from	urine	was	extracted	by	ultracentrifugation	before	analysis	by	
UPLC-QToF	using	the	Synapt	G2	Si	with	HDMSE	capability.	Method	development	was	completed	
with	plasma	 for	analysis	by	SDS-PAGE	and	UPLC-MALDI-QToF	with	MSE	capability.	Plasma	was	
further	profiled	through	a	novel	targeted	proteomic	technology,	SOMAscan.	726,	222	and	1243	
proteins	 were	 quantified	 from	 each	 technique,	 respectively.	 Statistical	 analysis	 identified	
differentially	expressed	proteins	between	patient	and	control	groups,	where	PEDF,	ORM1,	leptin	
and	ApoM	may	be	of	 relevance	 to	metabolic	 features	of	BBS.	 Finally,	within	 this	 chapter	 it	 is	
discussed	how	putative	markers	may	be	validated	using	larger	BBS	and	control	cohorts.	
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4.2	Results	
	
4.2.1	Label-free	UPLC-MS/MS	of	urine	
4.2.1.1	Quantitation	of	protein	from	urine	
To	 ascertain	 the	 same	 amount	 of	 protein	 from	 each	 sample	 for	 mass	 spectrometry,	 protein	
quantitation	by	bicinchoninic	acid	(BCA)	assay	was	completed.	Protein	absorbance	was	measured	
at	595nm	in	duplicate	alongside	bovine	serum	albumin	(BSA)	standards,	which	ranged	from	125	
to	2000ng/µl.	Using	the	equation	of	the	standard	curve	(figure	4.6),	the	average	absorbance	of	
each	sample	was	used	to	calculate	respective	sample	concentration	and	the	volume	required	for	
50µg	of	protein	for	further	processing	(table	4.1).	
	
Figure	4.6	–	Standard	curve	generated	for	quantitation	of	protein	extracted	from	urine.	
	
Progenesis	 QIP	 software	 version	 2	 (Nonlinear	 Dynamics,	Waters	 Corporation)	 was	 utilised	 to	
analyse	the	HPLC-MS/MS	experiment	featuring	25	samples.	These	samples	consisted	of	15	BBS	
patients,	6	controls	and	4	quality	control	(QC)	technical	replicates.	The	QC	sample	was	comprised	
of	 a	 pool	 of	 all	 samples	 and	was	 used	 to	 determine	 if	 instrument	 sensitivity	was	maintained	
throughout	the	course	of	the	run.	The	first	stage	of	the	analysis	pipeline	required	alignment	of	
MS1	 ion	 intensity	 maps	 to	 a	 reference	 run.	 The	 aim	 of	 this	 alignment	 was	 to	 minimise	 any	
variation	between	retention	times	for	the	same	ion	caused	by	instrument	fluctuations.	QC1	was	
chosen	by	the	software	as	the	best	reference	run,	as	this	contained	the	majority	of	peptide	ions	
represented	across	the	experiment.	Alignment	scores	were	generated	by	Progenesis	QIP,	where	
scores	 greater	 than	 80%	 are	 considered	 suitable	 for	 further	 analysis.	 High	 alignment	 scores	
ranging	from	85.3%	to	95.6%	(mean	score=	93.1%,	n=	25)	were	produced,	indicating	good	quality	
alignment.	
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Runs	were	next	aggregated	and	normalised	into	a	single	map	of	peptide	ion	peaks.	Normalisation	
aimed	to	reduce	differences	caused	by	sample	injection	and	ionisation	variability.	Finally,	before	
identification	of	peptides,	filters	were	applied	to	remove	unreliable	features	from	the	normalised	
runs.	Ions	with	a	retention	time	less	than	10	minutes	and	greater	than	45	minutes	were	removed	
from	 further	 analysis,	 as	 these	 ions	were	 indicative	 of	 a	 salt	 front	 or	 other	 contaminants.	 In	
general,	peptides	are	expected	to	have	a	charge	state	between	1	and	4,	therefore	 ions	with	a	
charge	greater	than	10	were	excluded.	High	charge	states	suggest	the	presence	of	large	peptides,	
which	are	not	suitable	for	mass	spectrometry	and	thus	would	negatively	impact	the	analysis.	
	
Sample	ID	
Average	
absorbance	
Concentration	
(µg/µl)	
Volume	for	50µg	
(µl)	
BBS001	 0.25	 2.8	 9.0	
BBS002	 0.26	 3.0	 8.5	
BBS003	 0.22	 2.1	 11.9	
BBS004	 0.18	 1.3	 19.2	
BBS005	 0.14	 0.6	 41.9	
BBS006	 0.28	 3.3	 7.5	
BBS007	 0.27	 3.1	 8.0	
BBS008	 0.23	 2.3	 10.8	
BBS009	 0.22	 2.1	 11.6	
BBS010	 0.18	 1.4	 18.0	
BBS011	 0.24	 2.6	 9.6	
BBS012	 0.21	 1.9	 13.0	
BBS013	 0.14	 0.5	 48.8	
BBS014	 0.15	 0.7	 35.2	
BBS015	 0.17	 1.2	 21.6	
CTRL019	 0.18	 1.5	 17.1	
CTRL021	 0.19	 1.5	 16.1	
CTRL023	 0.20	 1.9	 13.3	
CTRL024	 0.17	 1.2	 20.3	
CTRL025	 0.17	 1.3	 19.8	
CTRL026	 0.24	 2.5	 10.0	
Table	 4.1	 –	 Values	 from	 sample	 quantitation	 after	 BCA	 assay	 of	 proteins	 extracted	 from	 urine	 and	
corresponding	volume	of	protein	required	for	downstream	processing	for	mass	spectrometry.	
	
4.2.1.2	Identification	of	peptides	and	inferring	proteins	
For	peptide	 identification,	an	MSE	search	was	conducted	by	Progenesis	QIP	software	against	a	
fasta	file	containing	20,186	reference	human	proteome	sequences.	In	total,	8642	peptide	ions	
were	 identified	 across	 all	 samples.	 Peptides	were	 refined	 further	 by	 removing	 corresponding	
peptides	 with	 a	 sequence	 length	 less	 than	 5,	 leaving	 7901	 peptide	 identifications	 remaining.	
These	peptides	were	then	used	to	infer	protein	identifications	from	MS/MS	spectra	and	quantify	
proteins	by	relative	quantitation.	Overall,	815	proteins	were	identified.	However,	only	proteins	
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with	at	least	one	unique	peptide	could	be	confidently	called	and	quantified,	thus	86	proteins	were	
removed.	In	these	cases,	identified	peptides	aligned	with	other	homologous	proteins,	so	the	exact	
specification	of	the	protein	could	not	be	certain.	The	remaining	726	quantifiable	proteins	were	
identified	through	detection	of	5090	peptides,	of	which	448	proteins	contained	3	or	more	unique	
peptides,	and	152	were	identifiable	by	a	single	unique	peptide	(supplemental	data,	table	S.29).	
	
A	confidence	score	was	generated	for	each	protein,	corresponding	to	the	cumulative	sum	of	each	
peptide	score	that	made	up	the	protein.	The	peptide	score	refers	to	the	fragmentation	efficiency	
and	confidence	of	peptide	identification.	Generally,	proteins	with	a	greater	number	of	peptides	
had	a	larger	confidence	score,	regardless	of	the	number	of	unique	peptides.	In	this	experiment,	
protein	scores	ranged	from	3.35	to	962.62.	212	proteins	were	 flagged	as	having	a	confidence	
score	less	than	20.	This	score	is	recommended	as	a	helpful	guide,	but	should	not	be	depended	
on.	 The	 confidence	 is	 negatively	 affected	by	 spectra	 quality,	where	 low	 coverage	 can	 lead	 to	
spurious	calls.	Additionally,	the	score	is	influenced	by	protein	length	and	abundance.	
	
4.2.1.3	Quantification	metrics	
Progenesis	 QIP	 software	 provided	 quality	 control	 metrics	 to	 monitor	 the	 presence	 of	
experimental	 anomalies.	 The	 graphs	 shown	 in	 figure	 4.7	were	 generated	 from	each	 sample’s	
MS/MS	spectra	and	 illustrate	 that	 individually	 there	was	a	 large	 range	 in	peptide	and	protein	
abundances	over	the	experiment.	Samples	BBS004,	BBS005,	BBS008,	BBS015	and	CTRL026	had	a	
consistently	low	count	for	all	metrics.	This	is	indicative	of	poor	identification	data	from	the	MS/MS	
spectra.	 The	 samples	 at	 the	 upper	 limit	 of	 the	 box	 plots,	 namely	 BBS006,	 BBS007,	 BBS010,	
BBS011,	BBS012,	BBS014	and	CTRL021,	had	good	quality	identification	data.	
	
		
Figure	4.7	–	Urine	proteomics	QC	metrics	read-outs	(figure	legend	on	next	page).
Chapter	4:	Biomarker	discovery	
	
171	
Figure	4.7	(on	previous	page)	–	QC	metric	read-outs	from	Progenesis	QIP	for	urine	label-free	HPLC-MS/MS	
analysis,	 inclusive	 of	 quantifiable	 proteins	 without	 duplications.	 A)	 Box	 plots	 for	 aggregated	 data	 sets	
(excluding	QCs),	displaying	the	spread	of	peptide	ions,	peptide	identifications	and	subsequent	quantifiable	
proteins.	B)	Number	of	proteins	identified	across	patient	and	control	samples	(patient	mean	=	204	(70,228);	
control	 mean	 =	 256	 (148,	 363).	 C)	 Number	 of	 peptides	 identified	 across	 patient	 and	 control	 samples	
(patient	mean	=	1230	(333,	2126);	control	mean	=	1459	(752,	2165).	D)	Mean	number	of	peptides	identified	
in	a	protein	for	patient	and	control	samples	(patient	mean	=	5.1	(3.8,	6.7);	control	mean	=	5.5	(4.1,	6.8).	E)	
Percentage	of	peptide	ions	for	each	patient	and	control	out	of	the	total	number	of	identified	peptide	ions	
in	the	experiment	(patient	mean	=	3.5	(0.9,	6.1);	control	mean	=	4.1	(2.0,	6.2).	Outlying	samples	for	high	or	
low	 counts	 have	 been	 labelled.	 F)	 Venn	 diagrams	 illustrating	 the	 number	 of	 overlapping	 protein	
identifications	between	each	biological	group	and	QCs	
	
These	 graphs	 help	 illustrate	 the	 purpose	 of	 MS1	 spectra	 alignment	 and	 normalisation	 by	
Progenesis	QIP	for	quantitation.	If	the	MS/MS	spectra	is	poor	quality,	or	even	was	not	generated	
at	all,	it	does	not	prevent	Progenesis	QIP	from	accurately	quantifying	the	ions	from	MS1	data.	The	
identity	of	each	ion	can	be	found	from	the	other	samples	run	in	the	same	experiment.	Therefore,	
although	it	is	important	to	identify	anomalies	in	this	experiment,	these	QC	metric	results	would	
not	have	affected	the	final	quantitation	results.	The	Venn	diagrams	(figure	4.7F)	display	the	total	
count	 of	 proteins	 acquired	 through	 unique	 peptide	 identifications	 from	MS/MS	 spectra.	 This	
provides	a	visual	overview	of	which	biological	groups	 the	726	quantifiable	proteins	originated	
from.	The	quantitation	with	MS1	spectra	 then	aimed	 to	 identify	and	quantify	all	726	proteins	
across	all	samples.	426	proteins	were	found	in	both	patient	and	control	groups,	70	of	which	were	
not	also	shared	by	the	QCs.	This	may	be	due	to	undersampling	or	the	increased	complexity	of	the	
QCs	compared	to	individual	samples.	On	the	other	hand,	28	proteins	were	found	in	the	QCs	and	
not	in	either	biological	group	
	
Proteins	 were	 quantified	 from	 the	 normalised	 MS1	 ion	 spectra	 using	 relative	 label-free	 ion	
abundance	 quantitation.	 The	 abundance	 of	 726	 proteins	was	 detected	 over	 5	magnitudes	 of	
concentration	(figure	4.8).	To	display	the	distribution	of	abundance,	the	mean	abundance	for	all	
726	 quantifiable	 proteins	 was	 calculated	 and	 binned	 into	 groups.	 A	 normal	 distribution	 was	
observed	when	plotted	on	a	log10	scale.	Only	12	proteins	were	detected	at	a	relative	abundance	
less	than	100.	This	may	illustrate	that	low	abundance	proteins	were	not	identifiable,	either	due	
to	instrument	sensitivity,	sample	complexity,	or	methodological	error.	
Chapter	4:	Biomarker	discovery	
	
172	
Figure	4.8	–	Histogram	of	mean	relative	abundances	for	quantified	proteins	from	urine	HPLC-MS/MS.	
	
4.2.1.4	Statistical	testing	and	identification	of	differentially	expressed	proteins	
Quantified	data	was	plotted	 in	a	principle	component	space	 to	 identify	 sample	clustering	and	
outliers.	As	technical	replicates	consisting	of	a	sample	pool,	the	QCs	helped	to	determine	whether	
instrument	sensitivity	was	maintained	throughout	the	course	of	the	experiment.	Here,	all	4	QCs	
clustered	together	(figure	4.9A).	Because	they	grouped	in	the	centre	of	the	plot,	this	indicated	
that	they	were	a	good	representation	of	all	samples.	The	QCs	were	then	removed	to	focus	on	the	
relationship	between	patient	and	control	data	points.	Upon	first	observation,	patient	BBS004	was	
noted	to	outlie	from	the	main	plot.	At	this	stage,	it	could	not	be	established	the	reason	for	this	
outlier,	as	it	may	be	due	to	a	technical	artefact	or	a	biologically	interesting	finding.	BBS004	was	
therefore	removed	from	the	PCA	to	observe	the	difference	(figure	4.9B).	As	a	result,	there	was	
an	increase	in	spread	of	the	patient	data	points,	but	no	inherent	structure	observed	in	the	PCA.	
	
Using	ANOVA	statistical	testing,	p-values	were	generated	to	investigate	differentially	expressed	
(DE)	proteins	between	patient	and	control	groups.	P-values	were	adjusted	to	account	for	multiple	
testing	and	a	false	discovery	rate	(FDR)	for	each	protein	was	generated.	Furthermore,	 relative	
quantities	were	 transformed	 to	 log2	 format	 (log2RQ)	 and	 95%	 confidence	 intervals	 (CI)	were	
calculated	to	observe	the	spread	of	the	data	between	patient	and	controls.	
	
When	patient	BBS004	was	included,	a	single	protein	was	significant	after	multiple	testing,	namely	
alpha-1	 acid	 glycoprotein	 1	 (BBS	 mean	 log2RQ	 =	 16.46,	 95%	 CI=15.95,	 16.98;	 control	 mean	
log2RQ	=	14.15,	95%	CI	=	13.31,	15.00;	log2	fold	change	(FC)	=	2.31;	FDR	=	0.039).	The	top	10	
differentially	expressed	proteins,	ranked	by	FDR,	are	displayed	in	table	4.2.	
		
Figure	4.9	–	Principle	component	analysis	(PCA)	plots	generated	from	protein	quantitation	data	obtained	from	urine	HPLC-MS/MS	analysis,	where	patient	and	control	samples	are	blue	
and	purple,	respectively.	The	grey	cloud	represents	where	each	protein	(identifiable	by	UniProt	ID)	lies	on	the	PCA.	The	red	highlighted	proteins	are	the	most	significant	within	each	
plot.	A)	PCA	with	all	samples,	 including	QCs	(orange).	B)	PCA	without	BBS004	and	QCs	removed	from	analysis.	C)	PCA	of	significant	proteins	with	FDR<0.1,	where	red	highlighted	
proteins	have	FDR<0.05.
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Gene	name	 Protein	name	
Peptide	
count	
Unique	
peptides	
Score	 BBS	mean	 Control	mean	 FDR	 Log2FC	
ORM1	 Alpha-1	acid	
glycoprotein	1	
42	 24	 204.4	 16.46	
(15.95,	16.98)	
14.15	
(13.31,	15.00)	
0.039	 2.31	
ORM2	 Alpha-1	acid	glycoprotein	2	 33	 19	 211.1	
15.13	
(14.57,	15.69)	
13.01	
(12.34,	13.68)	 0.061	 2.12	
ARHGAP35	
Rho	GTPase-activating	
protein	35	 4	 3	 23.4	
11.96	
(11.47,	12.46)	
10.53	
(10.30,	10.77)	 0.262	 1.43	
LYVE1	
Lymphatic	vessel	
endothelial	hyaluronic	
acid	receptor	1	
19	 17	 121.7	 12.70	
(12.20,	13.19)	
11.20	
(10.48,	11.92)	
0.262	 1.50	
SERPINC1	 Antithrombin-III	 21	 16	 137.9	 11.44	
(10.98,	11.91)	
10.11	
(9.74,	10.48)	
0.262	 1.33	
DDX55	 ATP-dependent	RNA	
helicase	DDX55	
4	 1	 18.6	 13.57	
(12.98,	14.16)	
12.03	
(11.78,	12.28)	
0.262	 1.54	
	 Ig	heavy	chain	V-III	region	GAL	 6	 4	 56.0	
12.85	
(12.52,	13.18)	
13.88	
(13.44,	14.31)	 0.262	 -1.03	
DNAI1	
Dynein	intermediate	
chain	2,	axonemal	 2	 1	 9.5	
12.43	
(11.85,	13.01)	
10.89	
(10.27,	11.52)	 0.262	 1.53	
GP2	
Pancreatic	secretory	
granule	membrane	
major	glycoprotein	
GP2	
1	 1	 3.4	 6.26	
(5.52,	6.99)	
3.09	
(0.58,	5.60)	
0.262	 2.97	
GPRC5B	
G-protein	couple	
receptor	family	C	
group	5	member	B	
6	 1	 38.0	
8.68	
(7.98,	9.38)	
10.49	
(10.00,	10.97)	 0.262	 -1.80	
Table	4.2	–	Top	10	DE	proteins	ranked	by	FDR	between	patients	and	controls	(including	BBS004)	from	urine.	
Sample	mean	 for	BBS	and	control	 are	presented,	where	data	 is	expressed	as	 log2(relative	quantitation	
(RQ))	for	sample	mean	(95%	confidence	interval	(CI)).	Peptide	count	refers	to	the	total	number	of	peptides	
identified	for	each	protein,	whereas	unique	peptides	indicates	the	number	of	peptides	that	are	distinct	to	
each	finding.	‘Score’	refers	to	the	confidence	score	read	out	from	Progenesis	QIP.	
	
Upon	removal	of	BBS004	from	the	analysis,	a	greater	difference	in	protein	expression	between	
patient	and	control	became	apparent.	8	proteins	were	significantly	differentially	expressed	with	
an	FDR<0.05.	An	additional	31	proteins	were	significant	with	a	more	relaxed	FDR	<0.1	(figure	4.9C	
and	table	4.3).	Proteins	were	mapped	on	a	volcano	plot	by	log2(FC)	and	-log10(FDR)	to	observed	
the	distribution	of	differentially	expressed	proteins	(figure	4.10).
		
	
Gene	name	 Protein	name	
Peptide	
count	
Unique	
peptides	
Score	 BBS	mean	 Control	mean	 Log2FC	 FDR	 Relationship	to	disease	
SERPINF1	 Pigment	epithelium-derived	factor	 7	 2	 32.3	
9.36	
(8.86,	9.85)	
7.03	
(6.60,	7.46)	 2.56	 0.015	
Metabolic	syndrome	(Yamagishi	et	al.,	2006);	
Microvascular	complications	of	diabetes	
(OMIM:603933)	
ORM1	 Alpha-1-acid	glycoprotein	1		 42	 24	 204.4	
16.56	
(16.05,	17.08)	
14.15	
(13.31,	15.00)	 2.36	 0.029	
Cardiovascular	disesase	and	diabetes	
(Christiansen	et	al.,	2002;	Hou	et	al.,	2014)	
ORM2	 Alpha-1-acid	glycoprotein	2		 33	 19	 211.1	
15.23	
(14.66,	15.79)	
13.01	
(12.34,	13.68)	 2.35	 0.042	
Rheumatoid	arthritis	(Park	et	al.,	2016);		
Colorectal	cancer	(Zhang	et	al.,	2012)	
CA1	 Carbonic	anhydrase	1	 5	 3	 29.6	
12.41	
(11.89,	12.94)	
10.60	
(10.36,	10.84)	 2.19	 0.042	
Microvascular	complications	of	diabetes	
(OMIM:603933)	
ARVCF	
Armadillo	repeat	protein	
deleted	in	velo-cardio-facial	
(VCF)	syndrome	
2	 1	 9.1	
9.23	
(8.69,	9.77)	
7.13	
(6.39,	7.88)	 2.24	 0.042	 	
TTN	 Titin	 91	 36	 367.3	 13.96	
(13.71,	14.21)	
13.05	
(12.80,	13.30)	
0.96	 0.042	 Cardiomyopathy	(OMIM:	604145,	613765)	
DNAI1	 Dynein	intermediate	chain	1,	axonemal	 2	 1	 9.4	
12.61	
(12.16,	13.09)	
10.89	
(10.27,	11.52)	 1.83	 0.047	 Ciliary	dyskinesia	(OMIM:	244400)	
PHF6	 PHD	finger	protein	6	 6	 4	 50.1	 13.69	(13.29,	14.10)	
12.30	
(11.96,	12.65)	 1.55	 0.047	
Borjeson-Forssman-Lehmann	syndrome		
(OMIM:	301900)	
GPRC5B	 G-protein	coupled	receptor	family	C	group	5	member	B	 6	 1	 38.0	
8.49	
(7.86,	9.13)	
10.49	
(10.00,	10.97)	 -1.72	 0.064	 Type	II	diabetes	(Soni	et	al.	2013)	
PCDH10	 Protocadherin-10	 3	 2	 12.1	
15.38	
(14.90,	15.86)	
13.88	
(13.47,	14.29)	 1.70	 0.064	 	
RNF123	 E3	ubiquitin-protein	ligase	 2	 2	 17.7	
12.51	
(11.77,	13.24)	
9.94	
(8.77,	11.11	 2.72	 0.064	 	
TF	 Serotransferrin	 86	 67	 686.7	 14.60	
(14.15,	15.06)	
13.23	
(12.89,	13.57)	
1.59	 0.064	 Atransferrinemia	(OMIM:209300);		
type	II	diabetes	(Riaz,	2015;	Soggiu	et	al.,	2012)	
HMX3	 Homeobox	protein	 3	 3	 15.8	 11.26	
(10.54,	11.98)	
9.08	
(8.55,	9.62)	
2.84	 0.064	 	
		
GP1BA	 Platelet	glycoprotein	Ib	
alpha	chain	
3	 2	 13.3	 7.99	
(7.40,	8.57)	
5.80	
(4.61,	6.99)	
2.21	 0.064	
Bernard-Soulier	syndrome	(OMIM:	231200,	
153670);	von	Willebrand	disease	(OMIM:	
177820)	
ASAH1	 Acid	ceramidase	 16	 10	 101.37	 16.39	
(16.04,	16.75)	
15.34	
(15.14,	15.55)	
1.19	 0.064	
Farber	lipogranulomatosis	(OMIM:	228000);	
Spinal	muscular	atrophy	with	progressive	
myoclonic	epilepsy	(OMIM:	159950)	
POLD1	
DNA	polymerase	delta	
catalytic	subunit	 2	 1	 8.36	
15.50	
(15.03,	15.97)	
14.13	
(13.90,	14.36)	 1.60	 0.064	
Mandibular	hypoplasia,	deafness,	progeroid	
features	and	lipodystrophy	syndrome	(OMIM:	
615381)	
HSPA12B	 Heat	shock	70	kDa	protein	12B	 11	 6	 49.70	
13.81	
(13.16,	14.45)	
11.93	
(11.64,	12.22)	 2.37	 0.064	 Type	II	diabetes	(Soggiu	et	al.,	2012)	
SERPINC1	 Antithrombin-III	 21	 16	 137.87	
11.51	
(11.04,	11.99)	
10.11	
(9.74,	10.48)	 1.63	 0.066	
Thrombophilia	due	to	antithrombin	III	
deficiency	(OMIM:	613118)	
SCPEP1	
Retinoid-inducible	serine	
carboxypeptidase	 5	 5	 26.31	
10.71	
(9.94,	11.49)	
8.16	
(6.93,	9.38)	 2.52	 0.068	 	
LYVE1	 Lymphatic	vessel	endothelial	
hyaluronic	acid	receptor	1	
19	 17	 121.72	 12.79	
(12.30,	13.28)	
11.20	
(10.48,	11.92)	
1.61	 0.068	 	
ROBO4	 Roundabout	homolog	4	 28	 18	 182.39	 15.07	
(14.74,	15.39)	
14.04	
(13.59,	14.49)	
1.06	 0.068	 	
	 Ig	heavy	chain	V-III	region	 6	 4	 56.04	 12.94	
(12.64,	13.24)	
13.88	
(13.44,	14.31)	
-0.92	 0.076	 	
LRG1	
Leucine-rich	alpha-2-
glycoprotein	 17	 13	 133.77	
12.36	
(11.33,	13.38)	
8.99	
(7.20,	10.78)	 2.50	 0.077	 Type	II	diabetes	(Soggiu	et	al.,	2012)	
GP2	
Pancreatic	secretory	granule	
membrane	major	
glycoprotein	
1	 1	 3.38	 6.41	
(5.69,	7.13)	
3.09	
(0.58,	5.60)	
0.85	 0.078	 	
DDX55	
ATP-dependent	RNA	
helicase	 4	 1	 18.59	
13.66	
(13.05,	14.27)	
12.03	
(11.78,	12.28)	 2.04	 0.078	 	
ARHGAP35	
Rho	GTPase-activating	
protein	35	 4	 3	 23.35	
11.93	
(11.41,	12.45)	
10.53	
(10.30,	10.77)	 1.71	 0.078	 	
AADACL2	
Arylacetamide	deacetylase-
like	2	 2	 1	 7.95	
11.35	
(10.42,	12.29)	
8.62	
(7.43,	9.80)	 2.66	 0.080	 	
CDH2	 Cadherin-2	 22	 14	 149.92	
13.7	
(13.09,	14.38)	
11.97	
(11.41,	12.52)	 2.30	 0.080	 	
		
BSPH1	 Binder	of	sperm	protein	
homolog	1	
1	 1	 10.49	 12.31	
(11.52,	13.10)	
9.92	
(8.75,	11.09)	
2.62	 0.080	 	
TSPAN14	 Tetraspanin-14	 2	 1	 12.13	 15.12	
(14.71,	15.54)	
14.02	
(13.72,	14.32)	
1.26	 0.085	 	
CADPS	
Calcium-dependent	
secretion	activator	1	 5	 2	 25.23	
10.28	
(9.78,	10.79)	
9.00	
(8.86,	9.13)	 1.52	 0.085	 	
MAN2B2	 Epididymis-specific	alpha-mannosidase	 14	 8	 80.36	
12.55	
(12.09,	13.01)	
11.33	
(10.96,	11.70)	 1.41	 0.085	 	
FLNC	 Filamin-C	 12	 6	 63.05	 12.94	(12.66,	13.22)	
12.10	
(11.66,	12.53)	 0.84	 0.085	
Cardiomyopathy/	myopathy	(OMIM:	617047,	
614065,	609524)	
PYHIN1	 Pyrin	and	HIN	domain-containing	protein	1	 2	 2	 11.63	
10.00	
(9.64,	10.36)	
9.03	
(8.68,	9.39)	 1.10	 0.087	 	
HINT3	 Histidine	triad	nucleotide-
binding	protein	3	
2	 1	 7.77	 6.45	
(5.22,	7.67)	
1.57	
(-2.11,	5.25)	
1.77	 0.091	 	
LRRC8E	 Volume-regulated	anion	
channel	subunit	
2	 2	 9.09	 9.58	
(8.74,	10.41)	
7.51	
(7.19,	7.82)	
3.22	 0.094	 	
FAHD1	 Acylpyruvase,	mitochondrial	 1	 1	 6.33	 14.93	
(14.43,	15.42)	
13.68	
(13.37,	13.98)	
1.51	 0.094	 	
PRICKLE2	 Prickle-like	protein	2	 5	 1	 19.10	
9.08	
(8.48,	9.68)	
7.62	
(6.10,	8.42)	 1.65	 0.097	 	
LPA	 Apolipoprotein(A)	 13	 8	 69.24	
13.21	
(12.76,	13.67)	
14.36	
(14.02,	14.69)	 -0.95	 0.097	
LPA	deficiency,	Coronary	artery	disease	(OMIM:	
152200);	Type	II	diabetes	(Ruotolo	et	al.	1991)	
HERC6	 Probable	E3	ubiquitin-
protein	ligase	
6	 3	 25.35	 7.79	
(7.44,	8.13)	
9.22	
(8.03,	10.42)	
-1.92	 0.097	 	
Table	4.3	–	DE	proteins	between	patients	and	controls	(excluding	BBS004)	with	FDR<0.1	from	urine	HPLC-MS/MS	experiment.	Sample	mean	for	BBS	and	control	are	presented,	where	
data	is	expressed	as	log2(relative	quantitation(RQ))	for	sample	mean	(95%	CI).	Where	applicable,	an	established	link	to	disease	has	been	noted,	obtained	from	literature	mining	or	
from	the	Online	Mendelian	Inheritance	in	Man	(OMIM)	database.	Diseases	related	to	metabolic	syndrome	phenotypes	are	italicised.	
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Figure	4.10	–	Volcano	plot	displaying	DE	proteins	between	patient	and	controls	(excluding	BBS004).	Red	
data	points	represent	differentially	expressed	proteins	with	FDR<0.01.	Data	points	above	the	dashed	line	
have	FDR<0.05,	where	the	top	2	most	significantly	expressed	proteins	are	labelled.	
	
Pigment	epithelium	derived	factor	(PEDF,	encoded	by	SERPINF1)	was	the	most	significant	finding,	
which	was	upregulated	in	patients	(BBS	mean	log2RQ	=	9.36,	95%	CI=	8.86,	9.85;	control	mean	
log2RQ	=	7.03,	95%	CI=	6.60,	7.46;	log2(FC)=	2.56;	FDR=	0.015).	Other	statistically	significant	DE	
proteins	 with	 FDR<0.05	 included	 alpha-1	 acid	 glycoprotein	 1,	 alpha-1	 acid	 glycoprotein	 2,	
carbonic	anhydrase	1,	armadillo	repeat	protein,	titin,	dynein	intermediate	chain	1,	and	PHD	finger	
protein	 6	 (encoded	 by	 ORM1,	 ORM2,	 CA1,	 ARVCF,	 TTN,	 DNAI1	 and	 PHF6,	 respectively).	 All	
proteins	were	significantly	upregulated	compared	to	controls.	
	
The	39	proteins	with	FDR<0.1	were	subjected	to	a	 literature	and	OMIM	search	to	 identify	any	
known	relationships	to	disease	(table	4.3).	17	proteins	were	identified	to	be	linked	to	disease,	10	
of	which	were	CVD	or	type	II	diabetes.	4	of	the	8	proteins	with	FDR<0.05	were	known	to	either	
have	genetic	links	to	CVD	(ORM1	and	TTN)	or	were	previously	identified	biomarkers	for	diabetes	
(PEDF,	 alpha-1-acid	 glycoprotein	1	 and	 carbonic	 anhydrase	1).	 In	 addition,	mutations	 in	PHF6	
cause	 an	 X-linked	 disorder	 known	 as	 Borjeson-Forssman-Lehman	 syndrome,	 which	 has	
overlapping	features	with	BBS,	such	as	obesity,	intellectual	disability,	and	hypogonadism	(Lower	
et	al.	2002).	
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Subsequently,	 the	 difference	 in	 protein	 expression	 was	 observed	 at	 an	 individual	 level.	 The	
log2(RQ)	 was	 established	 for	 each	 individual	 for	 all	 proteins	 with	 FDR<0.01.	 The	 heatmap.2	
package	 from	 gplots	 was	 used	 to	 generate	 a	 heatmap	 in	 R,	 with	 hierarchical	 clustering	 to	
determine	 related	 groups	 of	 proteins	 or	 biological	 groups	 (figure	 4.11)	 (Warnes	 et	 al.	 2005).	
BBS004	was	also	 included	in	this	analysis	 in	an	attempt	to	 identify	anomalies	with	this	sample	
(highlighted	by	yellow	bar).	Within	the	heatmap,	values	were	normalised	for	each	protein	and	
scaled	by	row,	so	that	individuals	can	be	compared	relative	to	one	another	for	each	protein	(red	
=	high	expression,	blue	=	low	expression).	
	
	
Figure	 4.11	 –	 Heatmap	 of	 DE	 proteins	 with	 FDR<0.1,	 generated	 by	 heatmap.2	 in	 R	 from	 scaled	 and	
normalised	log2(relative	quantitation)	data,	where	blue	is	low	expression	and	red	is	high	expression.	Data	
is	organised	by	hierarchical	clustering,	where	the	top	bar	highlights	patients	(light	blue),	controls	(purple),	
and	 BBS004	 (yellow).	 Proteins	 that	 were	 significantly	 differentially	 expressed	 to	 FDR<0.05	 in	 patients,	
excluding	BBS004,	vs	controls	are	highlighted	in	red.	
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The	heatmap	demonstrated	that	there	were	two	clusters	of	patient	groups	(highlighted	by	the	
blue	bar),	where	BBS014,	BBS007,	BBS012,	BBS003,	BBS009,	and	BBS013	formed	one	group,	and	
BBS001,	 BBS002,	 BBS005,	 BBS006,	 BBS008,	 BBS010,	 BBS011,	 and	BBS015	 formed	 the	 second	
group.	The	control	individuals	clustered	separately	from	the	patients	(highlighted	by	the	purple	
bar),	yet	there	was	a	close	relationship	between	CTRL025	and	BBS008.	The	heatmap	validated	
that	BBS004	was	an	outlier,	as	it	did	not	cluster	with	any	of	the	other	samples.	This	sample	had	
the	lowest	expression	for	proteins	that	were	highly	expressed	in	other	patients,	such	as	PEDF,	
suggesting	that	the	reason	for	the	outlier	may	be	due	to	low	protein	abundance	in	this	sample.	
For	example,	 the	mean	 for	PEDF	 in	patients	excluding	BBS004	was	9.36	 log2RQ	 (95%	CI	8.86,	
8.85),	control	mean	of	7.03	log2RQ	(95%	CI=	6.60,	7.46),	and	only	3.47	log2RQ	for	BBS004.	
	
4.2.1.5	Pathway	analysis	
For	pathway	analysis,	gene	ontology	(GO)	term	databases	were	utilised	to	determine	whether	
identified	proteins	are	known	to	act	within	the	same	pathways	(Mi	et	al.	2017).	726	quantifiable	
proteins	 were	 entered	 into	 PANTHER	 database	 for	 statistical	 overrepresentation	 testing	 and	
searched	 against	 Reactome	 pathway,	 cell	 component,	 and	 biological	 process	 GO	 terms.	 58	
Reactome	pathways,	123	cellular	 component	 terms,	and	366	biological	processes	 terms	were	
identified	to	have	an	adjusted	p-value	<0.05	after	Bonferroni	correction	(supplemental	data,	table	
S.42).	The	top	10	most	significantly	enriched	GO	terms	are	presented	in	figure	4.12.	
	
Many	of	the	biological	processes	GO	terms	were	related	to	exocytosis	and	secretion,	which	would	
be	expected	for	a	biological	fluid	(Anderson	and	Anderson	2002).	This	was	supported	by	cellular	
component	GO	terms,	which	consist	of	terms	such	as	extracellular	exosome,	extracellular	vesicle,	
and	 secretory	 granule.	 There	 were	 also	 terms	 related	 to	 immunological	 processes,	 including	
complement	 cascade	 from	 Reactome	 pathways,	 and	 myeloid	 cell	 activation,	 neutrophil	
activation,	and	leukocyte	mediated	immunity	from	biological	processes.	
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Figure	4.12	–	PANTHER	overrepresentation	testing	pathway	analysis	from	urinary	proteins.	Top	10	most	
significant	terms	from	Reactome	pathways	(A),	GO	cellular	component	(B),	and	GO	biological	processes	(C)	
databases,	from	726	quantifiable	proteins	identified	from	urine.	
	
STRING	software	(Szklarczyk	et	al.	2015)	was	utilised	to	identify	protein-protein	interactions	(PPI)	
between	39	identified	proteins	with	FDR<0.1.	17	out	of	39	proteins	were	predicted	to	interact	
with	at	least	one	other	protein	in	the	test	list	(figure	4.13).	This	revealed	a	PPI	enrichment	p-value	
of	0.023,	suggesting	that	these	proteins	have	a	greater	number	of	interactions	among	themselves	
than	would	be	expected	by	chance.	STRING	investigated	the	connectivity	of	the	proteins	within	
the	list	and	identified	18	proteins	known	to	function	within	extracellular	exosomes	(p	=	0.0002;	
highlighted	 in	red).	13	edges/connections	were	present	out	of	an	expected	5	 for	the	 inputted	
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protein	set	size.	The	largest	interaction	with	7	edges	was	between	ORM1,	ORM2,	SERPINC1,	LPA,	
TF,	GP1BA,	and	FLNC,	where	SERPINC1	(antithrombin-III)	is	at	the	centre	of	the	network.	
	
	
Figure	 4.13	 –	 Protein-protein	 interaction	 analysis	 of	 39	 proteins	 with	 FDR<0.1.Connecting	 edges	
correspond	to	proteins	known	to	interact	by	experimental	means	(pink),	from	curated	databases	(blue),	
from	literature	(green),	and	co-expression	analysis	(black).	Red	nodes	are	known	to	localise	to	extracellular	
exosomes.	Image	generated	by	STRING	v.10.5.	
	
4.2.2	Proteomic	profiling	of	plasma	by	mass	spectrometry	
Plasma	requires	a	vast	amount	of	preparation	in	order	to	increase	the	prospect	of	detecting	the	
circulating	proteome.	The	first	necessity	is	to	remove	the	highly	abundant	proteins	that	make	up	
approximately	95%	of	plasma,	such	as	albumin,	 fibrinogen,	and	globulins	 (Millioni	et	al.	2011;	
Anderson	 and	 Anderson	 2002).	 These	 proteins	 can	 be	 removed	 through	 enrichment	 of	 low	
abundance	 proteins,	 technology	 demonstrated	 by	 ProteoMiner	 (Bio-Rad	 Laboratories),	 or	
depletion	 of	 highly	 abundant	 proteins	 by	 means	 of	 a	 ProteoPrep	 immunodepletion	 column	
(Sigma-Aldrich).	Due	to	the	high	cost	of	immunodepletion,	the	ProteoMiner	enrichment	kit	was	
utilised	here.	
	
Preliminary	 investigations	 were	 undertaken	 for	 method	 development	 purposes.	 In	 the	 first	
instance,	plasma	samples	obtained	from	2	individuals	were	enriched,	fractionated	by	SDS-PAGE	
and	analysed	by	UPLC-MS/MS.	Samples	were	quantified	by	BCA	assay,	where	the	standard	curve	
(figure	 4.14)	 was	 utilised	 to	 obtain	 sample	 concentrations	 and	 protein	 volumes	 for	 further	
processing	(table	4.4).	
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Figure	4.14	–	Standard	curve	generated	for	quantitation	of	protein	extracted	from	plasma.	
	
Sample	ID	
Average	
absorbance	
Concentration	
(µg/µl)	
Yield	(µg)	
Volume	for	
50µg	
BBS010	 0.80	 6.8	 405.7	 7.4	
BBS011	 0.82	 7.0	 418.7	 7.2	
Proteominer	FT	 0.43	 3.1	 187.1	 16.0	
Proteominer	wash	1	 0.36	 2.3	 139.8	 21.5	
Proteominer	wash	2	 0.42	 3.0	 177.5	 16.9	
	
Table	 4.4	 –	 Values	 from	 sample	 quantitation	 after	 BCA	 assay	 of	 protein	 obtained	 from	 plasma	 and	
corresponding	volume	of	protein	required	for	downstream	processing	for	mass	spectrometry	
	
4.2.2.1	Reduction	of	plasma	complexity	
Each	sample	was	enriched	using	a	primed	ProteoMiner	column,	where	the	plasma	sample	was	
loaded	onto	 chromatographic	 beads	 containing	 a	 library	 of	 highly	 diverse	hexapeptides.	 Each	
hexapeptide	uniquely	bound	to	a	different	protein.	Highly	abundant	proteins	oversaturated	their	
ligand	 and	 were	 washed	 through	 the	 column	 in	 sequential	 washing	 steps,	 whereas	
simultaneously,	low	abundance	proteins	were	concentrated.	The	final	eluate	contained	a	protein	
sample	with	reduced	complexity.	Each	stage	of	the	protocol	is	represented	in	figure	4.15,	where	
each	elution	step	was	retained	to	be	separated	by	SDS-PAGE.	The	resulting	gel	 illustrates	that	
highly	 abundant	 proteins	 were	 successfully	 washed	 through	 the	 column,	 and	 resulted	 in	 a	
comprehensible	sample	for	further	analysis.	As	an	example,	albumin	(molecular	weight	66.5kDa)	
saturated	the	gel	in	the	first	flow-through,	but	dramatically	reduced	throughout	the	subsequent	
washes.	 Although	 the	 final	 product	 contained	 albumin,	 it	 was	 notably	 reduced,	 revealing	
additional	bands	that	were	not	originally	visible.	
	
Following	ProteoMiner	enrichment,	samples	were	quantified	by	BCA	assay	and	50µg	of	protein	
was	prepared	 for	SDS-PAGE.	This	 separation	 technique	 segregates	proteins	according	 to	 their	
molecular	weight.	Each	sample	was	cut	into	8	pieces	of	gel	(figure	4.15).	The	size	of	the	gel	piece	
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varied	depending	on	the	approximate	concentration	within	each	band.	An	effort	was	made	to	
keep	the	bands	for	one	protein	intact	to	prevent	overlap	of	proteins	into	different	fractions.	The	
aim	was	to	produce	8	fractions	containing	~6.25µg	of	protein	each.	It	was	ensured	that	bands	
were	selected	at	the	same	position	for	both	samples,	so	that	they	could	be	compared.	
	
Figure	4.15	–	SDS-PAGE	gel	for	products	from	flow-through	(FT),	wash	1,	and	wash	2	of	the	ProteoMiner	
protocol.	The	final	lane	shows	a	lower	complexity	plasma	sample	than	prior	to	ProteoMiner.	The	positions	
where	the	8	fractions	were	cut	from	the	gel	is	also	shown.		
	
4.2.2.2	Label-free	UPLC-MS/MS	analysis	of	plasma	
For	 both	 individuals,	 each	 fraction	 generated	 a	 fragment	 ion	 spectrum	 file	 for	 input	 into	
Progenesis	QIP.	Sample	runs	from	a	single	fraction	were	analysed	separately	to	generate	protein	
abundances	and	identifications	in	8	different	Progenesis	QIP	experiments.	To	enhance	the	protein	
coverage,	all	8	experiments	were	merged	and	normalised	to	create	the	full	profile	of	each	sample.	
Normalisation	 occurred	 both	 within	 fractions	 and	 between	 fractions	 to	 reduce	 variability	
observed	 through	 systematic	 errors.	Although	 there	was	 some	 fluctuation	 in	peptide	number	
across	the	8	fractions,	in	general,	the	peptide	count	was	fairly	consistent	throughout	(figure	4.16).	
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Figure	4.16	–	The	distribution	of	peptides	from	plasma	over	8	fractions.	Peptides	are	representative	of	both	
samples	run	in	the	Progenesis	QIP	experiment.		
	
Overall,	237	proteins	were	identified,	of	which	222	were	quantifiable	through	identification	of	at	
least	 1	 unique	 peptide	 (supplemental	 data,	 table	 S.28).	 104	 of	 these	 proteins	 had	 3	 or	more	
unique	peptides,	whereas	75	proteins	were	identifiable	by	a	single	unique	peptide.	6	magnitudes	
of	abundance	were	recorded,	where	the	majority	had	a	relative	abundance	less	than	1	(figure	
4.17).	These	low	abundance	proteins	may	not	have	been	identifiable	without	the	ProteoMiner	
protein	 enrichment	 step.	 However,	 ProteoMiner	 does	 not	 completely	 remove	 the	 highly	
abundant	proteins,	as	3	different	fibronectin	chains,	complement	proteins,	and	serum	albumin	
dominate	the	10	most	abundant	proteins	(table	4.5).	
	
Figure	4.17	–	Histogram	of	mean	relative	abundances	for	quantified	proteins	from	plasma	LC-MS/MS.	
	
This	method	development	investigation	has	demonstrated	that	protein	enrichment	methods	and	
SDS-PAGE	 are	 suitable	 methods	 for	 reducing	 sample	 complexity.	 However,	 the	 circulating	
proteome	is	predicted	to	contain	approximately	3400	proteins,	which	span	up	to	12	magnitudes	
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of	concentration	(Gold	et	al.	2010).	Therefore,	the	222	proteins	observed	in	this	experiment	only	
made	a	small	indent	upon	the	full	plasma	proteome.	Due	to	the	limits	of	profiling	plasma	with	
mass	spectrometry,	this	was	technique	was	not	pursued	further.	Therefore,	a	different	profiling	
methodology	was	implemented	that	does	not	share	the	same	limitations	as	mass	spectrometry,	
to	attempt	a	more	comprehensive	analysis	of	patient	and	control	plasma.	
	
Gene	
name	
Protein	gene	
Peptide	
count	
Unique	
peptides	
Confidence	
score	
Relative	quantitation	
BBS010	 BBS011	 Mean	
FGG	
Fibrinogen	gamma	
chain	 76	 69	 660.326	 137.19	 152.43	 144.81	
FGA	 Fibrinogen	alpha	chain	 170	 168	 1124.698	 135.29	 150.48	 142.89	
FGB	 Fibrinogen	beta	chain	 107	 87	 959.443	 93.54	 106.46	 100.00	
ALB	 Serum	albumin	 104	 82	 702.502	 112.60	 34.29	 73.45	
APOA1	 Apolipoprotein	A	1	 61	 58	 624.243	 68.95	 76.75	 72.85	
VTN	 Vitronectin	 47	 43	 331.224	 67.04	 78.24	 72.64	
IGHM	 Ig	mu	chain	C	region	 60	 21	 399.970	 59.12	 54.87	 56.99	
F2	 Prothrombin	 52	 50	 484.531	 44.82	 54.73	 49.78	
TESK2	
Dual	specificity	testis-
specific	protein	kinase	2	 1	 1	 12.034	 31.99	 39.92	 35.96	
CLU	 Clusterin	 42	 42	 365.710	 32.74	 38.08	 35.41	
Table	4.5	–	Top	10	most	abundant	proteins	identified	from	mean	of	patient	BBS010	and	BBS011	plasma	by	
LC-MS/MS.	
	
4.2.3	Proteomic	profiling	by	a	targeted	technology:	SOMAscan	
4.2.3.1	Targeted	proteomic	profiling	of	plasma	
Plasma	was	taken	from	the	same	stock	used	for	mass	spectrometry	analysis	previously	described.	
15	BBS	patient	and	6	control	plasma	samples	were	assayed	by	UCL	Genomics	(UCL	GOS	Institute	
of	Child	Health)	and	the	corresponding	data	outputs	were	sent	to	SOMAlogic	(Boulder,	CO,	USA)	
for	QC	testing	and	quantitation.	Unfortunately,	patient	BBS003	did	not	pass	QC	tests,	therefore	
it	was	excluded	from	the	analysis.	Upon	retrieval	of	the	quantified	data,	samples	were	normalised	
to	allow	accurate	comparison	between	samples.	
	
The	full	capacity	of	the	SOMAscan	assay	was	to	detect	1310	proteins	(supplemental	data,	table	
S.41).	 In	this	experiment,	1243	proteins	were	detected	from	plasma	(supplemental	data,	table	
S.26).	The	samples	were	quantified	in	relative	fluorescent	units	(RFU),	which	is	a	relative	measure	
of	sample	protein	quantity.	The	quantitation	ranged	from	5.590	RFU	up	to	17.991	RFU.	The	mean	
20	most	and	least	abundant	proteins	are	presented	in	table	4.6.	In	some	cases,	there	are	multiple	
gene	names	for	a	single	protein	target,	for	example	Immunoglobulin	G.	This	is	present	for	proteins	
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with	shared	sequence	homology,	where	specific	aptamers	cannot	be	synthesised	to	distinguish	
between	closely	related	proteins.	
	
Gene	name	 Protein	name	
Mean	abundance	
(RFU)	
APOE	 Apolipoprotein	E	(isoform	E2)	 17.991	
SERPINA3	 Alpha-1-antichymotrypsin	 17.811	
APOE	 Apolipoprotein	E	(isoform	E4)	 17.710	
TF	 Serotransferrin	 17.707	
CFP	 Properdin	 17.596	
IGHG1/IGHG2/IGHG3
/IGHG4/IGK2/IGL2	 Immunoglobulin	G	 17.512	
APOE	 Apolipoprotein	E	(isoform	E3)	 17.460	
FGA/FGB/FGG	 Fibrinogen	 17.327	
C3	 C3a	anaphylatoxin	des	Arginine	 17.179	
F2	 Prothrombin	 17.053	
C4A/C4B	 Complement	C4	 16.963	
SERPINA5	 Plasma	serine	protease	inhibitor	 16.635	
C6	 Complement	component	C6	 16.632	
SERPINC1	 Antithrombin-III	 16.632	
F5	 Coagulation	Factor	V	 16.619	
C3	 Complement	C3	 16.336	
ALPL	 Alkaline	phosphatase	 16.332	
C9	 Complement	component	C9	 16.281	
CFH	 Complement	factor	H	 16.196	
FN1	 Fibronectin	Fragment	4	 16.183	
KLK5	 Kallikrein-5	 6.889	
IFNL2	 Interferon	lambda-2	 6.874	
		 Protein	Rev_HV2BE	 6.816	
IL10	 Interleukin-10	 6.813	
NANOG	 Homeobox	protein	NANOG	 6.793	
SIGLEC1	 Sialoadhesin	 6.784	
PRDX5	 Peroxiredoxin-5	 6.761	
MPL	 Thrombopoietin	Receptor	 6.744	
RPS6KA5	 Ribosomal	protein	S6	kinase	alpha-5	 6.719	
PON1	 Serum	paraoxonase/arylesterase	1	 6.647	
PTK2	 Focal	adhesion	kinase	1	 6.603	
IL17B	 Interleukin-17B	 6.591	
HCE004333	 HCE004333	 6.422	
THPO	 Thrombopoietin	 6.415	
RNASEH1	 Ribonuclease	H1	 6.407	
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LDLR	 Low-density	lipoprotein	receptor	 6.379	
LRRTM1	 Leucine-rich	repeat	transmembrane	neuronal	
protein	1	
6.257	
IL7	 Interleukin-7	 6.200	
CTLA4	 Cytotoxic	T-lymphocyte	protein	4	 5.822	
IFNA2	 Interferon	alpha-2	 5.590	
Table	4.6	–	The	20	most	abundant	and	least	abundant	proteins	identified	by	SOMAscan	from	plasma.	The	
average	abundance	is	presented	in	relative	fluorescence	units	(RFU).	
	
Statistical	analysis	was	completed	to	identify	DE	proteins	between	patients	and	control	biological	
groups	 (supplemental	data,	 table	S.25,	 table	S.27).	100	proteins	were	 found	to	be	statistically	
significant	with	 a	 p-value	 <0.05.	However,	 significance	was	 not	maintained	 after	 the	multiple	
testing	correction	was	applied.	The	top	25	differentially	expressed	proteins	are	presented	in	table	
4.7	and	figure	4.18.	Although	not	a	significant	finding,	the	protein	with	the	smallest	p-value	was	
leptin,	found	to	be	upregulated	in	patients	compared	to	controls	(BBS	mean	=	13.22	RFU,	95%	CI	
=	 12.69,	 13.75;	 control	mean	 =	 12.07	 RFU,	 95%	 CI	 =	 11.25,	 12.88;	 log2(FC)=	 1.269;	 p-value=	
0.0003;	FDR=	0.250).	This	may	be	biologically	interesting	as	BBS	patients	have	been	reported	to	
exhibit	leptin	resistance	(Feuillan	et	al.	2011).	Of	note,	CRP,	which	is	the	current	BBS	biomarker	
adopted	in	clinics,	is	also	present	in	the	top	25	most	significant	proteins	(BBS	mean	=	15.29	RFU,	
95%	CI	=	14.86,	15.72;	control	mean	=	14.01	RFU,	95%	CI	=	13.09,	14.93;	log2(FC)	=	1.280;	p-value	
=	0.0094;	FDR	=	0.503).	
	
Gene	name	 Target	name	
BBS	mean	
(RFU)	
Control	mean	
(RFU)	
Log2FC	 p-value	 FDR	
LEP	 Leptin	 13.22	
(12.69,	13.75)	
12.07	
(11.25,	12.88)	
1.269	 0.0003	 0.250	
PGAM1	 Phosphoglycerate	mutase	1	
11.53	
(10.90,	12.15)	
9.57	
(8.86,	10.27)	 1.877	 0.0006	 0.250	
OLR1	
Oxidized	low-
density	lipoprotein	
receptor	1	
11.58	
(11.34,	11.82)	
10.72	
(10.45,	10.98)	
0.849	 0.0006	 0.250	
HGF	 Hepatocyte	growth	
factor	
10.41	
(10.25,	10.58)	
9.87	
(9.74,	10.00)	
0.549	 0.0014	 0.441	
SOD2	
Superoxide	
dismutase,	
mitochondrial	
14.80	
(14.64,	14.95)	
15.35	
(15.10,	15.61)	 -0.548	 0.0022	 0.465	
MMP13	 Collagenase	3	
8.68	
(8.56,	8.80)	
9.14	
(8.94,	9.35)	 -0.464	 0.0022	 0.465	
CNTN5	 Contactin-5	
9.01	
(8.88,	9.14)	
8.58	
(8.40,	8.77)	 0.435	 0.0028	 0.480	
F9	
Coagulation	factor	
IX	
13.84	
(13.75,	13.94)	
13.48	
(13.33,	13.64)	 0.357	 0.0031	 0.480	
ENO1	 Alpha-enolase	 13.26	
(12.99,	13.54)	
12.40	
(11.88,	12.92)	
0.831	 0.0040	 0.482	
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WFIKKN2	
WAP,	Kazal,	Ig,	
Kunitz	and	NTR	
domain-containing	
protein	2	
11.87	
(11.67,	12.07)	
12.42	
(12.03,	12.81)	
-0.513	 0.0045	 0.482	
KLK3	 Prostate-specific	antigen	
9.46	
(9.05,	9.87)	
10.23	
(8.85,	11.61)	 -0.903	 0.0050	 0.482	
IGHG1/IGHG2/	
IGHG3/IGHG4/	
IGK2/IGL2	
Immunoglobulin	G	 17.39	
(17.24,	17.53)	
17.81	
(17.66,	17.95)	
-0.424	 0.0053	 0.482	
F9	
Coagulation	factor	
IXab	
13.35	
(13.26,	13.44)	
13.02	
(12.88,	13.17)	 0.323	 0.0054	 0.482	
IGFBP1	
Insulin-like	growth	
factor-binding	
protein	1	
7.89	
(7.31,	8.66)	
9.65	
(9.05,	10.26)	 -1.603	 0.0058	 0.482	
S100A9	 Protein	S100-A9	 12.85	(12.51,	13.19)	
11.78	
(10.99,	12.58)	 1.016	 0.0061	 0.482	
DSG2	 Desmoglein-2	
15.52	
(15.43,	15.62)	
15.85	
(15.70,	16.01)	 -0.323	 0.0064	 0.482	
APOM	 Apolipoprotein	M	
12.42	
(12.11,	12.73)	
13.27	
(12.87,	13.68)	 -0.836	 0.0066	 0.482	
FABP5	 Fatty	acid-binding	
protein,	epidermal	
9.69	
(9.54,	9.84)	
9.26	
(9.06,	9.45)	
0.420	 0.0077	 0.503	
IL1RAP	
Interleukin-1	
Receptor	accessory	
protein	
14.24	
(13.97,	14.50)	
15.05	
(14.49,	15.60)	 -0.787	 0.0082	 0.503	
IGHA1/IGHA2	 Immunoglobulin	A	
11.24	
(10.97,	11.51)	
11.84	
(11.65,	12.03)	 -0.624	 0.0087	 0.503	
IL1RN	
Interleukin-1	
receptor	antagonist	
protein	
11.91	
(11.56,	12.26)	
11.20	
(11.11,	11.29)	
0.744	 0.0090	 0.503	
IL12RB2	
Interleukin-12	
receptor	subunit	
beta-2	
9.42	
(9.24,	9.61)	
10.34	
(9.44,	11.24)	 -0.920	 0.0093	 0.503	
CRP	 C-reactive	protein	 15.29	(14.86,	15.72)	
14.01	
(13.09,	14.93)	 1.280	 0.0094	 0.503	
BCAN	
Brevican	core	
protein	
10.20	
(10.01,	10.40)	
10.70	
(10.51,	10.89)	 -0.483	 0.0097	 0.503	
GDF11/MSTN	
Growth	
differentiation	
factor	11/8	
9.14	
(8.92,	9.37)	
9.54	
(9.33,	9.76)	
-0.437	 0.0111	 0.554	
Table	4.7	–	The	top	25	DE	proteins	ranked	by	p-value	identified	from	plasma	by	SOMAscan.	Sample	mean	
for	BBS	and	control	are	also	presented,	where	data	is	expressed	as	mean	(95%	CI).	Note	that	significance	
was	not	maintained	after	multiple	testing	to	an	FDR	<0.05.	
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Figure	4.18	–	Volcano	plot	displaying	differential	expression	of	proteins	between	patient	and	controls	from	
plasma,	plotted	as	a	factor	of	fold	change	vs	p-value.	Red	data	points	represent	the	top	25	most	significant	
proteins	in	table	4.7.	
	
4.2.3.2	Comparison	of	proteins	by	targeted	and	untargeted	techniques	
The	 protein	 identifications	 for	 untargeted	 mass	 spectrometry	 and	 targeted	 SOMAscan	 were	
compared	to	determine	whether	these	techniques	were	able	to	recognise	the	same	proteins.	Out	
of	1243	SOMAscan	findings	and	222	proteins	identified	by	mass	spectrometry,	34	proteins	were	
shared	 (figure	4.19;	 appendix,	 table	A.5).	 This	demonstrates	 that	 these	different	 technologies	
may	 be	 suited	 to	 detect	 different	 types	 of	
proteins	 and	 suggests	 that	 they	 may	 be	 most	
effectively	used	in	combination	with	one	another.	
	
Figure	 4.19	 –	 The	 number	 of	 total	 protein	
identifications	from	plasma	for	SOMAscan,	untargeted	
mass	 spectrometry,	 and	 shared	 between	 both	
technologies.	
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4.3	Discussion	
In	this	chapter,	urine	and	plasma	samples	from	BBS	patients	were	profiled	using	label-free	and	
targeted	 proteomic	 techniques.	 To	 our	 knowledge,	 this	 is	 the	 first	 study	where	 the	 chemical	
composition	of	BBS	biofluids	have	been	investigated.	
	
4.3.1	Proteomic	profiling	of	urine	
For	proteomic	profiling	of	urine,	UPLC	coupled	to	the	Synapt	G2	Si	mass	spectrometer	was	utilised	
with	HDMSE	capability.	726	quantifiable	proteins	were	detected	by	identification	of	7901	peptide	
ions	across	15	BBS	patient	and	6	control	samples.	5	magnitudes	of	abundance	were	uncovered	
by	relative	quantitation;	however,	low	abundance	proteins	(<10	RQ)	were	not	found.	This	could	
be	due	to	high	complexity	of	sample,	limited	instrument	sensitivity,	or	undersampling.	Although	
urine	was	considered	to	have	relatively	low	complexity,	especially	compared	to	plasma,	previous	
studies	demonstrated	that	urine	is	actually	a	more	complicated	fluid	than	was	anticipated.	The	
current	urinary	proteome	is	known	to	exist	as	at	least	2362	proteins,	as	determined	by	Kentsis	
and	colleagues	(2009).	This	high	identification	rate	was	possible	due	to	extensive	fractionation	
and	 separation	 techniques,	 including	 ultracentrifugation,	 SDS-PAGE,	 ion	 exchange	
chromatography	and	reverse	phase	chromatography,	before	mass	spectrometry	(Kentsis	et	al.	
2009).	
	
During	analysis	by	Progenesis	QIP,	samples	BBS004,	BBS005,	BBS008,	BBS015,	and	CTRL026	were	
identified	as	having	low	quality	fragmentation	spectra	after	MS/MS.	Alignment	and	normalisation	
of	MS1	spectra,	and	use	of	ion	abundance	quantitation	by	Progenesis	QIP,	meant	that	this	should	
not	have	negatively	affected	protein	 identification.	However,	 the	software	could	only	quantify	
ions	if	they	were	also	seen	in	another	sample.	Therefore,	if	there	were	ions	unique	to	samples	
that	were	not	detected,	some	proteins	may	have	been	underrepresented.		
	
The	principle	component	analysis	of	the	experiment	presented	a	method	for	quality	control.	4	
QC	samples,	which	were	representative	of	all	samples,	were	run	throughout	the	course	of	the	
experiment.	The	PCA	plot	demonstrated	that	the	instrument	sensitivity	was	maintained	and	thus	
the	data	was	reliable	for	further	analysis.	The	PCA	plot	also	allowed	a	visual	characterisation	of	
the	data.	As	a	result,	BBS004	was	identified	as	a	possible	outlier.	It	was	originally	considered	that	
this	may	be	due	to	BBS004	not	displaying	a	metabolic	syndrome	phenotype	compared	to	other	
patients	 within	 the	 cohort.	 However,	 further	 investigation	 by	 heatmap	 analysis	 of	 the	 data	
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demonstrated	that	this	may	be	due	to	poor	sample	quality,	as	some	of	the	significantly	regulated	
proteins	were	found	only	in	low	quantities	in	BBS004,	including	PEDF.	
	
4.3.1.1	Statistical	analysis	of	proteins	from	urine	
In	the	first	instance,	DE	proteins	were	calculated	between	15	patients	and	6	control	samples.	A	
single	DE	protein	was	identified,	namely	alpha-1-acid	glycoprotein	1	(ORM1)	(BBS	mean	log2RQ=	
16.46,	95%	CI=	15.95,	16.98;	control	mean	log2RQ=	14.15,	95%	CI=	13.31,	15.00;	log2(FC)=	2.31;	
FDR=	0.039)	(table	4.2).	Upon	removal	of	BBS004	from	the	analysis,	the	statistical	significance	of	
this	protein	increased	(BBS	mean	log2RQ=	16.56,	95%	CI=	16.05,	17.08;	control	mean	log2RQ=	
14.15,	95%	CI=13.31,	15.00;	log2(FC)=	2.36;	FDR=	0.029)	and	the	FDR	of	an	additional	7	proteins	
decreased	to	less	than	0.05,	all	of	which	were	upregulated	in	patients.	Of	these,	4	proteins	have	
been	previously	linked	to	aspects	of	metabolic	syndrome,	such	as	diabetes	(PEDF	and	carbonic	
anhydrase	1)	or	CVD	(ORM1	and	titin)	(table	4.3)	(Yamagishi	et	al.	2006;	Christiansen	et	al.	2002;	
Hou	et	al.	2014).	These	proteins	may	be	indicative	of	onset	of	type	II	diabetes	or	cardiovascular	
complications	in	the	BBS	patients.	
	
4.3.1.2	Identification	of	urinary	protein	biomarkers	
Pigment	epithelium-derived	factor	(PEDF)	
PEDF	was	recognised	as	the	most	significantly	differentially	expressed	protein	between	patient	
and	control	biological	groups,	after	removal	of	BBS004	(BBS	mean	log2RQ=	9.36,	95%	CI=	8.86,	
9.85;	control	mean	log2RQ=	7.03,	95%	CI=	6.60,	7.46;	Log2(FC)	=	2.56;	FDR	=	0.015).	PEDF	is	a	
glycoprotein	belonging	to	the	family	of	serine	protease	inhibitors.	It	is	a	multifunctional	protein	
that	is	synthesised	in	adipose	tissue	and	secreted	to	negatively	regulate	angiogenesis	(Dawson	et	
al.	1999).	Studies	have	reported	PEDF	to	be	both	pro-inflammatory	(Crowe	et	al.	2009;	Chavan	et	
al.	2012)	and	anti-inflammatory	(Nakamura	et	al.	2009),	eliciting	the	assumption	that	this	protein	
may	exhibit	its	inflammatory	properties	in	a	tissue	specific	or	temporal	manner.	PEDF	has	been	
identified	as	a	serum	biomarker	 in	previous	studies	relating	to	metabolic	syndrome,	as	well	as	
renal	and	retinal	dysfunction	related	to	diabetes	(Nakamura	et	al.	2009;	Yamagishi	et	al.	2006;	
Crowe	et	al.	2009;	Jenkins	et	al.	2008).	It	was	shown	to	be	upregulated	in	patients	with	metabolic	
syndrome	 and	 thought	 to	 contribute	 to	 insulin	 resistance.	 Until	 now,	 there	 was	 no	 previous	
evidence	that	PEDF	could	also	be	a	urinary	biomarker.	
	
The	significant	upregulation	within	BBS	patients	compared	to	controls	may	be	due	to	PEDF	being	
one	of	the	most	abundantly	secreted	proteins	from	adipocytes	(Famulla	et	al.	2011).	Famulla	et	
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al.	(2011)	determined	that	PEDF	expression	significantly	increased	throughout	adipogenesis,	was	
further	augmented	by	treatment	of	insulin,	and	was	suppressed	by	induction	of	hypoxia.	PEDF	
was	also	demonstrated	 to	 induce	 insulin	 resistance	 in	 adipocytes	 and	mice	 in	 vivo,	 as	well	 as	
activate	inflammatory	signalling	(Famulla	et	al.	2011;	Crowe	et	al.	2009).	The	mechanism	for	this	
process,	however	was	not	elucidated.		
	
Interestingly,	PEDF	is	not	only	a	key	player	in	adiposity,	and	has	demonstrated	other	roles	relevant	
to	BBS.	PEDF	was	first	shown	to	be	expressed	in	cultured	retinal	pigmented	epithelium	(RPE)	cells	
(Tombran-Tink	et	al.	1991).	In	vivo,	RPE	cells	exist	as	a	pigmented	layer	behind	the	photoreceptor	
layer	 in	 the	 retina.	 RPE	 functions	 to	 support	 and	 maintain	 photoreceptor	 and	 neural	 retina	
function	(German	et	al.	2008).	PEDF	was	shown	to	be	secreted	from	RPE	cells,	where	it	exhibited	
neurotrophic	activity	to	promote	photoreceptor	and	retinal	neuronal	cell	survival	 (Steele	et	al.	
1993;	 Cayouette	 et	 al.	 1999).	 Furthermore,	 Cayouette	 and	 colleagues	 (1999)	 prolonged	 the	
survival	 of	 photoreceptors	 in	 a	mouse	model	 of	 retinal	 degeneration	 (rd)	 through	 intraocular	
injection	of	PEDF.	It	has	not	yet	been	established	whether	RPE	cells	increase	expression	of	PEDF	
in	response	to	photoreceptor	degeneration	in	models	of	retinal	dystrophy.	However,	it	is	worth	
investigating	 whether	 PEDF	 is	 upregulated	 in	 BBS	 patients	 compared	 to	 controls	 as	 a	
consequence	of	photoreceptor	death.	The	observation	that	a	protein	from	the	ocular	system	is	
found	in	the	urine	is	not	unlikely,	as	Kentsis	et	al.	(2009)	uncovered	proteins	from	urine	that	are	
uniquely	expressed	in	the	nervous	system.	
	
Alpha-acid	glycoprotein	1	and	2	(ORM1	and	ORM2)	
ORM1	and	ORM2	were	both	upregulated	in	patients	compared	to	control	with	log2(FC)	of	2.36	
(BBS	mean	log2RQ=	16.56,	95%	CI=	16.05,	17.08;	control	mean	log2RQ=	14.15,	95%	CI=	13.31,	
15.00;	FDR	=	0.029),	and	log2(FC)	of	2.35	(BBS	mean	log2RQ=	15.23,	95%	CI=	14.66,	15.79;	control	
mean	 log2RQ=	13.01,	95%	CI=	12.34,	13.68;	FDR	=	0.042),	 respectively.	These	paralogues	are	
both	acute	inflammatory	circulatory	glycoproteins.	ORM1	was	reported	as	a	urinary	biomarker	
for	chronic	heart	failure	(CHF)	(Hou	et	al.	2014),	which	was	upregulated	in	CHF	patients	compared	
to	 normal	 controls.	 CVD	 is	 a	 secondary	 phenotype	 of	 BBS,	 linked	 to	 the	 syndrome’s	 obesity	
phenotype.	 Indeed,	 patients	 in	 this	 cohort	 exhibit	 risk	 factors	 or	 features	 of	 CVD,	 such	 as	
hypertension	 (BBS002,	 BBS003,	 BBS005),	 aortic	 valve	 complications	 (BBS013),	 and	 angina	
pectoris	 (BBS005).	 In	 a	 gene	 expression	 experiment,	 upregulation	 of	ORM1	 was	 recorded	 in	
circulating	blood	of	metabolic	syndrome	patients,	but	not	in	patients	with	coronary	artery	disease	
(Grayson	 et	 al.	 2011).	 This	 may	 suggest	 that	 ORM1	 is	 an	 indicator	 of	 obesity-related	
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cardiovascular	 abnormalities.	 ORM2	 was	 shown	 to	 be	 significantly	 elevated	 in	 plasma	 from	
colorectal	 cancer	 (CRC)	 patients	 (Zhang	 et	 al.	 2012).	 As	 yet,	 there	 has	 been	 no	 connection	
between	BBS	and	an	increased	risk	of	CRC.	With	the	exception	of	Grayson	et	al.	(2011),	the	studies	
discussed	here	utilised	clinically	healthy	individuals	as	controls.	Thus,	it	is	possible	the	significant	
changes	in	expression	may	be	due	to	general	inflammatory	responses	and	not	specific	to	CHF	or	
CRC.	
	
Other	relevant	findings	
After	 investigation	 of	 the	 significant	 proteins	 at	 an	 FDR<0.05,	 the	 confidence	 interval	 was	
widened	 to	 90%,	 with	 the	 knowledge	 that	 this	 increased	 the	 chance	 of	 false	 positive	
identifications.	This	identified	5	more	markers	associated	with	type	II	diabetes,	namely	G-protein	
coupled	receptor-C	group	5B	(BBS	mean	log2RQ=	8.49,	95%	CI=	7.76,	9.13;	control	mean	log2RQ=	
10.49,	95%	CI=	10.00,	10.97;	log2(FC)=	-1.72;	FDR=	0.064),	serotransferrin	(BBS	mean	log2RQ=	
14.60,	95%	CI=	14.15,	15.06;	control	mean	log2RQ=	13.23,	95%	CI=	12.89,	13.57;	log2(FC)	=	1.59;	
FDR	=	0.064),	Heat	Shock	Protein	12B	(BBS	mean	log2RQ=	13.81,	95%	CI=	13.16,	14.45;	control	
mean	log2RQ=	11.93,	95%	CI=	11.64,	12.22;	log2(FC)	=	2.37;	FDR	=	0.064),	Leucine	rich	alpha-2-
glycoprotein	(BBS	mean	log2RQ=	12.36,	95%	CI=	11.33,	13.38;	control	mean	log2RQ	=	8.99,	95%	
CI=	7.20,	10.78;	log2(FC)	=	2.5;	FDR=0.077)	and	Apolipoprotein(A)	(BBS	mean	log2RQ=	13.21,	95%	
CI=	 12.76,	 13.67;	 control	 mean	 log2RQ=	 14.36,	 95%	 CI=	 14.02,	 14.69;	 log2(FC)	 =	 -0.95;	
FDR=0.097)	(Soni	et	al.	2013;	Soggiu	et	al.	2012;	Ruotolo	et	al.	1991).	Although	these	proteins	
may	have	a	genuine	specificity	to	BBS-related	metabolic	syndrome,	 it	 is	 important	to	consider	
that	 they	 may	 be	 an	 artefact	 of	 disease	 associated	 inflammation.	 To	 test	 this,	 further	
experimentation	will	be	required	with	larger	BBS	and	control	groups.	To	evaluate	whether	these	
differentially	 expressed	 proteins	 are	 specific	 to	 BBS,	 a	 control	 group	 composed	 of	metabolic	
syndrome	patients	could	be	used.	A	greater	improvement	would	be	to	compare	the	proteomes	
of	 BBS	 patients	 that	 manifest	 obesity	 with	 patients	 that	 have	 a	 normal	 BMI.	 Following	
identification	of	possible	biomarkers,	it	is	imperative	that	verification	through	targeted	analysis,	
such	as	ELISA,	is	performed.	
	
4.3.1.3	Cellular	components	of	urine	
Overrepresentation	analysis	by	PANTHER	of	all	726	quantifiable	proteins	identified	an	enrichment	
of	 proteins	 associated	 with	 extracellular	 vesicles	 and	 exosomes	 GO	 terms	 (p<0.0001).	
Furthermore,	 STRING	 protein-protein	 interaction	 analysis	 identified	 18	 proteins	 out	 of	 39	
proteins	with	FDR<0.1	associated	with	extracellular	exosomes.	Urinary	exosomes	are	shed	from	
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renal	 epithelial	 cells	 and	 contain	 RNAs,	 lipids,	 and	 proteins	 that	 characterise	 the	
pathophysiological	state	of	their	host	cells.	Previous	studies	have	shown	that	urinary	exosomes	
can	act	as	valuable	vehicles	for	biomarker	detection	(Dear	et	al.	2013;	Fang	et	al.	2013;	Gonzales	
et	al.	2009;	van	Balkom	et	al.	2011).	Indeed,	one	large-scale	study	identified	1132	proteins	specific	
to	urinary	exosomes,	177	of	which	were	associated	with	disease,	including	primary	cilia	proteins	
ARL6,	PKD1,	and	PKD2	(Gonzales	et	al.	2009).	
	
In	this	project,	proteins	were	separated	from	urine	by	ultracentrifugation	with	a	3kDa	molecular	
weight	 cut-off.	 This	 removed	 low	molecular	weight	molecules	 such	 as	metabolites,	 salts,	 and	
detergents,	however	the	resulting	mixture	would	have	retained	 its	complexity	of	proteins.	For	
future	investigations,	the	complexity	of	the	sample	could	be	reduced	by	sequencing	exclusively	
exosomes.	This	may	provide	a	greater	 insight	 into	disease-specific	 intracellular	 interactions,	as	
other	 secretions	will	 be	 removed.	 To	extract	 exosomes,	 further	 refinement	of	 the	protocol	 is	
required,	adding	sucrose	separation	and	size-exclusion	chromatography	steps	(Dear	et	al.	2013).	
The	will	result	in	a	less	complex,	more	specific	mixture;	however,	this	may	contain	more	sample	
variation	due	to	extensive	handling.	
	
4.3.2	Proteomic	profiling	of	plasma	
4.3.2.1	Investigation	of	plasma	proteome	by	UPLC-MS/MS	
Plasma	samples	from	BBS010	and	BBS011	were	profiled	for	a	method	development	experiment	
by	mass	spectrometry.	As	plasma	is	a	high	complex	biofluid,	consisting	mostly	of	highly	abundant	
proteins	 such	 as	 albumin	 and	 fibrinogen	 (Anderson	 and	 Anderson	 2002),	 plasma	 samples	
required	a	greater	number	of	processing	steps	compared	to	urine	analysis.	First,	low	abundance	
proteins	were	enriched	by	use	of	the	ProteoMiner	column,	followed	by	the	separation	of	proteins	
into	 8	 fractions	 by	 SDS-PAGE.	 Samples	were	 profiled	 using	UPLC	 coupled	 to	 the	MALDI-QToF	
Premier	mass	spectrometer	with	MSE	capability,	where	222	proteins	were	quantified	over	6	logs	
of	concentration.	
	
ProteoMiner	was	shown	to	successfully	reduce	the	complexity	of	the	sample,	where	SDS-PAGE	
illustrated	that	the	quantity	of	highly	abundant	proteins,	such	as	albumin,	had	reduced.	However,	
of	the	222	proteins	identified,	the	top	4	most	abundant	findings	consisted	of	3	fibrinogen	chains	
(gamma,	 alpha,	 and	 beta	 chains)	 and	 serum	 albumin	 (table	 4.5).	 The	 ProteoMiner	 column	 is	
composed	 of	 a	 dynamic	 library	 of	 hexapeptides	 that	 should	 have	 affinity	 for	 all	 proteins	 in	 a	
sample.	 Once	 a	 ligand	 is	 oversaturated,	 surplus	 proteins	 are	 washed	 through	 the	 column,	
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resulting	 in	 a	 less	 complex	 protein	 sample	 for	 mass	 spectrometry	 (Millioni	 et	 al.	 2011).	 The	
greatest	issue	with	this	technique	is	that	it	relies	on	the	specificity	of	the	column,	where	some	
non-specific	 proteins	may	be	washed	 through.	Moreover,	 this	method	 coincidently	 alters	 the	
protein	 quantity,	 thereby	 creating	 ambiguous	 results	 upon	 quantitation.	 Depletion	 of	 high	
abundance	proteins	through	an	immunodepletion	column	may	be	more	reliable.	This	technique	
uses	specific	antibodies	for	abundant	proteins,	such	as	albumin	and	fibrinogen,	to	retain	these	
on	the	column	and	allow	other	proteins	to	be	washed	through	(Jaros	et	al.	2013).	However,	these	
are	expensive	kits	that	were	not	obtainable	for	use	in	this	study.	
	
For	 plasma	proteomic	 analysis,	 the	MALDI-QtoF	 Premier	 instrument	was	 used	 rather	 than	 its	
high-performance	Synapt	G2	Si	counterpart.	The	difference	between	the	machines	is	presented	
at	the	MS/MS	level,	where	the	Synapt	G2	Si	utilises	HDMSE	to	enhance	ion	separation	within	the	
ToF	mass	analyser.	By	contrast,	the	Premier	mass	spectrometer	does	not	have	the	high	definition	
capability,	 so	 has	 reduced	 sensitivity.	 This	 difference	 in	 performance	 has	 been	 shown	 to	
dramatically	decrease	 the	number	of	protein	 identifications	by	up	 to	half	 (Tonge	et	al.	2011).	
Fractionation	 is	 able	 to	 enhance	 the	 identification	 potential	 to	 the	 same	 level	 as	 an	
unfractionated	 run	 on	 a	 UPLC-MS/MS	 system	 (Plumb	 et	 al.	 2006).	 In	 this	 study,	 protein	was	
separated	offline	by	SDS-PAGE	into	8	distinct	fractions.	The	benefit	of	SDS-PAGE	is	that	proteins	
can	be	visualised	on	the	gel	so	approximately	comparable	amounts	of	protein	can	be	separated	
in	each	 fraction.	This	 can	also	be	valuable	as	a	quality	 control	 step	 to	 identify	degradation	or	
missing	 proteins.	 Furthermore,	 the	 gel	 acts	 as	 a	 cleaning	 step	 as	 it	 removes	 salts	 and	
contaminants	before	analysis	(Jafari	et	al.	2012).	On	the	other	hand,	the	gel	can	only	accurately	
resolve	proteins	over	a	molecular	weight	of	11kDa.	Therefore,	very	small	proteins	or	polypeptides	
may	be	lost	from	the	bottom	of	the	gel.	
	
Despite	separating	the	proteins	into	8	fractions,	the	technique	described	in	this	project	was	only	
able	to	identify	~200	proteins,	which	represents	only	6.5%	of	the	reported	circulating	proteome	
(Anderson	 and	 Anderson	 2002).	 Proteins	 may	 have	 been	 lost	 through	 sample	 preparation,	
undersampling	 or	 remained	 undetected	 by	 the	 mass	 spectrometer.	 This	 is	 supported	 by	 76	
proteins	only	being	identified	through	a	single	unique	peptide	(supplemental	data,	table	S.28),	
indicating	that	many	peptides	were	missing.	The	small	sample	size	for	this	method	development	
would	not	have	helped	identification.	The	use	of	Progenesis	QIP	analysis	software	can	increase	
the	number	of	proteins	identified	through	alignment	of	ion	abundance	spectra,	but	this	requires	
a	large	sample	size.	
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The	hope	for	this	project	was	to	complete	profiling	by	mass	spectrometry	for	all	15	patients	and	
6	 control	 plasma	 samples.	 However,	 due	 to	 the	 limitations	 of	 this	 experiment,	 such	 as	 long	
preparation	 protocol	 and	 low	 sensitivity	 of	 the	 mass	 spectrometer,	 which	 led	 to	 limited	
identifications	in	the	method	development,	it	was	decided	to	proceed	with	a	different	technique	
for	plasma	profiling.	
	
4.3.2.2	Protein	profiling	using	a	targeted	technique:	SOMAscan	
The	plasma	of	15	BBS	patients	and	6	controls	were	analysed	by	the	targeted	SOMAscan	assay.	Of	
the	 1310	 probes	 available,	 1243	 targets	 were	 measured	 over	 12	 relative	 fluorescent	 units.	
Differentially	 expressed	 proteins	 were	 calculated	 between	 patients	 and	 control	 samples,	
however	no	statistically	significant	comparisons	with	FDR<0.05	were	identified.	This	suggests	that	
for	the	1310	proteins	on	the	SOMAscan	panel,	proteins	detected	within	the	plasma	samples	were	
expressed	similarly	between	patient	and	controls.	
	
Although	not	 statistically	 significant,	 there	were	BBS	 relevant	 findings	within	 the	 top	25	most	
significant	proteins	with	uncorrected	p-value	<0.05.	The	protein	that	had	the	lowest	p-value	was	
leptin,	which	was	upregulated	in	patients	compared	to	controls	(BBS	mean	RFU=	13.22,	95%	CI=	
12.69,	13.75;	control	mean	RFU=	12.0,	95%	CI=	11.25,	12.88;	log2(FC)	=	1.269;	p=0.0003).	This	
finding	 supports	 studies	where	obese	BBS	patients	were	 shown	 to	have	 leptin	 resistance	and	
elevated	circulatory	leptin	(Feuillan	et	al.	2011).	Leptin	is	a	hormone	secreted	by	adipocytes	in	
response	to	energy	intake	and	acts	to	regulate	energy	homeostasis	through	activation	of	leptin	
receptors	 on	 hypothalamic	 neurons	 (Rosenbaum	 and	 Leibel	 2014).	 Secreted	 leptin	 levels	
correlate	with	adiposity	(Han	and	Lean	2016),	thus	elevated	leptin	is	not	specific	to	BBS	patients.	
However,	in	a	study	conducted	by	Seo	et	al.	(2009),	obese	control	mice	could	be	rescued	by	leptin	
treatment,	 whereas	 BBS	 mice	 did	 not	 respond	 to	 leptin	 supplementation,	 suggesting	 that	
resistance	was	intrinsic	and	not	secondary	to	obesity.	As	leptin	elevation	is	known	to	exist	in	BBS	
patients,	it	is	surprising	that	a	significant	difference	is	not	observed	between	patient	and	control	
plasma	samples.	This	may	be	attributed	to	the	BBS1	p.M390R	mutation,	where	circulatory	leptin	
levels	were	shown	to	be	less	than	in	patients	with	mutations	in	other	BBS	genes	(Feuillan	et	al.	
2011).	
	
CRP	was	identified	to	be	upregulated	in	patients	compared	to	controls	(BBS	mean	RFU	=	15.29,	
95%	CI=	14.86,	15.72;	control	mean	RFU	=	14.01,	95%	CI=	13.09,	14.93;	log2(FC)	=	1.28;	p	=	0.009).	
Chapter	4:	Biomarker	discovery	
	
198	
Despite	being	used	as	a	biomarker	 in	clinic,	 this	protein	was	narrowly	within	 the	 top	25	most	
significantly	DE	 proteins.	Other	 inflammatory	markers	 indicative	 of	 the	 acute	 phase	 response	
were	also	present	in	the	top	25	DE	proteins,	such	as	immunoglobulins	and	interleukin	receptors.	
Apolipoprotein	M	(ApoM)	was	downregulated	compared	to	controls	(BBS	mean	RFU=	12.42,	95%	
CI=	12.11,	12.73;	control	mean	RFU=	13.27,	95%	CI=	12.87,	13.68;	log2(FC)	=	-0.836;	p	=	0.006).	
ApoM	is	a	component	of	high	density	lipoprotein	(HDL)	particles	that	function	to	scavenge	lipids,	
such	as	cholesterol,	phospholipids	and	triglycerides,	from	the	circulatory	system	(Mahley,	1988).	
Decreased	ApoM	is	associated	with	diabetes	and	metabolic	syndrome,	thought	to	be	caused	by	
insulin	 resistance	 (Dullaart	 et	 al.	 2009).	 Zheng	 et	 al.	 (2014)	 demonstrated	 that	 increased	
circulating	fatty	acid	levels	in	rats	decreased	expression	of	ApoM	and	reduced	insulin	sensitivity	
(Zheng	et	al.	2014).	This	 finding	may	be	relevant,	as	BBS	patients	exhibit	high	cholesterol	and	
hypertriglyceridemia	(Feuillan	et	al.	2011).	The	decrease	in	ApoM	expression	may	be	highlighting	
the	 metabolic	 abnormalities	 within	 these	 patients	 and	 could	 be	 a	 sign	 of	 insulin	 resistance.	
Further	validation	would	be	required	to	determine	whether	the	differential	expression	of	ApoM	
is	a	true	positive.	
	
4.3.3	Comparison	of	targeted	and	untargeted	proteomic	approaches	
The	SOMAscan	assay	was	a	novel	technology	only	recently	commercialised	for	use	in	research	
centres.	This	project	was	among	one	of	the	first	to	test	this	technology	at	UCL,	therefore	sample	
preparation	and	analysis	were	in	the	early	stages	of	development.	SOMAscan	was	optimised	for	
use	with	plasma,	and	thus	the	panel	consisted	mostly	of	soluble	proteins	commonly	secreted	into	
blood.	As	a	 targeted	panel,	 this	 technique	 is	 limited	by	 the	number	and	affinity	of	 the	SOMA	
aptamers.	 New	 aptamers	 may	 be	 available	 in	 the	 future,	 as	 the	 success	 rate	 for	 generating	
aptamers	specific	to	proteins	is	high	at	85%	(Gold	et	al.	2010).	On	the	other	hand,	aptamers	do	
not	yet	have	the	capability	of	always	recognising	proteins	with	very	similar	sequence	homology.	
For	example,	in	this	study,	immunoglobulin	G	(IgG)	was	identified	from	plasma,	which	may	refer	
to	6	different	homologues	of	IgG	(table	4.7).	At	the	same	time,	however,	the	assay	was	able	to	
detect	at	least	3	different	isoforms	of	apolipoprotein	E	(table	4.6).	
	
SOMAscan	 is	 highly	 sensitive	 and	 only	 requires	 a	 small	 sample	 volume	 (65µl).	 This	 makes	 it	
beneficial	for	clinical	analysis,	especially	for	patients	where	only	small	volumes	of	blood	can	be	
acquired	 (e.g.	 infants).	 Protease	 inhibitors	 are	 added	 upon	 sample	 collection,	 which	 acts	 to	
protect	 samples	 against	 degradation	 during	 transport	 from	 the	 clinic	 and	 sample	 storage.	 By	
contrast,	protease	 inhibitors	 cannot	be	utilised	 for	mass	 spectrometry,	as	 they	would	 impede	
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trypsinisation	 and	 proteocleavage.	 During	 sample	 preparation,	 minimal	 processing	 steps	 are	
required	prior	to	analysis,	which	reduces	experimental	variation.	As	a	targeted	technique,	mixture	
complexity	is	not	a	limiting	factor	for	SOMAscan,	as	each	probe	is	specific	and	cannot	be	masked	
by	other	proteins	with	similar	chemical	properties.	
	
Due	to	the	complexity	of	proteins	and	their	different	chemical	characteristics,	a	single	technique	
may	 not	 be	 able	 to	 provide	 a	 complete	 proteomic	 solution.	 To	 investigate	 this,	 protein	
identifications	for	targeted	and	untargeted	plasma	proteomics	were	compared.	Only	34	proteins	
were	seen	in	both	SOMAscan	and	mass	spectrometry	experiments	(figure	4.19).	This	highlights	
how	 different	 technologies	may	 be	more	 suited	 for	 detection	 of	 certain	 proteins,	 and	 that	 a	
combination	 of	 untargeted	 and	 targeted	 approaches	would	 be	 beneficial	 to	 resolve	 the	 total	
profile	of	a	sample.	Future	elucidation	would	be	required	to	determine	 if	data	can	be	directly	
compared	across	different	assays.	
	
4.3.4	Considerations	for	future	biomarker	experiments	
Another	key	point	to	make	is	that	a	single	sample	of	urine	or	plasma	reflects	only	a	narrow	time	
point	of	an	individual’s	proteome.	Serial	sampling	over	a	long	period	can	enhance	the	confidence	
of	a	true	biomarker	or	can	be	used	to	assess	disease	progression	(Jaffe	et	al.	2006).	Moreover,	
the	 proteomic	 composition	 can	 be	 heavily	 influenced	 by	 the	 time	 of	 day,	 diet,	 exercise,	 or	
medication,	and	therefore	can	be	variable,	even	for	samples	from	the	same	individual.	Protein	
abundance	can	also	be	influenced	by	hydration	levels,	particularly	for	urine	samples	(Dear	et	al.	
2013).	An	important	aspect	of	this	project	has	been	to	devise	standardised	protocols	to	reduce	
variability	in	sample	collection	and	preparation.	Inconsistencies	derived	through	storage	errors	
may	enhance	artificial	significances	and	mask	true	positives	during	analysis.	In	the	experiments	
presented	here,	samples	were	treated	equally,	and	randomisation	was	used	where	possible.	The	
greatest	inconsistency	would	arise	from	time	taken	to	transport	samples	from	clinic	to	the	lab,	
which	 was	 uncontrollably	 varied.	 This	 is	 an	 aspect	 that	 would	 need	 to	 be	 managed	 more	
effectively	in	the	future.	
	
4.3.4.1	Further	work	for	biomarker	discovery	and	validation	
In	 terms	of	morbidity	and	mortality	 in	BBS,	 renal	dysfunction	and	 secondary	 complications	of	
obesity	are	the	most	common	contributing	factors	(Guo	and	Rahmouni	2011;	Forsythe	and	Beales	
2013).	Therefore,	a	biomarker	for	both	of	these	phenotypes	would	aid	patient	management	and	
treatment.	 Although	 patients	 BBS003,	 BBS005,	 BBS007,	 and	 BBS014	 had	 structural	 renal	
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abnormalities,	it	was	not	possible	within	this	experiment	to	stratify	patients	by	this	feature	due	
to	lack	of	statistical	power.	Further	biomarker	discovery	studies	would	need	to	be	implemented	
with	larger	groups	of	BBS	patients,	where	individuals	with	renal	dysfunction	could	be	compared	
to	those	without.	This	investigation	would	benefit	from	a	longitudinal	study	with	serial	sampling	
to	follow	the	progression	of	the	disease.	
	
Within	this	chapter,	the	most	significant	findings	were	related	to	obesity,	diabetes,	or	CVD.	The	
most	promising	identification	was	PEDF,	which	was	found	to	be	statistically	upregulated	in	BBS	
patients	compared	to	controls,	and	previously	linked	to	insulin	resistance	(Famulla	et	al.	2011)	
and	photoreceptor	development	(Steele	et	al.	1993;	Cayouette	et	al.	1999).	Other	results	in	this	
chapter	support	previously	known	relationships	to	BBS,	such	as	elevated	leptin	and	CRP	(Feuillan	
et	al.	2011).	Furthermore,	the	finding	of	diminished	ApoM	in	BBS	patients	may	provide	insight	
into	hypertriglyceridemia	and	hypercholesterolemia	commonly	found	in	BBS.	All	identifications	
within	this	project	must	be	further	verified	by	a	different	proteomic	technique,	such	as	ELISA,	and	
validated	in	a	larger	sample	size.	To	determine	whether	any	of	these	findings	are	specific	to	BBS,	
patients	should	be	compared	to	BMI-matched	controls.	If	proteomic	profiling	techniques	were	to	
be	 implemented	 again,	 samples	 should	 be	 assayed	 by	 mass	 spectrometry	 in	 replicate	 after	
multistep	 fractionation	 to	 increase	 the	 reliability	 and	 sensitivity	 of	 the	 findings.	 A	 targeted	
proteomic	approach	could	be	used	to	help	validate	findings	and	identify	proteins	not	detected	by	
mass	spectrometry.	
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Chapter	5:	Exploration	of	cellular	pathways	in	BBS	patient	
fibroblasts	through	implementation	of	complete	mRNA	
transcriptomic	and	deep	proteomic	profiling	
	
5.1	Background	
5.1.1	Regulatory	pathways	for	control	of	ciliogenesis	
The	ciliome	is	predicted	to	consist	of	up	to	2500	cilia-interacting	genes	(Inglis	et	al.	2006;	Lai	et	
al.	2011;	van	Dam	et	al.	2017).	In	recent	years,	the	identification	of	new	proteins	in	the	ciliome	
has	dramatically	complicated	our	view	of	cilia,	but	simultaneously	has	provided	fascinating	insight	
into	 this	 complex	 organelle	 and	 the	 pathology	 of	 ciliopathies	 (Davis	 and	 Katsanis	 2012).	 The	
primary	 cilium	 is	 now	 known	 to	 be	 linked	 to	 cellular	 processes,	 including	 cell	 cycle	 control,	
cytoskeletal	regulation,	multiple	signalling	cascades,	proteostasis,	vesicle	transport	and	endocytic	
recycling,	cell	motility,	and	autophagy	(Kim	et	al.	2010;	Christensen	et	al.	2008;	Schneider	et	al.	
2005;	Takacs	and	Proikas-Cezanne	2016;	Wheway	et	al.	2015;	Boldt	et	al.	2016).	These	processes	
are	 thought	 to	 be	 involved	 in	 regulation	 and	 maintenance	 of	 ciliogenesis	 and	 cellular	
homeostasis,	though	it	is	currently	uncertain	whether	these	roles	influence	disease	phenotype	
within	the	ciliopathy	spectrum.	
	
5.1.1.1	The	relationship	between	cilia	and	the	cell	cycle	
The	processes	involved	in	cell	cycle	and	ciliogenesis	are	tightly	interconnected.	This	is	due	to	the	
dual	function	of	the	centrosome.	In	the	cell	cycle,	the	centrioles	act	as	a	microtubule	organising	
centre	(MTOC),	thus	controlling	mitotic	spindle	formation	and	chromosome	segregation	during	
mitosis	(Nigg	and	Stearns	2011).	After	cell	division,	the	centrioles	migrate	to	the	apical	cell	surface	
where	the	older,	mother	centriole	nucleates	to	form	the	basal	body	of	the	primary	cilium.	As	a	
result	of	this	multifaceted	role,	ciliogenesis	and	mitosis	cannot	occur	simultaneously,	where	the	
transition	 between	 cell	 cycling	 and	 cilia	 assembly	 must	 be	 tightly	 regulated.	 Cilia	 are	 not	 a	
necessity	for	the	cell	cycle	to	occur,	as	there	are	cell	types	that	do	not	ciliate,	yet	still	proliferate,	
such	as	lymphocytes	(Plotnikova	et	al.	2009).	Studies	in	Drosophila	melanogaster	and	mammalian	
cells	 have	 demonstrated	 that	 functional	 centrosomes	 are	 not	 necessary	 for	 mitotic	 spindle	
formation	and	mitosis	(Mahoney	et	al.	2006;	Uetake	et	al.	2007;	Basto	et	al.	2006),	however	the	
centriole	is	an	essential	requirement	for	cilia	assembly	(Santos	and	Reiter	2008;	Plotnikova	et	al.	
2009).		
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The	balance	between	ciliogenesis	and	cell	cycle	exit/entry	is	controlled	by	centrosome	proteins,	
such	as	CCP110	and	CEP97,	and	the	regulation	of	kinases,	including	PLK1,	NEK2,	and	TTBK2	(Izawa	
et	al.	2015).	CCP110	and	CEP97	form	a	complex	that	is	crucial	for	mitotic	spindle	function	and	
subsequent	 cytokinesis.	 Depletion	 of	 either	 protein	 results	 in	 polyploidy,	 but	 also	 induces	
premature	 ciliogenesis	 in	 proliferating	 cells,	 demonstrating	 that	 CCP110-CEP97	 acts	 as	 an	
inhibitory	 complex	 against	 cilia	 assembly	 (Spektor	 et	 al.	 2007).	 CCP110	 is	 thought	 to	 impede	
ciliogenesis	through	sequestration	of	CEP290,	which	thereby	prevents	recruitment	of	the	small	
GTPase	RAB8A	to	the	basal	body	(Tsang	et	al.	2008);	a	step	essential	for	cilia	biogenesis.	CCP110	
is	 inactivated	via	phosphorylation	by	TTBK2,	which	removes	it	from	the	mother	centriole,	thus	
initiating	 ciliogenesis	 (Tsang	 and	 Dynlacht	 2013).	 Ciliogenesis	 is	 also	 controlled	 through	
manipulation	 of	 microtubule	 dynamics.	 PLK1	 and	 NEK2	 induce	 cilia	 disassembly	 through	
phosphorylation	of	kinesins,	KIF2A	and	KIF24,	respectively	(Miyamoto	et	al.	2015;	S.	Kim	et	al.	
2015).	 Activation	 of	 these	 kinesins	 stimulates	 microtubule	 depolymerisation	 and	 induces	
deacetylation	of	tubulin.	NEK2	and	KIF24	also	act	to	prevent	reassembly	of	the	cilium	as	the	cell	
progresses	 into	 late	G1/S	 phase	 (Kobayashi	 et	 al.	 2011;	 Izawa	 et	 al.	 2015).	 Furthermore,	 key	
signalling	pathways,	such	as	sonic	hedgehog	(SHH)	pathway,	can	promote	cell	cycle	progression	
and	 cilia	 disassembly	 to	 induce	 proliferation	 (Kenney	 et	 al.	 2003).	 HH	 signalling	 upregulates	
expression	of	cyclin	proteins,	which	activates	cyclin-dependent	kinases	(CDKs),	promoting	entry	
into	G1/S	phase	(Kenney	et	al.	2003;	Ruiz	I	Altaba	et	al.	2002).	
	
There	have	been	many	studies	that	have	linked	proteins	crucial	to	cilia	function	with	additional	
roles	 in	cell	 cycle	 regulation.	For	example,	 IFT88	 localised	 to	 the	centrosome	during	cell	 cycle	
where	it	was	shown	to	regulate	G1/S	transition	in	non-ciliated	cells.	Furthermore,	overexpression	
of	 IFT88	prevented	progression	 into	S	phase	and	 induced	apoptosis	 (Robert	et	al.	2007).	Dual	
capabilities	have	also	been	demonstrated	by	the	centrosome	protein,	pericentrin	(encoded	by	
PCNT),	which	is	required	for	correct	localisation	of	IFT	proteins	(Jurczyk	et	al.	2004),	but	also	for	
mitotic	spindle	formation	and	entry	into	mitosis	(Zimmerman	et	al.	2004).	Moreover,	Kim	et	al.	
(2004)	elucidated	that	BBS4	is	essential	for	recruitment	of	cargo	to	the	centrioles	and	subsequent	
microtubule	nucleation.	Ablation	of	BBS4	 resulted	 in	mislocalisation	of	 pericentriolar	material	
protein	PCM1,	disruption	of	the	cell	cycle,	and	increased	apoptosis	(Kim	et	al.	2004).	This	role	was	
likely	to	be	in	addition	to	its	capacity	within	the	BBSome.	
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In	cell	culture,	 regular	replenishment	of	growth	factors	and	availability	of	space	for	expansion	
means	that	cells	can	cycle	continuously	until	confluence	at	a	higher	density	is	reached.	Therefore,	
in	order	 to	 induce	cell	 cycle	arrest,	cells	 in	culture	can	be	serum	starved,	which	consequently	
stimulates	ciliogenesis	(Tucker	et	al.	1979).	Maximal	ciliation	(>90%	of	cells)	has	been	reported	
to	occur	after	24-48	hours	of	serum	starvation	in	fibroblasts	(Schneider	et	al.	2005;	Christensen	
et	al.	2013).	Cilia	start	to	form	in	early	G1	phase,	and	are	most	abundant	in	G0.	Resorption	of	the	
primary	cilia	occurs	over	24	hours,	with	complete	disassembly	by	the	time	the	cell	has	committed	
to	DNA	replication	and	centrosome	duplication,	prior	to	mitosis	(Tucker	et	al.	1979)	(figure	5.1).	
	
5.1.1.2	Regulation	by	the	actin	cytoskeleton	
The	 cytoskeleton	 refers	 to	 three	 structural	 protein	 filaments;	 microtubules,	 intermediate	
filaments,	and	actin.	 In	addition	to	microtubule	dynamics,	the	actin	cytoskeleton	is	thought	to	
regulate	cilia	formation	(Malicki	and	Johnson	2017).	The	evidence	arises	from	research	showing	
that	 ablation	 of	 ciliary	 proteins	 increased	 actin	 stress	 fibre	 formation,	 shortened	 cilia,	 and	
reduced	cell	motility	(Hernandez-Hernandez	et	al.	2013).	Furthermore,	a	web	of	actin	filaments	
has	been	demonstrated	to	act	as	a	docking	site	for	the	basal	body	at	the	apical	surface	of	mouse	
primary	culture	epithelial	 cells	 (Pan	et	al.	2007).	This	 interaction	was	dependent	on	 the	 small	
GTPase	RHOA,	which	regulates	actin	dynamics	and	formation	of	focal	adhesions	between	cells.	
BBS	proteins	were	shown	to	control	RHOA	activity,	as	ablation	of	Bbs4	and	Bbs6	in	mouse	renal	
cells	 upregulated	 RhoA	 in	 the	 GTP	 active	 form,	 resulting	 in	 cytokinesis	 and	 motility	 defects	
(Hernandez-Hernandez	et	al.	2013).	
	
RHOA	activated	actin	remodelling	has	been	proposed	to	act	as	a	regulatory	event	for	ciliogenesis,	
where	actin	acts	to	recruit	the	basal	body	to	the	apical	surface	(Pan	et	al.	2007).	However,	actin	
has	also	demonstrated	an	inhibitory	role,	where	its	presence	prevents	ciliary	assembly.	Silencing	
of	the	ARP2/3	complex	required	for	actin	branching,	diminished	actin	nucleation	and	enhanced	
ciliogenesis,	even	in	the	absence	of	serum	starvation	(Kim	et	al.	2010;	Cao	et	al.	2012).	On	the	
other	hand,	upregulation	of	actin	destabilisation	protein,	gelsolin,	enhanced	cilia	 formation	(J.	
Kim	et	al.	2015;	Kim	et	al.	2010).	It	is	thought	that	actin	may	inhibit	ciliogenesis	by	operating	as	a	
mechanical	barrier	to	prevent	trafficking	of	vesicles	to	the	basal	body	(Malicki	and	Johnson	2017;	
Kim	et	al.	2010).	This	suggests	that	actin	aids	basal	body	targeting	to	the	apical	membrane,	and	
also	prevents	early	onset	of	ciliogenesis	before	the	basal	body	is	attached.	
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Figure	 5.1	 –	 Schematic	 representation	 of	 the	 centrosome’s	 dual	 function	 linking	 the	 cell	 cycle	 with	
ciliogenesis.	During	early	G1	of	the	cell	cycle,	the	centrosome	translocates	to	the	apical	membrane	where	
the	mother	centriole	nucleates	to	form	the	basal	body	of	the	primary	cilium.	Cilia	reach	their	full	length	
and	are	most	abundant	 in	G0	when	cells	are	 in	a	quiescent	state.	Upon	re-entry	 into	the	cell	cycle,	the	
cilium	disassembles	 prior	 to	 S	 phase	 entry.	 As	DNA	 replicates	 in	 S,	 the	 centrioles	 duplicate,	where	 the	
daughter	centriole	from	the	previous	cycle	matures	to	become	the	mother	centriole	for	the	next	cycle.	
During	 mitosis,	 the	 mature	 centrosomes	 form	 mitotic	 spindles	 at	 each	 pole,	 which	 segregates	 the	
chromosomes	for	cytokinesis.	
	
5.1.1.3	The	ciliary	function	in	proteostasis	
The	 regulation	 of	 proteins	 by	 proteostasis	 is	 essential	 for	 cellular	 function,	 signalling,	 and	
maintenance.	The	primary	cilium	is	a	fundamental	player	in	orchestrating	the	26S	proteasome,	a	
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complex	of	43	protein	subunits	that	exhibit	proteolytic	activity.	The	proteasome	consists	of	the	
19S	regulatory	subunit	and	20S	catalytic	subunit,	which	together	creates	the	26S	proteasome,	
responsible	 for	 degradation	 of	 ~80-90%	 of	 a	 cell’s	 proteins	 (Lilienbaum	 2013).	 In	 addition	 to	
degradation	 of	 surplus	 or	 defective	 proteins,	 the	 proteasome	 also	 acts	 as	 a	 modulator	 for	
signalling	pathways,	such	as	HH	and	Wnt	signalling.	The	proteasome	is	responsible	for	proteolytic	
cleavage	of	Gli2/3	from	an	active	to	a	repressor	form	(Wang	et	al.	2007),	in	addition	to	switching	
Wnt	 signalling	 to	b-catenin	 independent	 pathways	 by	 degradation	 of	b-catenin	 (Aberle	 et	 al.	
1997).	Proteins	are	marked	for	degradation	through	addition	of	ubiquitin	molecules	by	a	three-
step	 cascade,	 requiring	 respective	 activity	 of	 E1	 ubiquitin-activating	 enzymes,	 E2	 ubiquitin-
conjugating	enzymes,	and	E3	ubiquitin	ligases	(Lilienbaum	2013).	
	
Members	 of	 the	 19S	 regulatory	 proteasome	 localise	 to	 the	 basal	 body	 in	 wild	 type	 mouse	
epithelial	fibroblasts	(MEFs),	whereas	Psma5	of	the	20S	subunit,	localised	to	the	ciliary	base	and	
along	the	axoneme,	indicating	an	association	with	IFT	machinery.	Furthermore,	Psmd2,	a	member	
of	the	19S	regulatory	complex,	exhibited	a	direct	interaction	with	Rpgrip1l,	which	was	necessary	
for	 robust	 proteasome	activity	 (Liu	 et	 al.	 2014).	 Cilia	 genes,	 including	BBS4,	OFD1,	 BBS7,	 and	
RPGRIP1L,	have	been	reported	to	be	required	for	proper	localisation	of	proteasome	subunits	at	
the	centrosomes	and	basal	body	(Liu	et	al.	2014;	Gascue	et	al.	2012;	Gerdes	et	al.	2007;	Gerhardt	
et	al.	2015).	Loss	of	BBS4	resulted	in	aberrant	proteasome	targeting	to	centrosomes	and	the	basal	
body,	and	an	increase	in	cytoplasmic	b-catenin	(Gerdes	et	al.	2007;	Liu	et	al.	2014).	This	close	
interaction	with	ciliary	proteins	and	the	proteasome	may	assist	in	determining	a	mechanism	to	
explain	perturbed	planar	cell	polarity	in	BBS	mutants	(Ross	et	al.	2005;	Cui	et	al.	2013).	In	relation	
to	 proteostasis	 regulation,	 the	 ubiquitination	 machinery	 is	 also	 thought	 to	 closely	 regulate	
ciliogenesis	and	cilia	function	(Kasahara	et	al.	2014;	Wheway	et	al.	2012).	
	
5.1.2	Strategy	for	pathway	identification	in	BBS	
The	evidence	from	the	literature	presented	so	far	within	this	chapter	suggests	that	the	pathways	
involved	 in	 ciliary	 function	 and	 maintenance	 are	 highly	 dynamic,	 requiring	 continuous	
interactions	and	signalling	events	with	 the	 rest	of	 the	cell.	 Investigation	of	 ciliary	pathways	 in	
cellular	models	of	ciliopathies	have	rarely	been	studied	on	a	global	scale,	and	seldom	with	use	of	
patient	derived	cells.	Within	this	study,	 fibroblasts	 from	15	BBS	patients	manifesting	the	BBS1	
p.M390R	variant	have	been	utilised	to	identify	cellular	processes	that	are	differentially	regulated	
in	 response	 to	 serum	 starvation	 and	 by	 comparison	with	 fibroblasts	 obtained	 from	6	 healthy	
controls.	This	has	been	achieved	through	two	methods	of	large-scale	data	acquisition;	via	RNA-
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seq	to	attain	the	global	mRNA	transcriptome,	and	by	isobaric	tagging	for	relative	and	absolute	
quantitation	(iTRAQ)	mass	spectrometry	to	achieve	deep	proteomic	profiling.	
	
5.1.2.1	iTRAQ	proteomics	
In	chapter	4,	untargeted	label-free	proteomics	was	utilised	to	identify	proteins	within	plasma	and	
urine	samples.	Label-free	proteomics	 is	a	 low	cost	quantitation	method	with	rapid	turnaround	
times.	This	makes	it	advantageous	for	large	scale	biomarker	discovery	projects,	which	requires	
multiple	validation	steps	following	candidate	identification	(Griffin	et	al.	2010).	However,	as	each	
sample	is	separately	processed	and	analysed,	experimental	variability	may	occur	during	sample	
preparation	steps.	Isotopically-labelled	proteomics	provides	a	method	of	reducing	variation,	as	
samples	 are	distinctly	 labelled	and	pooled	prior	 to	processing.	 Furthermore,	 isotopic	 labelling	
offers	 a	 robust	 quantification	 method	 (Wang	 et	 al.	 2012).	 The	 accuracy	 of	 label-free	 mass	
spectrometry	relies	on	chromatographic	reproducibility,	and	the	sensitivity	of	the	instrument,	to	
measure	the	same	ion	precisely	across	different	samples.	In	contrast,	pooling	of	labelled	samples	
means	 that	each	 ion	 is	 identically	assayed	and	quantified	within	 the	exact	 same	experimental	
parameters.	This	reduces	any	external	variability	and	dramatically	increasing	accuracy	(Wiese	et	
al.	2007;	Timms	and	Cutillas	2010).	Within	this	chapter,	iTRAQ	mass	spectrometry	was	utilised	for	
deep	proteomic	profiling.		
	
iTRAQ	labels	samples	with	peptide-based	tags	that	are	chemically	identical,	but	can	be	detected	
by	mass	spectrometry	due	to	their	different	fragmentation	patterns	during	MS/MS	(Timms	and	
Cutillas	2010).	Peptides	undergo	derivatisation	with	the	 iTRAQ	tags	at	amine	groups	of	 the	N-
terminal	and	lysine	residues.	Within	the	iTRAQ	tag,	there	is	a	balancer	group	and	a	reporter	ion	
component,	where	the	two	together	have	a	total	mass	of	305.1	Da.	During	MS/MS	fragmentation,	
the	balancer	group	is	lost,	as	it	has	a	neutral	charge,	and	the	remaining	reporter	group	is	released	
(Aggarwal	and	Yadav	2016).	Within	this	study,	an	8-plex	iTRAQ	methodology	was	implemented,	
featuring	8	different	tags	with	reporter	groups	that	generate	ions	at	mass	to	charge	ratios	(m/z)	
of	113,	114,	115,	116,	117,	118,	119,	and	121,	respectively,	upon	MS/MS	fragmentation.	As	a	
result,	 both	peptide	 identification	 and	quantitation	occurred	 at	 the	MS/MS	 level.	 Since	 every	
peptide	of	each	sample	is	labelled	with	their	respective	tag,	relative	quantitation	occurs	by	direct	
comparison	of	ion	intensity	for	the	reporter	groups	of	each	peptide	(figure	5.3).	
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Figure	 5.2	 –	 Experimental	 and	 methodological	 design	 for	 iTRAQ	 mass	 spectrometry.	 Protein	 from	
fibroblasts	was	extracted	and	quantitated	before	pooling	into	7	groups	of	3	samples,	each	for	serum	fed	
and	serum	starved	samples.	An	iTRAQ	reagent	tag	was	assigned	to	each	pool.	The	bridge	sample	contained	
a	complete	pool	of	all	samples	and	was	added	as	the	8	sample	to	both	runs.	All	tagged	samples	were	pooled	
by	 serum	 fed	 or	 serum	 starved	 experiments	 for	 fractionation	 and	 mass	 spectrometry.	 Peptides	 were	
identified	and	quantified	from	MS/MS	spectra.	The	peptide	fragmentation	ions,	represented	by	the	black	
peaks,	 were	 used	 for	 peptide	 identification.	 iTRAQ	 tags	 produced	 a	 fragment	 ion,	 represented	 by	 the	
coloured	peaks,	with	a	specific	m/z.	Peptides	from	a	single	sample	were	quantifiable	by	the	intensity	of	the	
respective	 iTRAQ	 tag.	 The	 bridge	 sample	 was	 used	 to	 normalise	 the	 two	 iTRAQ	 runs	 for	 comparison	
between	fed	and	starved	groups.	
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As	an	8-plex	iTRAQ	kit	was	utilised,	in	order	to	profile	all	42	samples,	they	had	to	be	pooled	into	
groups	of	3	and	separated	into	two	iTRAQ	experiments.	One	8-plex	experiment	was	comprised	
of	 21	 serum	 starved	 fibroblast	 samples	 (15	 patients,	 6	 controls)	 and	 the	 other	 for	 21	 fed	
fibroblasts	samples.	The	8th	sample	on	each	iTRAQ	run	consisted	of	a	total	pool	of	all	samples,	
named	 a	 bridge	 sample.	 During	 analysis,	 this	 sample	 was	 used	 to	 normalise	 across	 the	 two	
experiments	 so	 that	 the	 serum	 starved	 experiment	 could	 be	 directly	 compared	with	 the	 fed	
experiment.	Deep	proteomic	profiling	was	ensured	by	fractionation	into	20	fractions	by	reverse	
phase	chromatography	prior	to	high	performance	liquid	chromatography	(HPLC)	coupled	to	triple	
quadrupole	time	of	flight	(Q-ToF)	mass	spectrometry	(figure	5.3).	
	
5.1.3	Aims	of	investigation	
The	15	patients	in	this	study	all	carry	the	p.M390R	mutation	in	BBS1,	the	pathobiology	of	which	
is	 generally	 unknown.	 Investigation	 of	 the	 crystal	 structure	 of	 the	 BBS1:ARL6GTP	 interaction	
demonstrated	 that	 p.M390R	 reduces	 the	BBS1’s	 affinity	 for	ARL6,	which	 is	 required	 for	 BBS1	
recruitment	 to	 the	 basal	 body	 (Mourão	 et	 al.	 2014).	 However,	 outside	 of	 the	 BBSome,	 the	
function	of	BBS1	remains	elusive.	Various	ciliopathy	proteins,	including	those	that	function	within	
the	 BBSome,	 have	 additional	 cellular	 duties	 (Hernandez-Hernandez	 et	 al.	 2013;	 Gascue	 et	 al.	
2012;	Liu	et	al.	2014).	With	this	knowledge,	this	study	aimed	to	identify	differentially	regulated	
pathways	that	may	help	determine	the	pathology	associated	with	the	BBS1	p.M390R	mutation.	
To	our	knowledge,	this	was	the	first	study	of	its	kind	to	globally	identify	differential	expression	
and	altered	pathways	in	such	patient-derived	cultures.	
	
Fibroblasts	from	15	BBS	patients	and	6	controls	were	cultured	under	2	conditions;	to	promote	
cell	cycle	progression	(serum	fed	with	10%	fetal	bovine	serum	(FBS)),	and	to	promote	ciliogenesis	
(serum	starved	with	0.5%	FBS	 for	48	hours).	 The	purpose	of	 this	was	 to	 identify	differentially	
expressed	 genes	 and	 proteins	 that	 would	 be	 up	 or	 downregulated	 as	 a	 consequence	 of	
ciliogenesis.	 These	could	also	be	compared	between	disease	and	control	groups.	The	analysis	
strategy	 was	 divided	 into	 three	 sections,	 which	 aimed	 to	 identify	 differentially	 expressed	
candidates,	 significantly	 enriched	 gene	 sets,	 and	 differentially	 regulated	 pathways,	 both	 for	
transcriptomic	 and	 proteomic	 datasets	 (figure	 5.4).	 Further	 to	 this,	 different	 datasets	 were	
integrated	 to	 find	pathways	 that	were	 interconnected	between	 transcriptomic	and	proteomic	
datasets,	thereby	enhancing	the	power	of	the	analysis.	These	aims	were	implemented	through	
use	 of	 various	 computational	 databases	 and	 analytical	 tools.	 Of	 note,	 unpublished	
experimentation	 from	 our	 lab	 has	 revealed	 no	 phenotypic	 and	 morphological	 dissimilarities	
Chapter	5:	Multi-omic	investigation	of	BBS	
	
209	
between	 fibroblast	 cultures	 obtained	 from	 controls	 and	 patients	 carrying	 the	BBS1	 p.M390R	
variant.	
	
The	 study	 design	 allowed	 a	 3-way	 comparison	 strategy.	 Firstly,	 serum	 starved	 BBS	 cells	were	
compared	with	starved	control	cultures	to	identify	differences	in	ciliated	cells;	secondly,	serum	
fed	BBS	fibroblasts	were	analysed	against	fed	control	cells	to	find	differences	in	proliferating	cells;	
and	finally,	BBS	starved	cells	were	compared	to	BBS	fed	cells,	with	an	equivalent	comparison	of	
control	cells.	In	this	way,	the	study	isolates	BBS	specific	findings	in	response	to	starvation.	Overall,	
this	analytical	strategy	has	instigated	the	identification	of	pathways	and	gene	sets	linked	to	BBS	
pathology.	This	has	 included	disease	 relevant	 findings	 related	 to	obesity,	 as	well	 as	processes	
involved	in	regulation	of	the	primary	cilium	such	as	centrosome	function,	RHO	GTPase	activity,	
and	cilium	assembly.	
Figure	5.3	–	Experimental	design	and	analysis	strategy	for	chapter	5.	RNA	and	protein	were	extracted	from	
serum	fed	and	serum	starved	fibroblasts	of	15	BBS	patients	and	6	controls.	RNA	and	protein	were	compared	
for	differentially	expressed	transcripts/proteins	between	treatment	groups	and	disease	status	i.e.	patient	
vs	control,	serum	starved	vs	serum	fed	cells.	Pathway	and	gene	set	enrichment	analyses	were	utilised	for	
each	comparison.	Finally,	 transcriptomic	and	proteomic	data	 from	BBS	cells	were	 integrated	to	 identify	
interconnecting	differentially	regulated	networks.	 	
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5.2	Results	
5.2.1	Experimental	design	and	quality	control	
5.2.1.1	Ciliation	of	fibroblasts	
In	cultured	cells,	ciliogenesis	was	induced	via	serum	starvation	by	decreasing	media	FBS	content	
from	10%	to	0.5%	for	48	hours.	The	response	to	starvation	was	first	tested	through	qPCR	and	
immunocytochemical	staining	to	ensure	that	there	was	a	sufficient	difference	to	implement	the	
experimental	design.	Ciliogenesis	 studies	were	carried	out	using	5	primary	 fibroblast	 cultures,	
randomly	 selected	 from	 the	 cohort.	Gene	expression	 analysis	was	 completed	by	qPCR,	which	
established	that	serum	starvation	significantly	increased	expression	of	BBS1	(relative	fold	change	
(RFC)=	7.35;	 fed	mean	∆CT=	6.81,	95%	CI	=	5.95,	7.67;	starved	mean	∆CT=	3.93,	95%	CI=	3.40,	
4.46;	p=	0.0005),	BBS2	(RFC=	5.16;	fed	mean	∆CT=	7.22,	95%	CI=	6.51,	7.92;	starved	mean	∆CT=	
4.85,	95%	CI=	4.22,	5,48;	p=0.0012),	BBS8	(RFC=	3.64;	fed	mean	∆CT=6.58,	95%	CI=	5.77,	7.38;	
starved	∆CT=4.72,	95%	CI=	3.94,	5.49;	p=	0.0115),	and	CEP290	(RFC=	4.81;	fed	mean	∆CT=	8.53,	
95%	CI=	7.78,	9.28;	starved	mean	∆CT=	6.26,	95%	CI=	5.53,	7.00;	p=	0.0028)	transcripts	(figure	
5.4A).	
	
Protein	analysis	of	serum	fed	and	starved	cells	was	determined	through	 immunocytochemical	
staining	 of	 acetylated	 tubulin.	 There	 was	 an	 increase	 in	 ciliated	 cells	 after	 48	 hours	 serum	
starvation	 (figure	 5.4B).	 Furthermore,	 the	 percentage	 of	 ciliated	 cells	 for	 fed	 and	 starved	
fibroblasts	was	established	using	an	ImageJ	macro	for	cilia	counting.	The	frequency	of	observed	
cilia	per	image	was	divided	by	the	number	of	nuclei.	30	images	were	taken	over	5	cultures	for	
each	treatment	group	and	the	mean	calculated	(figure	5.4C).	There	was	a	significant	increase	in	
ciliated	cells	after	serum	starvation	compared	serum	fed	cells	 (starved	mean=	78.0%,	95%	CI=	
70.6,	85.3;	fed	mean=	33.8%,	95%	CI=	25.2,	42.4;	p<0.0001).	Despite	this	 large	difference,	fed	
cells	 demonstrated	 a	 greater	 number	 of	 ciliated	 cells	 than	 expected.	 It	 was	 noted	 that	 the	
majority	of	ciliated	cells	in	fed	cultures	were	found	in	fibroblasts	grown	to	a	higher	confluency,	
which	would	also	have	induced	cell	cycle	arrest.	Therefore,	following	this	method	development	
experiment,	serum	fed	cell	cultures	used	for	RNA-seq	and	iTRAQ	proteomic	experiments	were	
controlled	for	cell	cycling	by	fixation	at	70-80%	confluency.	
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Figure	5.4	–	Increase	in	ciliogenesis	induced	by	serum	starvation.	A)	Relative	fold	change	of	gene	expression	
of	basal	body	genes	BBS1,	BBS2,	BBS8	and	CEP290	upon	starvation	of	 fibroblasts.	Error	bars	show	95%	
confidence	intervals	(CI)	established	from	5	biological	repeats.	Samples	were	normalised	to	reference	gene	
ACTB.	B)	Immunocytochemical	analysis	of	cilia	by	staining	with	acetylated	tubulin	(white	arrows)	for	serum	
fed	(top)	and	serum	starved	cells	 (bottom),	where	nuclei	were	stained	with	DAPI.	C)	The	percentage	of	
ciliated	fibroblasts	with	and	without	starvation,	averaged	over	5	fibroblasts	cultures.	Error	bars	show	95%	
CI,	calculated	from	30	images	per	treatment	over	5	cell	cultures.	
	
5.2.1.2	Quantification	and	quality	control	of	RNA	
Prior	to	RNA-seq,	total	RNA	was	assessed	for	quality	and	concentration	using	the	Agilent	4200	
TapeStation.	 An	 RNA	 integrity	 number	 (RIN)	 was	 provided	 by	 the	 TapeStation	 output	 as	 a	
numerical	 assessment	 of	 the	 quality	 of	 RNA.	A	 score	 of	 10	 indicates	 intact	 RNA	whereas	 1	 is	
completely	 degraded;	 a	 recommended	 threshold	 for	 good	 quality	 is	 a	 RIN	 score	 above	 8.	 All	
samples	that	were	sequenced	had	an	RIN	of	8	or	above.	The	results	featuring	RNA	extracted	from	
serum	 starved	 (treated)	 and	 fed	 (untreated)	 fibroblasts	 from	 15	 patients	 and	 6	 controls	 are	
displayed	in	table	5.1.	
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Patient	ID	 Condition	 Concentration	(ng/µl)	 Yield	(µg)	 RIN	 28S/18S	
BBS001	 Starved	(treated)	 36.8	 1.104	 9.4	 3.2	
BBS002	 Starved	(treated)	 66	 1.98	 9.8	 2.2	
BBS003	 Starved	(treated)	 53.1	 1.593	 10	 2.4	
BBS004	 Starved	(treated)	 57.4	 1.722	 8.9	 2.8	
BBS005	 Starved	(treated)	 45.6	 1.368	 9.5	 3.1	
BBS006	 Starved	(treated)	 64.4	 1.932	 9.9	 2.5	
BBS007	 Starved	(treated)	 98.6	 2.958	 9.9	 3.4	
BBS008	 Starved	(treated)	 63	 1.89	 10	 3	
BBS009	 Starved	(treated)	 66.1	 1.983	 10	 3.1	
BBS010	 Starved	(treated)	 83.3	 2.499	 10	 3.1	
BBS011	 Starved	(treated)	 31.4	 0.942	 9.4	 2.4	
BBS012	 Starved	(treated)	 123.0	 3.69	 9.9	 2.6	
BBS013	 Starved	(treated)	 46.8	 1.404	 9.3	 2.8	
BBS014	 Starved	(treated)	 49.6	 1.488	 8.9	 3.3	
BBS015	 Starved	(treated)	 88.0	 2.64	 10	 2.6	
CTRL019	 Starved	(treated)	 75.5	 2.265	 9.8	 3.1	
CTRL020	 Starved	(treated)	 98.6	 2.958	 9.8	 3.3	
CTRL031	 Starved	(treated)	 50.2	 1.506	 8.9	 3.1	
CTRL032	 Starved	(treated)	 306	 9.18	 10	 3.2	
CTRL033	 Starved	(treated)	 19.4	 0.582	 9.4	 2	
CTRL030	 Starved	(treated)	 138	 4.14	 10	 2.8	
BBS001	 Fed	(untreated)	 79.8	 2.394	 10	 2.8	
BBS002	 Fed	(untreated)	 60.2	 1.806	 10	 2.7	
BBS003	 Fed	(untreated)	 55.2	 1.656	 9.4	 3.8	
BBS004	 Fed	(untreated)	 74.4	 2.232	 9.4	 2.7	
BBS005	 Fed	(untreated)	 89.2	 2.676	 10	 2.9	
BBS006	 Fed	(untreated)	 19.94	 0.5982	 9.4	 3.3	
BBS007	 Fed	(untreated)	 47.6	 1.428	 9	 3.7	
BBS008	 Fed	(untreated)	 114	 3.42	 10	 3	
BBS009	 Fed	(untreated)	 21.2	 0.636	 9.5	 2.7	
BBS010	 Fed	(untreated)	 20.8	 0.624	 8.6	 2.1	
BBS011	 Fed	(untreated)	 153.0	 4.59	 10	 3.1	
BBS012	 Fed	(untreated)	 181.0	 5.43	 10	 3.1	
BBS013	 Fed	(untreated)	 135.0	 4.05	 10	 3	
BBS014	 Fed	(untreated)	 95.6	 2.868	 10	 3.6	
BBS015	 Fed	(untreated)	 354.0	 10.62	 8.3	 2.2	
CTRL019	 Fed	(untreated)	 116	 3.48	 9.9	 3.3	
CTRL020	 Fed	(untreated)	 218	 6.54	 10	 3	
CTRL031	 Fed	(untreated)	 68.4	 2.052	 8	 3.1	
CTRL032	 Fed	(untreated)	 127	 3.81	 9.9	 3.9	
CTRL033	 Fed	(untreated)	 267	 1.716	 9.4	 3.1	
CTRL030	 Fed	(untreated)	 129	 3.87	 10	 3.5	
Table	5.1	–	Sample	quantitation	and	quality	control	results	from	RNA	extracted	from	serum	fed	or	serum	
starved	fibroblasts.	
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RNA	quality	was	 additionally	 assessed	by	 the	 ribosomal	 28S/18S	 ratio.	 This	was	 calculated	by	
electrophoretic	 separation	 of	 the	 RNA	 within	 the	 TapeStation	 chip	 and	 comparison	 of	 the	
molecular	weights	 against	 the	 ladder.	 There	 should	 be	 two	distinct	 peaks	 on	 the	 read	out	 at	
~2000nt	and	~4000nt,	which	represent	 the	18S	and	28S	ribosomal	subunits,	 respectively.	The	
ribosomal	ratio	is	calculated	from	the	area	of	the	28S	peak	divided	by	the	area	of	the	18S	peak.	
Small	RNAs	can	also	be	detected	with	a	peak	~200nt.	An	electropherogram	representative	of	RNA	
with	a	high	integrity	score	is	presented	in	figure	5.5A.	Ideally,	the	base	of	the	28S	peak	should	be	
twice	the	width	of	18S	and	have	greater	signal	 intensity.	Less	distinct	or	shifted	peaks	suggest	
RNA	degradation	 (figure	 5.5B).	 The	 electrophoresis	 gel	 image	 for	 each	 sample	 is	 displayed	 in	
figure	5.6.	
	
Figure	5.5	–	Electropherogram	traces	of	RNA	run	on	the	TapeStation	chip.	A)	RNA	with	high	integrity	score	
(RIN	10),	demonstrating	how	to	recognise	quality	from	the	electropherogram.	B)	Illustration	of	RNA	with	
reduced	integrity.	A	sample	with	RIN	8.1	can	still	be	sequenced,	whereas	a	score	of	3.7	shows	significant	
degradation.	
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Figure	5.6	–	Single	lane	electrophoresis	outputs	from	TapeStation	showing	the	bands	of	ribosomal	subunits,	
28S	and	18S,	and	corresponding	RIN	for	each	sample	(where	S	and	F	 indicate	starved	and	fed	samples,	
respectively).	
	
5.2.1.3	Quantitation	of	protein	from	fibroblasts	
Serum	starved	and	serum	fed	fibroblasts	from	15	patients	and	6	controls	sent	to	Beijing	Genome	
Institute	(Hong	Kong,	China)	for	iTRAQ	mass	spectrometry.	Protein	extracted	from	fibroblasts	by	
homogenisation	was	quantitated	by	Bradford	assay,	where	absorbance	was	measured	at	595nm	
and	a	standard	curve	was	generated	from	BSA	standards	(figure	5.7).	The	quantity	of	protein	for	
each	sample	was	calculated	using	the	equation	of	the	standard	curve	(table	5.2).	Samples	were	
then	pooled	into	sets	of	3,	forming	7	pools	for	the	serum	starved	experiment,	and	7	pools	for	the	
serum	fed	experiment.	A	complete	pool	of	all	samples	made	the	8th	sample,	which	was	run	on	
both	mass	spectrometry	runs.	This	sample	was	used	to	normalise	samples	across	the	two	runs	to	
ensure	they	were	comparable.	
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Figure	 5.7	 –	 Standard	 curve	 generated	 by	 Bradford	 assay	 that	was	 used	 for	 quantitation	 of	 fibroblast-
derived	protein.	
	
Sample	Name	
Sample	name	
analysis	
Concentration	
(µg/µl)	
Yield	(µg)	 Pooling	info	 Run	info	
BBS001	 Starved	(treated)	 1.49	 447.82	 Pool	1	 Run	1	
BBS002	 Starved	(treated)	 1.48	 443.45	 Pool	1	 Run	1	
BBS003	 Starved	(treated)	 1.74	 520.55	 Pool	1	 Run	1	
BBS004	 Starved	(treated)	 1.87	 559.82	 Pool	2	 Run	1	
BBS005	 Starved	(treated)	 1.52	 456.73	 Pool	2	 Run	1	
BBS006	 Starved	(treated)	 2.29	 686.00	 Pool	2	 Run	1	
BBS007	 Starved	(treated)	 2.08	 624.00	 Pool	3	 Run	1	
BBS008	 Starved	(treated)	 1.44	 430.55	 Pool	3	 Run	1	
BBS009	 Starved	(treated)	 1.54	 463.27	 Pool	3	 Run	1	
BBS010	 Starved	(treated)	 1.09	 326.18	 Pool	4	 Run	1	
BBS011	 Starved	(treated)	 1.39	 416.00	 Pool	4	 Run	1	
BBS012	 Starved	(treated)	 1.68	 502.55	 Pool	4	 Run	1	
BBS013	 Starved	(treated)	 2.46	 736.73	 Pool	5	 Run	1	
BBS014	 Starved	(treated)	 1.68	 502.55	 Pool	5	 Run	1	
BBS015	 Starved	(treated)	 1.42	 426.55	 Pool	5	 Run	1	
CTRL019	 Starved	(treated)	 1.50	 450.91	 Pool	6	 Run	1	
CTRL020	 Starved	(treated)	 1.34	 402.00	 Pool	6	 Run	1	
CTRL030	 Starved	(treated)	 1.18	 355.27	 Pool	6	 Run	1	
CTRL031	 Starved	(treated)	 1.20	 361.09	 Pool	7	 Run	1	
CTRL032	 Starved	(treated)	 1.47	 440.36	 Pool	7	 Run	1	
CTRL033	 Starved	(treated)	 1.33	 400.36	 Pool	7	 Run	1	
BBS001	 Fed	(untreated)	 1.34	 401.64	 Pool	1	 Run	2	
BBS002	 Fed	(untreated)	 1.26	 376.55	 Pool	1	 Run	2	
BBS003	 Fed	(untreated)	 1.24	 370.55	 Pool	1	 Run	2	
BBS004	 Fed	(untreated)	 1.51	 453.64	 Pool	2	 Run	2	
y	=	1.6446x	+	0.0396
R²	=	0.99343
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16 0.18 0.2
Ab
so
rb
an
ce
	(5
95
nm
)
BSA	concentration	(µg/µl)
Chapter	5:	Multi-omic	investigation	of	BBS	
	
216	
BBS005	 Fed	(untreated)	 1.58	 474.36	 Pool	2	 Run	2	
BBS006	 Fed	(untreated)	 1.53	 459.09	 Pool	2	 Run	2	
BBS007	 Fed	(untreated)	 1.44	 430.55	 Pool	3	 Run	2	
BBS008	 Fed	(untreated)	 1.46	 438.55	 Pool	3	 Run	2	
BBS009	 Fed	(untreated)	 1.63	 488.00	 Pool	3	 Run	2	
BBS010	 Fed	(untreated)	 1.53	 458.73	 Pool	4	 Run	2	
BBS011	 Fed	(untreated)	 1.52	 457.09	 Pool	4	 Run	2	
BBS012	 Fed	(untreated)	 1.54	 461.82	 Pool	4	 Run	2	
BBS013	 Fed	(untreated)	 1.58	 472.55	 Pool	5	 Run	2	
BBS014	 Fed	(untreated)	 1.47	 440.36	 Pool	5	 Run	2	
BBS015	 Fed	(untreated)	 1.60	 480.18	 Pool	5	 Run	2	
CTRL019	 Fed	(untreated)	 1.60	 478.55	 Pool	6	 Run	2	
CTRL020	 Fed	(untreated)	 1.25	 374.18	 Pool	6	 Run	2	
CTRL030	 Fed	(untreated)	 1.70	 508.91	 Pool	6	 Run	2	
CTRL031	 Fed	(untreated)	 1.57	 471.82	 Pool	7	 Run	2	
CTRL032	 Fed	(untreated)	 1.22	 365.45	 Pool	7	 Run	2	
CTRL033	 Fed	(untreated)	 1.02	 365.45	 Pool	7	 Run	2	
Bridge	Protein	 Bridge	Protein	 		 		 Pool	8	–	all	samples	
Table	5.2	–	Protein	concentrations	and	yields	from	sample	quantitation	by	Bradford	assay,	where	pooling	
and	run	information	for	each	sample	is	also	provided.	
	
5.2.2	Analysis	of	RNA-seq	data	
5.2.2.1	Identification	of	differentially	expressed	genes	
From	RNA-seq	of	42	fibroblast	samples,	a	total	of	16,336	transcripts	were	detected	(supplemental	
data,	table	S.2,	table	S.3),	of	which	14,573	were	protein-coding	genes.	These	were	analysed	to	
determine	differentially	expressed	 (DE)	 transcripts	between	comparisons	based	on	treatment,	
starved	vs.	fed	for	BBS	fibroblasts	and	starved	vs.	fed	for	control	fibroblasts	(figure	5.8	A-B);	and	
comparisons	based	on	disease	status,	BBS	vs.	control	for	starved	fibroblasts	and	BBS	vs.	control	
for	fed	fibroblasts	(figure	5.8	C-D).	DE	transcripts	were	determined	through	T-test	with	Benjamini-
Hochberg	adjustment	for	multiple	correction,	which	generated	a	false	discovery	rate	(FDR)	for	
each	transcript.	Transcripts	were	considered	differentially	expressed	with	an	FDR	less	than	0.05	
(supplemental	data,	tables	S.4-S.8).	
	
The	number	of	up	and	downregulated	transcripts	are	found	in	table	5.3.	Comparisons	between	
starved	and	fed	fibroblasts	yielded	the	greatest	number	of	DE	transcripts,	with	5968	and	2167	for	
BBS	and	control	comparisons,	respectively.	By	contrast,	there	were	far	fewer	DE	transcripts	upon	
comparison	between	BBS	and	control	cells;	only	29	DE	transcripts	were	identified	for	starved	BBS	
vs	control	and	817	for	fed	BBS	vs	control.	
	
Chapter	5:	Multi-omic	investigation	of	BBS	
	
217	
Figure	5.8	–	MA	plots	displaying	significantly	differentially	expressed	transcripts	(red)	for	each	comparison.	
Transcripts	are	plotted	by	the	average	normalised	read	counts	per	million	(CPM)	in	log2	form	against	the	
log2	 of	 fold	 change	 (FC).	 Transcripts	 were	 defined	 as	 differentially	 expressed	 with	 FDR	 <0.05.	 A-B)	
Distribution	 of	 DE	 genes	 within	 treatment	 comparisons.	 C-D)	 Spread	 of	 DE	 transcripts	 within	 disease	
comparisons.	
	
Table	5.3	 Downregulated	
Not	differentially	
expressed	
Upregulated	 TOTAL	
TOTAL	DE	
transcripts	
Control	starved	vs	fed	 1003	 14,169	 1164	 16,336	 2167	
BBS	starved	vs	fed	 1852	 10,368	 4116	 16,336	 5968	
Fed	BBS	vs	control	 690	 15,522	 124	 16,336	 817	
Starved	BBS	vs	control	 9	 16,307	 20	 16,336	 29	
Table	 5.3	 –	 The	 number	 of	 transcripts	 detected	 as	 differentially	 expressed	 for	 each	 experimental	
comparison.	
	
5.2.2.2	Gene	set	enrichment	analysis	
The	first	challenge	with	a	large	dataset,	such	as	the	one	generated	in	this	study,	was	to	reduce	
the	size	of	the	data	into	more	manageable	groups.	This	is	achievable	through	pathway	analysis,	
which	not	only	allows	simplification,	but	also	uses	knowledge	driven	analysis	 to	rearrange	the	
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data	 into	biologically	meaningful	 processes	 (Khatri	 et	 al.	 2012).	Gene	 set	 enrichment	 analysis	
(GSEA)	with	Hallmark	gene	sets	was	used	to	probe	the	data.	The	advantage	of	this	technique	is	
two-fold.	Firstly,	the	Hallmark	gene	sets	encompass	a	broad	range	of	biological,	non-overlapping	
processes,	 allowing	 a	 refined	 and	 concise	 analysis.	 Secondly,	 the	 input	 for	GSEA	 is	 the	 entire	
transcriptome	dataset,	which	is	not	restricted	by	a	p-value	threshold.	Therefore,	it	can	reliably	be	
used	 on	 experiments	 such	 as	 starved	 BBS	 vs	 control,	 where	 only	 a	 handful	 of	 genes	 were	
identified	after	multiple	correction	was	applied.	
	
GSEA	was	applied	to	all	protein-coding	genes	within	the	RNA-seq	experiment,	pre-ranked	by	fold	
change.	48	Hallmark	gene	sets	were	identified	that	were	considered	significantly	enriched	with	
FDR<0.25	in	at	least	one	comparison	(supplemental	data,	tables	S.17-S.24).	Gene	sets	that	may	
be	of	 interest	for	further	 investigation	are	highlighted	by	yellow	or	blue	boxes	in	the	heatmap	
showing	 significantly	 positively	 or	 negatively	 enriched	 gene	 sets	 (figure	 5.9).	 Although	 the	
Hallmark	gene	sets	were	derived	to	allow	a	broad	overview	of	general	pathways,	there	were	a	
handful	of	significantly	enriched	gene	sets	that	were	relevant	to	primary	cilia	or	BBS	pathology.	
Two	gene	 sets	were	 found	 to	be	negatively	enriched	 in	 starved	BBS	vs	 control,	namely	notch	
signalling	and	cholesterol	homeostasis	(normalised	enrichment	score	(NES)=-1.336,	FDR=0.1415;	
NES=-1.928,	FDR=0.0006,	respectively).	Notch	signalling	 is	a	pathway,	 that	 like	hedgehog	(HH)	
and	Wnt	signalling,	is	thought	to	be	partly	orchestrated	by	the	primary	cilium	(Ezratty	et	al.	2011;	
Leitch	 et	 al.	 2014).	 The	 cholesterol	 homeostasis	 gene	 set	 may	 be	 worth	 investigation	 as	
hypercholesterolemia	is	commonly	present	in	BBS	patients	(Forsythe	et	al.	2015).	An	additional	
finding	related	to	obesity	in	BBS	was	a	positive	enrichment	of	the	adipogenesis	gene	set	in	the	
fed	BBS	 vs	 control	 comparison	 (NES=1.682,	 FDR=0.0149).	 This	was	 also	 positively	 enriched	 in	
starved	BBS	vs	control,	but	this	finding	was	not	significant	to	FDR<0.25	(NES=1.083;	FDR=0.6442)	
(figure	5.10).	This	suggests	that	a	shift	to	genes	that	are	upregulated	during	adipogenesis	genes	
may	be	specific	to	serum	fed	conditions.	
	
The	statistically	enriched	gene	sets	of	adipogenesis,	notch	signalling,	and	cholesterol	homeostasis	
were	investigated	in	more	detail.	The	genes	that	contribute	to	the	enrichment	of	the	gene	set	is	
called	the	leading	edge.	These	are	all	of	the	genes	that	are	present	before	(if	positively	enriched)	
or	after	(if	negatively	enriched)	the	peak	of	the	enrichment	score	graph	(figure	5.10).	The	gene	
expression	levels	(log2	counts	per	million	(CPM))	were	plotted	for	all	genes	of	the	leading	edge	
for	adipogenesis,	notch	signalling,	and	cholesterol	homeostasis	(figure	5.11).	
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Figure	 5.9	 –	 Heatmap	 featuring	 results	 of	 enriched	Hallmark	 gene	 sets	 generated	 by	GSEA.	 Significant	
negatively	or	positively	enriched	pathways	where	FDR<0.25	are	marked	with	–	or	+,	respectively.	As	the	
FDR	value	decreases	(i.e.	becomes	more	significant)	by	each	factor	of	10,	the	colour	intensity	increases.	
The	yellow	box	illustrates	gene	sets	that	are	biologically	relevant	to	primary	cilia	or	BBS	pathology.	The	blue	
box	highlights	gene	sets	that	are	discordantly	enriched	between	different	starved	vs	fed	experiments.	
	
79	 genes	 contributed	 to	 the	 leading	 edge	of	 the	 adipogenesis	 gene	 set	 in	 fed	BBS	 vs	 control	
experiment	(figure	5.11A).	Of	interest,	the	gene	with	the	greatest	fold	change	was	LEP	(log2(FC)=	
2.38),	which	 encodes	 the	 satiety	 hormone	 known	 to	 be	 elevated	 in	 BBS,	 leptin.	 Other	 genes	
upregulated	 in	 the	 leading	 edge	 include	 those	 required	 for	 adipocyte	 differentiation,	 CD36,	
PPARG,	SLC27A1,	and	MTCH2,	and	fatty	acid	biosynthesis,	SLC25A1,	ECH1,	ACAA2,	ACADS,	and	
SCP2.	Of	 note,	PPARG	 and	ECH1	overlap	with	 the	 cholesterol	 homeostasis	 gene	 set,	which	 is	
negatively	enriched	in	starved	BBS	vs	control	cultures.	Other	cholesterol	homeostasis	genes	that	
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are	downregulated	in	starved	BBS	fibroblasts	include	SREBF1,	ACAT2,	CYP51A1,	and	LDL,	involved	
in	 lipid	 metabolism	 (figure	 5.11B).	 This	 may	 suggest	 a	 mechanism	 for	 high	 adiposity	 in	 BBS	
patients,	where	there	is	an	imbalance	between	adipose	tissue	biogenesis	and	lipid	metabolism.	
Finally,	there	were	8	genes	associated	with	a	negative	enrichment	of	Notch	signalling,	including	
downstream	 effectors	 (HEYL	 and	 HES1)	 and	 processors	 of	 Notch	 signalling	 (DLL1,	 PSEN2	 and	
DTX4)	(figure	5.11C).	
	
Figure	5.10	–	GSEA	profiles	for	enriched	Hallmark	gene	sets	that	may	link	to	BBS	pathobiology.	Enrichment	
is	considered	significant	when	FDR<0.25.	
	
5.2.2.3	Comparison	of	RNA-seq	pathways	between	starved	vs	fed	
The	next	step	in	the	analysis	was	to	identify	gene	sets	that	were	discordantly	enriched	between	
starved	vs	 fed	experiments.	 It	was	hypothesised	 that	any	 similarities	would	be	 in	 response	 to	
starvation	and	cell	cycle	arrest,	and	any	differences	uncovered	may	be	due	to	the	BBS1	defect	in	
the	patient	cells.	There	were	two	differentially	enriched	pathways;	myogenesis	(BBS	starved	vs	
fed:	 NES	 =	 -1.360,	 FDR	 =	 0.0519;	 control	 starved	 vs	 fed:	 NES	 =	 1.341,	 FDR	 =	 0.0731),	 and	
inflammatory	response	(BBS	starved	vs	fed:	NES	=	-1.412,	FDR	=	0.0456;	control	starved	vs	fed:	
NES	 =	 1.385,	 FDR	 =	 0.0555),	which	were	 both	 negatively	 enriched	 in	 BBS	 starved	 vs	 fed	 and	
positively	 enriched	 in	 control	 starved	 vs	 fed	 (figure	5.9).	 A	 link	between	myogenesis	 and	BBS	
pathobiology	 has	 not	 yet	 been	 reported,	 so	 this	 may	 require	 further	 experimentation	 to	
determine	 the	 significance	 of	 this	 finding.	 Components	 of	 the	 acute	 phase	 inflammatory	
response,	such	as	C-reactive	protein,	are	raised	in	BBS	patients	as	a	consequence	of	secondary	
responses	 to	 obesity	 (Mirhafez	 et	 al.	 2016).	 Therefore,	 future	 research	 would	 be	 needed	 to	
determine	whether	there	is	a	biological	explanation	for	a	negative	enrichment	of	inflammatory	
response	in	starved	BBS	cells,	compared	to	fed.	
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Figure	5.11	–	Gene	expression	for	each	gene	of	the	leading	edge	for	disease	relevant	findings	from	GSEA.	
Genes	are	plotted	on	the	x-axis	 from	highest	 to	 lowest	 log2(FC),	against	 log2(CPM).	As	a	 log2	 function,	
genes	with	negative	expression	levels	have	CPM	less	than	1.	Error	bars	represent	95%	CI.	
	
Many	of	the	highly	significant	enriched	gene	sets	correlate	between	starved	vs.	fed	comparisons,	
suggesting	that	these	were	enriched	as	a	consequence	of	starvation.	For	example,	the	strongest	
enrichment	was	a	negative	correlation	with	G2M	checkpoint	genes,	with	a	NES	of	-3.129	and	-
3.163	for	BBS	and	control,	respectively	(FDR<0.0001	for	both)	(figure	5.12).	This	finding	appears	
consistent	 with	 induction	 of	 cell	 cycle	 arrest.	 Other	 gene	 sets	 that	 support	 this	 observation	
include	significant	negative	enrichment	of	mitotic	spindle	(figure	5.12),	hypoxia,	and	E2F	targets.	
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Figure	5.12	–	GSEA	profiles	for	treatment	comparisons.	Significant	negatively	enriched	Hallmark	gene	sets	
for	BBS	starved	vs	fed	and	control	starved	vs	fed	analyses.	Normalised	enrichment	score	(NES)	and	false	
discovery	rate	(FDR)	are	displayed	for	each	gene	set.	Enrichment	is	considered	significant	when	FDR<0.25.	
	
5.2.2.4	Comparison	of	treatment	with	respect	to	disease	
As	the	aim	of	this	study	was	to	capture	differences	in	ciliated	cells	between	disease	and	control	
cultures,	the	most	biologically	valuable	comparison	was	anticipated	to	be	between	serum	starved	
BBS	 vs	 controls.	 However,	 there	 were	 only	 29	 DE	 transcripts	 for	 this	 comparison,	 making	 it	
challenging	 to	 draw	 any	 inferences	 from	 such	 a	 small	 statistically	 significant	 set	 of	 genes.	
Therefore,	a	different	method	for	analysis	was	adopted,	where	BBS	starved	vs	fed	and	control	
starved	vs	fed	experiments	were	directly	compared	with	one	another.	For	this	investigation,	the	
PANTHER	 statistical	 enrichment	 test	 was	 implemented	 with	 gene	 sets	 from	 the	 Reactome	
pathways	database.	Compared	to	the	Hallmark	gene	sets,	the	Reactome	database	features	a	vast	
range	of	biological	processes,	which	may	increase	biological	understanding	to	complement	GSEA.	
PANTHER	 statistical	 enrichment	 test	 was	 completed	 with	 all	 protein-coding	 genes,	 where	
log2(FC)	 for	 each	 protein	 was	 inputted	 as	 enrichment	 criteria.	 Pathways	 were	 considered	
statistically	enriched	after	Bonferroni	correction	with	adjusted	p<0.05	(figure	5.13).	
	
The	 resulting	 pathways	 were	 compared	 for	 BBS	 starved	 vs	 fed	 and	 control	 starved	 vs	 fed	
experiments,	selecting	pathways	that	were	unique	or	shared	for	the	comparisons.	As	expected	in	
response	to	cell	cycle	arrest	by	starvation,	negative	enrichment	of	cell	cycle	and	mitotic	pathways	
were	 identified,	 including	 “mitotic	 anaphase”,	 “mitotic	 prometaphase”,	 “cyclin	 E	 association	
events	during	G1/S	 transition”,	 “APC:Cdc20	mediated	degradation	of	 cell	 cycle	proteins”,	 and	
“cell	cycle”.	This	negative	enrichment	of	cell	cycle	components	was	concordant	with	GSEA.	There	
was	also	evidence	of	 reduced	cytoskeletal	 remodelling	 in	 response	 to	 starvation,	 indicated	by	
negative	 enrichment	 of	 actin	 regulation,	 such	 as	 “RHO	 GTPase	 effectors”,	 “cooperation	 of	
prefoldin	and	TriC/CCT	in	actin	and	tubulin	folding”,	and	“cytoskeletal	regulation	by	Rho	GTPase”.	
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Figure	5.13	–	Reactome	pathways	significantly	positively	or	negatively	enriched	by	PANTHER	enrichment	
test	in	starved	vs	fed	cultures.	Statistically	significant	pathways	were	compared	to	identify	those	unique	to	
BBS	starved	vs	fed	(green),	control	starved	vs	fed	(blue),	or	shared	(orange).	Pathways	were	statistically	
significant	with	adjusted	p<0.05,	ranked	in	the	figure	with	most	significant	at	the	top	of	each	section.	
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There	were	some	terms	that	are	similar	but	not	identical	between	BBS	starved	vs	fed	and	control	
starved	 vs	 fed,	 highlighting	 the	 overlapping	 nature	 of	 the	 Reactome	 gene	 sets.	 For	 example,	
“G2/M	transition”	 in	BBS	and	“G2/M	checkpoints”	 in	control,	or	“transcriptional	 regulation	by	
TP53”	 in	BBS	and	“regulation	of	TP53	activity”	 in	control.	Although	these	respective	pathways	
have	different	connotations,	there	were	genes	shared	across	the	respective	processes.	Unique	
pathways	in	BBS	starved	vs	fed	included	“PCP/CE	pathway”,	“HH	‘off’	state”,	and	“centromere	
maturation”,	all	of	which	are	negatively	enriched.	The	HH	and	PCP	pathways	may	be	of	interest,	
as	they	are	both	known	to	utilise	the	primary	cilia	as	a	signalling	hub	(Goetz	and	Anderson	2010).	
Interestingly,	 the	 pathway	 “assembly	 of	 the	 primary	 cilium”	 is	 negatively	 enriched	 in	 control	
starved	vs	fed,	yet	“ciliary	part”	is	positively	enriched	in	BBS	starved	vs	fed.	This	discordant	finding	
was	investigated	further	through	analysis	of	DE	genes	that	interact	in	the	pathway	“assembly	of	
the	primary	cilium”	in	BBS	starved	vs	fed	and	control	starved	vs	fed.	
	
The	 assembly	 of	 the	 primary	 cilium	 is	 a	well-orchestrated	 pathway	 that	 requires	 a	 functional	
switch	from	centrosome	genes	required	for	mitosis	to	basal	body	and	IFT	associated	genes	(Izawa	
et	 al.	 2015).	 In	 order	 to	 investigate	 whether	 differential	 regulation	 occurred	 within	 an	
interconnected	 biological	 network,	 protein-protein	 interactions	 were	 mapped	 within	 STRING	
(figure	5.14).	In	total,	there	were	186	genes	associated	with	the	term	“assembly	of	the	primary	
cilium”,	 of	 which	 80	 were	 significantly	 differentially	 expressed	 in	 BBS	 starved	 vs	 fed,	 and	 43	
differentially	expressed	in	control	starved	vs	fed.	30	DE	genes	were	shared	across	both	BBS	and	
control	comparisons.	
	
The	protein-protein	interaction	map	revealed	at	least	4	key	interacting	networks,	defined	as	IFT	
machinery,	BBS-causing,	tubulin,	and	transition	zone/centrosome	genes.	There	was	also	a	group	
of	genes	involved	in	vesicular	trafficking,	though	this	did	not	present	itself	as	a	complex	network.	
There	were	5	TriC/CCT	chaperone	genes,	CCT2,	CCT3,	CCT5,	CCT8,	and	TCP1,	that	connected	the	
BBS-causing	genes	to	the	rest	of	the	network	through	interactions	with	the	tubulin	complex.	Of	
note,	the	transition	zone/centrosome	genes	were	separated	into	2	subnetworks	depending	on	
their	direction	of	expression.	For	example,	genes	such	as	TCTN1,	TMEM216,	CEP290,	TMEM67,	
AHI1,	B9D1,	and	CC2D2A	were	upregulated,	whereas	ALMS1,	PLK1,	PLK4,	CDK1,	NEK2,	and	CENPJ	
were	downregulated.	 These	are	 roughly	assembled	 into	upregulated	 transition	 zone	proteins,	
and	downregulated	gene	products	that	localise	to	the	centrosome	for	mitotic	spindle	formation,	
centriole	duplication,	or	kinases	responsible	for	the	negative	regulation	of	ciliogenesis.
		
Figure	5.14	–	Interactions	between	DE	genes	from	the	Reactome	pathway	“assembly	of	the	primary	cilium”,	featuring	genes	shared	(orange)	or	unique	to	patients	(yellow)	and	
controls	(blue)	from	starved	vs	fed	comparisons.	Up	and	downregulated	genes	are	distinguished	by	green	or	red	bordered	nodes,	respectively.	Gene	interactions	were	plotted	
using	STRING	using	evidence	obtained	from	curated	databases	(represented	by	blue	edges).
Chapter	5:	Multi-omic	investigation	of	BBS	
	
226	
There	 were	 a	 larger	 number	 of	 DE	 genes	 for	 cilia	 assembly	 within	 the	 BBS	 starved	 vs	 fed	
comparison	compared	to	the	control	group.	It	is	possible	that	this	is	a	result	of	having	a	larger	
group	of	BBS	patients	than	controls,	creating	a	statistical	artefact.	Therefore,	making	inferences	
from	 the	 comparison	 of	 BBS	 compared	 to	 control	 may	 be	 biased.	 However,	 if	 there	 were	
differences	observed	in	controls	that	were	not	in	BBS,	this	may	be	a	real	finding.	For	example,	
there	were	12	DE	genes	in	control	starved	vs	fed	that	were	not	found	in	BBS.	Of	these,	there	was	
a	cluster	of	10	genes	within	the	transition	zone/centrosome	complex	that	were	all	significantly	
downregulated	in	control	starved	vs	fed,	but	not	BBS	(figure	5.15).	
	
Research	of	this	group	of	genes	found	that	they	are	involved	in	centrosome	duplication	(CEP72	
and	CEP152),	mitotic	 spindle	 formation	 (CKAP5,	HAUS3,	HAUS6,	 and	HAUS8),	 or	 are	 negative	
regulators	 of	 ciliogenesis	 (CEP97	 and	 KIF24)	 (Spektor	 et	 al.	 2007;	 Kobayashi	 et	 al.	 2011).	
Moreover,	 HAUS3,	 HAUS6,	 and	 HAUS8	 form	 part	 of	 a	 hetero-octamer	 complex	 named	
Homologous	 to	 Augmin	 subunits	 (HAUS),	 and	 are	 required	 for	 mitotic	 spindle	 assembly	 and	
maintenance	of	centrosome	integrity	 (Lawo	et	al.	2009).	Therefore,	 it	would	be	expected	that	
expression	 of	 these	 genes	 would	 downregulate	 in	 response	 to	 cell	 cycle	 arrest.	 Further	
investigation	 of	 expression	 data	 for	 these	 genes	 demonstrated	 that	 read	 counts	 were	 not	
significantly	different	between	starved	BBS	and	starved	control	fibroblasts,	but	4	out	of	the	10	
genes	 were	 significantly	 different	 between	 fed	 BBS	 and	 fed	 control	 (figure	 5.15;	 table	 5.4).	
Furthermore,	expression	was	significantly	higher	in	fed	control	compared	to	starved	control	for	
all	 genes,	whereas	 this	was	not	 the	 case	 for	BBS	 comparisons.	 Expression	of	HAUS3	 (BBS	 fed	
mean=	3.87,	95%	CI=	3.65,	4.26;	control	fed	mean=	4.67,	95%	CI=	4.29,	5.06;	FDR=	0.0157),	CEP41	
(BBS	 fed	mean=	3.98,	 95%	CI=	 3.87,	 4.10;	 control	 fed	mean=	4.54,	 95%	CI=	 4.28,	 4.80;	 FDR=	
0.0251),	CEP152	(BBS	fed	mean=	3.54,	95%	CI=	3.18,	3.89;	control	fed	mean=	4.70,	95%	CI=	4.04,	
5.36;	FDR=	0.0478),	and	CEP97	(BBS	fed	mean=	4.01,	95%	CI=	3.79,	4.23;	control	fed	mean=	4.69,	
95%	CI=	4.24,	5.14;	FDR=	0.0478)	was	significantly	lower	in	BBS	fed	compared	to	control	fed.	
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Figure	5.15	–	Gene	expression	 for	a	 cluster	of	10	genes	 from	the	Reactome	pathway	“assembly	of	 the	
primary	cilium”	that	were	significantly	downregulated	in	control	starved	vs	fed,	but	not	BBS	starved	vs	fed.	
Error	bars	represent	95%	CI,	where	*	FDR<0.05	and	**	FDR<0.005	for	control	starved	vs	fed	or	fed	BBS	vs	
control.	
	
Gene	 BBS	starved	 BBS	fed	
Control	
starved		
Control	fed	
BBS	starved	
vs	fed	FDR	
Control	
starved	vs	
fed	FDR	
Fed	BBS	vs	
control	FDR	
Starved	BBS	
vs	control	
FDR	
HAUS3	
4.06	
(3.85,	4.26)	
3.87	
(3.71,	4.02)	
3.96	
(3.65,	4.26)	
4.67	
(4.29,	5.06)	
0.3613	 0.0380	 0.0157	 0.8610	
HAUS6	
4.55	
(4.44,	4.67)	
4.70	
(4.50,	4.90)	
4.39	
(4.09,	4.68)	
5.27	
(4.80,	5.74)	
0.4931	 0.0108	 0.1418	 0.7381	
HAUS8	 2.24	
(1.98,	2.50)	
2.78	
(2.44,	3.11)	
2.19	
(2.07,	2.31)	
3.65	
(2.82,	4.47)	
0.0915	 0.0092	 0.1338	 0.9540	
CEP72	
0.90	
(0.61,	1.19)	
1.22	
(0.84,	1.59)	
0.94	
(0.84,	1.05)	
2.19	
(1.36,	3.01)	
0.4233	 0.0453	 0.0978	 0.9870	
CEP41	
3.81	
(3.68,	3.94)	
3.98	
(3.87,	4.10)	
3.91	
(3.77,	4.04)	
4.54	
(4.28,	4.80)	
0.1974	 0.0048	 0.0251	 0.9404	
CEP152	 3.15	
(2.81,	3.50)	
3.54	
(3.18,	3.89)	
3.25	
(2.79,	3.70)	
4.70	
(4.04,	5.36)	
0.2712	 0.0157	 0.0478	 0.9892	
CEP97	
4.13	
(3.99,	4.28)	
4.01	
(3.79,	4.23)	
3.86	
(3.51,	4.21)	
4.69	
(4.24,	5.14)	
0.6033	 0.0260	 0.0478	 0.6878	
CKAP5	
7.63	
(7.54,	7.73)	
7.77	
(7.62,	7.91)	
7.54	
(7.40,	7.67)	
8.13	
(7.81,	8.45)	
0.3760	 0.0154	 0.1758	 0.8036	
KIF24	 1.84	
(1.43,	2.24)	
2.50	
(1.95,	3.04)	
2.02	
(1.78,	2.27)	
3.69	
(2.66,	4.72)	
0.1269	 0.0329	 0.6384	 0.9746	
RPGRIP1L	
5.30	
(5.17,	5.44)	
5.41	
(5.23,	5.58)	
4.77	
(4.60,	4.93)	
5.58	
(5.27,	5.90)	
0.5545	 0.0020	 0.1485	 0.1869	
Table	5.4	–	Data	for	each	biological	group	for	the	10	genes	from	the	Reactome	pathway	“assembly	of	the	
primary	cilium”	that	were	significantly	downregulated	in	control	starved	vs	fed,	but	not	BBS	starved	vs	fed.	
Figures	are	expressed	as	sample	mean	(log2(CPM))	and	95%	CI	(upper,	lower	limit),	as	well	as	the	FDR	for	
each	comparison.	
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5.2.3	Identifications	of	proteins	from	iTRAQ-MS/MS	
The	 spectra	 obtained	 from	 iTRAQ	mass	 spectrometry	 runs	 for	 serum	 fed	 and	 serum	 starved	
samples	 were	 analysed	 for	 identifications	 separately,	 and	 implemented	 by	 the	 BGI.	 Peptide	
identifications	 were	 made	 using	MascotPercolator	 software	 version	 2.3.02	 (Käll	 et	 al.	 2007),	
against	a	human	proteome	database	of	134,169	sequences.	Matching	peptides	required	an	FDR	
<0.01	to	be	considered	a	true	positive	for	protein	identification.	30,590	peptides	from	360,137	
spectra	were	identified	from	serum	starved	fibroblasts,	which	corresponded	to	5439	proteins.	Of	
these	peptides,	29,554	were	unique.	The	experiment	from	serum	starved	fibroblasts	identified	
30,587	peptides	 from	357,751	spectra.	5633	proteins	were	 identified,	where	29,517	peptides	
were	unique.	Only	proteins	with	at	 least	1	unique	peptide	were	kept	 for	quantitation.	MS/MS	
spectra	were	used	for	protein	quantitation	by	Iquant	(Wen	et	al.	2014),	which	normalised	and	
quantified	findings.	Data	was	provided	as	a	protein	ratio	between	each	isobaric	tag,	where	only	
proteins	with	FDR<0.01	were	included	for	further	statistical	analysis	(supplemental	data,	tables	
S.34-S.39).	
	
The	 runs	 were	 compared	 to	 determine	 how	 many	 quantifiable	 proteins	 were	 overlapping.	
Between	the	2	runs,	65.7%	of	proteins	were	shared,	whereas	1050	(15.7%)	were	only	detected	
in	serum	fed	fibroblasts,	and	1244	(18.6%)	were	only	identified	by	serum	starved	cells.	Therefore,	
for	statistical	analysis	between	the	2	experiments,	only	4389	proteins	could	be	compared.	
	
5.2.3.1	Differentially	expressed	proteins	from	iTRAQ	experiments	
Statistical	 analysis	with	 T-test	 and	multiple	 correction	 for	 FDR	was	 applied	 to	 comparisons	 of	
protein	 ratios	 between	 biological	 groups	 (supplemental	 data,	 tables	 S.30-S.33).	 The	 same	
analytical	design	that	compared	treatment	and	disease	data	in	RNA-seq	experiments	were	also	
utilised	here.	Proteins	were	considered	differentially	expressed	with	an	FDR	less	than	0.05	(figure	
5.16).	 The	 numbers	 of	 differentially	 up	 or	 downregulated	 proteins	 for	 each	 comparison	 are	
presented	in	table	5.5.	As	many	proteins	were	statistically	significant,	proteins	with	a	greater	fold	
change	difference	(-0.5<	log2(FC)	>0.05)	were	also	counted.	The	greatest	number	of	DE	proteins	
were	identified	between	starved	BBS	vs	control,	where	1194	proteins	were	downregulated	and	
1279	proteins	were	upregulated.	Fed	BBS	vs	control	also	exhibited	a	significant	number	of	DE	
proteins,	where	 1267	 and	 961	were	 down	 and	 upregulated,	 respectively.	 Comparison	 of	 BBS	
starved	vs	 fed	 identified	773	downregulated	and	1313	upregulated	proteins,	whereas	 control	
starved	 vs	 fed	 resulted	 in	 fewer	 DE	 proteins,	 with	 211	 downregulated	 and	 373	 upregulated	
proteins.	The	comparison	with	the	greatest	DE	proteins	with	log2(FC)	less	than	-0.5	or	greater	
than	0.5	was	BBS	starved	vs	fed,	with	118	downregulated	and	349	upregulated	genes.	
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Figure	5.16	–	Volcano	plots	displaying	differentially	expressed	proteins	(blue)	for	each	comparison.	Proteins	
are	plotted	by	log2	fold	change	against	–log10(FDR).	Proteins	were	defined	as	differentially	expressed	with	
FDR	<0.05.	DE	proteins	with	log2(FC)	>0.5	or	<-0.5	are	highlighted	in	red.	A-B)	Distribution	of	DE	proteins	
within	treatment	comparisons.	C-D)	Spread	of	DE	proteins	within	disease	comparisons.	
	
Table	5.5	
Down	
regulated	
Not	differentially	
expressed	
Up	
regulated	
Log2FC	
<-0.5	
Log2FC	
>0.5	
Total	
Total	DE	
Proteins	
Control	
starved	vs	fed	 211	 3805	 373	 52	 96	 4389	 584	
BBS	starved	
vs	fed	
773	 2303	 1313	 118	 349	 4389	 2086	
Fed	BBS	vs	
control	
1267	 3211	 961	 62	 23	 5439	 2228	
Starved	BBS	
vs	control	
1194	 3160	 1279	 66	 47	 5633	 2473	
Table	5.5	–	The	number	of	proteins	detected	as	differentially	expressed	for	each	experimental	comparison.	
DE	proteins	were	defined	as	FDR<0.05.	The	number	of	genes	with	-0.5	<	log2(FC)	>	0.5	are	also	recorded	
in	the	table.	
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5.2.3.2	Gene	set	enrichment	analysis	with	iTRAQ	proteomics	data	
The	GSEA	methodology	was	applied	to	the	iTRAQ	proteomics	data	to	simplify	the	data	and	obtain	
gene	 sets	 that	 were	 enriched	 at	 the	 protein	 level.	 26	 Hallmark	 gene	 sets	 were	 returned	 as	
significantly	enriched	in	at	least	one	comparison	with	FDR<0.25	(figure	5.17,	supplemental	data,	
tables	 S.9-S.16).	 The	 significantly	 enriched	 gene	 sets	 were	 explored	 to	 find	 disease-relevant	
findings	for	starved	BBS	vs	control,	fed	BBS	vs	control,	and	between	BBS	and	control	for	starved	
vs	fed	comparisons.	Interestingly,	adipogenesis	was	found	to	be	positively	enriched	in	fed	BBS	vs	
control	cultures,	in	accordance	with	the	RNA-seq	GSEA.	However,	no	gene	sets	were	identified	
as	significantly	enriched	in	opposing	directions	for	BBS	starved	vs	fed	and	control	starved	vs	fed.	
Figure	5.17	–	Heatmap	featuring	enriched	Hallmark	gene	sets	generated	by	GSEA	with	iTRAQ	proteomics	
data.	 Significantly	 negatively	 or	 positively	 enriched	pathways	where	 FDR<0.25	 are	marked	with	 –	 or	 +,	
respectively.	As	the	FDR	value	decreases	(i.e.	becomes	more	significant)	by	each	factor	of	10,	the	colour	
intensity	increases.	Gene	sets	that	were	identified	as	biologically	relevant	are	highlighted	with	yellow	boxes.	
	
Of	 interest	 to	 cilia	 function,	 the	 mTOR	 signalling	 pathway	 was	 established	 as	 significantly	
enriched.	This	pathway	functions	to	regulate	cellular	growth	in	response	to	cellular	energy	levels.	
Dysregulation	of	the	mTOR	pathway	has	been	shown	to	reduce	ciliary	length,	and	is	implicated	in	
polycystic	 kidney	 disease	 (Basten	 and	 Giles	 2013;	 Ibraghimov-Beskrovnaya	 and	 Natoli	 2011).	
mTOR	signalling	pathway	is	covered	by	two	different	Hallmark	gene	sets,	namely	PI3K	AKT	mTOR	
and	mTORC1.	Both	of	these	sets	were	found	in	be	significantly	enriched	in	BBS	comparisons,	but	
not	in	control	starved	vs	fed	(figure	5.18).	mTORC1	signalling	was	significantly	negatively	enriched	
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in	fed	BBS	vs	control	comparison	(NES=-1.911;	FDR=-0.0045),	whereas	starved	BBS	vs	control	was	
positively	enriched	for	PI3K	AKT	mTOR	signalling	(NES=1.843;	FDR=0.0142).	Both	pathways	were	
significantly	positively	enriched	in	BBS	starved	vs	fed	comparisons.	This	suggests	that	the	mTOR	
pathway	is	induced	in	response	to	starvation	in	BBS	fibroblasts,	but	not	in	controls.	
	
	
Figure	5.18	–	GSEA	profiles	for	enriched	Hallmark	gene	sets	related	to	mTOR	signalling	from	proteomics	
data.	Enrichment	is	considered	significant	when	FDR<0.25.	
	
5.2.3.3	Pathway	analysis	for	iTRAQ	BBS	vs	control	experiments	
In	contrast	to	the	RNA-seq	experiment,	there	was	a	large	set	of	DE	proteins	for	starved	BBS	vs	
control.	 As	 it	 was	 not	 possible	 to	 investigate	 this	 comparison	 in	 detail	 through	 analysis	 of	
transcripts,	the	opportunity	was	taken	for	the	iTRAQ	dataset.	To	investigate	Reactome	pathways	
that	were	significantly	enriched,	all	proteins	identified	from	starved	BBS	vs	control	were	entered	
into	 PANTHER	 statistical	 enrichment	 test,	 where	 log2(FC)	 for	 each	 protein	 was	 used	 as	
enrichment	criteria.	Pathways	were	considered	statistically	enriched	after	Bonferroni	correction	
with	adjusted	p<0.05	(figure	5.19).	
	
17	 pathways	 were	 found	 to	 be	 significantly	 positively	 enriched	 and	 a	 single	 pathway	 was	
significantly	negatively	enriched.	From	this	analysis,	there	were	5	pathways	that	were	recognised	
as	 biologically	 interesting	 due	 to	 association	with	 ciliary	maintenance,	 signalling,	 or	 function.	
These	were	“assembly	of	the	primary	cilium”,	“hedgehog	‘off’	state”,	“RHO	GTPase	effectors”,	
“centrosome	maturation”,	 and	 “cytoskeletal	 regulation	by	RHO	GTPase”.	As	 these	have	 some	
overlapping	functions,	it	was	hypothesised	that	proteins	within	these	pathways	would	form	a	rich	
highly	connected	network.	This	was	tested	by	creating	a	STRING	protein-protein	interaction	map,	
based	on	knowledge	from	curated	databases,	and	featuring	the	DE	proteins	from	the	5	relevant	
pathways.	 It	 was	 also	 investigated	 whether	 these	 pathways	 may	 be	 implicated	 with	 BBS1	
function,	 thereby	 forming	 a	 link	 between	 protein	 dysfunction	 caused	 by	 the	 BBS1	 p.M390R	
variant	and	 the	upregulation	of	pathways	 found	 in	 the	 starved	BBS	vs	 control	experiment.	To	
Chapter	5:	Multi-omic	investigation	of	BBS	
	
232	
model	these	interactions,	proteins	that	were	known	to	interact	with	BBS1	were	also	added	to	the	
network,	which	featured	BBS1,	BBS2,	ARL6,	BBS4,	BBS5,	BBS5,	BBS7,	TTC8,	BBS12,	BBIP1,	LZTFL1,	
and	RAB3IP	(note	that	with	the	exception	of	LZTFL1,	these	proteins	were	not	detected	by	the	
iTRAQ	experiment).	The	resulting	network	is	presented	in	figure	5.20.	
	
Figure	5.19	–	Reactome	pathways	found	to	be	significantly	positive	or	negatively	enriched	by	PANTHER	
statistical	enrichment	test	for	starved	BBS	vs	control	comparison	from	iTRAQ	proteomics	data.	Pathways	
were	considered	statistically	enriched	with	adjusted	p<0.05,	ranked	in	the	figure	with	most	significant	at	
the	top.	
	
Upon	closer	review	of	DE	proteins	within	each	pathway,	there	were	large	overlaps.	Of	the	27	DE	
proteins	 found	 in	 “centrosome	maturation”,	many	overlapped	with	 “assembly	 of	 the	primary	
cilium”,	 which	 consisted	 of	 45	 DE	 proteins.	 These	 included	 CEP78,	 CEP290,	 FGRF1OP,	 and	
ACTR1A,	and	emphasised	the	dual	function	of	many	centrosome	proteins.	These	2	pathways	also	
shared	some	proteins	with	“RHO	GTPase	effectors”,	including	CLASP1,	MAPRE1,	YWHAE,	YWHAG,	
and	tubulins.	Unsurprisingly,	there	was	also	a	large	overlap	in	DE	proteins	between	“RHO	GTPase	
effectors”	 and	 “cytoskeletal	 regulation	 by	 RHO	 GTPases”,	 which	 had	 73	 and	 28	 DE	 proteins,	
respectively.	Finally,	“hedgehog	‘off’	state”	was	associated	with	40	DE	genes.	27	of	these	were	
subunits	 of	 the	 proteasome,	 including	 alpha	 subunits	 (PSMA1-7),	 beta	 subunits	 (PSMB1-8),	
proteasome	ATPases	(PSMC1-4,6),	non-ATPases	(PSMD1-14),	and	activator	subunits	(PSME1,3).	
Components	of	the	proteasome	also	interacted	with	proteins	of	other	pathways,	including	many	
from	“RHO	GTPase	effectors”	through	PSMA7	subunit.	The	presence	of	the	proteasome	in	the	
HH	pathway	is	suggestive	of	GLI	protein	processing	into	the	repressor	state	(Gerhardt	et	al.	2016).	
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Overall,	assembly	of	these	DE	proteins	into	a	protein-protein	interaction	map	uncovered	a	vast	
interconnected	network.	
	
Next,	 the	 protein	 network	map	was	 used	 to	model	 the	 putative	 involvement	 of	 BBS1,	where	
mutation	of	p.M390R	may	have	led	to	the	upregulation	of	these	5	pathways	in	starved	cultures.	
BBS1	is	incorporated	into	the	network	through	interactions	with	RAB3IP,	also	known	as	RABIN8,	
SMO,	 and	 TriC/CCT	 chaperone	 proteins	 that	 partake	 in	 the	 assembly	 of	 the	 BBSome.	 The	
interaction	with	these	intermediates	is	shown	to	connect	BBS1	with	proteins	from	all	5	pathways.	
For	example,	BBS1	incorporates	into	“Hedgehog	‘off’	state”	through	direct	interaction	with	SMO,	
a	HH	effector	that	controls	HH	signalling	depending	on	its	localisation	with	respect	to	the	primary	
cilium.	The	interaction	of	the	BBSome	with	SMO	is	thought	to	allow	trafficking	of	SMO	into	the	
cilium	 for	 HH	 signalling,	 an	 interaction	 also	 involving	 LZTFL1	 (Seo	 et	 al.	 2011),	 which	 was	
upregulated	in	starved	BBS	fibroblasts	compared	to	starved	controls.	SMO	is	also	predicted	to	
interact	 with	 the	 cAMP-dependent	 protein	 kinase,	 PRKACB,	 which	 in	 turn	 networks	 with	
members	of	the	“RHO	GTPase	effectors”	and	“cytoskeletal	regulation	by	RHO	GTPase”	pathways.	
Furthermore,	BBS1	 is	 linked	to	components	of	“assembly	of	primary	cilium”	and	“centrosome	
maturation”	 through	 RAB3IP.	 Although	 RAB3IP	 was	 not	 identified	 by	 the	 iTRAQ	 proteomics	
experiment,	it	can	provide	an	insight	into	how	the	presence	of	the	BBS1	p.M390R	variant	impacts	
these	pathways.	The	interaction	with	BBS1	and	RAB3IP	is	required	for	transport	of	cargo	to	the	
ciliary	 membrane	 (Nachury	 et	 al.	 2007).	 Unfortunately,	 further	 investigation	 into	 expression	
levels	of	these	proteins	could	not	be	completed	due	to	pooling	of	samples;	a	limitation	that	was	
understood	upon	conception	of	the	experimental	design.	
	
5.2.4	Integration	of	transcriptomic	and	proteomic	datasets	
Due	to	the	volume	of	information	and	low	availability	of	sophisticated	analytical	techniques,	data	
observed	from	a	single	omics	technology	may	contain	a	high	number	of	false	positive	and	false	
negative	findings	(Ge	et	al.	2003).	Although	statistical	analysis	attempts	to	reduce	these,	there	is	
still	a	5%	chance	of	a	false	finding	with	an	FDR	threshold	of	0.05.	To	increase	the	confidence	and	
reliability	of	a	true	biological	finding,	multiple	independent	omic	techniques	can	be	integrated.	
However,	 due	 to	 sample	 heterogeneity	 and	 often	 low	 correlation	 between	 different	 types	 of	
technology,	this	is	not	a	trivial	task	(Gomez-Cabrero	et	al.	2014).	This	challenge	is	exacerbated	
when	attempting	to	integrate	data	at	the	individual	gene/protein	level,	as	there	are	far	too	many	
differentially	 expressed	 findings	 to	 consider.	 Therefore,	within	 this	 study,	 datasets	 have	been	
integrated	at	the	pathway	level.	
		
Figure	5.20	–	Protein-protein	interaction	network	of	upregulated	pathways	from	starved	BBS	vs	control	comparison	(figure	legend	on	next	page)	
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Figure	 5.20	 (on	 previous	 page)	 –	 Protein-protein	 interaction	 network	 featuring	 DE	 proteins	 from	 5	
pathways	significantly	positively	enriched	by	PANTHER	statistical	enrichment	test.	DE	proteins	from	the	5	
different	pathways	are	coloured	differently,	where	proteins	may	be	coloured	multiple	colours	if	involved	
in	 more	 than	 one	 pathway.	 Grey	 nodes	 were	 added	 manually	 to	 model	 the	 interconnectivity	 of	 the	
pathways	with	BBS1.	These	were	not	identified	in	the	iTRAQ	experiment,	unless	labelled	with	additional	
colours.	Protein	interactions	were	plotted	using	STRING	using	evidence	obtained	from	curated	databases	
(represented	by	blue	edges).	
	
The	 analysis	 completed	 with	 RNA-seq	 and	 iTRAQ	 proteomics	 data	 by	 GSEA	 and	 PANTHER	
statistical	 enrichment	 testing	 were	 assessed	 to	 determine	 whether	 there	 were	 overlapping	
findings.	In	total,	17	pathways	were	identified	as	significantly	enriched	in	both	RNA	and	protein	
datasets	(table	5.6).	Starved	BBS	vs	control	found	2	pathways	from	GSEA,	fed	BBS	vs	control	had	
7	shared	pathways	from	GSEA,	and	there	were	8	pathways	found	from	PANTHER	enrichment	test	
that	were	present	 in	BBS	starved	vs	 fed	but	not	control	 starved	vs	 fed.	These	pathways	were	
highlighted	for	dysregulation,	where	it	was	not	important	whether	pathways	were	consistently	
positively	 or	 negatively	 enriched,	 or	 contained	 the	 exact	 same	 genes,	 across	 different	 omic	
technologies.	Interestingly,	epithelial	mesenchymal	transition	was	identified	for	both	starved	BBS	
vs	 control	 and	 fed	 BBS	 vs	 control,	 and	 were	 both	 positively	 enriched	 in	 transcriptome	 and	
negatively	enriched	at	the	protein	level.	This	suggests	that	it	may	be	a	dysfunctional	pathway	in	
BBS	cells,	which,	as	a	novel	finding,	may	be	tissue	specific.	Out	of	the	GSEA	pathways,	for	fed	BBS	
vs	control,	there	were	many	overlapping	pathways	which	were	correlated	in	the	same	direction.	
This	may	illustrate	that	starvation	increases	cellular	heterogeneity,	making	it	more	challenging	to	
make	statistically	significant	findings.	
	
A	finding	that	was	well	supported	from	the	different	omics	datasets,	and	is	biologically	relevant	
to	BBS,	is	adipogenesis.	This	gene	set	was	identified	as	positively	enriched	in	both	transcriptome	
and	proteomic	studies	in	fed	BBS	vs	control	experiments.	The	genes	from	these	pathways	were	
investigated	to	determine	whether	the	leading	edge	genes/proteins	were	interrelated.	A	STRING	
network	was	compiled	of	all	leading	edge	genes,	including	79	from	RNA-seq	analysis	and	40	from	
iTRAQ	proteomic	analysis,	21	of	which	were	shared.	65	of	these	were	predicted	to	interact	with	
information	 from	databases,	experimental	data,	or	 from	text	mining.	The	 resulting	network	 is	
presented	in	figure	5.21.	
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Experiment	 Pathway/	gene	set	description	
Enrichment	
transcripts	
Enrichment	
protein	
Method	
Starved	BBS	vs	
control	
KRAS	signalling	(up)	 Negative	 Negative	 GSEA	
Epithelial	mesenchymal	transition	 Positive	 Negative	 GSEA	
Fed	BBS	vs	
control	
MYC	targets,	1	 Negative	 Negative	 GSEA	
E2F	targets	 Negative	 Negative	 GSEA	
IL2	STAT5	signalling	 Positive	 Positive	 GSEA	
Adipogenesis	 Positive	 Positive	 GSEA	
Oxidative	phosphorylation	 Positive	 Positive	 GSEA	
Hypoxia	 Positive	 Negative	 GSEA	
Epithelial	mesenchymal	transition	 Positive	 Negative	 GSEA	
BBS	starved	vs	
fed	that	were	
not	in	control	
starved	vs	fed	
G2/M	Transition	 Negative	 Positive	 PANTHER	
Hedgehog	‘off’	state	 Negative	 Positive	 PANTHER	
HH	mutants	abrogate	ligand	secretion	 Negative	 Positive	 PANTHER	
Regulation	of	APC/C	activators	between	
G1/S	and	early	anaphase	
Negative	 Positive	 PANTHER	
Regulation	of	mRNA	stability	by	proteins	
binding	AU-rich	elements	
Negative	 Positive	 PANTHER	
Respiratory	electron	transport	 Negative	 Positive	 PANTHER	
rRNA	processing	in	the	nucleus	and	cytosol	 Negative	 Positive	 PANTHER	
Ubiquitin-dependent	degradation	of	Cyclin	D	 Negative	 Positive	 PANTHER	
Table	5.6	–	Significantly	enriched	pathways	or	gene	sets	that	were	identified	in	both	analysis	of	RNA-seq	
and	iTRAQ,	either	by	GSEA	or	PANTHER	statistical	enrichment	test	using	Reactome	pathways	database.	
	
The	 protein-protein	 interaction	map	 output	 from	 STRING	was	 highly	 complex,	with	 few	well-
structured	 complexes	 or	 networks.	 Therefore,	 interacting	 genes	 from	 the	 respective	
transcriptome	and	proteome	datasets	were	highlighted	and	reanalysed	to	find	more	manageable	
clusters	of	protein-protein	interactions.	This	grouped	the	nodes	into	5	complexes	depending	on	
their	 molecular	 function.	 The	 first	 identified	 network	 within	 the	 transcriptome	 dataset	 was	
adipocyte	 differentiation,	 which	 featured	 genes	 that	 are	 regulators	 of	 adipogenesis,	 such	 as	
PPARG,	 CD36,	 LEP,	 and	 SLC27A1.	 Another	 complex	 from	 the	 RNA-seq	 analysis	 was	 glucose	
metabolism,	 featuring	components	of	 the	pentose	phosphate	pathway,	TALDO1	 and	TKT,	 and	
glycolysis,	such	as	PFKL,	PFKFB3,	and	PGM1.	Within	the	proteomic	set	there	were	rich	interactions	
involving	 mitochondrial	 components,	 including	 those	 involved	 in	 the	 respiratory	 chain	 (also	
known	as	oxidative	phosphorylation),	UQCR10,	UQCRQ,	NDUF	subunits,	ATP1B3,	COX6A1,	and	
ATP5O.	Nodes	were	also	found	for	both	transcriptomic	and	proteomic	datasets	to	be	involved	in	
fatty	 acid	metabolism,	 including	 the	 genes	 SLC25A1,	 EPHX2,	DHCR7,	 ACAA2,	 and	ACADS,	 and	
proteins	HADH,	ACOX1	and	ACO2.	Although	these	were	represented	as	two	distinct	networks,	
they	were	interconnected	by	shared	nodes,	PEX14	and	ECH1.	This	demonstrated	that	individual	
networks	could	be	reintegrated	via	the	shared	nodes	back	into	the	larger,	complex	network.	
		
Figure	5.21	–	Protein-protein	interaction	map	of	the	Hallmark	adipogenesis	gene	set	identified	as	statistically	positively	enriched	in	fed	BBS	vs	control	by	GSEA	of	2	omic	technologies	(right).	Nodes	
were	coloured	by	genes/proteins	in	the	GSEA	leading	edge	from	RNA-seq	(yellow)	or	proteomic	(blue)	analyses,	where	orange	nodes	are	found	in	both.	The	integrated	map	was	separated	to	
identify	functional	complexes	found	for	genes	(blue	overlay,	top	left)	or	proteins	(green	overlay,	bottom	left),	which	are	denoted	by	the	broken	lines.	Protein	interactions	were	plotted	using	
STRING,	using	information	from	curated	databases	(blue	edges),	experimental	data	(pink	edges),	or	text	mining	(green	edges).
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5.3	Discussion	
Previous	studies	investigating	the	cellular	effects	of	BBS-causing	variants	have	mainly	focussed	
on	 gene	 expression	 and	 protein	 localisation	 of	 a	 handful	 of	markers	 related	 to	 cilia	 function.	
Therefore,	many	of	the	intricate	pathways	that	are	required	for	ciliary	maintenance	have	been	
overlooked.	To	our	knowledge,	this	was	the	first	study	to	utilise	BBS	patient	derived	cells	to	obtain	
a	global	cellular	profile,	which	allowed	identification	of	dysregulated	pathways	beyond	the	cilium.		
	
This	 investigation	 aimed	 to	 identify	 dysregulation	 of	 cellular	 pathways	 in	 BBS	 fibroblasts	
compared	to	controls	to	elucidate	the	pathobiology	of	BBS1	p.M390R.	BBS	and	control	fibroblasts	
were	 probed	 at	 both	 mRNA	 transcriptomic	 and	 proteomic	 levels,	 unveiling	 over	 15,000	
differentially	expressed	 transcripts	and	proteins	combined,	and	over	100	statistically	enriched	
gene	 sets	 and	 pathways.	 Furthermore,	 integration	 of	 omic	 technologies	 at	 the	 pathway	 level	
refined	 and	 enhanced	 reliability	 of	 findings,	 identifying	 17	 pathways	 across	 the	 different	
experimental	 comparisons	 that	 were	 found	 in	 both	 transcript	 and	 protein	 datasets.	 The	
experimental	design	presented	a	novel	approach	for	analysis	of	cellular	components	that	were	
differentially	regulated	in	conditions	to	promote	cell	cycle	progression	or	to	promote	ciliogenesis.	
These	 were	 then	 compared	 between	 disease	 and	 control	 groups.	 The	 consequence	 was	
identification	 of	 processes	 associated	 with	 obesity,	 upregulation	 of	 signalling	 pathways,	 and	
downregulation	 of	 genes	 involved	 in	 centrosome	 integrity.	 Although	 there	 were	 additional	
significant	findings,	these	were	identified	as	most	biologically	relevant	to	BBS	pathobiology	and	
prioritised	for	further	investigation.	They	will	be	the	focus	of	this	discussion.	
	
5.3.1	Enrichment	of	pathways	associated	with	adipogenesis	in	serum	fed	BBS	cultures	
GSEA	presented	a	knowledge	driven	and	methodical	approach	to	probing	the	datasets	against	50	
concise,	 yet	 relatively	 general,	 Hallmark	 gene	 sets.	 The	 analysis	 identified	 the	 gene	 set	
adipogenesis,	as	statistically	positively	enriched	for	the	fed	BBS	vs	control	comparison.	This	was	
a	 highly	 interesting	 and	 relevant	 finding,	 as	 obesity	 is	 a	 cardinal	 feature	 of	 BBS.	 Increased	
confidence	of	this	result	was	achieved	through	positive	enrichment	of	both	transcriptomic	and	
proteomic	 datasets	 (RNA-seq	 NES=	 1.682,	 FDR=	 0.0149;	 protein	 NES=	 1.447,	 FDR=	 0.1780),	
making	it	a	convincing	candidate	as	a	dysregulated	pathway	in	proliferating	BBS	fibroblasts.	
	
Adipogenesis	describes	the	differentiation	of	a	mesenchymal	stem	cell	(MSC)	through	to	a	mature	
adipocyte	(Ali	et	al.	2013).	The	role	of	the	adipocyte	is	to	maintain	lipid	homeostasis	and	control	
the	 energy	 balance	 through	 the	 storage	 of	 triglycerides.	 In	 a	 period	 of	 nutritional	 deficit,	
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triglycerides	are	metabolised	by	lipases	into	fatty	acids,	which	can	be	converted	into	glucose	by	
the	liver	via	the	TCA	cycle.	The	primary	regulator	of	adipogenesis	is	the	transcription	factor	PPARg	
(encoded	by	PPARG),	which	is	essential	for	adipogenic	induction	and	activation	of	C/EBP	proteins,	
required	for	terminal	adipocyte	differentiation	(Rosen	et	al.	2002).	PPARg	expression	is	switched	
on	early	during	adipocyte	differentiation	and	is	highly	expressed	in	adipose	tissue	(Tontonoz	et	
al.	1994).	Interestingly,	impromptu	differentiation	of	murine	fibroblasts	to	adipocytes	has	been	
demonstrated	by	overexpression	of	both	PPARg	and	C/EBPa	(Tontonoz	et	al.	1994;	Freytag	et	al.	
1994).	Signalling	pathways	Wnt	and	HH	have	also	been	shown	to	orchestrate	adipogenesis	and	
are	potent	inhibitory	factors	(Kopinke	et	al.	2017;	Marion	et	al.	2009).	For	example,	disruption	of	
Wnt	signalling	was	sufficient	to	induce	spontaneous	differentiation	of	myoblasts	to	adipocytes	
(Ross	et	al.	2000).	
	
Genes	that	induce	adipocyte	differentiation	were	upregulated	within	the	GSEA	leading	edge	of	
the	transcriptomic	data	for	fed	BBS	vs	control	experiments,	including	PPARG,	CD36,	SLC27A1,	and	
LEP	 (Tontonoz	et	 al.	 1994;	Qiao	et	 al.	 2008;	Challa	 et	 al.	 2015).	 To	determine	how	 these	 key	
adipogenic	genes	 interacted	with	the	rest	of	 the	enriched	adipogenesis	gene	set,	gene	names	
from	the	GSEA	leading	edge	from	RNA-seq	and	proteomics	data	were	incorporated	into	a	protein-
protein	 interaction	map	 (figure	5.21).	This	 revealed	a	 complex	network,	 that	when	simplified,	
identified	 components	 of	 glucose	metabolism,	mitochondrial	 respiratory	 chain,	 and	 fatty	 acid	
metabolism,	 in	 addition	 to	 adipocyte	 differentiation.	Many	 components	 of	 the	 network	were	
involved	in	mitochondrial	biogenesis	and	function.	This	included	a	number	of	proteins	involved	
in	 the	 mitochondrial	 respiratory	 chain,	 such	 as	 subunits	 of	 complex	 I	 (NDUFB7,	 NDUFA5,	
NDUFAB1,	and	NDUFS3),	complex	III	(UQCR10	and	UQCRQ),	complex	IV	ATP	synthase	(ATP5O),	
and	cytochrome	c	oxidase	(COX6A1).	Mitochondria	have	an	important	role	in	the	regulation	of	
adipocyte	 differentiation,	 as	 during	 adipogenesis,	 increased	 oxygen	 consumption	 and	
mitochondrial	 biogenesis	 has	 been	 observed	 (Lu	 et	 al.	 2010;	 Shi	 et	 al.	 2008).	 Concurrently,	
inhibition	 of	 mitochondrial	 function	 results	 in	 diminished	 ability	 to	 store	 triglycerides	 and	
prevented	 differentiation	 of	 MSCs	 into	 adipocytes	 (Zhang	 et	 al.	 2013).	 The	 upregulation	 of	
mitochondrial	 function	 in	 fed	BBS	vs	 control	 cells	 is	 also	 supported	by	positive	enrichment	of	
oxidative	phosphorylation	by	GSEA	in	both	transcriptomic	and	proteomic	datasets	(table	5.6).	
	
A	network	containing	components	required	for	fatty	acid	metabolism	was	enriched	in	both	RNA-
seq	and	proteomic	adipogenesis	gene	sets.	These	mostly	included	those	involved	in	fatty	acid	b-
oxidation,	such	as	ACAA2,	ACADS,	ECH1,	HADH,	ACOX1,	and	SLC25A1.	Fatty	acid	b-oxidation	is	
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the	 mitochondrial	 generation	 of	 acetyl-CoA	 from	 triglycerides	 for	 energy	 production,	 and	 is	
particularly	high	in	brown	adipose	tissue	for	thermogenesis	(Festuccia	et	al.	2011).	A	significant	
increase	in	brown,	as	well	as	white	adipose	tissue	was	demonstrated	in	the	Bbs1	M390R	knock-
in	mouse	 (Davis	 et	 al.	 2007).	 Overall,	 there	 were	many	 genes	 within	 the	 positively	 enriched	
adipogenesis	gene	set	related	to	mitochondrial	function.	As	fatty	acid	metabolism	and	multiple	
other	mitochondrial	 components	were	 featured	 in	 the	 leading	 edge	 of	 both	 datasets,	 it	may	
suggest	that	upregulation	of	adipogenesis	genes	in	fed	BBS	cultures	was	driven	by	unbalanced	
mitochondrial	activity	and/or	fatty	acid	homeostasis.	
	
MSCs	can	give	rise	to	both	fibroblasts	and	adipocytes	(Friedenstein	1976),	and	reports	suggest	
that	 morphologically,	 fibroblasts	 can	 be	 difficult	 to	 distinguish	 from	 preadipocytes	 (Ali	 et	 al.	
2013).	 Furthermore,	 dermal	 fibroblasts	 can	 be	 reprogrammed	 into	 adipocytes,	 either	 by	
overexpression	of	PPARG	(Tontonoz	et	al.	1994)	or	by	exogenous	adipogenic	induction	through	
cell	culture	(Marion	et	al.	2009).	With	this	knowledge	and	upregulation	of	proadipogenic	factors	
within	 this	 study,	 it	 is	 tempting	 to	 speculate	 that	 serum	 fed	 BBS	 fibroblasts	 exhibit	 a	 gene	
expression	signature	similar	to	differentiating	adipocytes.	Specific	markers	of	adipocytes,	such	as	
FABP4,	PEPCK,	CEBPA,	GLUT4,	and	LPL	(Moseti	et	al.	2016),	weren’t	detected	in	transcriptomic	
and	proteomic	data	 (supplemental	data,	 table	S.5,	 table	S.32),	and	 fibroblast	markers	 such	as	
fibroblast	specific	protein	1	(FSP1,	encoded	by	S100A4)	and	collagen	genes	(Strutz	et	al.	1995)	
were	highly	expressed,	demonstrating	 that	cultures	were	 fibroblastic	 in	nature.	However,	 it	 is	
possible	that	BBS	fibroblasts	exhibited	a	basal	level	of	proadipogenic	expression,	demonstrated	
by	upregulation	of	PPARG	and	LEP	and	mitochondrial	processes.	This	finding	would	support	other	
studies	that	suggest	obesity	is	not	exclusively	a	consequence	of	leptin	insensitivity,	but	may	also	
be	linked	to	aberrant	cellular	processes	leading	to	increased	adiposity	(Marion	et	al.	2009;	Marion	
et	al.	2012).	
	
Further	experiments	would	be	required	to	determine	whether	BBS	patients’	fibroblasts	have	a	
predisposition	 to	 adipogenesis.	 Firstly,	 validation	 of	 markers,	 such	 as	 PPARG	 and	 LEP,	 in	
fibroblasts	 would	 be	 essential	 in	 a	 larger	 cohort	 to	 determine	 whether	 there	 is	 a	 significant	
increase	 in	 gene	 expression	 compared	 to	 controls.	 Secondly,	 it	 would	 be	 an	 interesting	
experiment	to	induce	differentiation	of	BBS	fibroblasts	into	adipocytes	and	serially	follow	gene	
expression	 of	 adipocyte	 markers,	 with	 the	 hypothesis	 that	 BBS	 fibroblasts	 have	 a	 higher	
differentiation	efficiency	than	controls.	The	finding	of	dysregulated	mitochondrial	biogenesis	and	
fatty	acid	metabolism	could	also	be	validated	within	the	same	experiment.	Similar	studies	have	
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previously	 demonstrated	 that	 ablation	 of	 BBS10	 and	 BBS12	 increased	 leptin	 and	 PPARG	
expression	in	differentiating	adipocytes,	which	was	coupled	to	downregulation	of	antiadipogenic	
signalling	pathways,	such	as	Wnt	and	HH	(Marion,	Mockel,	et	al.	2012).	Experiments	such	as	this	
have	yet	to	be	performed	with	patient-derived	cells	carrying	the	BBS1	p.M390R	variant,	and	thus	
may	provide	further	insight	into	high	prevalence	of	obesity	in	patients.	
	
5.3.2	Analysis	of	the	effects	of	serum	starvation	on	BBS	and	control	fibroblasts	
The	experimental	design	for	this	study	enabled	comprehensive	analysis	of	fibroblasts	 in	either	
cell	 cycling	 or	 ciliated	 states.	 It	 also	 provided	 an	 opportunity	 to	 detect	 differences	 between	
starved	and	fed	cells,	thereby	identifying	putative	cellular	defects	that	may	present	in	response	
to	serum	starvation.	Serum	starvation	is	a	common	method	for	induction	of	ciliogenesis	in	cell	
culture,	as	it	stimulates	cell	cycle	arrest	and	cellular	quiescence	(Tucker	et	al.	1979;	Uetake	et	al.	
2007).	It	is	also	used	routinely	to	reduce	basal	cellular	signalling	activity	(Pirkmajer	and	Chibalin	
2011).	 GSEA	 revealed	many	 parallels	 between	 BBS	 starved	 vs	 fed	 and	 control	 starved	 vs	 fed	
cultures,	 demonstrating	 cellular	 similarities	 in	 regulation	 as	 a	 response	 to	 starvation.	 These	
included	 a	 highly	 significant	 negative	 enrichment	 of	 processes	 associated	with	 the	 cell	 cycle,	
including	mitotic	 spindle,	G2M	checkpoint,	 and	E2F	 targets,	 and	downregulation	of	other	 key	
pathways,	such	as	HH,	mTORC1,	hypoxia,	and	unfolded	protein	response.	Two	differences	were	
identified	 between	 BBS	 and	 control	 for	 starved	 vs	 fed	 comparisons,	 namely	myogenesis	 and	
inflammatory	response,	which	were	both	negatively	enriched	in	BBS	and	positively	enriched	in	
control	 experiments.	 Further	 elucidation	 is	 required	 to	 determine	 the	 significance	 of	 these	
findings,	 as	 there	 is	 little	 evidence	 of	 cilia-specific	 dysregulation	 of	 these	 processes	 in	 the	
literature.	
	
GSEA	provided	a	broad	overview	of	enriched	cellular	processes,	but	did	not	identify	biologically	
interesting	differences	between	BBS	and	control	experiments.	Therefore,	an	alternative	pathway	
analysis	was	 applied,	 PANTHER	enrichment	 test	 using	 the	Reactome	pathways	 database.	 This	
identified	that	“ciliary	part”	was	upregulated	in	BBS	starved	vs	fed,	but	“assembly	of	the	primary	
cilium”	was	downregulated	 in	 control	 starved	 vs	 fed.	As	 serum	 starvation	 intended	 to	 induce	
ciliary	 assembly,	 it	 was	 unexpected	 that	 this	 pathway	 was	 downregulated	 in	 controls,	 and	
therefore	 was	 explored	 further	 by	 investigation	 of	 complexing	 interactions	 for	 DE	 genes.	
Annotation	of	differential	regulation	for	DE	genes	found	in	patients,	controls,	and	both,	revealed	
clear	complexes	of	genes	that	were	up	and	downregulated	in	response	to	starvation	for	induction	
of	ciliogenesis.	This	highlighted	a	limitation	of	pathway	analysis,	where	the	quality	of	the	gene	set	
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determines	the	efficiency	of	the	analysis.	In	this	case,	the	gene	set	for	“assembly	of	the	primary	
cilium”	contained	components	that	would	be	expected	to	be	upregulated,	such	as	the	BBSome	
and	IFT	machinery.	Simultaneously,	genes	involved	cell	cycle	and	centrosome	maturation,	which	
play	an	important	role	in	ciliary	assembly,	would	be	expected	to	be	downregulated	(Pedersen	et	
al.	2008).	This	shows	the	importance	of	referring	back	to	the	gene	level	after	pathway	analysis.	
	
Within	the	network	of	“assembly	of	the	primary	cilium”	there	were	a	larger	number	of	DE	genes	
from	the	BBS	starved	vs	fed	experiment	than	the	control	group.	However,	this	may	be	due	to	
statistical	 bias	 created	 by	 analysing	 a	 larger	 patient	 than	 control	 group.	 This	 was	 a	 known	
limitation	of	the	study	design,	and	was	not	possible	to	overcome	due	to	limited	access	to	control	
material	at	the	time	of	conducting	experiments.	However,	one	may	be	able	to	infer	differences	if	
seen	 in	 the	 control	 group	 and	 not	 patients.	 10	 genes	 that	 interacted	 within	 the	 complex	 of	
transition	zone/centrosome	were	downregulated	in	control	and	not	in	the	BBS	experiment.	These	
included	 centrosomal	 genes	 involved	 in	microtubule	 nucleation	 and	 centrosome	 integrity,	 or	
were	negative	regulators	of	ciliogenesis.		
	
The	gene	products	of	6	genes	identified	in	the	complex	are	involved	in	mitotic	spindle	dynamics	
and	centrosome	 integrity.	HAUS3,	HAUS6,	and	HAUS8	 form	a	complex	 responsible	 for	mitotic	
spindle	generation	and	cytokinesis	(Uehara	et	al.	2009;	Lawo	et	al.	2009).	The	complex	localises	
to	 interphase	centrosomes	and	 regulates	 the	 formation	of	mitotic	 spindles.	Deletion	of	HAUS	
subunits	 was	 shown	 to	 result	 in	 delayed	 attachment	 of	 microtubules	 to	 kinetochores	 and	
diminished	 centrosome	 integrity	 (Lawo	 et	 al.	 2009;	 Uehara	 et	 al.	 2009).	 CKAP5	 also	 plays	 an	
essential	 role	 in	 dynamics,	 organisation,	 and	 nucleation	 of	 the	mitotic	 spindle	 (Gergely	 et	 al.	
2003).	CEP72	localises	to	the	pericentriolar	material	(PCM)	of	the	centrosome	and	acts	to	recruit	
other	centrosomal	proteins	for	centrosome	duplication	(Kodani	et	al.	2015).	Furthermore,	CEP72	
overexpression	was	shown	to	induce	chromosomal	instability	and	abnormal	mitotic	microtubule	
assembly	(Lüddecke	et	al.	2016).	CEP152	directly	interacts	with	CEP72	and	functions	together	to	
promote	centrosome	duplication	(Kodani	et	al.	2015;	Brown	et	al.	2013).	CEP152	also	acts	as	a	
molecular	 scaffold	 to	orchestrate	 the	 interaction	between	PLK4	and	CENPJ	 (Cizmecioglu	et	al.	
2010),	both	of	which	are	also	 involved	 in	centrosome	duplication	and	were	downregulated	 in	
response	 to	starvation	 (figure	5.14).	Analysis	of	 transcriptomic	data	 for	 these	genes	 identified	
that	gene	expression	was	lower	in	fed	BBS	cultures	than	fed	controls,	where	expression	of	HAUS3	
and	CEP152	was	significantly	reduced	(figure	5.15).	The	finding	that	mitotic	spindle	organisation	
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is	disrupted	in	cycling	BBS	cells	was	supported	by	GSEA,	which	established	a	significantly	negative	
enrichment	of	the	mitotic	spindle	gene	set	for	fed	BBS	vs	control.	
	
CEP97	and	KIF24,	which	negatively	regulate	ciliogenesis,	were	also	significantly	downregulated	in	
control,	but	not	BBS,	serum	starved	cultures.	CEP97	forms	an	inhibitory	complex	with	CCP110,	
which	 prevents	 premature	 ciliogenesis	 (Spektor	 et	 al.	 2007).	 KIF24	mediates	 this	 process	 by	
ensuring	destabilisation	of	microtubules	at	 the	mother	centriole,	 to	prevent	nucleation	of	 the	
basal	 body	 (Kobayashi	 et	 al.	 2011).	 Furthermore,	 upon	 re-entry	 into	 the	 cell	 cycle,	 KIF24	 is	
upregulated	to	stimulate	depolymerisation	of	microtubules	at	the	basal	body,	a	process	driven	
by	 the	kinase,	NEK2	 (S.	Kim	et	al.	2015).	Thus,	cilia	assembly	 is	 induced	by	 inactivation	of	 the	
CCP110-CEP97	complex	and	KIF24,	via	phosphorylation	by	kinases,	such	as	TTBK2	(Čajánek	and	
Nigg	2014).	Downregulation	of	CEP97	and	KIF24	is	therefore	a	logical	finding	for	cells	stimulated	
for	 ciliogenesis	 by	 serum	 starvation.	 Interestingly,	 CCP110	 is	 significantly	 upregulated	 in	 BBS	
starved	vs	fed.	The	fact	that	CCP110,	CEP97,	and	KIF24	expression	is	reduced	or	opposite	to	what	
is	 expected	 for	 the	 assembly	 of	 the	 cilium,	 may	 suggest	 that	 the	 process	 of	 inhibition	 of	
ciliogenesis	is	dysregulated.	
	
5.3.3	Many	upregulated	proteins	linked	to	ciliary	pathways	in	starved	BBS	vs	control	
RNA-seq	analysis	detected	the	global	mRNA	transcripts	to	provide	a	comprehensive	snapshot	of	
the	 cellular	 physiological	 state.	 Identification	 of	 DE	 genes	 revealed	 that	 there	 were	 large	
differences	between	starved	and	fed	cells,	resulting	in	up	to	6000	DE	genes.	On	the	other	hand,	
there	were	smaller	differences	between	BBS	and	control	fibroblasts.	There	were	only	29	DE	genes	
for	starved	BBS	vs	control	comparison,	which	was	anticipated	to	be	the	most	biologically	relevant	
comparison	to	this	study.	The	reason	for	the	smaller	number	of	DE	genes	may	be	due	to	one	of	
two	explanations.	Firstly,	starvation	may	have	reduced	the	basal	cellular	activity	to	a	state	where	
the	BBS	and	control	samples	were	more	homogeneous,	and	thus	differential	expression	could	
not	be	 inferred.	The	second	explanation	may	be	for	the	opposite	reason;	starvation	may	have	
resulted	in	a	greater	level	of	heterogeneity	across	all	cells,	that	transcript	levels	within	biological	
groups	were	too	variable	to	 identify	statistical	differences,	particularly	with	a	small	number	of	
samples.	 The	 issue	 seen	 for	 transcripts	 of	 starved	 BBS	 vs	 control	was	 not	 observed	with	 the	
proteomics	dataset.	This	is	possibly	due	to	the	greater	stability	of	proteins	compared	to	mRNA,	
where	inside	a	cell,	mRNA	has	a	half-life	of	several	hours,	whereas	proteins	can	last	up	to	2	days	
(Schwanhäusser	et	al.	2011).		
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PANTHER	 enrichment	 testing	 was	 used	 to	 simplify	 the	 data	 and	 categorise	 DE	 proteins	 into	
biological	 groups.	Out	of	18	pathways	 from	 the	Reactome	database	 shown	 to	be	 significantly	
enriched,	5	were	recognised	as	being	involved	in	the	regulation	or	maintenance	of	the	primary	
cilium,	namely	“assembly	of	the	primary	cilium”,	“hedgehog	‘off’	state”,	“RHO	GTPase	effectors”,	
“centrosome	 maturation”,	 and	 “cytoskeletal	 regulation	 by	 RHO	 GTPases”.	 The	 DE	 proteins	
enriched	 for	 these	 pathways	 were	 predicted	 by	 pathway	 topology	 mapping	 to	 be	 highly	
interconnected.	It	was	then	considered	how	BBS1	and	its	interacting	partners	were	incorporated	
into	the	network,	with	the	postulation	that	the	BBS1	p.M390R	variant	was	driving	the	pathways	
to	be	upregulated	 in	contrast	 to	controls.	Due	 to	 the	complexity	of	 the	network	presented	 in	
figure	5.20,	it	was	challenging	to	make	reliable	inferences	without	further	validation.	However,	
the	implication	of	the	interaction	of	BBS1	within	the	pathway	network	has	been	considered	and	
shall	be	discussed	here.	
	
BBS1	was	incorporated	into	the	network	via	LZTFL1,	and	the	GPCR	that	controls	the	induction	of	
HH	signalling,	SMO.	LZTFL1	is	a	cytoplasmic	protein	that	has	been	hypothesised	to	interact	with	
BBSome	as	a	negative	regulator	of	its	trafficking	to	the	ciliary	membrane.	Together	LZTFL1	and	
the	BBSome	were	found	to	regulate	trafficking	of	SMO	in	the	primary	cilium	(Seo	et	al.	2011).	
Furthermore,	LZTFL1	was	recognised	as	the	17th	gene	to	manifest	BBS	in	a	consanguineous	family,	
with	 unusual	 presentation	 featuring	 situs	 inversus	 and	 insertional	 polydactyly,	 in	 addition	 to	
visual,	renal,	endocrine,	and	cognitive	phenotypes	(Marion,	Stutzmann,	et	al.	2012).	These	BBS-
like	 features	were	 shown	 to	be	 caused	by	defective	 regulation	of	 SMO,	as	 loss	of	 function	of	
LZTFL1	resulted	in	increased	SMO,	PTCH1,	and	GLI2	expression	(Marion,	Stutzmann,	et	al.	2012).	
Within	the	present	study,	SMO	was	classified	to	function	within	the	“HH	‘off’	state”,	due	to	the	
presence	of	negative	 regulators	of	HH,	 such	as	KIF7,	NUMB,	and	 the	proteasome	 (Liem	et	al.	
2009;	Di	Marcotullio	et	al.	2006;	Gerhardt	et	al.	2016).	For	example,	KIF7	is	thought	to	localise	to	
the	basal	body	and	block	entry	of	GLIs	into	the	primary	cilium,	which	promotes	degradation	of	
GLIs	by	transporting	them	away	from	the	base	of	the	cilium	(Liem	et	al.	2009;	Goetz	and	Anderson	
2010).	 To	determine	whether	 “HH	 ‘off’	 state”	 is	 a	 true	 finding,	 it	 is	 crucial	 to	understand	 the	
localisation	of	proteins,	such	as	SMO	and	the	proteasome;	information	that	mass	spectrometry	
cannot	provide.	Localisation	of	some	proteins	determines	their	function.	For	example,	if	SMO	has	
accumulated	 in	 the	 cytoplasm	 of	 the	 cell,	 then	 this	 induces	 processing	 of	 repressor	 GLIs.	
However,	 SMO	 localises	 to	 the	 ciliary	membrane	upon	binding	of	HH	 ligand	 to	PTCH1,	which	
activates	GLIs	and	triggers	downstream	HH	pathways	(Rohatgi	et	al.	2007;	Goetz	and	Anderson	
2010)	 (see	 figure	1.2).	As	 it	 requires	 additional	purification	 steps	 to	 isolate	membrane	bound	
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proteins	(Mirza	et	al.	2007),	within	this	experiment	it	is	more	likely	that	SMO	has	been	detected	
in	the	cytoplasm.	This	would	need	to	be	verified	by	protein	localisation	experiments.	
	
BBS1	was	also	 interconnected	 to	 the	network	via	direct	 interaction	with	RABIN8	 (encoded	by	
RAB3IP),	which	 is	 a	guanine	nucleotide	exchange	 factor	 (GEF)	 required	 for	activation	of	RAB8	
(Hattula	 et	 al.	 2002).	 The	 interaction	 of	 the	 BBSome,	 RABIN8,	 and	 RAB8	 is	 crucial	 for	 the	
mediation	of	vesicle	docking	and	fusion	to	the	ciliary	membrane	(Nachury	et	al.	2007;	Jin	et	al.	
2010).	 Furthermore,	 relocalisation	 of	 RABIN8	 to	 the	 centrosome	 by	 interaction	with	 another	
small	GTPase,	RAB11,	is	required	for	initiation	of	ciliogenesis	(Knödler	et	al.	2010;	Westlake	et	al.	
2011;	Feng	et	al.	2012).	This	occurs	upstream	of	the	interaction	with	BBS1	(Westlake	et	al.	2011).	
Although	the	majority	of	BBSome	components,	such	as	BBS2,	BBS4,	and	BBS7,	are	not	essential	
for	cilia	assembly,	knockdown	of	BBS1	 resulted	 in	 reduction	of	cilia	on	RPE	cells	 (Loktev	et	al.	
2008;	Jin	et	al.	2010).	This	evidence	suggests	that	the	interaction	between	RABIN8	and	BBS1,	but	
not	other	components	of	the	BBSome,	is	necessary	for	cilia	assembly	(Nachury	et	al.	2007;	Jin	et	
al.	 2010).	 Within	 the	 network,	 the	 connection	 with	 RABIN8	 links	 BBS1	 to	 components	 of	
“centrosome	maturation”	and	“assembly	of	the	primary	cilium”,	such	as	CEP290,	OFD1,	EXOCs,	
and	 ARF4,	 but	 also	 proteins	 involved	 in	 “RHO	GTPase	 Effectors”,	 including	MAPRE1,	 CLASP1,	
YWHAG,	and	YWHAE.	
	
RHO	GTPases	act	as	a	molecular	switch	to	control	cytoskeletal	dynamics	and	cellular	remodelling	
(Pan	et	al.	2007).	RABIN8	has	been	shown	to	modulate	actin	organisation	and	reduce	stress	fibre	
formation	(Hattula	et	al.	2002).	As	a	result,	it	has	been	suggested	that	RABIN8	modulates	delivery	
of	vesicles	to	the	ciliary	membrane	through	reorganisation	of	actin	and	microtubules	(Hattula	et	
al.	2002).	This	is	supported	by	RABIN8	interaction	with	the	exocyst	complex,	featuring	EXOC1-8	
(Feng	et	al.	2012),	which	in	turn	interacts	with	CDC42	to	regulate	the	cytoskeleton	(Zhang	et	al.	
2001).	Components	of	the	“RHO	GTPase	effectors”	that	are	involved	in	actin	remodelling	were	
significantly	upregulated	in	starved	BBS	vs	control,	such	as	CDC42,	ROCK1/2,	RHOC,	and	members	
of	the	ARP2/3	complex,	including	ARPC2-5.	The	loss	of	BBS1	has	been	demonstrated	to	increase	
expression	of	RHO	GTPases,	which	 increased	actin	 fibres	and	prompted	defective	ciliogenesis.	
This	led	to	the	conclusion	that	BBS	proteins	may	also	be	involved	in	actin	regulation	(Hernandez-
Hernandez	et	al.	2013),	and	that	actin	can	negatively	modulate	ciliogenesis	(Kim	et	al.	2010;	Pan	
et	al.	2007).	The	mechanism	for	how	BBS1	regulates	the	cytoskeleton	is	not	understood,	however	
it	 is	 possible	 that	 it	 occurs	 through	 RABIN8	 and	 its	 many	 effectors	 related	 to	 cytoskeletal	
organisation.	
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The	results	presented	by	pathway	enrichment	and	topological	mapping	analysis	has	successfully	
categorised	a	large	complex	dataset	and	presented	the	data	to	aid	hypothesis	generation.	The	
main	 finding	 is	 that	 BBS1	 interacts	 indirectly	 with	 members	 of	 5	 pathways	 related	 to	 ciliary	
function,	that	were	statistically	positively	enriched	 in	starved	BBS	vs	control	experiments.	This	
occurs	 through	 direct	 interaction	 with	 SMO	 or	 RABIN8.	 As	 a	 result,	 a	 new	 hypothesis	 was	
developed	stating	that	the	observed	upregulation	of	the	components	in	the	presented	pathways	
are	due	to	reduced	function	of	BBS1,	caused	by	harbouring	the	variant	p.M390R.	This	may	be	
driven	 by	 diminished	 affinity	 for	 BBS1	with	 its	 interactors.	 It	 has	 previously	 been	 shown	 that	
p.M390R	induces	a	conformational	change	in	BBS1	that	reduces	its	affinity	with	ARL6	(Mourão	et	
al.	2014).	Therefore,	it	is	possible	that	p.M390R	also	affects	the	direct	interaction	with	RABIN8,	
which	results	 in	the	accumulation	of	proteins	in	BBS	cells.	The	RNA-seq	data	may	also	support	
this	 hypothesis,	 as	 a	 greater	 number	 of	 upregulated	 transcripts	 for	 “assembly	 of	 the	 primary	
cilium”	 were	 found	 in	 BBS	 starved	 vs	 fed	 compared	 to	 control	 starved	 vs	 fed.	 As	 previously	
discussed,	this	may	be	a	statistical	artefact,	thus	must	be	validated	in	a	larger	sample	size	with	a	
greater	number	of	control	samples.	
	
5.3.4	Experimental	limitations	
5.3.4.1	Pathway	enrichment	analysis	
Statistical	 enrichment	 tools,	 such	 as	 GSEA	 and	 PANTHER	 used	within	 this	 chapter,	 addressed	
limitations	of	other	pathway	analyses,	such	as	overrepresentation	testing,	by	not	restricting	the	
data	by	p-value	thresholds	(Khatri	et	al.	2012).	 In	the	enrichment	tests,	genes	are	not	treated	
equally	but	 ranked	by	 a	metric,	 such	as	 log2(FC)	used	 in	 this	 study.	Although	a	more	 reliable	
analysis	than	overrepresentation	testing,	there	are	limitations.	It	is	commonly	understood	that	a	
gene	or	a	complex	of	genes	can	function	in	multiple	different	pathways;	however,	enrichment	
testing	 considers	 each	 pathway	 independently.	 For	 example,	 the	 proteasome	 is	 a	 negative	
regulator	 of	 multiple	 cellular	 processes,	 including	 Wnt	 signalling,	 HH	 signalling,	 cell	 cycle,	
apoptosis,	and	cancer	associated	pathways	(Adams	2003;	Malicki	and	Johnson	2017).	Therefore,	
differential	 regulation	 of	 a	 component	 such	 as	 the	 proteasome	may	 return	 many	 significant	
pathways,	where	it	is	challenging	to	ascertain	whether	they	are	true	findings	without	functional	
determination.	
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5.3.4.2	Pathway	topology	mapping	analysis		
Gene	 enrichment	 analysis	 is	 well	 complemented	 by	 pathway	 topology	 mapping,	 as	 it	
demonstrates	 how	 pathways	 are	 interconnected	 and	 cross-talking.	 As	 demonstrated	 in	 this	
thesis,	 it	 also	 allows	 identification	 of	 complexes	 that	 are	 up	 or	 downregulated,	 or	 that	 are	
contributing	the	most	to	significant	enrichment.	The	utility	of	topological	analysis	relies	on	well	
characterised	pathways,	where	 some	 interactions	will	 be	more	 comprehensively	 studied	 than	
others.	For	example,	within	the	STRING	database,	interactions	involved	in	cilium	assembly	were	
extensively	 documented	 by	 experimental	 data	 or	 in	 curated	 databases.	 On	 the	 other	 hand,	
interactions	 for	 genes	 involved	 in	 adipogenesis	 were	 less	 confident,	 thus	 to	 strengthen	 the	
network	generated	for	figure	5.21,	connections	obtained	from	text	mining	were	also	included.	
	
5.3.4.3	Database	annotation	
Pathway	 analysis	 can	be	 an	 invaluable	 tool	 for	 simplifying	overwhelmingly	 large	datasets	 into	
biologically	meaningful	and	statistically	significant	groups,	as	has	been	demonstrated	within	this	
study.	However,	their	utility	is	limited	by	the	robustness	of	databases	and	gene	sets,	which	are	
currently	struggling	to	keep	up	with	the	high-resolution	datasets	generated	by	NGS	technologies.	
Data	 used	 to	 create	 gene	 sets	 and	 pathways	 are	 typically	 generated	 from	 gene	 expression	
experiments	implemented	by	different	labs	under	different	conditions,	often	with	different	cell	
types	(Khatri	et	al.	2012).	Although	most	databases	have	been	manually	curated	to	ensure	gene	
sets	 are	 reliable	 and	 non-overlapping	 (Liberzon	 et	 al.	 2015;	 Croft	 et	 al.	 2011),	 databases	 are	
currently	lacking	information	about	the	exact	conditions	experiments	were	undertaken.	This	 is	
particularly	relevant	to	tissue	specific	findings,	as	pathways	may	be	distinctive	in	different	cells	
due	to	cell-specific	gene	expression	signatures.	Furthermore,	different	transcript	isoforms	cannot	
be	distinguished	by	databases,	thus	are	mapped	to	the	same	gene,	removing	tissue	or	condition	
specific	information	(Khatri	et	al.	2012).	
	
Another	obvious	limitation	is	that	pathway	analysis	can	only	be	completed	with	genes	that	are	
annotated.	This	 immediately	removes	all	non-protein	coding	transcripts,	the	function	of	which	
are	 predominantly	 undefined.	 Therefore,	 within	 this	 study	 this	 immediately	 excluded	 ~2000	
transcripts	from	RNA-seq	experiments	from	consideration.	Moreover,	PANTHER	is	comprised	of	
13,387	human	protein-coding	genes	(Mi	et	al.	2017)	meaning	that	~7000	genes	are	not	annotated	
in	PANTHER.	These	limitations	are	well	comprehended	by	curators	and	are	being	addressed	by	
new	database	builds,	which	are	frequently	being	released.	
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5.3.4.4	Limits	of	the	study	design	and	future	work	
This	study	was	designed	to	observe	the	differences	between	cell	cycling	and	ciliated	fibroblast	
cultures	between	BBS	and	controls.	This	 identified	thousands	of	differentially	expressed	genes	
and	proteins	when	serum	starved	and	serum	fed	cells	were	compared.	There	was	less	significant	
variation	between	BBS	and	control	groups,	which	was	reflected	by	fewer	differentially	expressed	
genes.	 One	 reason	 for	 fewer	 significant	 differences	 between	 biological	 groups	 is	 likely	 to	 be	
heterogeneity	 between	 different	 samples.	 Regulation	 of	 gene	 expression	may	 be	 affected	 by	
genetic	background	or	environmental	factors,	thereby	generating	variability	between	different	
cultures	within	the	same	biological	group.	In	order	to	reduce	this	variance,	greater	sample	sizes	
would	be	required	to	increase	statistical	power.	
	
In	 total,	14,573	protein-coding	 transcripts	and	6,683	proteins	were	detected	 from	fibroblasts,	
generating	a	46%	rate	of	protein	detection	 for	expressed	genes.	This	 is	a	high	detection	 rate,	
which	can	be	attributed	to	the	reduced	sample	complexity	achieved	by	separating	samples	into	
20	 peptide	 fractions	 each.	 On	 the	 other	 hand,	 many	 BBS	 proteins,	 including	 BBS1	 and	 its	
interactors,	were	not	detected	by	iTRAQ	proteomics.	This	may	be	due	to	the	low	expression	levels	
of	these	genes	in	fibroblasts	(for	example,	RAB3IP	mean	log2CPM=	1.77;	BBS1	mean	log2CPM=	
1.88;	whereas	GAPDH	mean	 log2CPM=	 10.45,	 supplemental	 data,	 table	 S.2).	 It	 is	 possible	 to	
increase	the	depth	of	coverage	for	a	single	cell	type,	as	10,255	proteins	were	identified	from	HeLa	
cells	(Nagaraj	et	al.	2011).	However,	this	required	separation	into	72	fractions,	which	accounted	
for	288	hours	of	mass	spectrometry	instrument	time	(Nagaraj	et	al.	2011).	This	depth	of	coverage	
was	not	 realistic	 to	obtain	 for	 this	project,	due	 to	 the	expense	of	 fractionation	and	extensive	
instrument	running	time	required	for	the	number	of	samples	used.	Furthermore,	sample	pooling	
may	have	also	 reduced	 the	sensitivity	of	 the	mass	spectrometer,	as	 sample	complexity	would	
have	increased.	This	was	an	unavoidable	step	within	this	experiment	due	to	the	high	cost	of	iTRAQ	
proteomics	technology.	The	main	limitation	of	pooling	was	that	protein	expression	for	samples	
could	not	be	considered	individually,	and	thus	it	was	not	possible	to	identify	the	true	variance	of	
the	experiment.		
	
Fibroblasts	may	not	be	considered	as	a	disease	relevant	cell	type,	as	BBS	patients	do	not	have	a	
known	dermal	phenotype.	However,	they	were	used	in	this	study	as	they	can	be	isolated	from	a	
dermal	skin	biopsy	that	can	be	taken	from	patients	in	the	clinic	via	a	simple	procedure.	This	results	
in	a	cellular	disease	model	that,	in	theory,	harbours	the	same	genetic	background	of	each	patient.	
Furthermore,	fibroblasts	were	also	suited	to	this	study	design	as	they	are	well-known	to	ciliate	
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efficiently	under	serum	starved	conditions	(Schneider	et	al.	2005;	Christensen	et	al.	2013).	In	this	
study,	these	cells	presented	a	valuable	cellular	resource	that	were	manageable	to	culture	to	vast	
numbers	when	large	quantities	of	RNA	and	protein	were	required.	They	provided	an	appropriate	
cellular	model	 for	a	 large-scale	pilot	project,	such	as	this	one,	where	 implementation	of	novel	
techniques	may	have	squandered	precious	patient	tissues	if	experimental	strategies	had	not	gone	
to	plan.	This	study	has	subsequently	allowed	development	of	multi-omic	methodology	for	future	
work,	where	more	disease	relevant	tissue,	or	models	derived	from	iPSC	differentiations,	may	be	
utilised.	
	
Even	though	the	skin	does	not	exhibit	a	known	molecular	phenotype	in	BBS	patients,	this	study	
has	uncovered	some	interesting	findings	that	would	warrant	further	research.	Pathway	analysis	
of	iTRAQ	proteomics	data	for	starved	BBS	vs	control	comparisons	identified	the	upregulation	of	
key	modulators	of	ciliogenesis,	 including	 those	 involved	 in	cilium	assembly,	actin	cytoskeleton	
remodelling,	and	HH	signalling.	 I	have	hypothesised	that	this	upregulation	may	be	an	effect	of	
reduced	affinity	of	BBS1	with	 its	 interactors,	such	as	SMO	or	RABIN8,	caused	by	the	p.M390R	
variant.	 Firstly,	 this	 finding	 would	 need	 to	 be	 validated	 in	 a	 larger	 sample	 size	 to	 determine	
whether	 this	 collective	upregulation	 is	 reproducible.	Next,	 it	would	be	 interesting	 to	establish	
whether	 this	 difference	 is	 enhanced	 in	 BBS	 fibroblasts	 when	 stimulated	 to	 induce	 ciliary	
trafficking.	Smoothened	agonist	(SAG)	may	present	an	efficient	method	to	accomplish	this,	as	it	
induces	an	upregulation	of	SMO	trafficking	to	the	primary	cilium	(Sinha	and	Chen	2006).	Ciliary	
localisation	of	SMO	was	shown	to	be	depleted	in	cells	lacking	BBS1,	both	with	and	without	SAG	
treatment	(Seo	et	al.	2011).	Therefore,	this	would	be	a	suitable	agonist	to	test	this	hypothesis.	
Preliminary	testing	would	investigate	the	localisation	of	SMO	in	response	to	SAG	in	BBS1	p.M390R	
fibroblasts	compared	to	control	by	immunochemical	staining.	If	this	is	successful,	a	targeted	assay	
could	be	developed,	featuring	the	upregulated	proteins	in	key	pathways	identified	in	this	study,	
to	establish	whether	treatment	induces	a	significant	increase	in	gene	and	protein	expression	in	
BBS	compared	to	control	cells.	
	
Chapter	6:	Model	for	retinal	dystrophy	with	iPSCs	
	
250	
Chapter	6:	Generation	of	an	in	vitro	retinal	model	from	BBS	
patient-derived	induced	pluripotent	stem	cells	for	the	study	of	
retinal	dystrophy	
	
6.1	Background	
6.1.1	Development	of	the	eye	
There	 are	 three	 primary	 germ	 layers	 that	 can	 be	 produced	 from	 a	 human	 blastocyst	 after	
fertilisation,	during	the	phase	of	gastrulation.	These	 layers	are	the	endoderm,	being	the	 inner	
most	layer	that	gives	rise	to	epithelial	linings	including	most	organs;	the	mesoderm,	which	forms	
mesenchymal	cells,	muscles,	and	aspects	of	the	cardiovascular	system;	and	the	ectoderm,	the	
outer	most	layer	that	manifests	as	the	central	and	peripheral	nervous	systems,	sensory	epithelia,	
and	 the	 epidermis.	 These	 germ	 layers	 are	 formed	 from	 embryonic	 stem	 cells	 that,	 driven	 by	
chemical	factors	such	as	morphogens,	eventually	differentiate	into	their	terminal	cell	fate.	Two	
germ	layers	are	required	to	interact	to	form	the	complex	vertebrate	eye,	which	are	formed	from	
the	neural	ectoderm,	the	surface	ectoderm,	and	the	periocular	mesenchyme	(Heavner	and	Pevny	
2012).	
	
Genes	involved	with	eye	development	are	highly	conserved	across	all	bilaterally	sighted	species.	
The	 importance	 of	 these	 key	 developmental	 genes	 is	 emphasised	 by	 the	 fact	 that	 aberrant	
variation	can	lead	to	severe	congenital	defects	(Graw	2003;	Danno	et	al.	2008;	Azuma	et	al.	1999).	
A	series	of	intricately	balanced	transcription	factors	coordinate	to	form	a	regulatory	network	for	
accurate	development	of	different	eye	components.	The	first	set	of	these	transcription	factors	
activate	to	molecularly	define	the	eye	field,	a	single	region	within	the	anterior	neural	plate	of	the	
developing	forebrain,	which	are	triggered	shortly	after	gastrulation.	These	are	termed	the	eye	
field	transcription	factors	(EFTFs),	which	feature	PAX6,	RX,	SIX3,	and	LHX2,	and	are	coordinated	
by	SOX2	and	OTX2	(Zuber	et	al.	2003).	Following	the	establishment	of	the	developmental	midline,	
the	single	eye	field	is	divided	into	bilateral	hemispheres,	coordinated	by	SHH	and	SIX3,	to	make	
two	distinct	sites	for	eye	development	(Jeong	et	al.	2008).	Evagination	of	these	individual	sites	
then	leads	to	the	formation	of	the	optic	vesicle.	
	
The	 formation	 of	 the	 eye	 structure	 requires	 a	 double	 invagination	 caused	 by	 close	 mutual	
interactions	between	the	neural	and	surface	ectoderms	(Heavner	and	Pevny	2012;	Graw	2010)	
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(figure	6.1).	The	surface	ectoderm	 invaginates	and	separates	 to	 form	the	 lens,	 leaving	behind	
what	then	becomes	the	cornea	and	the	epithelial	layers	at	the	front	of	the	eye.	Simultaneously,	
the	 neural	 ectoderm	 forms	 from	 the	 optic	 vesicle,	 an	 outgrowth	 of	 the	 neural	 tube,	 which	
invaginates	 to	 form	 the	 optic	 cups,	 comprised	 of	 the	 neural	 retina	 (NR),	 retinal	 pigmented	
epithelial	 (RPE)	 cells,	 and	 other	 epithelial	 layers	 continuous	 with	 the	 retina.	 The	 periocular	
mesenchyme	 is	 a	 population	 of	 neural	 crest	 cells	 that	 differentiate	 into	 cells	 responsible	 for	
formal	 ocular	 development,	 such	 as	 the	 stroma,	 ciliary	 body	 and	 extraocular	muscles,	 blood	
vessels,	and	endothelium	of	the	eye.	
	
Figure	6.1	–	A	schematic	to	depict	the	formation	of	the	retina	and	lens	from	the	optic	vesicle	and	surface	
ectoderm	during	development.	
	
6.1.2	The	retina	
The	retina	develops	from	the	two	layers	of	the	optic	cup,	where	the	inner	layer	represents	the	
NR	and	the	outer	 layer	the	RPE.	The	prospective	NR	is	first	characterised	by	the	expression	of	
VSX2,	whereas	the	future	RPE	expresses	MITF	(Horsford	et	al.	2005;	Capowski	et	al.	2014).	These	
two	genes	have	an	antagonistic	relationship,	which	essentially	creates	a	partition	between	the	
NR	and	the	RPE	to	allow	for	separate	differentiation.	MITF	is	essential	for	RPE	specification	and	
expression	occurs	prior	to	VSX2,	where	upon	VSX2	upregulation,	MITF	is	repressed	in	the	neural	
retina	 (figure	 6.2).	 In	 vivo,	 this	 phenomenon	 is	 orchestrated	 by	 the	 surface	 ectoderm,	which	
secretes	 fibroblast	 growth	 factors,	 FGF1	 and	 FGF2	 (Horsford	 et	 al.	 2005).	 The	 RPE	 has	 a	
fundamental	role	in	maintaining	and	supporting	the	cells	within	the	retina	(Marmorstein	et	al.	
1998),	 and	 is	 recognisable	 by	 its	 distinctive	 dark	 appearance.	 An	 intimate	mutually	 beneficial	
relationship	exists	between	photoreceptors	and	the	RPE;	deleterious	mutations	in	one	cell	type	
results	in	degeneration	of	the	other	(Gu	et	al.	1997).	
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Figure	6.2	–	Specification	and	organisation	of	the	optic	cup,	where	MITF	and	VSX2	expression	dictate	the	
formation	of	the	RPE	(yellow)	and	NR	(blue),	respectively.	This	process	is	orchestrated	by	FGF1	and	FGF2,	
expressed	by	the	surface	ectoderm.	Adapted	from	Horsford	et	al.	(2005).	
	
The	mature	retina	consists	of	three	layers	of	laminar	organisation;	the	outer	nuclear	layer,	where	
the	 sensory	 photoreceptors	 reside;	 the	 inner	 nuclear	 layer,	 represented	 by	 the	 processor	
interneurons	 called	horizontal,	bipolar,	 and	amacrine	cells;	 and	 the	 retinal	 ganglion	cell	 layer,	
which	 is	 responsible	 for	 transmitting	 the	 chemical	 signal	 to	 the	 visual	 centres	 in	 the	 brain	
(Heavner	and	Pevny	2012).	Additionally,	the	retinal	extracellular	environment	is	maintained	by	
specialised	Müller	glial	cells,	which	span	the	entirety	of	the	neural	retina	and	regulates	various	
homeostatic	and	metabolic	pathways	(Luo	et	al.	2008).	Neural	retina	progenitor	cells	differentiate	
in	a	temporal	manner	that	is	conserved	across	vertebrates,	where	each	cell	type	is	characterised	
by	certain	cell	markers	(summarised	in	figure	6.3).	
	
The	photoreceptor	exists	as	two	cell	types,	namely	rods	and	cones.	The	rod	photoreceptors	are	
responsible	for	scotopic	vision	and	are	highly	sensitive	to	low	light	levels	(100	fold	more	sensitive	
than	 its	 cone	 counterpart	 (Luo	 et	 al.	 2008)),	 which	 is	 detected	 by	 the	 only	 visual	 pigment	
expressed	 in	 these	 cells,	 called	 rhodopsin.	 Conversely,	 cone	 photoreceptors	 are	 receptive	 to	
conditions	of	bright	light,	in	addition	to	providing	visual	acuity	and	colour	perception.	Cones	are	
accountable	for	trichromatic	vision,	as	each	cone	cell	expresses	one	of	three	visual	pigments;	S-
opsin	 absorbs	 short-wavelength	 ‘blue’	 light;	 M-opsin,	 sensitive	 to	 medium-long	 wavelength	
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‘green’	 light;	and	L-opsin,	which	allows	detection	of	 long	wavelength	‘red’	 light	(Nathans	et	al.	
1986).	
	
During	human	development,	differentiation	from	progenitor	to	mature	rod	photoreceptor	occurs	
over	several	weeks.	At	fetal	week	(Fwk)	10.5,	rods	are	identified	by	expression	of	the	rod-specific	
transcription	 factor	 NRL.	 By	 Fwk	 11-12,	 markers	 indicative	 of	 functionality	 appear,	 such	 as	
recoverin	(encoded	by	RCVRN),	CRX,	and	 IRBP.	 It	 is	not	until	Fwk	15	that	proteins	essential	for	
photosensitivity,	 including	 rhodopsin,	 emerge	 (Hendrickson	 et	 al.	 2008).	 Conversely,	 cone	
photoreceptors	start	to	materialise	at	fwk	8,	with	S-opsin	expressing	from	fwk	11,	which	is	earlier	
than	 rods	 despite	 being	 outnumbered	 20:1	 in	 the	 mature	 human	 retina.	 In	 maturing	
photoreceptors,	outer	segment	elongation	initiates	at	~fwk	32	(Vajzovic	et	al.	2012)	(figure	6.3).	
	
Figure	6.3	–	The	laminated	structure	of	the	retina.	Differentiation	of	the	retinal	cell	layers	from	the	neural	
epithelium	in	human	development,	where	key	markers	are	expressed	throughout	development,	indicative	
of	different	cell	types.	
	
6.1.3	The	photoreceptor	and	the	cilium	
Blindness	caused	by	photoreceptor	degeneration	is	one	of	the	most	genetically	heterogeneous	
disorders	 in	 humans	 with	 over	 250	 genes	 identified,	 with	 a	 prevalence	 of	 around	 1	 in	 3000	
(Hartong	 et	 al.	 2006;	Wright	 et	 al.	 2010).	 The	 largest	 category	 of	 gene	mutations	 that	 cause	
photoreceptor	degeneration	are	involved	in	ciliary	trafficking,	accounting	for	20%	of	these	250	
genes	 (Daiger	 et	 al.	 1998).	 This	 demonstrates	 that	 there	 is	 obviously	 a	 link	 between	 the	
photoreceptor	and	the	cilia.	The	answer	to	understanding	this	link	can	be	found	by	studying	the	
photoreceptor	structure	in	more	detail.	
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The	photoreceptor	cell	stretches	across	the	outer	nuclear	layer	of	the	retina,	creating	synaptic	
connections	with	neurons	found	in	the	inner	nuclear	layer,	such	as	bipolar	and	horizontal	cells.	
The	cell	projects	deeper	into	the	retina,	forming	two	distinct	compartments;	the	mitochondria	
rich	 inner	 segment	 and	 the	 photosensitive	 outer	 segment.	 The	 outer	 segment	 is	 a	 dynamic	
structure	 consisting	 of	 layers	 of	 membranous	 discs,	 maintenance	 of	 which	 requires	 rapid	
morphogenesis	and	turnover	of	proteins.	In	fact,	it	can	turn	over	up	to	10%	of	its	volume	per	day	
to	prevent	accumulation	of	proteins	that	may	be	damaged	by	photo-oxidation	(Besharse	et	al.	
1977).	One	role	of	the	RPE	is	to	phagocytose	the	distal	outer	segment	to	prevent	accumulation	
of	damaged	proteins	through	photooxidative	stress	(Finnemann	et	al.	1997).	The	outer	segment,	
however,	does	not	possess	its	own	machinery	to	synthesise	essential	proteins	and	so	they	must	
be	delivered	from	the	inner	segment	via	the	connecting	cilium	(figure	6.4).	
	
Figure	 6.4	 –	 Schematic	 of	 a	 rod	 photoreceptor	 and	 the	 connecting	 cilia	machinery.	 Phototransduction	
proteins,	such	as	rhodopsin,	are	synthesised	and	folded	in	the	inner	segment	of	the	rod	photoreceptor.	
The	BBSome	recruits	the	folded	protein	for	entry	into	the	connecting	cilium	and	is	trafficked	to	the	outer	
segments	by	anterograde	intraflagellar	transport	(Wright	et	al.	2010).	
	
The	presence	of	 the	cilium	 in	 the	photoreceptor	means	 that	 the	outer	 segment	behaves	as	a	
complex	 specialised	 cilium,	 the	axoneme	of	which	 stretches	more	 than	half	 the	 length	of	 the	
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outer	segment	in	rods	and	the	entire	length	in	cone	cells	(Luby-Phelps	et	al.	2008).	Under	a	light	
stimulus,	the	connecting	cilium	is	vital	for	rapid	shuttling	of	membrane-bound	and	membrane-
associated	proteins	that	are	essential	for	phototransduction,	such	as	rhodopsin,	to	the	optic	discs	
that	 run	 perpendicular	 to	 the	 axoneme	 (Wolfrum	 and	 Schmitt	 2000;	 Smith	 et	 al.	 2013).	 The	
connecting	 cilium	 is	 also	 required	 for	 cell	 maintenance,	 as	 well	 as	 retrograde	 transport	 of	
intraflagellar	transport	(IFT)	machinery	(Krock	et	al.	2009).	Although	very	similar	in	structure	to	
the	standard	primary	cilium,	the	connecting	cilium	is	essentially	the	structural	equivalent	to	the	
transition	 zone	 of	 primary	 cilia	 on	 other	 cell	 types	 (Mykytyn	 et	 al.	 2004;	 Pazour	 et	 al.	 2002).	
Through	 this	organelle,	 the	 turnover	of	proteins	must	be	efficient	and	well	organised	as	each	
minute	 an	 estimated	 2000	 opsin	molecules	 are	 transported	 to	 the	 outer	 segment	 through	 a	
narrow	 space	 of	 only	 0.25µm	 in	 diameter	 (Besharse	 et	 al.	 1985).	 As	 one	 would	 surmise,	
aberrations	in	trafficking	within	this	complex	organelle	can	lead	to	severe	complications.		
	
6.1.4	Impacts	of	impaired	connecting	cilium	
Evaluation	of	 ciliopathy	 in	 vivo	models	 can	provide	an	 insight	 into	 the	pathobiology	of	 retinal	
degeneration	when	IFT	 is	disrupted.	Aberrant	anterograde	IFT	 in	mice,	 induced	through	knock	
out	of	Kif3a,	led	to	complete	mislocalisation	and	accumulation	of	key	phototransduction	proteins	
in	the	inner	segment,	ultimately	resulting	in	progressive	photoreceptor	death	(Marszalek	et	al.	
2000).	 Many	 groups	 have	 recapitulated	 this	 study	 with	 disruption	 of	 other	 principle	 IFT	
components,	such	as	IFT88	(Pazour	et	al.	2002),	IFT122	(Boubakri	et	al.	2016;	Keady	et	al.	2011;	
Ross	et	al.	2005;	Kulaga	et	al.	2004),	and	IFT20	(Keady	et	al.	2011).	Although	this	shows	a	clear	
link	 with	 IFT	 function,	 the	 BBS	mouse	model	 shows	 that	 regulation	 of	 vesicle	 trafficking	 and	
entry/exit	to	IFT	has	an	impact	on	photoreceptor	structure	and	degeneration.	For	example,	the	
Bbs6-/-	mouse	shows	a	progressive	loss	of	photoreceptors	where	onset	starts	at	3	weeks	of	age	
and	 continues	 until	 total	 loss	 of	 the	 outer	 segment	 by	 26	 weeks	 of	 age	 (Ross	 et	 al.	 2005).	
Additionally,	 transmission	 electron	 microscopy	 (TEM)	 shows	 structural	 disorganisation	 and	
fragmentation	of	outer	segments	at	13	weeks	of	age	(Ross	et	al.	2005).	This	pattern	is	mimicked	
in	the	Bbs1-/-,	Bbs2-/-,	Bbs4-/-,	and	Bbs1M390R/M390R	knock-in	mice	(Nishimura	et	al.	2004;	Mykytyn	et	
al.	 2004;	 Davis	 et	 al.	 2007;	 Kulaga	 et	 al.	 2004).	 Although	 these	 studies	 closely	 imitate	 the	
progressive	loss	of	eyesight	seen	in	BBS	patients,	the	exact	mechanism	for	photoreceptor	death	
still	remains	uncertain.	
	
Accumulation	of	phototransduction	proteins	 in	an	erroneous	compartment	in	the	cell,	such	as	
rhodopsin	and	arrestin	localised	across	the	inner	segment	and	outer	nuclear	layer,	is	commonly	
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seen	in	BBS	mutant	models	(Louie	et	al.	2010;	Mockel	et	al.	2012).	It	is	thought	that	this	is	due	to	
impaired	docking	and	fusion	caused	by	the	faulty	BBS	proteins,	which	leads	to	high	toxicity,	and	
subsequent	cell	death	(Moritz	et	al.	2001).	However,	 it	cannot	be	ascertained	in	these	studies	
whether	the	BBS	mutation	was	the	primary	cause	of	the	mislocalisation,	or	these	proteins	have	
become	misplaced	due	to	the	cell	undergoing	apoptosis.	Conversely,	there	is	evidence	that	the	
BBSome	 interactor	 Rab8	 docks	 and	 fuses	 with	 rhodopsin-bearing	 vesicles,	 thus	 providing	 a	
functional	 link	between	rhodopsin	and	the	BBSome	(Moritz	et	al.	2001).	Furthermore,	a	study	
featuring	a	BBS4-/-	mouse	found	that	even	as	early	as	2	weeks	of	age	mislocalised	opsin	proteins	
were	 seen	 and,	 to	 a	 lesser	 extent,	 some	 apoptotic	 nuclei	 (Abd-El-Barr	 et	 al.	 2007).	 They	
hypothesised	 that	 since	 the	 quantity	 of	 mislocalised	 proteins	 was	 greater	 than	 the	 latter,	
apoptosis	must	 succeed	 this	 aberrant	 localisation,	 and	 thus	 photoreceptor	 death	 occurs	 as	 a	
consequence	of	defectively	trafficked	proteins.		
	
Datta	 et	 al.	 (2015)	 have	 suggested	 that	 the	 cause	 of	 photoreceptor	 death	 is	 not	 due	 to	
mislocalisation	of	phototransduction	proteins,	but	of	aberrant	protein	localisation	to	the	outer	
segment	 (Datta	 et	 al.	 2015).	 In	 contrast	 to	 other	 studies,	 they	 found	 that	 rhodopsin	 did	 not	
noticeably	 accumulate	 in	 the	 inner	 segment	 of	 a	 Lztfl1/(Bbs17)-/-	 mouse	 retina.	 In	 the	 outer	
segment,	however,	 there	was	an	enrichment	of	membrane	 fusion	Syntaxin	proteins,	Stx3	and	
Stxbp1,	which	are	normally	confined	to	the	connecting	cilium	and	are	components	of	the	SNARE	
complex	required	for	vesicle	trafficking.	Suitably,	Stx3	has	previously	been	shown	to	be	involved	
in	the	trafficking	of	rhodopsin	(Chuang	et	al.	2007;	Mazelova	et	al.	2009).	Datta	and	colleagues	
hypothesised	that	a	lack	of	functional	proteins	in	the	inner	segment	may	contribute	to	apoptosis	
of	 the	 photoreceptors,	 and	 the	 BBSome	 functions	 to	 prevent	 entry	 of	 non-outer	 segment	
proteins	to	the	outer	segment	(Datta	et	al.	2015).	
	
Although	 a	 great	 deal	 of	 focus	 has	 been	 dedicated	 to	 researching	 the	 role	 of	 anterograde	
transport	in	photoreceptor	degeneration,	the	process	of	retrograde	transport	has	received	less	
interest.	 It	 is	generally	accepted	that,	due	to	the	 large	turnover	of	the	photoreceptor	through	
shedding	vesicles	at	its	distal	tip,	damaged	proteins	are	removed	and	do	not	need	shuttling	back	
to	 the	cell	body	 (Insinna	and	Besharse	2008).	Additionally,	 some	proteins,	 such	as	 transducin,	
require	 ultra-rapid	movement	 from	 the	 outer	 segment	 to	 the	 inner	 segment,	 and	 can	 do	 so	
passively,	 without	 the	 need	 for	 IFT	 (Sokolov	 et	 al.	 2002).	 Nevertheless,	 knock	 down	 of	 the	
retrograde	 IFT	 molecule	 dynein-2	 in	 zebrafish	 led	 to	 truncated	 outer	 segments	 and	 swollen	
axonemes,	induced	by	the	accumulation	of	anterograde	machinery	at	the	ciliary	tip	(Krock	et	al.	
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2009).	This	study	showed	that	retrograde	transport	is	required	for	recycling	of	IFT	machinery,	but	
not	 for	 phototransduction	 proteins.	 However,	 the	 build-up	 of	 IFT	 proteins	 alone	 could	 be	
responsible	for	cell	stress	and	ultimately	apoptosis.		
	
One	 aspect	 that	 is	 particularly	 reproducible	 in	 ciliopathy	 retinopathy	 models	 is	 the	 highly	
unstructured	 and	 disorganised	 optic	 discs.	 Perhaps	 this	 alone	 is	 the	 reason	 that	 these	 cells	
undergo	apoptosis,	as	they	have	reduced	functionality	(Datta	et	al.	2015).		
	
To	further	support	the	model	that	suggests	apoptosis	is	triggered	due	to	accumulation	of	proteins	
in	 the	 inner	 segment,	 Mockel	 et	 al.	 shows	 that	 the	 unfolded	 protein	 response	 (UPR)	 is	
upregulated	in	Bbs12	depleted	retina	(Mockel	et	al.	2012).	This	is	a	mechanism	that	is	initiated	
due	to	stress	on	the	endoplasmic	reticulum	caused	by	protein	misfolding,	and	aims	to	restore	
homeostasis	 to	 the	 cell.	 If	 cellular	 balance	 is	 not	 reinstated,	 apoptosis	 is	 activated.	 Indeed,	
inhibition	of	certain	players	in	the	UPR,	such	as	a	caspase12	inhibitor	(INH)	or	BiP	agonist	valproic	
acid	 (VPA),	 significantly	 decreased	 the	number	 of	 apoptotic	 nuclei	 in	 the	outer	 nuclear	 layer.	
Interestingly,	they	also	saw	a	swelling	of	the	ER	cisternae	in	the	photoreceptors	of	the	Bbs12-/-	
mouse,	which	they	accredited	to	the	accumulation	of	proteins	in	the	inner	segment	(Mockel	et	
al.	2012)	.	This	strongly	suggests	a	mechanism	that	accounts	for	apoptosis	in	BBS	photoreceptors,	
and	an	interesting	opportunity	for	therapeutic	intervention,	especially	since	VPA	is	already	being	
used	for	retinal	diseases	such	as	ischemia-reperfusion	injury	(Zhang	et	al.	2012).	
	
From	a	review	of	the	literature,	it	is	clear	that	understanding	the	mechanism	of	photoreceptor	
degeneration	in	BBS	is	not	trivial,	and	there	are	many	contradictory	studies.	To	add	an	additional	
layer	of	complexity,	although	it	is	believed	that	the	connecting	cilium	behaves	similarly	to	a	typical	
primary	cilium,	mislocalisation	of	proteins	has	not	been	recorded	in	other	tissue	types.	This	could	
be	 explained	 by	 a	 degree	 of	 tissue	 specificity,	 where	 BBS	 proteins	 behave	 differently	 in	
photoreceptors	compared	to	other	primary	cilia.	
	
6.1.5	Protocols	for	iPSC	differentiation	into	optic	cups	
As	previously	described,	 the	development	of	 the	mammalian	eye	 is	a	complex	process,	which	
requires	 the	 coordination	 of	 multiple	 events	 to	 occur	 at	 precise	 time	 points.	 The	 idea	 of	
generating	 an	 eye	 in	 vitro	 therefore,	 may	 seem	 far-fetched	 and	 futuristic.	 In	 recent	 years	
however,	 there	 has	 been	 vast	 progress	 in	 being	 able	 to	 develop	 features	 of	 the	 eye	 from	
embryonic	stem	cells	(ESCs),	such	as	 lens-like	structures	(Yang	et	al.	2010),	retinal	neurons,	or	
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RPE	cells	(Meyer	et	al.	2009;	Lamba	et	al.	2006;	Osakada	et	al.	2008).	The	greatest	breakthrough	
came	from	the	Sasai	 lab,	who	used	murine	ESCs	to	recreate	optic	cup	development,	 including	
invagination	of	the	optic	vesicle,	expression	of	RPE	and	NR	markers,	and	generation	of	all	major	
neural	retinal	layers	(Eiraku	et	al.	2011).	Astoundingly,	this	morphogenesis	occurred	without	the	
presence	of	a	lens	or	surface	ectodermal	tissues,	suggesting	that	the	process	is	self-directed	and	
influenced	by	internal	transcription	factors	only	(Eiraku	et	al.	2011).	The	following	year,	the	same	
group	published	a	similar	study,	showing	that	a	self-directed	optic	cup	can	also	form	using	human	
ESCs	(Nakano	et	al.	2012).	
	
Building	on	 the	 foundation	made	by	Sasai’s	 lab,	 the	next	advancement	was	 recapitulating	 the	
success	of	photoreceptor	development	from	ESCs	in	iPSCs	(Zhong	et	al.	2014;	Wright	et	al.	2014;	
Meyer	et	al.	2011),	which	could	later	be	utilised	to	model	retinal	diseases	with	patient	material,	
such	as	Usher	syndrome	(USH)	and	Leber	Congenital	Amaurosis	(LCA)	(Tucker	et	al.	2013;	Parfitt	
et	al.	2016).	 In	recent	years,	a	wealth	of	publications	have	been	released	describing	protocols	
with	different	modifications,	such	as	 the	use	of	a	variety	of	exogenous	 factors,	 two-	or	 three-
dimensional	systems,	or	different	stem	cell	culturing	systems	(Tucker	et	al.	2013;	Zhong	et	al.	
2014;	Meyer	et	al.	2009;	Reichman	et	al.	2014;	Sridhar	et	al.	2013;	Mellough	et	al.	2012;	Lamba	
et	al.	2006;	Osakada	et	al.	2008;	Gonzalez-Cordero	et	al.	2013;	Boucherie	et	al.	2013).	Despite	
the	contrasting	methods	seen	in	these	studies,	they	were	all	able	to	reach	the	same	conclusion,	
where	precursor	photoreceptors	were	expressed.	
	
An	extra	level	of	achievement	was	reached	by	the	Canto-Soler	lab,	who	demonstrated	that	their	
differentiation	 protocol	 was	 able	 to	 promote	 maturation	 of	 photoreceptors	 to	 produce	
intracellular	membrane	discs	similar	 to	outer	segment	discs	 (Zhong	et	al.	2014).	Furthermore,	
they	conducted	perforated	patch	clamp	experiments	on	putative	rod	cells	to	establish	 if	there	
was	evidence	of	functionality	when	stimulated	by	light.	In	total,	two	out	of	thirteen	cells	tested	
exhibited	 a	 response	 to	 the	 light	 stimulus.	 What	 is	 surprising	 about	 this	 particular	
accomplishment	 is	 that	 unlike	 other	 labs,	 this	 protocol	 did	 not	 add	 exogeneous	 agonists	 or	
antagonists	 to	 their	 culturing	 system.	 The	 phenomenon	 of	 retinal	 cup	 formation	 occurred	
spontaneously	 and	 only	 through	 secreted	 endogeneous	 factors	 in	 this	 native-like	 micro-
environment	(Zhong	et	al.	2014).	
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6.1.6	Aims	of	investigation	
Murine	systems	are	popular	models	for	the	study	of	rod-cone	dystrophy	in	BBS,	since	they	mimic	
the	 progressive	 disease	 presentation	 seen	 in	 patients.	 However,	 with	 the	 advent	 of	 iPSC	
technology,	we	are	presented	with	a	novel	opportunity	to	create	an	in	vitro	human	model	system	
from	iPSCs	derived	from	BBS	patient	fibroblasts.	
	
There	 are	 clear	 advantages	 to	 using	 a	model	 developed	 from	patient-derived	 iPSCs.	 For	 one,	
retinal	 tissue	 from	 BBS	 patients	 is	 inaccessible,	 unless	 obtained	 post-mortem,	 and	 thus	 the	
patient’s	degenerative	progression	cannot	be	investigated	in	vivo.	Therefore,	iPSC	derived	optic	
cups	can	be	used	to	interrogate	the	pathobiology	of	rod-cone	dystrophy,	specifically	investigating	
whether	 there	 is	an	underlying	developmental	defect	or	a	 light	stimulus	 is	 required	 to	 induce	
degeneration.	 Furthermore,	 successful	 development	 of	 the	 retina	 would	 allow	 validation	 of	
therapeutic	interventions,	such	as	gene	therapy	correction	or	drug	screening,	in	a	patient	specific	
model	system.	
	
The	work	 in	this	chapter	utilises	patient	 iPSC	cells	derived	by	the	HipSci	project	funded	by	the	
Wellcome	Trust	and	the	Medical	Research	Council.	 In	total,	skin	biopsies	from	50	BBS	patients	
were	accepted	for	reprogramming	by	the	project.	From	the	available	reprogrammed	lines,	3	BBS	
patients	 with	 retinal	 dystrophy	 and	 2	 clinically	 healthy	 control	 lines	 were	 chosen.	 The	 three	
patients	in	question	were	BBS001,	BBS007	and	BBS008,	all	of	whom	carry	a	homozygous	p.M390R	
variant	in	BBS1.	
	
The	aim	of	this	investigation	was	to	develop	a	protocol	for	differentiation	of	these	5	iPSC	lines	
into	3D	optic	cups.	The	procedure	was	based	on	the	published	methods	by	Zhong	and	colleagues	
(2014),	which	was	chosen	due	to	the	demonstration	of	photoreceptor	functionality.	Additionally,	
Zhong’s	method	was	less	complex	than	others	available,	such	as	Nakano	et	al.	(2012),	which	was	
reported	as	technically	challenging	to	achieve	for	large-scale	cultures.	The	main	feature	of	this	
study	 that	 differed	 from	 other	 published	 methods	 was	 the	 use	 of	 a	 iPSC	 culturing	 system	
comprised	of	vitronectin	and	E8	media,	in	contrast	to	Matrigel	and	mTESR.	
	
The	differentiation	protocol	was	followed	up	to	day	198	(28	weeks)	until	mature	optic	cups	had	
developed.	 To	 determine	 whether	 differentiation	 followed	 the	 same	 course	 as	 in	 vivo	
development,	key	gene	markers	were	assayed	 for	expression	at	8	 time	points	 throughout	the	
protocol.	 The	 results	 of	 this	 chapter	 demonstrate	 a	 large	 amount	of	 differentiation	 efficiency	
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between	different	cell	lines.	Two	out	of	five	cell	lines	failed	to	differentiate	completely.	As	this	
affected	both	patient	and	control	lines,	this	was	not	a	problem	specific	to	BBS.	On	the	other	hand,	
iPSCs	 derived	 from	 patient	 BBS001	 differentiated	 well	 into	 mature	 optic	 cups.	 Immuno-
histochemical	 staining	 exhibited	 a	 well	 organised	 structure	 of	 retinal	 cells,	 expression	 of	
phototransduction	 proteins,	 and	 correct	 localisation	 of	 connecting	 cilium	 proteins.	 The	
ultrastructure	was	investigated	by	transmission	electron	microscopy,	which	revealed	presence	of	
mitochondria	rich	inner	segments,	connecting	cilia	and	nascent	outer	segments.	Finally,	within	
this	chapter	it	is	discussed	whether	this	in	vitro	model	could	realistically	be	scalable,	reproducible	
and	utilised	as	a	means	of	therapeutic	testing.	
Chapter	6:	Model	for	retinal	dystrophy	with	iPSCs	
	
261	
6.2	Results	
	
6.2.1	Maintenance	and	experimental	design	
6.2.1.1	Culturing	of	iPSC	lines	
iPSC	 lines	 were	 reprogrammed	 from	 patient	 fibroblasts	 by	 the	 HipSci	 laboratories	 at	 the	
Wellcome	Trust	Sanger	Institute.	Following	the	popularisation	of	stem	cell	culturing,	there	have	
been	 a	myriad	of	 culturing	 systems	 released	 for	 research	use,	 such	 as	 different	matrices	 and	
media.	The	lines	obtained	from	HipSci	were	feeder-free	and	utilised	the	E8	media	with	vitronectin	
matrices.	This	culturing	system	was	adopted	and	maintained	throughout	iPSC	culturing.	The	key	
difference	 in	 differentiation	 protocol	 in	 this	 study	 compared	 to	 Zhong	 et	 al.	 was	 the	 use	 of	
vitronectin/E8	culturing	system	over	a	Matrigel	matrix	and	mTESR	medium.	
	
The	lines	received	were	contamination	free	and	checked	for	mycoplasma	prior	to	differentiation,	
as	well	as	passing	HipSci	quality	control	tests,	including	karyotyping.	To	minimise	variability,	it	was	
ensured	that	each	line	had	been	passaged	3	times	to	expand	the	culture	prior	to	commencing	
differentiation.	 The	 level	 of	 spontaneous	 differentiation	 was	 monitored	 to	 enhance	
differentiation	efficiency.	Each	 line	was	subjected	to	rigorous	testing	 for	pluripotency,	such	as	
assessment	by	PluriTest	(Müller	et	al.	2011),	at	the	HipSci	laboratories.	
	
6.2.1.2	Validation	of	disease	causing	mutation	in	iPSC	lines	
Before	commencing	differentiation	of	the	BBS	lines	into	3D	optic	cups	it	was	important	to	validate	
the	presence	of	the	primary	driving	mutation,	BBS1	p.M390R,	 in	each	line.	The	reason	for	this	
was	twofold:	first	to	ensure	that	the	patient	identity	was	correct,	and	second,	to	confirm	that	the	
mutation	had	not	been	lost	 in	the	reprogramming	process,	for	example,	through	a	deletion	or	
chromosomal	aberration.	Sanger	sequencing	of	genomic	DNA	extracted	 from	 iPSCs	confirmed	
the	 presence	 of	 the	 reference	 genotype	 in	 control	 lines,	 CTRL037	 and	 CTRL038.	 Similarly,	
sequencing	affirmed	the	mutation	in	all	three	BBS	patient	lines,	derived	from	patients	BBS008,	
BBS001	and	BBS007,	where	 substitution	of	a	T	 to	a	G	 resulted	 in	an	amino	acid	 change	 from	
methionine	to	arginine	(figure	6.5).	Further	details	for	each	individual	in	the	study	are	presented	
in	table	6.1.	
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Figure	6.5	–	Confirmation	by	Sanger	sequencing	of	homozygous	BBS1	p.M390R	in	iPSC	lines	derived	from	
patients	BBS001,	BBS007,	and	BBS008.	This	variant	was	absent	from	control	lines,	CTRL037	and	CTRL038.	
	
		 iPSC	line	ID	 Donor	age	 Donor	sex	 Genotype	allele	1	 Genotype	allele	2	
Patient	 BBS001	 30-34	 Female	 BBS1	p.M390R	 BBS1	p.M390R	
Patient	 BBS007	 40-44	 Male	 BBS1	p.M390R	 BBS1	p.M390R	
Patient	 BBS008	 35-39	 Male	 BBS1	p.M390R	 BBS1	p.M390R	
Control	 CTRL037	 65-69	 Male	 Reference	 Reference	
Control	 CTRL038	 40-44	 Female	 Reference	 Reference	
Table	6.1	–	Table	presenting	patient	and	control	iPSC	line	information,	where	genotype,	age,	and	sex	of	
each	individual	included	in	the	study	is	shown.	
	
6.2.1.3	Identification	of	a	suitable	reference	gene	
Correct	quantitative	real-time	PCR	(qPCR)	practice	requires	the	use	of	at	least	one	reference	gene	
to	normalize	the	target	gene	data	to.	This	normalisation	reduces	the	variability	found	through	
differences	 in	 mRNA	 extraction	 and	 reverse	 transcription	 performance,	 prior	 to	 qPCR	 setup.	
Housekeeping	genes	are	genes	that	are	required	for	typical	cell	survival,	such	as	metabolic	genes,	
and	are	commonly	used	as	a	reference	since	they	are	constitutively	expressed.	One	of	the	most	
commonly	used	reference	genes	is	GAPDH.	However,	there	have	been	reports	that	GAPDH	and	
other	 popular	 housekeeping	 genes	 can	 vary	 across	 different	 organisms,	 conditions,	 and	
importantly,	cell	types	(Kozera	and	Rapacz	2013;	Barber	et	al.	2005).		
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In	this	study,	the	aim	was	to	assess	the	variability	of	gene	expression	over	a	period	of	 in	vitro	
development.	During	this	period,	a	variety	of	ever-changing	cell	types	will	develop	and	mature.	It	
was	 therefore	 imperative	 that	 a	 reliable	 housekeeping	 gene	 was	 established	 that	 remained	
consistently	 expressed	 over	 the	 differentiation	 time	 frame.	 In	 order	 to	 determine	 a	 suitable	
housekeeping	gene,	cDNA	was	obtained	from	mRNA	extracted	from	the	patient	BBS001	line	at	
day	0,	6,	16,	37,	60,	98,	and	124	after	 initial	differentiation.	Six	commonly	used	housekeeping	
genes	were	 selected	 to	 test,	namely	GAPDH,	HPRT1,	SNRPD3,	 LDHA,	TBP,	 and	PGK1.	Samples	
were	normalised	to	day	0	within	each	gene	set	and	the	fold	change	plotted	across	the	time	course	
(figure	6.6).	
	
Figure	6.6	–	Relative	fold	change	of	expression	for	6	putative	reference	genes	from	optic	cup	samples	taken	
over	 a	 124-day	 differentiation	 process.	 iPSCs	 were	 derived	 from	 patient	 BBS001.	 Error	 bars	 show	
transformed	95%	confidence	intervals	(CI)	for	each	experiment,	which	was	performed	in	triplicate.	
	
The	qPCR	results	showed	that	GAPDH	exhibited	the	greatest	variability,	which	demonstrated	the	
greatest	fold	change	difference	from	day	0	at	day	60	(FC	=	7.32;	day	0	relative	expression	=	1,	
95%	CI=	0.01,	2.01;	day	60	relative	expression=	7.32,	95%	CI=	7.18,	7.46).	This	supports	studies	
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that	show	GAPDH	is	not	consistently	expressed	across	different	tissue	types	(Barber	et	al.	2005).	
Other	putative	reference	genes	also	showed	variability	over	the	time	course,	for	example,	the	
largest	differences	in	fold	change	existed	between	day	0	and	day	37	for	HPRT1	(FC	=	4.18;	day	0	
relative	expression	=	1,	95%	CI=	0.02,	2.02;	day	37	relative	expression=	4.18,	95%	CI=	3.94,	4.42),	
day	 6	 for	 LDHA	 (FC	 =	 4.79;	 day	 0	 relative	 expression=	 1,	 95%	 CI=	 0.02,	 2.02;	 day	 6	 relative	
expression	=	4.79,	95%	CI=	4.58,	5.00),	day	37	for	TBP	(FC	=	4.55;	day	0	relative	expression=	1,	
95%	CI=	0.01,	2.01;	day	37	relative	expression	=	4.55,	95%	CI=	4.34,	4.78),	and	day	37	for	PGK1	
(FC	=	5.19;	day	0	relative	expression	=	1,	95%	CI=	0.01,	2.01;	day	37	relative	expression=	5.19,	
95%	CI=	5.00,	5.39).	Additionally,	TBP	was	an	unsuitable	reference	gene	since	the	CT	values	were	
relatively	low,	ranging	between	27	and	30.	The	most	consistently	expressed	gene	was	SNRPD3,	
which	showed	a	maximum	increase	at	day	37	(FC	=	1.90;	day	0	relative	expression=	1,	95%	CI=	
0.00,	2.00;	day	37	expression	=	1.90,	95%	CI=	1.03,	2.26).	As	SNRPD3	showed	the	most	consistent	
expression	over	the	time	course,	this	was	utilised	as	the	reference	gene	for	all	 following	qPCR	
experiments.	
	
6.2.2	Differentiation	of	iPSCs	into	3D	optic	cups	
As	described	above,	differentiations	were	undertaken	using	5	independent	iPSC	lines.	However,	
due	to	variables	outlined	here	and	in	detail	in	the	discussion,	there	was	limited	success	in	reaching	
the	terminal	differentiation	point	for	many	of	these	cell	lines	(day	198/	week	28).	The	best	quality	
differentiations	 followed	 the	 correct	 gene	 expression	 patterns	 and	morphology	 at	 a	 suitable	
frequency	 so	 that	 samples	 could	 be	 taken	 for	 analysis	 throughout.	 One	 particular	 line,	 from	
patient	 BBS001,	 differentiated	 accordingly,	 mimicking	 gene	 expression	 of	 both	 in	 vivo	
development	and	other	published	protocols	(Meyer	et	al.	2009;	Zhong	et	al.	2014;	Parfitt	et	al.	
2016;	 Hirami	 et	 al.	 2009).	 The	 results	 described	 first	 will	 follow	 the	 differentiation	 this	 line,	
BBS001.	Differentiations	of	other	lines	were	then	compared	to	BBS001,	the	findings	of	which	are	
outlined	later.	
	
6.2.2.1	Embryoid	body	formation	
The	first	stage	of	the	differentiation	protocol	required	the	removal	of	anti-differentiation	factors	
from	the	culturing	media.	The	media	was	changed	from	E8	media	to	embryoid	body	media	(EBM),	
which	was	supplemented	with	ROCK	inhibitor	on	the	first	day	of	differentiation	(day	0)	to	prevent	
dissociation	induced	apoptosis.	This	change	in	conditions	resulted	in	the	formation	of	embryoid	
bodies	(EBs),	three-dimensional	non-adherent	cell	aggregates.	These	aggregates	epitomise	the	
molecular	and	cellular	morphogenic	interactions	implemented	during	development,	and	can	also	
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differentiate	 to	give	 rise	 to	 the	 three	germ	 layers	 (Rungarunlert	et	al.	2009).	Thus,	 this	was	a	
common	method	for	inducing	differentiation	in	vitro	for	both	iPSC	and	ESC	systems.	Images	of	
iPSC	colonies	and	resulting	EBs	from	patient	BBS001	can	be	found	in	the	appendix,	figure	A1	A-B.	
	
Over	 the	 first	 days	 of	 EB	 development	 it	 was	 expected	 that	 the	 expression	 of	 pluripotency	
markers	would	decrease	and	developmental	transcription	factors	would	be	upregulated	(Meyer	
et	al.	2009).	qPCR	analysis	of	NANOG	expression	was	conducted	from	material	extracted	from	
day	0,	day	6,	and	day	16	of	differentiation.	Over	this	time	period,	NANOG	expression	decreased,	
suggesting	that	the	differentiation	procedure	had	successfully	commenced.	RT-PCR	analysis	for	
NANOG	 complemented	qPCR	data,	 showing	 that	expression	had	diminished	by	day	6.	On	 the	
other	hand,	OCT4	expression	decreased	more	gradually	and	residual	expression	was	still	visible	
by	day	37	(figure	6.7).	
Figure	6.7	–	Gene	expression	of	pluripotency	genes	from	patient	BBS001	samples.	RT-PCR	expression	(top)	
of	NANOG	and	OCT4	over	the	differentiation	process	from	day	0	to	day	198.	GAPDH	was	used	as	a	positive	
control.	 Relative	 fold	 change	 was	 determined	 by	 qPCR	 (bottom)	 for	NANOG	 over	 day	 0,	 6	 and	 16	 of	
differentiation.	Samples	were	normalised	to	the	reference	gene	SNRPD3	and	day	0	for	each	experiment.	
Error	bars	represent	transformed	95%	CI	calculated	from	triplicate	experiments.	Relative	fold	change	was	
calculated	through	calculation	of	2(-∆∆CT).	
	
On	day	4	of	the	differentiation	protocol,	the	media	was	switched	from	EBM	to	neural	induction	
media	 (NIM),	 which	 contained	 N2	 supplementation.	 This	 media	 was	 designed	 to	 encourage	
differentiation	 towards	 a	 neuroepithelial	 specification,	 which	 was	 reflected	 by	 expression	 of	
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EFTFs.	 On	 day	 6,	 the	 matured	 EBs	 were	 transferred	 to	 laminin-coated	 culture	 plates,	 which	
allowed	the	colonies	to	adhere	and	promoted	the	development	of	eye	field	domains.	
	
Through	day	6	to	day	37,	as	expected,	PAX6	and	RX	showed	a	close	relationship	by	imitating	each	
other’s	expression	patterns.	Together	these	genes	are	responsible	for	the	formation	of	the	eye	
field	during	gastrulation	(Zuber	et	al.	2003).	RT-PCR	analysis	of	both	PAX6	and	RX	showed	that	
expression	had	commenced	by	day	6	(figure	6.8).	PAX6	is	crucial	for	the	development	of	the	eye,	
which	is	demonstrated	by	an	eyeless	phenotype	caused	by	deletion	of	the	Pax6	homologue	in	D.	
melanogaster	 (Quiring	et	al.	1994).	RT-PCR	experiments	verify	the	presence	of	both	PAX6(-5a)	
and	PAX6(+5a)	isoforms,	which	is	evident	by	the	two	bands	on	the	agarose	gel.	RX	is	involved	in	
upregulation	of	other	EFTFs	including	LHX2,	which	was	coregulated	with	RX	and	PAX6	during	EB	
maturation,	 and	 was	 strongly	 expressed	 by	 day	 6.	 Both	 RX	 and	 LHX2	 are	 involved	 in	
regionalisation	of	the	optic	vesicle,	and	lack	of	their	expression	results	in	failure	to	define	between	
the	neural	retina	and	the	RPE	in	the	native	retina	(Yun	et	al.	2009;	Medina-Martinez	et	al.	2009).	
	
Figure	6.8	–	Gene	expression	analysis	of	EFTF	genes	from	patient	BBS001	samples.	RT-PCR	expression	(top)	
of	PAX6,	RX	and	LHX2	over	the	differentiation	process	from	day	0	to	day	198.	GAPDH	was	used	as	a	positive	
control.	Relative	fold	change	was	determined	by	qPCR	(bottom)	for	RX	and	PAX6	over	day	6,	16,	and	37	of	
differentiation.	Samples	were	normalised	to	the	reference	gene	SNRPD3	and	day	6	for	each	experiment.	
Error	bars	represent	transformed	95%	CI	calculated	from	triplicate	experiments.	Relative	fold	change	was	
calculated	through	calculation	of	2(-∆∆CT).	
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6.2.2.2	Formation	of	neural	retina	and	retinal	pigmented	epithelium	
On	day	16	of	the	differentiation	protocol,	the	media	was	switched	to	retinal	differentiation	media	
(RDM)	 containing	 B27	 supplementation.	 B27	 has	 been	 shown	 to	 promote	 neural	 progenitor	
differentiation	 and	 facilitate	 development	 of	 phototransduction	 machinery	 (Mellough	 et	 al.	
2012).	 Switching	 to	 RDM	 encouraged	 differentiation	 towards	 a	 retinal	 progenitor	 fate	 and	
initiated	expression	of	markers	that	distinguish	the	optic	vesicle.		
	
Neural	 retinal	 (NR)	 domains	 in	 BBS001	 patient	 cultures	 were	 identifiable	 by	 their	 distinctive	
horseshoe	shaped	lamination	that	is	evocative	of	the	optic	cup	in	vivo	(figure	6.9	A-C).	On	day	28	
of	culture,	these	structured	NR	domains	were	manually	detached	and	transferred	to	non-coated	
cell	culture	plates	(figure	6.9D),	where	they	matured	into	non-adherent	three-dimensional	optic	
cups.	Once	in	suspension,	the	NR	thickened	over	time	and	RPE	gradually	pigmented	(figure	6.9	E-
J).	Contrary	to	in	vivo	development,	the	RPE	was	isolated	from	the	neural	retina,	either	packaged	
at	the	tip	of	the	cup	(figure	6.9	F-G)	or	in	the	middle	(figure	6.9	I-J).	By	day	70	of	differentiation,	
these	cups	had	formed	a	well-defined	self-laminated	NR	structure	and	approximately	80%	were	
expressing	RPE.	
	
To	facilitate	maintenance	and	maturation	of	the	optic	cup,	the	media	was	supplemented	with	
FBS	and	taurine	at	day	42.	FBS	had	been	shown	to	enhance	retinal	differentiation	(Nakano	et	al.	
2012),	but	also	prevented	necrosis	at	the	centre	of	the	cup	(Zhong	et	al.	2014).	Retinoic	acid	at	
1µM	was	added	to	the	media	at	day	70,	and	then	reduced	to	0.5µM	at	day	98.	Zhong	et	al.	had	
previously	shown	that	intervention	with	retinoic	acid	significantly	enhanced	rhodopsin	expression	
by	week	21	(Zhong	et	al.	2014).	These	conditions	were	able	to	support	the	thickening	of	the	NR	
up	until	the	experiment	end	point,	day	198.	
	
For	specification	and	subsequent	cell	identity	of	the	NR,	two	antagonistically	expressed	regulatory	
genes	 are	 pivotal,	MITF	 and	 VSX2.	 During	 development	 of	 the	 mammalian	 eye,	 the	 surface	
ectoderm	controls	expression	of	MITF	and	VSX2	through	FGF1	and	FGF2	signalling	(Horsford	et	
al.	2005).	In	the	native	NR,	VSX2	represses	MITF	expression	and	restricts	it	to	the	RPE.	Therefore,	
these	signalling	pathways	lead	to	the	compartmentalisation	of	the	NR	where	VSX2	is	prominent,	
and	the	RPE,	which	is	characterised	by	MITF	expression	(Horsford	et	al.	2005).	
	
Chapter	6:	Model	for	retinal	dystrophy	with	iPSCs	
	
268	
	
Figure	6.9	–The	progression	of	differentiating	optic	cups	from	patient	BBS001	samples	at	day	28	through	
to	day	198.	A-D)	Cultures	at	day	28	show	distinctive	horseshoe	shaped	NR	(dashed	line,	arrow	heads),	which	
was	manually	lifted	for	culture	in	suspension	(D).	E-G)	At	day	70	the	NR	(arrow	heads)	had	thickened	and	
RPE	(red	arrow)	had	formed.	H-J)	Optic	cups	in	suspension	show	thickening	of	the	NR	over	time	where	H)	
day	98,	I)	day	147	and	J)	day	198.	
	
Concordantly,	 it	 was	 important	 to	 assess	 the	 presence	 of	 these	 two	 genes	 during	 the	
development	 of	 the	 neural	 retina.	 RT-PCR	 analysis	 showed	 VSX2	 and	MITF	 expression	 was	
activated	 as	 early	 as	 day	 6	 of	 the	 differentiation	 process	 (figure	 6.10).	 qPCR	 experiments	
demonstrated	a	4.42-fold	increase	in	MITF	between	day	6	to	day	16	(day	6	mean	∆CT=	4.39,	95%	
CI=	4.22,	4.56;	day	16	mean	∆CT=	2.25,	95%	CI=	2.09,	2.39;	p=	0.0012),	which	was	maintained	at	
day	37	(day	37	mean	∆CT=	2.34,	95%	CI=	2.19,	2.48).	By	day	60,	MITF	expression	began	to	rise	
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again,	which	coincided	with	RPE	development,	suggesting	an	RPE	specific	expression	of	MITF	(day	
60	mean	∆CT=	1.69,	95%	CI=	1.58,	1.81).	VSX2	expression	increased	288.27-fold	from	day	6	to	day	
60	(day	6	∆CT=	4.47,	95%	CI=	4.23,	4.72;	day	60	mean	∆CT=	-3.70,	95%	CI=	-4.05,	-3.35;	p<0.0001),	
which	 perhaps	 quenched	MITF	 expression	 in	 the	 neural	 retina.	 Both	 genes	 were	maintained	
through	to	the	end	point	of	differentiation,	as	shown	by	RT-PCR	analysis	(figure	6.10).	
	
Figure	6.10	–	Gene	expression	of	neural	retina	specification	markers	from	patient	BBS001	samples.	RT-PCR	
expression	(top)	of	VSX2	and	MITF	over	the	differentiation	process	from	day	0	to	day	198.	GAPDH	was	used	
as	a	positive	control.	Relative	fold	change	was	determined	by	qPCR	(bottom)	for	VSX2	and	MITF	over	day	
6,	16,	37	and	60	of	differentiation.	Samples	were	normalised	to	the	reference	gene	SNRPD3	and	day	6	for	
each	experiment.	Error	bars	represent	transformed	95%	CI	calculated	from	triplicate	experiments.	Relative	
fold	change	was	calculated	through	calculation	of	2(-∆∆CT).	
	
6.2.2.3	Expression	of	photoreceptor	specific	cells	
Photoreceptor	precursors	were	expected	to	develop	in	the	apical	layer	of	the	optic	cups	(Zhong	
et	 al.	 2014).	 The	 putative	 expression	 and	 localisation	 of	 photoreceptor	 precursor	 cells	 was	
investigated	 through	 analysis	 of	 two	 photoreceptor	 specific	 genes,	CRX	 and	RCVRN.	CRX	 is	 a	
transcription	 factor	 specific	 to	 rod	 and	 cone	 photoreceptor	 precursors	 and	 is	 key	 for	 the	
prospective	expression	of	phototransduction	proteins.	Failure	to	express	CRX	in	mice	in	vivo	leads	
to	lack	of	outer	segments	and	subsequent	photoreceptor	degeneration	(Furukawa	et	al.	1999;	
Swaroop	 et	 al.	 2010).	RCVRN	 encodes	 a	 phototransduction	 protein,	 Recoverin,	 that	 precedes	
expression	of	opsins	 in	development	of	the	fetal	retina	(Hendrickson	et	al.	2008).	This	pattern	
was	 mimicked	 in	 the	 optic	 vesicles	 studied	 here,	 as	 RCVRN	 expression	 was	 observed	 in	 the	
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cytoplasm	and	the	developing	outer	segment	of	both	rod	and	cone	photoreceptors	(Figure	6.12	
A-B).	
	
RT-PCR	experiments	 indicated	 that	RCVRN	expression	was	 lowly	expressed	at	day	6-16,	which	
was	earlier	than	has	been	reported	in	similar	studies	(Figure	6.11).	Previously,	the	earliest	account	
of	RCVRN	expression	was	day	60	(Tucker	et	al.	2013).	qPCR	analysis	demonstrated	that	RCVRN	
expression	increased	from	day	37	through	day	98	by	19.72-fold	(day	37	mean	∆CT=	2.73,	95%	CI=	
2.61,	 2.86;	 day	 98	 ∆CT=	 -1.57,	 95%	 CI=	 -1.58,	 -1.55;	 p<0.0001),	 then	 significantly	 heightened	
during	maturation	to	day	147	to	a	fold	change	increase	of	139.96	compared	to	day	37	(day	147	
∆CT=	-4.39,	95%	CI	=	-4.40,	-4.39;	p<0.0001).	CRX	expression	showed	a	similar	upregulation	during	
the	same	time	frame	(relative	fold	change	(RFC)=	7.95;	day	37	mean	∆CT=	2.13,	95%	CI=	2.04,	
2.23;	day	147	mean	∆CT=	-0.86,	95%	CI=	-0.93,	-0.79;	p<0.0001),	though	qPCR	analysis	indicated	
that	the	difference	between	day	37	and	day	147	was	less	pronounced	than	for	RCVRN.	RT-PCR	
analysis	suggested	a	later	onset	of	expression	at	day	98	and	a	down-regulation	prior	to	the	end	
of	differentiation	at	day	198.	
	
	
Figure	6.11	–	Gene	expression	analysis	of	phototransduction	markers	from	patient	BBS001	samples.	RT-
PCR	expression	(top)	of	RCVRN	and	CRX	over	the	differentiation	process	from	day	0	to	day	198.	GAPDH	was	
used	as	a	positive	control.	Relative	fold	change	was	determined	by	qPCR	(bottom)	for	RCVRN	and	CRX	over	
day	37,	60,	98,	and	147	of	differentiation.	Samples	were	normalised	to	the	reference	gene	SNRPD3	and	day	
37	for	each	experiment.	Error	bars	represent	transformed	95%	CI	calculated	from	triplicate	experiments.	
Relative	fold	change	was	calculated	through	calculation	of	2(-∆∆CT).	
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The	 expression	 of	 phototransduction	 proteins	 in	 patient	 BBS001	 can	 be	 compared	 against	 a	
control	 line	that	was	previously	published	by	Parfitt	et	al.	(2016)	(figure	6.12	A-B).	At	week	21	
(day	147),	 the	control	photoreceptors	differentiated	by	Parfitt	and	colleagues	was	abundantly	
expressing	recoverin,	cone	arrestin	and	rhodopsin	in	the	apical	cell	layer	of	the	optic	cup.		
	
Within	 patient	 BBS001,	 immunohistochemistry	 specific	 for	 recoverin	 at	 day	 98	 mimicked	
expression	 seen	 for	 Parfitt	 et	 al.	 Furthermore,	 CRX	 was	 also	 expressed	 in	 cells	 expressing	
recoverin,	demonstrating	that	the	majority	of	CRX-	and	RCVRN-positive	cells	were	concentrated	
in	the	outer	nuclear	layer	(Figure	6.12	C-D).	By	day	198,	limited	expression	of	phototransduction	
proteins,	 rhodopsin	 and	 cone	 arrestin	 was	 detected	 (figure	 6.12	 E-F).	 In	 comparison	 to	 the	
number	 of	 recoverin	 expressing	 cells,	 it	 was	 surprising	 that	 so	 few	 cells	 matured	 to	 exhibit	
phototransduction	proteins.	This	frequency	of	cells	was	also	less	than	seen	at	the	same	time	point	
in	other	protocols	(Parfitt	et	al.	2016;	Zhong	et	al.	2014)	(figure	6.12	A-B).	However,	the	majority	
of	rhodopsin-	and	cone	arrestin-positive	cells	resided	in	the	inner	nuclear	layer.	Therefore,	it	may	
be	possible	that	these	cells	had	not	yet	reached	maturity	and	were	yet	to	migrate	to	the	outer	
nuclear	layer	in	these	cups.	
	
Taken	together,	this	demonstration	showed	that	it	was	possible	to	differentiate	a	BBS	patient-
derived	iPSC	line	into	a	model	of	a	3D	optic	cup.	This	was	achievable	in	a	temporal	manner	similar	
to	that	of	 in	vivo	retinal	development	and	closely	recapitulated	the	protocol	that	was	adapted	
from	Zhong	and	colleagues	(2014).	
	
Chapter	6:	Model	for	retinal	dystrophy	with	iPSCs	
	
272	
	
Figure	 6.12	 –	 Immunohistochemical	 analysis	 of	 phototransduction	 proteins	 in	 optic	 cups	 from	 patient	
BBS001,	with	comparative	control	images	taken	from	Parfitt	et	al.	(2016).	A-B)	Optic	cups	differentiated	
from	control	human	iPSCs	generated	by	Parfitt	et	al.	at	week	21	(~day	147)	demonstrating	expression	of	
recoverin	and	cone	arrestin	(A)	and	rhodopsin	(B)	in	the	apical	layer.	Scale	bar	=	20µm.	C-D)	Expression	of	
recoverin	and	CRX	at	day	98.	E)	Some	rhodopsin	positive	cells	at	day	198.	F)	Expression	of	cone	arrestin	
positive	cells	at	day	198.	Nuclei	were	stained	with	DAPI.	
	
6.2.3	Differentiation	of	iPSCs	from	BBS008	and	CTRL037	
The	aim	of	this	study	was	to	determine	whether	it	was	possible	to	differentiate	BBS	lines	into	3D	
optic	cups	and	assess	the	practicality	of	developing	this	protocol	as	an	 in	vitro	model	to	study	
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disease	pathobiology.	Although	it	has	been	demonstrated	that	the	former	was	an	achievable	goal,	
there	were	some	issues	experienced	during	this	project	that	will	contribute	towards	the	latter	
goal.	
	
Consistent	with	previous	reports	(Meyer	et	al.	2009;	Yu	et	al.	2007;	Zhong	et	al.	2014),	there	was	
considerable	variability	in	efficiency	for	differentiation	across	the	five	different	lines.	Indeed,	even	
differentiations	from	the	same	individual	showed	variability,	where	some	cultures	had	defined	
morphology,	yet	others	failed	to	generate	viable	embryoid	bodies	or	neural	retinas.	Through	RT-
PCR	analysis	to	validate	the	presence	of	key	genes	throughout	attempted	differentiations,	only	
35%	of	efforts	 showed	 inclusive	expression	of	PAX6,	RX,	VSX2,	MITF,	CRX,	 and	RCVRN	 (n=26).	
Unfortunately,	the	control	line	CTRL038	and	patient	line	from	BBS007	failed	to	differentiate	into	
any	operable	cultures.	
	
The	level	of	PAX6	expression	has	been	correlated	with	the	differentiation	efficiency	of	hiPSCs	into	
the	neural	retina	(Meyer	et	al.	2009).	Therefore,	it	was	hypothesised	that	there	was	a	link	with	
expression	levels	of	PAX6,	NANOG,	and	RX,	and	differentiation	efficiency.	Samples	were	chosen	
from	 CTRL037	 and	 BBS008	 that	 differentiated	 with	 the	 most	 successful	 morphology	 and	
investigated	further	by	qPCR.	Since	BBS001	followed	the	correct	morphology	and	temporal	gene	
expression,	 these	 samples	were	 used	 to	 compare	 against	 other	 differentiations	 (figure	 6.13).	
Images	of	iPSC	colonies	and	resulting	EBs	from	patient	BBS008	and	control	line	CTRL037	can	be	
found	in	the	appendix,	figure	A1	C-F.	
	
During	the	first	16	days	of	differentiation,	both	BBS008	and	CTRL037	exhibited	downregulation	
of	NANOG	 (figure	6.13A).	Compared	 to	BBS001	and	BBS008,	CTRL037	had	significantly	higher	
levels	of	expression	of	NANOG	at	day	0	(CTRL037	∆CT	mean=	2.02,	95%	CI=	1.67,	2.36;	BBS001	
∆CT	mean=	2.92,	95%	CI=	2.64,	3.21;	CTRL037	vs	BBS001	p=	0.0162;	BBS007	∆CT	mean=	2.98,	95%	
CI=	 2.70,	 3.25;	 CTRL037	 vs	 BBS008	 p=	 0.0129).	 In	 CTRL037,	 NANOG	 expression	 decreased	 as	
expected	 over	 the	 first	 16	 days,	 however,	 it	 remained	 significantly	 higher	 than	 BBS001	 and	
BBS008	over	this	period	(day	16:	CTRL037	∆CT	mean=	4.21,	95%	CI=	3.87,	4.57;	BBS001	∆CT	mean=	
6.75,	95%	CI=	6.28,	7.24;	CTRL037	vs	BBS001	p=	0.0011;	BBS008	∆CT	mean=	5.41,	95%	CI=	5.22,	
5.60;	 CTRL037	 vs	 BBS008	 p=	 0.0043).	 It	 is	 possible	 that	 this	 may	 be	 linked	 to	 the	 poor	
differentiation	efficiency	seen	in	CTRL037	cultures.	
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Figure	6.13	A-H	–	Relative	fold	change	of	gene	expression	profiles	by	qPCR	for	key	genes	involved	in	the	
development	 of	 the	 retina.	 Expression	 for	 BBS008	 (green)	 and	 CTRL037	 (purple)	 were	 normalised	 to	
BBS001	 (red),	 allowing	 comparison	 across	 the	 differentiation	 process.	 All	 experiments	 were	 primarily	
normalised	 to	 the	 reference	 gene	 SNRPD3.	 Error	 bars	 represent	 transformed	 95%	 CI	 calculated	 from	
triplicate	experiments.	Relative	fold	change	was	calculated	through	calculation	of	2(-∆∆CT).	
	
RX	and	PAX6	expression	for	BBS008	followed	the	same	pattern	of	increased	expression	as	BBS001	
from	day	0	 to	day	6	 (RX:	RFC=	137.6;	PAX6:	RFC=	166.96)	 (figure	6.13	B-C),	but	decreased	as	
differentiation	 continued	 through	 to	 day	 37,	 effecting	RX	 in	 particular	 (RX:	 RFC=	 34.1;	PAX6:	
RFC=393.10).	 Though	 there	 was	 reduced	 expression	 of	 RX	 and	 PAX6	 compared	 to	 BBS001,	
BBS008	 still	 exhibited	expression	of	other	 key	markers	by	qPCR	analysis,	 such	as	MITF	 (figure	
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6.13D),	 VSX2	 (figure	 6.13E),	 CRX	 (figure	 6.13F),	 and	 RCVRN	 (figure	 6.13G).	 Within	 CTRL037	
cultures,	PAX6	 did	 not	 reach	 the	 same	 high	 expression	 levels	 as	 BBS001	 or	 BBS008	 (day	 37:	
CTRL037	∆CT	mean=	1.13,	95%	CI=	1.00,	1.26;	BBS001	∆CT	mean=	-3.35,	95%	CI=	-3.45,	 -3.25;	
BBS008	∆CT	mean=	-1.91,	95%	CI=	-2.02,	-1.80),	and	RX	was	very	minimally	expressed	with	RFC	of	
0.94,	compared	to	249.70	and	34.17	for	BBS001	and	BBS008,	respectively	(day	37:	CTRL037	∆CT	
mean=	10.03,	95%	CI=	9.08,	 10.98;	BBS001	∆CT	mean=	1.99,	 95%	CI=	0.75,	 3.22;	BBS008	∆CT	
mean=	 4.85,	 95%	 CI=	 3.30,	 6.41)	 (figure	 6.13	 B-C).	 These	 results	 would	 fit	 with	 personal	
observations	that	the	least	successful	line	for	differentiation	was	CTRL037,	which	concordantly	
had	 the	 lowest	 PAX6	 and	 RX	 expression	 levels	 over	 the	 first	 37	 days	 of	 differentiation.	
Furthermore,	CTRL037	also	exhibited	low	VSX2	expression	compared	to	BBS001	and	BBS008	(day	
60:	CTRL037	RFC=	0.11,	∆CT	mean=	7.62,	95%	CI=	7.29,	7.96;	BBS001	RFC=	288.27,	∆CT	mean=-
3.70,	95%	CI=	-4.04,	-3.35;	BBS008	RFC=	49.71,	∆CT	mean=	-1.16,	95%	CI=	-1.63,	-0.69).	Despite	
this,	there	was	expression	of	CRX	and	RCVRN	from	day	98	onwards	(figure	6.13	F-G;	figure	6.14).	
This	may	be	due	to	collection	of	optic	cups	with	more	successful	morphology	at	later	time	points,	
and	is	a	reflection	on	how	variable	this	line	was	throughout	the	differentiation	process.	
	
The	 viable	 CTRL037	 and	 BBS008	 differentiations	were	 kept	 in	 culture	 until	 day	 147	 and	 160,	
respectively.	The	optic	cups	with	a	morphology	featuring	defined	NR	and	RPE	were	retained	for	
immunohistochemical	staining.	Both	CTRL037	and	BBS008	expressed	CRX	and	RCVRN	at	day	98	
and	day	 147,	 respectively	 (figure	 6.13	 F-G).	Overall,	 CTRL037	optic	 cups	 had	 a	 less	 organised	
structure	(figure	6.14	D-G)	and	showed	little	lamination	compared	with	BBS001.	Although	CRX	
and	RCVRN	were	detected	in	the	apical	layer	of	the	cup,	expression	was	sparse	and	disjointed	in	
places	 (Figure	 6.14	D-F).	 Conversely,	 BBS008	 showed	 a	well-ordered	outer	 nuclear	 layer	with	
consistent	CRX	and	RCVRN	expression	throughout	the	optic	cup	(Figure	6.14	A-B).	In	the	outer	
nuclear	 layer,	cone	arrestin	was	also	distinguishable	by	day	98	 in	CTRL037	 (Figure	6.14G)	and	
abundant	by	day	160	in	BBS008	(Figure	6.14C).	On	the	other	hand,	rhodopsin	was	absent	in	both	
cultures.	qPCR	analysis	validated	minimal	expression	of	RHO	in	CTRL037	and	BBS008	compared	
to	BBS001	 from	day	98	to	day	147	 (BBS001	RFC=	15.32,	∆CT	mean=	4.20,	95%	CI=	4.16,	4.23;	
BBS008	RFC=	0.94,	∆CT	mean=	8.23,	95%	CI=	8.06,	8.39;	CTRL037	RFC=	0.40,	∆CT	mean=	9.74,	
95%	CI=	8.89,	10.05)	(figure	6.13H).	Overall,	there	was	a	greater	level	of	variability	between	cups	
derived	from	CTRL037	and	BBS008	compared	with	BBS001,	which	resulted	in	fewer	optic	cups	
for	experiments.	
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Figure	6.14	–	Immunohistochemical	analysis	of	phototransduction	proteins	in	optic	cups	from	CTRL037	and	
BBS008.	A-B)	Expression	of	recoverin	and	CRX	in	the	apical	layer	of	line	derived	from	patient	BBS008	at	day	
147	(A)	and	at	day	160	(B).	C)	Expression	of	cone	arrestin	from	BBS008	at	day	160.	D-F)	Recoverin	and	CRX	
positive	cells	in	the	control	line	CTRL037	at	day	98.	G)	Some	cone	arrestin	positive	cells	in	CTRL037	at	day	
98.	Nuclei	were	stained	with	DAPI.	
	
6.2.4	BBS-specific	staining	
To	my	knowledge,	this	is	the	first	account	of	using	BBS	patient-derived	iPSCs	to	obtain	optic	cups	
in	vitro.	Therefore,	the	next	aim	was	to	ascertain	whether	there	was	a	BBS-specific	phenotype	
observed	in	these	photoreceptors,	which	may	provide	an	insight	into	the	disease	pathobiology.	
These	 experiments	 were	 conducted	 in	 BBS001	 derived	 optic	 cups	 collected	 at	 day	 198	 of	
differentiation.	
	
Immunohistochemical	 staining	 revealed	 that	 BBS1	 was	 exclusively	 expressed	 on	 the	 apical	
surface	of	optic	cups	and	appeared	to	localise	to	the	basal	body	of	the	developing	photoreceptors	
(figure	6.15	A-B).	The	location	of	the	basal	body	was	verified	by	immunohistochemical	staining	
for	BBS5,	another	constituent	member	of	the	BBSome	complex	(figure	6.15C).	Using	an	antibody	
for	 acetylated	 tubulin,	 some	connecting	 cilia	 extending	 from	 the	basal	body	were	 identifiable	
(figure	6.15	B-D).	Taken	together,	this	suggests	that	the	p.M390R	missense	variant	in	BBS1	does	
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not	prevent	expression	or	localisation	of	the	BBSome,	nor	does	it	prevent	connecting	cilia	from	
forming.	
Figure	6.15	–	Immunohistochemical	staining	to	observe	localisation	of	primary	cilia	proteins	BBS1	(A-B),	
BBS5	(C),	and	IFT88	(D).	Assays	were	completed	in	day	198	optic	vesicles	from	patient	BBS001.	Acetylated	
tubulin	was	used	as	a	marker	for	connecting	cilia,	which	project	from	the	apical	surface	of	the	optic	cups	
(white	triangles).	Nuclei	were	stained	with	DAPI.	
	
Finally,	it	was	investigated	whether	there	was	functional	intraflagellar	transport	and	ciliogenesis	
occurring	within	the	patient	optic	cup.	IFT88	is	a	member	of	the	IFT-B	particle,	which	is	vital	for	
anterograde	 transport	 to	 the	 ciliary	 tip.	 Immunohistochemical	 staining	 showed	 that	 IFT88	
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localised	to	the	connecting	cilium,	which	was	identifiable	by	staining	of	acetylated	tubulin	(figure	
6.15D).	There	were	some	IFT-B	particles	present	at	the	ciliary	tip,	suggesting	that	there	was	active	
ciliogenesis	taking	place.	These	results	indicate	that	the	defect	within	the	BBSome	does	not	affect	
ciliogenesis	during	photoreceptor	development.	This	suggests	that	the	p.M390R	variant	in	BBS1	
induces	 photoreceptor	 degeneration	 after	 development	 of	 the	 photoreceptor	 rather	 than	
causing	an	early-developmental	defect.	
	
6.2.5	Transmission	Electron	microscopy	
Transmission	 electron	 microscopy	 (TEM)	 is	 a	 powerful	 tool	 to	 investigate	 the	 ultrastructural	
features	of	a	cell	 in	exact	detail.	This	method	was	utilised	to	determine	an	accurate	picture	of	
photoreceptor	development	and	observe	outer	segment	formation	within	BBS001	optic	cups	at	
day	198.	It	was	also	an	opportunity	for	identification	of	any	abnormalities	that	could	be	a	result	
of	the	disease	genotype.	TEM	processing	and	imaging	was	conducted	by	Dr	Peter	Munro	from	
the	UCL	Institute	of	Ophthalmology.	
	
TEM	 images	 of	 the	 apical-most	 surface	 of	 these	 vesicles	 showed	 inner	 segments	 of	
photoreceptors,	identifiable	due	to	their	ellipsoid	shape	and	abundant	mitochondria	(figure	6.16	
A-H).	The	presence	of	tight	junctions	and	an	outer	limiting	membrane	demonstrated	polarisation	
and	organisation	of	this	cell	layer	(figure	6.16A,	F,	H).	Inner	segments	that	were	sectioned	in	the	
corresponding	plane	of	view	showed	an	intact	emerging	connecting	cilium	(figure	6.16	B-E).	The	
lengths	 of	 these	 cilia	 varied,	 possibly	 due	 to	 cells	 maturing	 at	 different	 rates.	 Some	 images	
displayed	horizontal	cross-sections	of	the	basal	body	or	centrosome,	revealing	their	distinctive	
microtubule	arrangement	(9x3	+	0	or	9x2	+	0,	respectively),	at	the	apex	of	the	cell	(figure	6.16A,	
F-H).	Vertical	cross-sections	revealed	the	complex	structure	of	the	developing	connecting	cilium,	
including	the	axoneme	that	extended	from	the	basal	body	into	a	membranous	vesicle	at	the	distal	
tip.	This	club-shaped	vesicle	has	become	a	characteristic	of	the	developing	outer	segment	in	iPSC	
derived	optic	cups	(Parfitt	et	al.	2016;	Nakano	et	al.	2012).	 In	fact,	the	BBS	optic	cups	showed	
presence	of	disorganised	material	in	this	outer	segment,	which	could	be	attributed	to	disordered,	
developing	outer	segment	discs,	similar	to	that	seen	by	Parfitt	et	al	 (2016).	This	 is	particularly	
prominent	in	figure	6.16D.	
	
As	described	earlier,	there	were	difficulties	in	reaching	the	end	point	of	well-developed	optic	cups	
for	all	lines.	As	a	consequence	of	this,	there	were	no	control	optic	cups	available	for	comparison	
TEM	experiments.	However,	the	results	I	have	presented	here	are	substantiated	by	control	optic	
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cups	 in	 the	 literature,	which	 present	 indistinguishable	 structural	 features	 (Zhong	 et	 al.	 2014;	
Parfitt	et	al.	2016).	Therefore,	at	this	stage	in	development	there	are	no	obvious	developmental	
defects	seen	in	this	BBS	patient’s	optic	cups.	
	
Figure	6.16	–	Transmission	electron	microscopic	analysis	of	optic	cups	at	day	198	from	patient	BBS001.	
Images	were	taken	from	the	apical	layer	and	display	mitochondria	rich	inner	segments	(A,	C,	D,	F),	basal	
bodies	(*),	tight	 junctions	(^),	connecting	cilia	(CC)	and	club-like	nascent	outer	segments	(arrow	heads).	
Basal	bodies	 (*)	are	distinguishable	 from	connecting	cilia	 (CC)	due	to	their	microtubule	arrangement	of	
9x3+0	(H),	compared	to	9x2+0	(G).	TEM	and	imaging	was	completed	by	Dr	Peter	Munro	at	the	UCL	Institute	
of	Ophthalmology.	
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6.3	Discussion	
	
6.3.1	Formation	of	optic	cups	from	BBS	iPSCs	
6.3.1.1	Recapitulation	of	the	neural	retina	
It	has	been	shown	for	the	first	time	that	BBS	patient-derived	iPSCs	can	be	differentiated	into	3D	
optic	cups.	These	cups	recapitulated	in	vivo	development,	including	topological	organisation	of	
retinal	neural	cells	and	expression	of	distinct	genes	required	for	mammalian	eye	development.	
Furthermore,	 in	 late	 stage	 differentiations	 spanning	 day	 147	 to	 day	 198,	 mature	
phototransduction	 proteins	 were	 detectable,	 including	 rhodopsin	 and	 cone	 arrestin.	
Disappointingly,	there	were	fewer	mature	rhodopsin-	and	cone	arrestin-expressing	cells	 in	the	
cultures	of	this	study	compared	to	published	protocols	(Nakano	et	al.	2012;	Zhong	et	al.	2014),	
despite	abundant	expression	of	CRX	and	RCVRN.	However,	rhodopsin	expression	has	been	shown	
to	be	variable,	perhaps	depending	on	retinoic	acid	exposure	or	particular	differences	between	
cell	lines	(Zhong	et	al.	2014;	Mellough	et	al.	2012).	
	
Moreover,	 the	neural	 retina	was	able	 to	 form	without	 the	presence	of	 the	surface	ectoderm,	
which	is	known	to	have	a	crucial	role	in	retinal	specification.	Zhong	et	al.	(2014)	hypothesise	that	
this	 was	 able	 to	 occur	 due	 to	 the	 formation	 of	 a	micro-environment,	 established	 by	 cell-cell	
interactions	and	endogenous	secretions.	These	signalling	cues	were	able	 to	 induce	self-driven	
lamination	that	led	to	a	well-organised	NR	displaying	the	innate	inner	nuclear	and	outer	nuclear	
layers	seen	in	the	native	retina.	The	neuronal	cells	were	not	as	abundant	and	more	scattered	than	
in	vivo,	which	this	is	likely	due	to	lack	of	rigid	borders	in	the	optic	cup	in	vitro.	
	
6.3.1.2	Formation	of	connecting	cilia	and	outer	segments	
The	 ultrastructure	 of	 BBS	 patient-derived	 optic	 cups	 was	 analysed	 by	 transmission	 electron	
microscopy.	TEM	imaging	identified	an	organised	and	well-structured	photoreceptor	layer,	where	
connecting	cilia	had	started	to	emerge	from	mitochondria-rich	inner	segments.	Connecting	cilia	
were	 identifiable	by	their	9	+	0	arrangements	and	 long	microtubular	axonemes	that	extended	
from	a	distinctive	basal	body.	At	the	distal	tip	of	some	of	these	connecting	cilia,	club-like	outer	
segments	were	starting	to	form.	These	immature	structures	were	reminiscent	of	the	developing	
outer	segments	of	photoreceptors	 in	vivo	at	 fetal	week	18	 (Hendrickson	et	al.	2008).	 In	some	
cases,	disordered	tubulovesicular	structures	were	distinguishable	in	the	nascent	outer	segment.	
This	material	 could	be	 rudimentary	undeveloped	discs,	 such	as	 those	published	 from	other	 in	
vitro	developing	photoreceptor	cultures	(Saga	et	al.	1996;	Parfitt	et	al.	2016).		
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During	formation	of	the	optic	cup	 in	vivo,	the	NR	and	RPE	form	adjacent	layers,	where	each	is	
mutually	 beneficial	 to	 the	 other.	 The	 RPE	 is	 known	 to	 be	 essential	 for	 the	 development	 and	
maintenance	 of	 photoreceptors,	 but	 its	 direct	 role	 in	 maturation	 of	 the	 NR	 is	 not	 entirely	
understood.	 In	 the	 current	 literature,	 the	 remarkable	 characteristic	 of	 in	 vitro	 photoreceptor	
differentiation	is	that	they	can	develop	without	direct	contact	between	the	NR	and	the	RPE;	the	
cultures	presented	here	were	no	exception.	Although	a	great	proportion	of	optic	cups	developed	
RPE	cells,	they	were	always	seen	bundled	at	the	tip	or	in	the	middle	of	the	cup,	and	never	lining	
the	surface	of	the	cup.	RPE	cells	secrete	a	wealth	of	growth	factors,	including	FGF1,	FGF2,	insulin-
like	growth	factor	1,	ciliary	neurotrophic	factor,	and	pigment	epithelium	derived	factor	(German	
et	al.	2008).	It	may	be	that	these	secretions	were	enough	to	initiate	photoreceptor	development,	
and	thus	direct	RPE	contact	is	not	essential	for	the	very	early	stages	of	outer	segment	formation.	
However,	 it	 is	 known	 that	 during	 development	 in	 vivo,	 photoreceptors	 extend	 and	 elongate	
towards	 the	RPE	 (German	et	 al.	 2008).	 As	 a	 result,	 it	 is	 likely	 that	 outer	 segment	maturation	
cannot	occur	without	support	and	direct	contact	with	RPE	cells.	With	regards	to	functionality,	
efficient	 phototransduction	 and	maintenance	 of	 the	 visual	 cycle	 cannot	 occur	 without	 direct	
contact	between	photoreceptors	and	RPE.	Therefore,	adjustments	should	be	made	to	current	
protocols	 to	 develop	 methods	 for	 co-culturing	 RPE	 and	 photoreceptors	 in	 their	 native	
configuration.	
	
6.3.2	Expression	of	the	BBSome	and	IFT	machinery	
Having	 established	 the	 presence	 of	 photoreceptors	 in	 BBS	 patient-derived	 optic	 cups,	 it	 was	
investigated	whether	cilia	proteins	were	expressed	and	correctly	localised	in	the	BBS	patient	line	
BBS001.	My	findings	show	that	BBS1	localised	to	the	apical	surface	of	the	optic	cup,	where	inner	
segments	have	formed.	It	was	then	determined	that	BBS5	is	expressed	in	the	same	outer	layer	as	
BBS1.	 These	 two	 proteins	 are	 components	 of	 the	 BBSome.	 In	 some	 cases,	 acetylated	 tubulin	
staining	 identified	connecting	cilia,	which	emerged	from	inner	segments	positive	for	BBS1	and	
BBS5.	I	therefore	surmise	that	the	BBSome	is	localised	to	the	basal	body	of	nascent	connecting	
cilium	of	these	rudimentary	photoreceptors.	This	is	consistent	with	localisation	of	the	BBSome	
within	photoreceptors	in	vivo	(Jin	et	al.	2010;	Smith	et	al.	2013).		
	
Although	 it	 is	 generally	 thought	 that	BBS	patients	are	born	with	normal	 vision,	 it	 is	not	100%	
certain	 as	 most	 patients	 are	 diagnosed	 after	 eyesight	 has	 started	 to	 deteriorate.	 Through	
executing	these	experiments,	the	target	was	to	gain	some	understanding	of	the	pathobiology	of	
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retinal	 degeneration	 in	 BBS	 patients.	 However,	 from	 the	 example	 of	 the	 line	 obtained	 from	
patient	BBS001,	there	were	no	recognisable	developmental	abnormalities	related	to	BBS	protein	
localisation.	Consistent	with	the	findings	presented	here,	the	p.M390R	point	mutation	has	not	
been	shown	to	affect	BBS1	localisation	in	vivo,	but	is	predicted	to	influence	entry	and	exit	into	
the	cilium	to	control	IFT	(Liew	et	al.	2014;	Jin	et	al.	2010;	Mourão	et	al.	2014).	Therefore,	IFT88,	
a	member	of	the	IFT-B	machinery	critical	for	photoreceptor	assembly	and	maintenance	(Pazour	
et	al.	2002),	was	explored.	Immunohistochemical	staining	for	IFT88	demonstrated	expression	of	
some	 IFT	 particles	 at	 the	 distal	 tips	 of	 the	 connecting	 cilia.	 These	 results	 indicate	 that	 active	
ciliogenesis	 was	 able	 to	 occur,	 which	 suggests	 that	 during	 development	 the	 BBSome	 allows	
normal	entry	into	the	connecting	cilium.	
	
Despite	 the	underlying	BBS1	mutation	 seen	 in	 this	 patient,	 the	differentiation	procedure	was	
consistent	with	in	vivo	development,	and	BBS	and	IFT	proteins	localised	correctly.	Therefore,	from	
the	experiments	conducted	in	this	study,	there	were	no	recognisable	BBS-specific	abnormalities	
discovered	 in	 these	developing	photoreceptors.	 This	observation	 is	 supported	by	 a	 functional	
study	by	Mockel	et	al.	(2012),	where	apoptosis	of	Bbs12-/-	photoreceptors	occurred	only	once	the	
outer	segments	had	differentiated	and	matured.	Accordingly,	I	would	surmise	that	in	general	BBS	
proteins	 are	 not	 required	 for	 the	 development	 of	 photoreceptors,	 but	 are	 essential	 for	
photoreceptor	function.	This	late	deterioration	of	photoreceptors	could	provide	an	opportunity	
for	early	intervention	that	would	prevent	visual	loss	before	it	occurs.	
	
If	BBS	proteins	are	involved	only	in	functionality	of	photoreceptors,	this	points	to	the	conclusion	
that	 visual	 degeneration	 is	 triggered	 by	 a	 light	 stimulus.	 In	 support	 of	 this,	 the	 BBSome	 has	
demonstrated	 some	 light	 sensitivity.	 BBS5	 has	 been	 shown	 to	 undergo	 phosphorylation	 in	
response	to	light	to	facilitate	arrestin	transport	(Smith	et	al.	2013)	and	BBS4	is	required	for	light-
dependent	 protein	 transport	 to	 the	 outer	 segment	 (Abd-El-Barr	 et	 al.	 2007).	 Encompassing	
evidence	 from	 my	 own	 and	 published	 studies,	 I	 present	 a	 model	 as	 the	 foundation	 of	
photoreceptor	degeneration	in	BBS	patients:	The	transportation	of	phototransduction	proteins	
to	 the	 outer	 segment	 is	 activated	 by	 a	 light	 stimulus.	 These	 phototransduction	 proteins	 are	
shuttled	from	the	inner	segment	to	the	outer	segment	via	the	connecting	cilium,	entry	into	which	
is	controlled	by	the	BBSome.	Under	a	light	stimulus,	IFT	must	occur	efficiently	as	an	estimated	
2000	opsin	molecules	are	delivered	each	minute	through	the	connecting	cilium	(Wolfrum	and	
Schmitt	2000;	Pazour	et	al.	2002).	As	a	result	of	a	faulty	BBSome,	the	proteins	cannot	be	shuttled	
quickly	enough,	thus	proteins	accumulate	in	the	inner	segment	and	outer	nuclear	layer	(Abd-El-
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Barr	 et	 al.	 2007;	Mockel	 et	 al.	 2012).	 This	 accumulation	 leads	 to	 stress	 on	 the	 endoplasmic	
reticulum	and	triggers	the	unfolded	protein	response	pathway	and	imminent	apoptosis	(Mockel	
et	al.	2012).	In	order	to	investigate	this	hypothesis	further,	I	would	need	to	conduct	light	response	
experiments	 on	 photoreceptors	 with	 mature	 outer	 segments,	 and	 importantly	 have	 control	
photoreceptors	available	for	these	studies.	
	
6.3.3	Variability	within	iPSC	cultures	
Upon	starting	this	project,	the	aim	was	to	differentiate	5	different	iPSC	lines.	Unfortunately,	the	
success	 rate	 was	 low	 and	 two	 lines	 failed	 to	 express	 key	 retinal	 genes	 entirely.	 Due	 to	 the	
irregularities	 between	 cultures	 being	 so	 great,	 comparison	 between	 lines	 for	 functional	
experiments	 would	 be	 unreliable.	 It	 would	 be	 impossible	 to	 ascertain	 whether	 significant	
differences	were	real	or	due	to	experimental	variability.	Variation	between	lines	is	not	uncommon	
in	iPSC	cultures	(Hirami	et	al.	2009;	Zhong	et	al.	2014;	Meyer	et	al.	2009;	Kilpinen	et	al.	2017)	and	
shall	be	addressed	in	this	section.	
	
6.3.3.1	Embryoid	body	formation	
Embryoid	 body	 formation	 can	 create	 one	 of	 the	 greatest	 sources	 of	 variation	 in	 stem	 cell	
differentiation	cultures.	Although	they	present	an	efficient	method	of	initiating	differentiation,	
EB	size,	number,	and	quality	are	difficult	to	control.	These	variables	influence	the	cell-cell	spatial	
coordination	within	the	EB,	which	affects	the	course	of	differentiation	and	makes	reproducibility	
difficult	to	ensure	(Rungarunlert	et	al.	2009).		
	
There	are	different	methods	for	maintaining	EBs.	A	static	suspension	method	was	used	in	this	
project.	This	cultures	all	EBs	for	each	experiment	in	a	single	environment,	such	as	in	a	T25	cell	
culture	 flask.	 This	method	was	advantageous	because	 it	was	 the	 least	 labour	 intensive	and	 is	
popular	for	differentiations	into	neural	lineages	(Rungarunlert	et	al.	2009).	On	the	other	hand,	
difficulties	were	faced	when	generating	aggregates	due	to	agglomeration	of	multiple	EBs	and	in	
some	cases	premature	attachment	to	the	surface	of	the	culture	plate.	These	problems	led	to	high	
cell	death	rates	and	heterogeneity	within	a	single	experiment,	which	could	have	had	a	big	impact	
on	differentiation	downstream.	These	issues	could	be	overcome	in	future	experiments	through	
use	of	 a	 different	method	 for	 EB	development,	 such	 as	 a	hanging	drop	or	using	 a	 96-well	U-
bottomed	plate.	Both	techniques	prevent	agglomeration	and	ensure	high	uniformity	as	EBs	are	
kept	separate	from	one	another	(Rungarunlert	et	al.	2009).	
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6.3.3.2	Epigenetic	variability	
During	one	differentiation,	a	bundle	of	cardiomyocytes	was	discovered,	which	 formed	around	
day	 20	 in	 the	 control	 line	 CTRL038	 (supplemental	 data,	 movie	 S.1).	 The	 presence	 of	 this	
demonstrates	 the	 unpredictability	 associated	with	 iPSC	 culture	 and	 shows	 the	 importance	 of	
checking	cultures	regularly	for	any	abnormalities.	This	phenomenon	may	also	have	occurred	due	
to	reprogramming	inefficiencies	associated	with	incomplete	reprogramming	of	the	epigenome.	
Reprogramming	of	somatic	cells	to	iPSCs	is	induced	through	epigenetic	transformation	and	not	a	
genetic	alteration.	Although	studies	have	shown	that	at	a	transcriptomic	level	iPSCs	are	almost	
identical	 to	 ESCs,	 multiple	 reports	 have	 identified	 that	 iPSCs	 possess	 an	 epigenetic	 memory	
retained	from	their	host	cell	(Lister	et	al.	2011;	Kim	et	al.	2010;	Polo	et	al.	2010;	Hu	et	al.	2010).	
This	epigenetic	memory	can	be	transmitted	at	a	high	frequency	through	differentiation	and	affect	
differentiation	 propensity.	 For	 example,	 cardiomyocytes	 and	 fibroblasts	 both	 belong	 to	 the	
mesodermal	germ	layer.	Therefore,	the	line	CTRL038	may	have	been	predisposed	to	differentiate	
into	cardiomyocytes	due	to	its	epigenetic	memory	of	mesenchymal	cells.	This	could	also	explain	
why	no	viable	differentiations	were	obtainable	from	this	line.	
	
Using	keratinocytes	as	a	host	 cell	 for	 reprogramming	could	enhance	 the	chance	of	 successful	
optic	cup	differentiation.	Compared	to	dermal	fibroblasts,	keratinocytes	have	proved	to	be	twice	
as	fast	and	100-fold	more	efficient	at	reprogramming	(Maherali	et	al.	2008;	Barrero	et	al.	2012).	
Additionally,	keratinocytes	arise	from	the	ectoderm	and	thus	are	the	same	germ	lineage	as	the	
neural	retina.	iPSCs	derived	from	Usher	patient	keratinocytes	have	been	used	to	generate	defined	
neural	retina	and	RPE	layers,	closely	mimicking	the	configuration	seen	in	vivo	(Tucker	et	al.	2013).	
As	yet,	this	has	not	been	reported	in	iPSCs	derived	from	fibroblasts.	
	
6.3.3.3	Genetic	variability	
The	recent	study	from	the	HipSci	project	characterised	iPSC	lines	derived	from	189	individuals	
and	 showed	 that	 the	 greatest	 variation	 factor	 in	 reprogrammed	 iPSCs	 was	 in	 fact	 genetic	
background	 from	 the	 donor	 (Kilpinen	 et	 al.	 2017).	 These	 differences	 were	 shown	 to	 affect	
pluripotency,	 cell	 morphology	 and	 importantly,	 differentiation	 capacity.	 Concordantly,	 in	 my	
experiments,	 large	 differences	 were	 noticeable	 in	 differentiation	 capacity	 between	 lines,	
irrespective	of	whether	they	were	BBS	patient-derived	or	from	healthy	control	 individuals.	For	
example,	 the	 iPSCs	 derived	 from	 BBS001	 differentiated	 very	 well	 compared	 to	 the	 line	 from	
BBS007,	and	the	control	line	CTRL038,	which	both	failed	to	produce	operable	differentiations.	
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One	of	the	contributors	to	genetic	variability	may	arise	from	somatic	mutations	found	in	dermal	
fibroblasts.	 The	 skin	 is	 typically	 prone	 to	 ultraviolet	 radiation	 exposure,	 which	 causes	 a	 high	
frequency	of	point	mutations	that	would	otherwise	be	absent	 in	germ	cells.	The	selection	and	
accumulation	 of	 somatic	 mutations	 occurs	 through	 reprogramming	 and	 passaging	 selection	
during	fibroblast	and	iPSC	culture	(Gore	et	al.	2011).	This	also	poses	problems	downstream	for	
therapeutic	uses	of	 iPSCs	and	introduces	the	need	for	high-throughput	functional	genomics	to	
identify	 detrimental	 or	 carcinogenic	 mutations	 before	 clinical	 use.	 The	 HipSci	 project	 have	
addressed	this	issue	by	implementation	of	genotyping	arrays	on	both	somatic	cells	and	iPSCs	prior	
to	 banking.	 This	 aimed	 to	 validate	 that	 genetic	 integrity	 was	 maintained	 throughout	 the	
reprogramming	process	and	allowed	removal	of	cell	 lines	 that	accumulated	aberrant	variants,	
such	as	chromosomal	aberrations	or	structural	variants	(Kilpinen	et	al.	2017).	
	
6.3.3.4	Media	and	culturing	techniques		
The	results	described	here	were	consistent	with	the	protocol	published	by	Zhong	et	al.	 (2014)	
despite	the	difference	in	iPSC	culturing	system.	However,	the	success	rate	of	differentiation	was	
generally	lower	than	Zhong	and	colleagues,	who	were	able	to	successfully	differentiate	three	iPSC	
lines	with	50-70%	efficiency.	One	reason	for	the	difference	in	efficiency	may	be	due	to	using	an	
E8	and	vitronectin	system,	which	was	not	possible	to	optimise	due	to	time	constraints	within	this	
project.	
	
E8	was	developed	by	Chen	et	al.	(2011)	as	a	replacement	to	mTESR	for	iPSC	feeder-free	culture	
(Chen	et	al.	2011).	mTESR	tends	to	be	more	commonly	used,	but	contains	over	20	highly	variable	
ingredients,	 typically	obtained	 from	animal	 sera,	 such	as	albumin	and	Matrigel	 (Ludwig	and	A	
Thomson	2007).	As	a	result,	variability	across	cultures	grown	with	mTESR	can	be	substantial.	On	
the	 other	 hand,	 E8	 is	 nonxenogeneic	 and	 contains	 8	 essential	 ingredients	 that	 ensure	
pluripotency	and	cell	health,	whilst	controlling	for	variability.	Despite	the	benefits	of	iPSC	culture	
using	E8,	 there	have	 yet	 to	be	any	published	 reports	 that	have	used	E8	maintained	 iPSCs	 for	
differentiation.	Similarly,	no	studies	are	available	demonstrating	that	iPSCs	grown	on	vitronectin	
can	differentiate	successfully	to	a	neuroepithelial	lineage.	In	all	cases	in	the	literature,	a	Matrigel	
substrate	 is	 utilised	 for	 differentiation	 into	 neurospheres.	Matrigel’s	 efficiency	 is	 owing	 to	 its	
heterogeneity,	 which	 favourably	 recapitulates	 the	 extracellular	 matrix	 in	 vivo	 (Hughes	 et	 al.	
2010).	 In	contrast,	vitronectin	is	comprised	of	a	single	component,	which	may	not	provide	the	
same	level	of	support.	
	
Chapter	6:	Model	for	retinal	dystrophy	with	iPSCs	
	
286	
6.3.4	Future	role	for	this	model	
6.3.4.1	Optimisation	of	culture	system	
Optic	cup	development	is	a	complex	process	orchestrated	by	elaborate	time	sensitive	signalling	
pathways.	This	process	was	possible	without	the	addition	of	exogenous	factors	to	the	culturing	
system.	Explicitly,	 this	was	one	of	 the	reasons	why	the	Zhong	et	al.	protocol	was	chosen	over	
other	publications.	A	low	maintenance,	unelaborate	protocol	was	more	compatible	for	a	single	
person	to	undertake	several	simultaneous	differentiations.	 In	hindsight,	 the	 lack	of	exogenous	
factors	created	a	long-winded	experiment	with	low	success	rates.	
	
For	future	experiments,	the	addition	of	retinogenesis	specific	agonists	and	antagonists	could	be	
included	to	enhance	photoreceptor	differentiation	and	efficiency.	As	an	example,	 inhibition	of	
BMP	and	Wnt	signalling	can	increase	PAX6	and	RX	expression	(Meyer	et	al.	2009),	which	could	
enhance	the	prosperity	of	eye	field	development	in	the	early	stages	of	differentiation.	Similarly,	
Notch	suppression	by	DAPT	treatment	has	shown	to	exhibit	strong	acceleration	of	photoreceptor	
differentiation	(Nakano	et	al.	2012)	and	doubled	early	CRX	and	RCVRN	expression	between	week	
3	 and	 4	 of	 differentiation	 (Reichman	 et	 al.	 2014).	 Additionally,	 introduction	 of	 FGF2	may	 be	
sufficient	 to	 represent	 an	 environment	 similar	 to	 the	 surface	 ectoderm.	 These	 exogeneous	
factors	will	require	precise	optimisation	with	time	sensitive	delivery.	If	used	appropriately,	they	
may	enhance	reproducibility,	as	differentiation	will	no	 longer	depend	on	micro-environmental	
cues	or	endogenous	secretions.	
	
There	are	other	modifications	that	would	benefit	future	experiments.	A	small	adjustment	would	
be	 to	 switch	 a	 6-well	 culture	 plate	with	 a	 96-well	 U-bottomed	 plate.	 This	 would	 allow	more	
precision	 and	 control	 over	 the	 development	 of	 each	 individual	 optic	 cup.	 Additionally,	 this	
technique	would	reduce	some	of	the	variability	caused	by	EB	agglomeration.	On	the	other	hand,	
this	would	 increase	maintenance	 time	 each	day,	which	would	make	multiple	 lines	 difficult	 to	
manage	for	one	person.	
	
Another	option	would	be	to	switch	from	a	3D	culture	system	to	2D	culture.	The	benefit	of	this	
technique	is	a	higher	cell	viability,	as	growth	factors	do	not	have	to	penetrate	several	cell	layers	
of	the	optic	cup.	Additionally,	multiple	homogenous	biopsies	can	be	easily	extracted	for	analysis	
or	further	subculture,	without	affecting	future	development.	Tucker	et	al.	(2013)	were	successful	
in	their	recapitulation	of	layered	RPE	and	NR,	similar	to	in	vivo	configuration,	and	expression	of	
opsins	by	day	120	of	culture	(Tucker	et	al.	2013).	
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6.3.4.2	Model	for	therapeutic	use	
This	project	has	shown	differentiation	of	BBS	patient-derived	iPSCs	into	optic	cups	is	possible,	but	
there	 is	 much	 to	 accomplish	 before	 utilisation	 as	 a	 disease	 model.	 The	 greatest	 barrier	 to	
overcome	 is	 the	 lack	of	 reproducibility	and	unpredictability	of	 the	differentiation	process.	The	
best	way	to	ensure	reproducibility	would	be	to	increase	the	number	of	differentiations	per	line	
and	also	add	clones	to	assess	differences	in	the	reprogramming	procedure.	To	reliably	evaluate	
biological	differences	between	disease	and	control	groups,	multiple	lines	for	each	group	would	
need	 to	 be	 successfully	 differentiated.	 As	 a	 whole,	 this	 process	 would	 be	 extremely	 time	
consuming	and	expensive.	On	the	other	hand,	if	optimised	properly,	this	technique	could	provide	
an	exciting	patient	specific	model	for	therapeutic	uses.	
	
In	this	research	field,	the	challenge	is	to	recreate	functional	outer	segments	that	are	rich	with	
membranous	discs.	Zhong	et	al.	(2014)	revealed	some	excitation	in	response	to	a	light	stimulus	
with	immature	nascent	outer	segments	similar	to	those	generated	in	this	project.	Due	to	time	
restraints,	 it	 was	 not	 possible	 to	 test	 BBS	 optic	 cups	 for	 functionality.	 For	 future	 work,	
demonstration	 of	 a	 light	 response	 may	 provide	 answers	 to	 the	 role	 of	 the	 BBSome	 in	
photoreceptors.	If	functionality	were	observed,	the	utility	of	the	optic	cups	could	be	invaluable	
to	 test	 therapeutics	 in	 a	patient	 specific	model.	 For	 example,	 gene	 therapy	models	 are	being	
developed	to	rescue	eyesight	in	BBS1M390R/M390R	knock-in	mice.	This	involves	injecting	a	functional	
gene	 copy	 packaged	 in	 Adeno-Associated	 Virus	 (AAV)	 vectors	 into	 the	 retina.	 Before	 use	 in	
patients,	 this	 therapy	would	 need	 to	 be	 optimised	 and	 validated	 in	 a	 patient-specific	model.	
Furthermore,	this	model	could	be	used	for	a	drug	screen	to	decelerate	the	loss	of	photoreceptors.	
Mockel	 et	 al.	 demonstrated	 that	 drug	 intervention	 to	 inhibit	 the	 unfolded	 protein	 response	
pathway	prolonged	photoreceptor	viability	in	Bbs12-/-	mice	(Mockel	et	al.	2012).	
	
Finally,	there	is	potential	for	the	transplantation	of	photoreceptors	grown	in	vitro	into	the	patient	
retina	(Gonzalez-Cordero	et	al.	2013;	MacLaren	et	al.	2006;	Lakowski	et	al.	2011;	Tucker	et	al.	
2013;	Homma	et	al.	 2013;	 Lamba	et	al.	 2010;	Tucker	et	 al.	 2011).	 iPSCs	derived	 from	patient	
somatic	 cells	 allows	 autologous	 transplantation,	 which	 would	 avoid	 immune	 rejection	 and	
therefore	treatment	with	immunosuppressors.	There	has	been	success	with	transplantation	of	
retinal	cells	derived	from	both	ESC	and	iPSC	models	back	into	mouse	disease	models	(MacLaren	
et	al.	2006;	Gonzalez-Cordero	et	al.	2013).	Following	transplantation,	photoreceptor	precursors	
expressing	CRX	have	been	shown	to	integrate	into	the	host	retina,	extend	neuronal	projections,	
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develop	 outer	 segments	 that	 extend	 towards	 the	 RPE,	 and	 induce	 partial	 restorations	 of	
electrophysiological	function	(Tucker	et	al.	2011;	Lakowski	et	al.	2011;	Tucker	et	al.	2013).	
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Chapter	7:	Final	Conclusions	
	
7.1	Summary	of	findings	
	
This	project	was	the	first	of	its	kind	to	investigate	multiple	biological	materials	from	BBS	patients	
with	the	overall	objectives	to:	
	
• Investigate	whether	interfamilial	heterogeneity,	which	presents	as	differences	in	disease	
onset	or	severity,	is	a	consequence	of	genetic	modifying	alleles	that	interact	with	BBS1	in	
the	primary	cilium.	
	
• Utilise	different	proteomic	profiling	technologies	to	discover	molecular	biomarkers	that	
may	be	used	to	measure	disease	progression	or	detect	secondary	features	of	BBS	from	
urine	and	plasma	biofluids.	
	
• Using	 a	multi-omic	 strategy,	 integrate	 transcriptomic	 and	 proteomic	 profiling	 data	 to	
uncover	differentially	regulated	pathways	between	BBS	and	control	fibroblasts	that	may	
elucidate	BBS	pathology.	
	
• Develop	a	tissue	specific	model	from	BBS	patient-derived	iPSCs	for	the	investigation	of	
retinal	dystrophy	in	vitro.	
	
• Trial	novel	technologies,	as	well	as	develop	protocols	for	use	in	future	multi-omic	studies	
for	rare	diseases.	
	
The	main	findings	of	this	thesis	are	discussed	here	and	summarised	in	figure	7.1:	
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Figure	7.1	–	Summary	of	findings	for	each	chapter.	
	
7.1.1	There	is	evidence	of	secondary	modifying	variants	in	BBS	patients,	which	may	
point	towards	the	underlying	causes	of	phenotypic	variability.	However,	these	variants	
do	not	contribute	to	the	overall	mutational	burden	of	BBS	
	
Phenotypic	heterogeneity	is	a	common	feature	of	BBS,	which	has	been	proposed	to	be	controlled	
by	genetic	modifiers	(Beales	et	al.	2003;	Katsanis,	Lupski,	et	al.	2001;	Khanna	et	al.	2009;	Zaghloul	
and	 Katsanis	 2009;	 Katsanis,	 Ansley,	 et	 al.	 2001;	 Badano	 et	 al.	 2006;	 Zaki	 et	 al.	 2011).	 This	
variability	was	reflected	within	the	cohort	of	this	project;	therefore,	it	was	investigated	whether	
genetic	modifiers	could	be	identified	that	may	attribute	to	interfamilial	heterogeneity	(described	
in	chapter	3).	Within	this	project,	I	generated	a	4-tier	categorisation	system	for	identification	of	
modifiers	from	whole	genome	sequencing	data.	This	demonstrated	its	effectiveness	through	the	
discovery	of	3	known	modifiers	 in	4	patients,	namely	RPGRIP1L	p.A229T	 (Khanna	et	al.	2009),	
TTC21B	p.L1002V	(Davis	et	al.	2011),	and	BBS12	p.S429T	(Zaghloul	et	al.	2010).	Furthermore,	an	
additional	4	variants,	ARL6	p.T32M,	BBS4	p.V266G,	CEP164	pQ1410*,	and	AHI1	p.R548H,	were	
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uncovered	and	assigned	high	confidence	due	to	evidence	collected	by	protein	interactions	with	
BBS1,	 pathogenic	 prediction	 algorithms,	 or	 for	 the	 case	 of	 AHI1,	 a	 previously	 established	
modifying	gene	in	ciliopathies	(Tory	et	al.	2007;	Louie	et	al.	2010;	Coppieters	et	al.	2010).	Further	
work	will	be	required	to	determine	whether	putative	modifiers	have	the	capability	of	altering	the	
expression	BBS1	p.M390R	in	these	patients.	This	would	best	be	achieved	through	a	series	of	gene	
correction	studies	discussed	further	in	chapter	3.	
	
Mutational	 burden	 analysis	 was	 then	 completed	 to	 establish	 whether	 the	 genetic	 modifying	
variants	found	in	BBS	patients	attributed	to	enhanced	genetic	burden.	This	project	determined	
that,	within	this	cohort	and	another	set	of	16	patients	sequenced	by	whole	exome	sequencing,	
there	was	no	evidence	that	modifying	variants	contributed	to	the	total	mutational	 load	of	the	
disease.	This	was	determined	with	2	primary	cilia	gene	sets	(ciliopathy	and	SCGSv1	panels),	and	
a	non-related	CMT	disease	gene	panel	for	use	as	a	control.	The	finding	of	no	mutational	burden	
supported	 a	 previous	 study,	 which	 determined	 a	 similar	 finding	 with	 31	 ciliopathy	 patients	
(Shaheen	et	al.	2016).	Further	investigation	of	patients	with	BBS1	p.M390R	uncovered	that	they	
had	 significantly	 fewer	 variants	 than	 control	 individuals	 when	 the	 BBS1	 p.M390R	 allele	 was	
removed	from	the	total	variant	count.	This	was	an	unexpected	finding	as	it	conflicted	with	the	
result	of	the	burden	analysis	with	16	WES	BBS	patients.	This	outcome	may	have	complicated	our	
understanding	of	the	underlying	genetics	of	BBS1	p.M390R	patients.	Further	work	is	required	to	
determine	 whether	 this	 was	 a	 true	 finding,	 or	 a	 consequence	 of	 small	 sample	 sizes	 or	
experimental	design.	
	
7.1.2	Proteomic	profiling	uncovered	molecular	biomarkers	that	may	be	indicative	of	
secondary	features	of	obesity	
	
This	was	the	first	study	to	utilise	biofluids	obtained	from	ciliopathy	patients	for	identification	of	
protein	biomarkers	(described	in	chapter	4).	The	current	marker	tested	in	BBS	clinics	 is	CRP,	a	
generic	 indicator	 of	 inflammation.	 Thus,	 there	was	 a	 need	 for	molecular	 biomarkers	 that	 are	
indicative	of	disease	progression,	that	may	be	specific	to	BBS,	or	specific	to	phenotypic	features	
of	BBS.	This	project	implemented	label-free	mass	spectrometry	and	a	novel	targeted	technology,	
SOMAscan,	to	detect	differentially	expressed	proteins	in	urine	and	plasma	between	BBS	patients	
and	control	subjects.	Both	technologies	and	biofluids	revealed	markers	that	are	associated	with	
obesity	or	secondary	features	of	high	adiposity,	such	as	type	II	diabetes	or	cardiovascular	disease.	
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The	biomarker	identification	strategy	used	in	this	project	uncovered	candidate	markers,	such	as	
PEDF	and	ORM1	from	urine,	and	ApoM	from	plasma.	Importantly,	further	investigation	must	be	
completed	 to	 determine	 the	 reliability	 of	 these	 findings	 in	 a	 larger	 BBS	 cohort.	 Biomarker	
discovery	 hierarchy	 described	 by	 Rifai	 et	 al.	 (2006)	 indicates	 that	 verification	 should	 be	
implemented	 with	 100s	 of	 patients	 (figure	 4.1).	 This	 could	 be	 completed	 in	 a	 large	 profiling	
project,	implementing	urine	samples	from	all	BBS	patients	in	the	clinic,	for	which	there	are	520	
patients	in	the	UK	(Prof	P.	Beales,	personal	communication).	The	benefit	of	urine	is	that	it	is	non-
invasive	and	already	routinely	obtained	for	clinical	testing.	
	
7.1.3	A	multi-omic	strategy	identified	dysregulated	pathways	in	BBS	cell	cycling	and	
ciliated	fibroblasts	compared	to	controls	
	
Fibroblasts	 from	patients	 and	 controls	were	 investigated	under	 serum	 fed	and	 serum	starved	
conditions,	to	compare	differences	in	cell	cycling	and	ciliated	cells	(described	in	chapter	5).	To	
our	knowledge,	the	resulting	3-way	comparison	strategy	was	the	first	example	of	an	investigation	
of	differences	between	ciliated	and	non-ciliated	cells,	 as	well	 as	 the	global	analysis	of	patient	
derived	cultures.	This	analysis	uncovered	a	highly	complex	response	to	starvation,	as	well	as	some	
biologically	relevant	changes	between	BBS	and	controls	at	the	pathway	level.	These	processes	
shall	be	targets	for	further	validation	as	a	consequence	of	this	study.	
	
Pathway	 analysis	 of	 RNA-seq	 genes	 uncovered	 discordant	 expression	 of	 centrosomal	 genes	
between	BBS	and	control	cells.	It	was	revealed	that	genes	involved	in	mitotic	spindle	nucleation,	
such	 as	 HAUS3	 and	 CEP152,	 were	 significantly	 downregulated	 in	 serum	 fed	 BBS	 cultures	
compared	to	controls.	This	may	suggest	a	disruption	of	mitotic	spindle	organization	or	cytokinesis	
in	 BBS	 cell	 cycling	 cultures.	 This	 study	 also	 investigated	 proteomics	 data	 from	 iTRAQ	 mass	
spectrometry,	which	revealed	upregulated	processes,	including	regulators	of	actin	cytoskeleton,	
cilia	assembly,	and	hedgehog	signaling.	Incorporation	of	BBS1	and	its	interacting	proteins	into	a	
protein	network	with	DE	proteins	allowed	assessment	of	possible	mechanisms	for	upregulation	
of	these	pathways.	Although	highly	complex,	this	technique	enabled	speculation	that	the	BBS1	
p.M390R	variant	in	patient	cells	has	reduced	affinity	of	BBS1	with	its	interactions,	and	thus	has	
resulted	in	accumulation	of	proteins.	
	
The	gene	set	adipogenesis	was	positively	enriched	by	both	transcriptomic	and	proteomic	profiling	
technologies	 in	 the	serum	fed	BBS	vs	control	comparison,	which	elucidate	mechanistic	 insight	
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into	 obesity	manifested	 by	 BBS	 patients.	 Although,	 individually	 genes	were	 rarely	 statistically	
significant,	GSEA	determined	that	the	collective	trend	was	significant.	Evaluation	of	the	individual	
genes	 and	 pathway	 topology	mapping	 identified	 that	 components	 predominantly	 involved	 in	
mitochondrial	 function	 were	 upregulated,	 which	 may	 suggest	 that	 the	 enrichment	 for	
adipogenesis	 was	 driven	 by	 unbalanced	 mitochondrial	 activity	 in	 BBS	 fed	 cells	 compared	 to	
controls.	 This	 work	 may	 support	 previous	 findings	 that	 suggest	 increased	 adiposity	 in	 BBS	
patients,	thought	to	be	driven	by	aberrantly	upregulated	adipogenic	drivers	(Marion	et	al.	2009;	
Marion	et	al.	2012).	Further	work	to	validate	this	finding	was	discussed	in	chapter	5.	
	
Within	 this	 thesis,	 RNA-seq	 was	 analysed	 by	 looking	 at	 changes	 in	 gene	 expression	 and	
dysregulation	of	pathways	between	biological	groups.	However,	integration	of	RNA-seq	data	with	
genetic	variation	information	can	be	used	to	aid	analysis	of	the	genome.	For	example,	differences	
in	 gene	 expression	may	 be	 linked	 to	 regulatory	 variants,	 such	 as	 eQTLs,	 which	 influence	 the	
expression	level	of	genes	(Morley	et	al.	2004).	Although,	large	sample	sizes	are	required	for	eQTL	
association	 studies,	 this	project	 identified	 some	 interesting	 variants	 for	 further	 study,	 such	as	
RPGRIP1L,	which	was	 flagged	 in	 both	 the	 genetic	modifier	 and	 RNA-seq	 studies	 (discussed	 in	
chapter	 3	 and	 5,	 respectively).	 There	 were	 2	 qualifying	 variants	 in	 RPGRIP1L	 from	 the	 4-tier	
categorisation	system	found	 in	2	patients;	p.A229T	 in	BBS003	and	p.A1183G	 in	BBS013	 (table	
3.3iv).	In	addition,	RPGRIP1L	was	highlighted	as	discordantly	expressed	in	response	to	starvation	
in	patients	compared	to	controls	(figure	5.14	and	5.15).	Therefore,	future	work	would	also	entail	
analysis	of	the	RNA-seq	data	to	determine	whether	there	are	genetic	explanations	for	significant	
changes	in	gene	expression,	such	as	with	RPGRIP1L.	
	
7.1.4	BBS-patient	derived	iPSCs	were	used	to	develop	a	model	for	investigation	of	
retinal	dystrophy	in	vitro,	which	successfully	recapitulated	gene	expression	of	the	native	
developing	retina	
	
Within	 this	 thesis,	 it	was	demonstrated	 for	 the	 first	 time	 that	 iPSCs	derived	 from	BBS	patient	
fibroblasts	 could	 differentiate	 into	 3D	 optic	 cups,	 which	 exhibited	 the	 key	 stages	 of	 gene	
expression	required	for	in	vivo	retinal	development	(described	in	chapter	6).	Investigation	of	the	
ultrastructure	by	TEM	of	optic	cups	at	day	198	of	differentiation	revealed	nascent	photoreceptor	
outer	segments,	morphologically	similar	to	differentiating	outer	segments	from	wild	type	cells	in	
other	studies	(Saga	et	al.	1996;	Zhong	et	al.	2014;	Parfitt	et	al.	2016).	Furthermore,	this	was	the	
first	 study	 to	 investigate	 the	 expression	 BBSome	 proteins	 within	 iPSC	 models,	 which	
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demonstrated	that	BBS1	and	BBS5	were	 localised	to	the	basal	body	of	the	connecting	cilia,	as	
expected.	Although	at	this	stage	of	development	there	were	no	control	cultures	for	comparison,	
using	knowledge	taken	from	the	literature	(Smith	et	al.	2013;	Jin	et	al.	2010;	Parfitt	et	al.	2016),	
it	appeared	that	the	BBSome	localisation	and	ciliogenesis	was	not	affected	in	the	BBS	patient-
derived	optic	cups.	
	
Several	types	of	biological	material	obtained	from	BBS	patients	were	utilised	in	this	thesis,	namely	
urine,	plasma,	and	dermal	fibroblast	cultures.	Although	each	element	has	its	advantage,	they	are	
not	 tissue	 types	 that	 are	 known	 to	 exhibit	 BBS-specific	 phenotypes.	 Disease	 relevant	 tissues	
obtained	from	patients	may	be	a	more	valuable	source	of	biological	information,	such	as	renal	
progenitors	to	study	polycystic	kidney	disease,	hypothalamic	neurons	for	investigation	of	satiety	
response,	 or	 retina	 to	 model	 rod-cone	 dystrophy.	 These	 tissues	 are	 difficult	 to	 obtain	 from	
patients	for	research	purposes,	which	is	why	iPSCs	are	a	highly	valuable	resource.	A	future	project	
would	be	to	 implement	models,	such	as	BBS	patient-derived	optic	cups,	 in	a	multi-omic	study	
with	 the	 framework	 developed	 in	 this	 thesis.	 This	 would	 provide	 valuable	 insight	 into	 the	
pathological	mechanisms	within	 a	 disease	 relevant	 tissue,	 as	 well	 as	 being	 able	 to	 study	 the	
development	of	the	disease	in	vitro.	
	
7.2	Considerations	for	further	work	
This	 thesis	 doubled	 as	 a	 pilot	 project	 to	 develop	 and	 implement	 a	 multi-omic	 strategy	 for	
investigation	of	rare	diseases.	Typical	challenges	were	faced	that	relate	to	studying	rare	disease	
cohorts,	such	as	disease	heterogeneity	and	small	sample	sizes.	However,	having	confronted	these	
challenges,	future	studies	can	be	devised	with	improved	study	designs,	encompassing	optimised	
standard	 operating	 protocols	 (SOPs).	 Some	 considerations	 to	 consider	 for	 future	 work	 are	
described	here.	
	
Patients	with	the	variant	BBS1	p.M390R	were	chosen	for	this	study	for	two	key	reasons.	Firstly,	
this	 is	the	most	common	variant	 in	European	populations	(Mykytyn	et	al.	2002),	therefore	the	
largest	population	of	patients	in	the	BBS	clinic	carry	at	least	one	disease	causing	BBS1	p.M390R	
variant.	This	not	only	means	that	this	variant	carries	the	greatest	burden	on	the	population,	but	
also	that	larger	cohorts	can	be	assembled	of	patients	with	the	same	genotype,	attributing	to	more	
statistical	power.	Secondly,	despite	it	being	very	common	in	the	population,	the	pathobiology	of	
BBS1	p.M390R	is	not	well	understood,	partly	accredited	to	the	complex	nature	of	a	hypomorphic	
variant.	This	is	reflected	by	the	spectrum	of	phenotypes	associated	with	BBS1	p.M390R,	where	
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presentation	varies	from	all	cardinal	features	of	BBS	to	asymptomatic	 individuals	(Beales	et	al.	
2003;	Estrada-Cuzcano	et	al.	2012;	Cox	et	al.	2012).	 In	many	ways,	 this	disease	heterogeneity	
complicated	the	outcome	of	the	study	and	due	to	statistical	problems	created	by	small	sample	
size,	it	made	interpretation	of	results	quite	challenging.	For	example,	there	were	few	differentially	
expressed	genes	found	at	the	transcriptome	level	between	starved	BBS	and	control	fibroblasts	
(described	 in	chapter	5).	 It	 is	possible	 that	 the	study	of	a	 loss	of	 function	mutation	may	have	
exhibited	a	greater	difference.	
	
As	 well	 as	 advancing	 our	 understanding	 of	 BBS1	 p.M390R	 pathobiology,	 this	 study	 has	
demonstrated	proof	of	 principle,	 and	ensured	optimisation	of	methodology	 and	expertise	 for	
future	experiments.	Increased	sample	size	has	already	been	discussed	as	a	limitation	throughout	
this	 thesis,	 therefore,	 this	would	 need	 to	 be	 addressed	 first.	 There	 are	 520	 patients	 that	 are	
registered	to	attend	the	BBS	clinics	headed	by	Professor	Phil	Beales,	of	which	~166	individuals	
(32%)	manifest	at	least	one	BBS1	p.M390R	variant	(Prof	P.	Beales,	personal	communication).	The	
next	stage	of	this	analysis	would	therefore	be	to	recruit	patients	for	validation	of	findings.	Further	
to	this,	patients	with	different	disease-causing	variants	could	also	be	recruited	to	the	study.	The	
variant	p.C91Lfs*5	in	BBS10	is	responsible	for	~20%	of	BBS	cases,	and	is	the	next	most	common	
mutation	 found	 in	 BBS	 (Forsythe	 and	 Beales	 2013),	 present	 in	 ~145	 registered	 patients	 at	
Professor	 Beale’s	 clinics	 (Prof	 P.	 Beales,	 personal	 communication).	 It	 would	 be	 interesting	 to	
determine	whether	the	findings	of	this	study	were	specific	to	BBS1	p.M390R,	or	a	general	finding	
to	 BBS	 by	 comparison	 between	 these	 two	 genotypes.	 As	 a	 loss	 of	 function	 variant,	 I	 would	
hypothesise	 that	 patients	with	BBS10	 variants	would	 exhibit	 greater	 differences	 compared	 to	
controls.	Finally,	it	would	be	imperative	that	a	reliable	control	group	be	recruited	for	this	study,	
where	it	would	be	preferable	that	there	are	double	the	number	of	controls	to	patients.	This	would	
benefit	statistical	power	and	allow	reliable	inferences	from	the	data.	
	
Appendix	
	
296	
Appendix	
	
AHI1	 BBS9	 EVC2	 NEK1	 SPATA7	 USH1C	
ARL13B	 BBIP1	 GLIS2	 NEK8	 TCTN1	 USH1G	
ARL6	 C2orf71	 GPR98	 NPHP1	 TCTN2	 USH2A	
ATXN10	 C8orf37	 HYLS1	 NPHP3	 TMEM138	 VHL	
B9D1	 CC2D2A	 IFT43	 NPHP4	 TMEM216	 WDPCP	
B9D2	 CCDC28B	 IFT80	 OFD1	 TMEM231	 WDR19	
BBS1	 CDH23	 IFT172	 PCDH15	 TMEM237	 WDR35	
BBS10	 CEP164	 INVS	 PKD2	 TMEM67	 XPNPEP3	
BBS12	 CEP290	 IQCB1	 PKHD1	 TOPORS	 ZNF423	
BBS2	 CEP41	 KIF7	 RPGR	 TRIM32	 		
BBS4	 DFNB31	 LCA5	 RPGRIP1	 TTC21B	 		
BBS5	 DYNC2H1	 MKKS	 RPGRIP1L	 TTC8	 		
BBS7	 EVC	 MKS1	 SDCCAG8	 TULP1	 		
Table	A.1	–	Genes	known	to	cause	nonmotile	ciliopathies,	referred	to	as	the	ciliopathy	panel.	
	
ADCY3	 CEP97	 HSPB11	 NEK4	 RPGR	 TRAPPC9	
AHI1	 CLDN2	 HTR6	 NEK8	 RPGRIP1	 TRIM32	
ALMS1	 CLUAP1	 HTT	 NGFR	 RPGRIP1L	 TRIP11	
ARF4	 CP110	 HYLS1	 NME5	 RTTN	 TTC12	
ARL13B	 CRB3	 IFT122	 NME7	 SASS6	 TTC21B	
ARL3	 CROCC	 IFT140	 NOTO	 SCLT1	 TTC26	
ARL6	 CTNNB1	 IFT172	 NPHP1	 SDCCAG8	 TTC30A	
ASAP1	 DCDC2	 IFT20	 NPHP3	 SEPT2	 TTC30B	
ATXN10	 DCDC2	 IFT27	 NPHP4	 SEPT7	 TTC8	
AZI1	 DFNB31	 IFT43	 OCRL	 SHH	 TTK	
B9D1	 DPYSL2	 IFT46	 ODF2	 SLC47A2	 TTLL3	
B9D2	 DRD1	 IFT52	 OFD1	 SMO	 TTLL6	
BBS1	 DRD2	 IFT57	 PARD3	 SNAP25	 TTLL9	
BBS10	 DRD5	 IFT74	 PARD6A	 SNX10	 TUBA1A	
BBS12	 DVL1	 IFT80	 PCDH15	 SPATA7	 TUBA1C	
BBS2	 DYNC2H1	 IFT81	 PCM1	 SPEF2	 TUBA4A	
BBS4	 DYNLT1	 IFT88	 PDE6D	 SSNA1	 TUBB2A	
BBS5	 DYX1C1	 INPP5E	 PDZD7	 SSTR3	 TUBB2B	
BBS7	 EVC	 INVS	 PHF17	 STIL	 TUBB3	
BBS9	 EVC2	 IQCB1	 PIBF1	 STK38L	 TUBE1	
BBIP1	 EXOC4	 KIF17	 PKD1	 STOML3	 TUBGCP2	
C21orf2	 EXOC5	 KIF19	 PKD1L1	 STX3	 TUBGCP3	
C2CD3	 EXOC6	 KIF24	 PKD2	 SUFU	 TUBGCP4	
C2orf71	 EXOC6B	 KIF27	 PKHD1	 SYNE2	 TUBGCP5	
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C8orf37	 FAM161A	 KIF3A	 PLK1	 TBC1D30	 TUBGCP6	
CBY1	 FBF1	 KIF3B	 POC1A	 TBC1D7	 TULP1	
CC2D2A	 FLNA	 KIF3C	 PTCH1	 TCTN1	 TULP3	
CCDC28B	 FOPNL	 KIF7	 PTPDC1	 TCTN2	 USH1C	
CCDC37	 FOXJ1	 LCA5	 RAB11A	 TCTN3	 USH1G	
CCDC41	 FUZ	 LZTFL1	 RAB11FIP3	 TMEM138	 USH2A	
CDH23	 GLI1	 MAK	 RAB17	 TMEM216	 VHL	
CENPJ	 GLI2	 MAL	 RAB23	 TMEM231	 WDPCP	
CEP104	 GLI3	 MAPRE1	 RAB3IP	 TMEM237	 WDR19	
CEP135	 GLIS2	 MCHR1	 RAB8A	 TMEM67	 WDR35	
CEP164	 GPR161	 MDM1	 RABL5	 TNPO1	 WDR60	
CEP250	 GPR98	 MKKS	 RFX3	 TOPORS	 XPNPEP3	
CEP290	 GSK3B	 MKS1	 RILPL1	 TPPP2	 ZNF423	
CEP41	 HAP1	 MLF1	 RILPL2	 TRAF3IP1	 		
CEP72	 HNF1B	 NEK1	 RP1	 TRAPPC10	 		
CEP89	 HSPA8	 NEK2	 RP2	 TRAPPC3	 		
Table	A.2	–	Nonmotile	cilia	genes	from	the	SYSCILIA	gold	standard	version	1	gene	panel.	
	
PLEKHG5	 FGD4	 PIKFYVE	 IKBKAP	 DNMT1	 CARS	
KIF1B	 HSPB8	 SOD1	 SETX	 DYNC1H1	 NARS	
MFN2	 TDP1	 SOX10	 GJB1	 INF2	 IARS	
YARS	 SLC12A6	 RAB7A	 PRPS1	 TFG	 VARS	
NGF	 LITAF	 CCT5	 MED25	 HARS	 SARS	
LMNA	 KARS	 SH3TC2	 PMP22	 KIF1A	 EPRS	
NTRK1	 GAN	 FIG4	 TRPV4	 FAM134B	 SPTLC3	
MPZ	 SEPT9	 GARS	 AARS	 HK1	 GNB4	
EGR2	 CTDP1	 HSPB1	 LRSAM1	 RARS	 PDK3	
SBF2	 DNM2	 ARHGEF10	 MARS	 TARS	 		
BSCL2	 PRX	 GDAP1	 SPTLC2	 FARSA	 		
IGHMBP2	 DCTN1	 NDRG1	 ATP7A	 FARSB	 		
WNK1	 HOXD10	 SPTLC1	 ATL1	 DARS	 		
Table	A.3	–	Genes	associated	with	causing	Charcot-Marie-Tooth	disease,	from	(Gonzaga-Jauregui	et	al.	
2015).	
	
Sample	ID	 Status	
Batch	
number	 Disease		
BBS001	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS002	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS003	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS004	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS005	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS006	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS007	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
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BBS008	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS009	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS010	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS011	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS012	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS013	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS014	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
BBS015	 Patient	genome	 WGS	batch	2	 Bardet-Biedl	Syndrome	
SRS002	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS003	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS005	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS006	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS008	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS009	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS011	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS012	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS014	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS015	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS017	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS018	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS020	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS021	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS023	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS024	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS026	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS027	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS029	 Control	genome	 WGS	batch	3	 Clinically	healthy	
SRS030	 Control	genome	 WGS	batch	3	 Clinically	healthy	
IBD001	 Control	genome	 WGS	batch	1	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD002	 Control	genome	 WGS	batch	1	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD003	 Control	genome	 WGS	batch	1	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD006	 Control	genome	 WGS	batch	1	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD007	 Control	genome	 WGS	batch	1	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD010	 Control	genome	 WGS	batch	1	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD011	 Control	genome	 WGS	batch	1	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD012	 Control	genome	 WGS	batch	3	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD016	 Control	genome	 WGS	batch	3	 Very	Early	Onset	Inflammatory	Bowel	Disease	
IBD018	 Control	genome	 WGS	batch	3	 Very	Early	Onset	Inflammatory	Bowel	Disease	
UCLG_502	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_518	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_520	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_523	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
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UCLG_508	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_511	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_512	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_513	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_514	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_519	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_521	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_522	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_524	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_525	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_506	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
UCLG_507	 Patient	exome	 WES	batch	3	 Bardet-Biedl	Syndrome	
PE_1	 Control	exome	 WES	batch	1	 Cleft	lip	and	palate	
PE_2	 Control	exome	 WES	batch	1	 Cleft	lip	and	palate	
PE_3	 Control	exome	 WES	batch	1	 Cleft	lip	and	palate	
PE_27	 Control	exome	 WES	batch	4	 Severe	Combined	Immunodeficiency	
PE_7	 Control	exome	 WES	batch	4	 Spina	Bifida	Occulta	
PE_8	 Control	exome	 WES	batch	4	 Spina	Bifida	Occulta	
PE_5	 Control	exome	 WES	batch	4	 Spina	Bifida	Occulta	
PE_4	 Control	exome	 WES	batch	4	 Spina	Bifida	Occulta	
PE_10	 Control	exome	 WES	batch	4	 Spina	Bifida	Occulta	
PE_11	 Control	exome	 WES	batch	4	 Spina	Bifida	Occulta	
PE_51	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_55	 Control	exome	 WES	batch	5	 Severe	Combined	Immunodeficiency	
PE_43	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_45	 Control	exome	 WES	batch	5	 Multiple	Congenital	Anomalies	
PE_40	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_42	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_36	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_38	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_37	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_37	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_49	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_53	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_52	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_54	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
PE_41	 Control	exome	 WES	batch	5	 Congenital	Melanocytic	Naevus	
Table	A.4	–	Whole	genome	and	whole	exome	sequencing	samples	and	batches	used	in	burden	analysis,	
with	disease	information.	
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FGG	 VTN	 IGHG1	 PROS1	 C3	 TF	
FGA	 F2	 C1S	 IGHG2	 FN1	 C1QA	
FGB	 CLU	 APOE	 CFH	 SERPINA1	 HBA1	
ALB	 PON1	 ITIH4	 IGHA1	 HBB	 PLG	
APOA1	 C4B	 C1QC	 C1QB	 SERPINC1	 C1R	
C4A	 F9	 CRP	 HP	 		 		
Table	A.5	–	Proteins	detected	by	both	SOMAscan	and	LC-MS/MS	from	plasma.	
	
	
Figure	A.1	–	iPSC	colonies	and	embryoid	bodies	from	lines	used	in	chapter	6.	iPSC	colonies	(left	images)	
and	EBs	at	day	4	of	differentiation	(right	images)	are	shown	from	BBS001	(A-B),	BBS008	(C-D),	and	
CTRL037	(E-F).	Scale	bars	for	A,	C	and	E	=	100µm,	scale	bars	for	B,	D	and	F	=	50µm.	
	
		
Supplemental	data	
All	supplemental	data	is	available	on	the	USB	stick	attached	to	the	back	page	of	this	thesis,	including	raw	files	from	transcriptomic	and	proteomic	experiments.	All	
files	are	outlined	in	table	S.1	below.	
	
File	ID	 File	name	 Description	 Location	
Table	S.1	 Supplemental	data	contents	 Contents	of	the	supplemental	data	folders	 Supplemental_data	
Table	S.2	 RNA-seq_expression-matix-cpm.txt	 Normalised	gene	expression	data	from	RNA-seq,	
expressed	as	log2CPM	
Supplemental_data>RNA-seq	
Table	S.3	 RNA-seq_expression-matrix-rpkm.txt	
Normalised	gene	expression	data	from	RNA-seq,	
expressed	as	reads	per	kilobase	million	(RPKM)	
Supplemental_data>RNA-seq	
Table	S.4	 RNA-seq_edger-disease.txt	
Master	file	of	DE	transcripts	produced	by	the	edge	R	
programme	
Supplemental_data>RNA-seq	
Table	S.5	 RNA-seq_Fed.BBSvscontrol	 Processed	RNA-seq	data	with	DE	transcripts	for	fed	BBS	
vs	control	
Supplemental_data>RNA-seq	
Table	S.6	 RNA-seq_Starved.BBSvscontrol	
Processed	RNA-seq	data	with	DE	transcripts	for	starved	
BBS	vs	control	
Supplemental_data>RNA-seq	
Table	S.7	 RNA-seq_BBS.starvedvsfed	
Processed	RNA-seq	data	with	DE	transcripts	for	BBS	
starved	vs	fed	
Supplemental_data>RNA-seq	
Table	S.8	 RNA-seq_control.starvedvsfed	 Processed	RNA-seq	data	with	DE	transcripts	for	control	
starved	vs	fed	
Supplemental_data>RNA-seq	
Table	S.9	 iTRAQ_Hallmark_bbs.starvedvsfed.gsea_report_for_na_neg_enriched.xlsx	
Hallmark	gene	sets	negatively	enriched	in	BBS	starved	
vs	fed	from	iTRAQ	data	
Supplemental_data>RNA-seq	
Table	S.10	 iTRAQ_Hallmark_bbs.starvedvsfed.gsea_report_for_na_pos_enriched.xlsx	
Hallmark	gene	sets	positively	enriched	in	BBS	starved	vs	
fed	from	iTRAQ	data	
Supplemental_data>RNA-seq	
Table	S.11	 iTRAQ_Hallmark_control.starvedvsfed.gsea_report_for_na_neg_enriched.xlsx	
Hallmark	gene	sets	negatively	enriched	in	control	
starved	vs	fed	from	iTRAQ	data	 Supplemental_data>RNA-seq	
Table	S.12	 iTRAQ_Hallmark_control.starvedvsfed.gsea_report_for_na_pos_enriched.xlsx	
Hallmark	gene	sets	positively	enriched	in	control	
starved	vs	fed	from	iTRAQ	data	
Supplemental_data>RNA-seq	
Table	S.13	 iTRAQ_Hallmark_fed.bbsvscontrol.gsea_report_for_na_neg_enriched.xlsx	
Hallmark	gene	sets	negatively	enriched	in	starved	BBS	
vs	control	from	iTRAQ	data	
Supplemental_data>RNA-seq	
		
Table	S.14	 iTRAQ_Hallmark_fed.bbsvscontrol.gsea_report_for_na_pos_enriched.xlsx	 Hallmark	gene	sets	positively	enriched	in	starved	BBS	vs	
control	from	iTRAQ	data	
Supplemental_data>RNA-seq	
Table	S.15	 iTRAQ_Hallmark_starved.bbsvscontrol.gsea_report_for_na_neg_enriched.xlsx	
Hallmark	gene	sets	negatively	enriched	in	fed	BBS	vs	
control	from	iTRAQ	data	
Supplemental_data>RNA-seq	
Table	S.16	 iTRAQ_Hallmark_starved.bbsvscontrol.gsea_report_for_na_pos_enriched.xlsx	
Hallmark	gene	sets	positively	enriched	in	fed	BBS	vs	
control	from	iTRAQ	data	
Supplemental_data>RNA-seq	
Table	S.17	 RNA_Hallmark_BBS.starvedvsfed_gsea_report_for_neg_enriched.xls	 Hallmark	gene	sets	negatively	enriched	in	BBS	starved	
vs	fed	from	RNA-seq	data	
Supplemental_data>RNA_GSEA	
Table	S.18	 RNA_Hallmark_BBS.starvedvsfed_gsea_report_for_pos_enriched.xls	
Hallmark	gene	sets	positively	enriched	in	BBS	starved	vs	
fed	from	RNA-seq	data	
Supplemental_data>RNA_GSEA	
Table	S.19	 RNA_Hallmark_control.starvedvsfed_gsea_report_for_neg_enriched.xls	
Hallmark	gene	sets	negatively	enriched	in	control	
starved	vs	fed	from	RNA-seq	data	
Supplemental_data>RNA_GSEA	
Table	S.20	 RNA_Hallmark_control.starvedvsfed_gsea_report_for_pos_enriched.xls	
Hallmark	gene	sets	positively	enriched	in	control	
starved	vs	fed	from	RNA-seq	data	 Supplemental_data>RNA_GSEA	
Table	S.21	 RNA_Hallmark_starved.bbsvscontrol_gsea_report_for_neg_enriched.xls	
Hallmark	gene	sets	negatively	enriched	in	starved	BBS	
vs	control	from	RNA-seq	data	
Supplemental_data>RNA_GSEA	
Table	S.22	 RNA_Hallmark_starved.bbsvscontrol_gsea_report_for_pos_enriched.xls	
Hallmark	gene	sets	positively	enriched	in	starved	BBS	vs	
control	from	RNA-seq	data	
Supplemental_data>RNA_GSEA	
Table	S.23	 RNA_Hallmark_fed.bbsvscontrol_gsea_report_for_neg_enriched.xls	
Hallmark	gene	sets	negatively	enriched	in	fed	BBS	vs	
control	from	RNA-seq	data	 Supplemental_data>RNA_GSEA	
Table	S.24	 RNA_Hallmark_fed.bbsvscontrol_gsea_report_for_pos_enriched.xls	
Hallmark	gene	sets	positively	enriched	in	fed	BBS	vs	
control	from	RNA-seq	data	
Supplemental_data>RNA_GSEA	
Table	S.25	 BBS-limma-plasma_SOMA.txt	 Limma	file	for	SOMAscan	plasma	
Supplemental_data>Proteomics>	
SOMAscan	
Table	S.26	 plasma_SOMA_raw.txt	 Raw	SOMAscan	data	from	SOMAlogic	
Supplemental_data>Proteomics>	
SOMAscan	
Table	S.27	 SOMA_plasma_analysis	 SOMAscan	processed	data,	with	RFU	for	each	individual	
Supplemental_data>Proteomics>	
SOMAscan	
Table	S.28	 Plasma_label_free_MS	
Data	processed	by	Progenesis	QIP	from	plasma	SDS-
PAGE	fractionated	label-free	LC-MS/MS	
Supplemental_data>Proteomics>Label-
free_mass_spectrometry	
Table	S.29	 Urine_label_free_MS	
Data	processed	by	Progenesis	QIP	from	urine	label-free	
LC-MS/MS	
Supplemental_data>Proteomics>Label-
free_mass_spectrometry	
Table	S.30	 iTRAQ_BBS.starvedvsfed	 Processed	iTRAQ	data	with	DE	proteins	for	BBS	starved	
vs	fed	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.31	 iTRAQ_control.starvedvsfed	
Processed	iTRAQ	data	with	DE	proteins	for	control	
starved	vs	fed	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
		
Table	S.32	 iTRAQ_fed.BBSvscontrol	 Processed	iTRAQ	data	with	DE	proteins	for	fed	BBS	vs	
control	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.33	 iTRAQ_starved.BBSvscontrol	 Processed	iTRAQ	data	with	DE	proteins	for	starved	BBS	
vs	control	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.34	 iTRAQ_Treated-raw_quant.txt	 iTRAQ	raw	normalised	quantitation	data	from	BGI,	for	
serum	starved	fibroblasts	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.35	 iTRAQ_Untreated-raw_quant.txt	
iTRAQ	raw	normalised	quantitation	data	from	BGI,	for	
serum	fed	fibroblasts	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.36	 iTRAQ_peptideSummary_treated.txt	 iTRAQ	peptide	summary	from	serum	starved	fibroblasts	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.37	 iTRAQ_proteinSummary_treated.txt	 iTRAQ	protein	summary	from	serum	starved	fibroblasts	 Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.38	 iTRAQ_peptideSummary_untreated.txt	 iTRAQ	peptide	summary	from	serum	fed	fibroblasts	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.39	 iTRAQ_proteinSummary_untreated.txt	 iTRAQ	protein	summary	from	serum	fed	fibroblasts	
Supplemental_data>Proteomics>	
iTRAQ_mass_spectrometry	
Table	S.40	 Ingenuity_variant_count_vs_controls	
Number	of	variants	at	each	stage	of	the	Ingenuity	
filtering	cascade	for	WGS	patient	and	control	samples	 Supplemental_data>Other	
Table	S.41	 SOMAsan-Assay-protein-panel.pdf	 List	of	1310	proteins	in	the	SOMAscan	assay	 Supplemental_data>Other	
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